PNEUMONIA A M EDICAL D ICTIONARY , B IBLIOGRAPHY , AND A NNOTATED R ESEARCH G UIDE TO I NTERNET R E FERENCES
J AMES N. P ARKER , M.D. AND P HILIP M. P ARKER , P H .D., E DITORS
ii
ICON Health Publications ICON Group International, Inc. 4370 La Jolla Village Drive, 4th Floor San Diego, CA 92122 USA Copyright 2003 by ICON Group International, Inc. Copyright 2003 by ICON Group International, Inc. All rights reserved. This book is protected by copyright. No part of it may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise, without written permission from the publisher. Printed in the United States of America. Last digit indicates print number: 10 9 8 7 6 4 5 3 2 1
Publisher, Health Care: Philip Parker, Ph.D. Editor(s): James Parker, M.D., Philip Parker, Ph.D. Publisher's note: The ideas, procedures, and suggestions contained in this book are not intended for the diagnosis or treatment of a health problem. As new medical or scientific information becomes available from academic and clinical research, recommended treatments and drug therapies may undergo changes. The authors, editors, and publisher have attempted to make the information in this book up to date and accurate in accord with accepted standards at the time of publication. The authors, editors, and publisher are not responsible for errors or omissions or for consequences from application of the book, and make no warranty, expressed or implied, in regard to the contents of this book. Any practice described in this book should be applied by the reader in accordance with professional standards of care used in regard to the unique circumstances that may apply in each situation. The reader is advised to always check product information (package inserts) for changes and new information regarding dosage and contraindications before prescribing any drug or pharmacological product. Caution is especially urged when using new or infrequently ordered drugs, herbal remedies, vitamins and supplements, alternative therapies, complementary therapies and medicines, and integrative medical treatments. Cataloging-in-Publication Data Parker, James N., 1961Parker, Philip M., 1960Pneumonia: A Medical Dictionary, Bibliography, and Annotated Research Guide to Internet References / James N. Parker and Philip M. Parker, editors p. cm. Includes bibliographical references, glossary, and index. ISBN: 0-597-83634-5 1. Pneumonia-Popular works. I. Title.
iii
Disclaimer This publication is not intended to be used for the diagnosis or treatment of a health problem. It is sold with the understanding that the publisher, editors, and authors are not engaging in the rendering of medical, psychological, financial, legal, or other professional services. References to any entity, product, service, or source of information that may be contained in this publication should not be considered an endorsement, either direct or implied, by the publisher, editors, or authors. ICON Group International, Inc., the editors, and the authors are not responsible for the content of any Web pages or publications referenced in this publication.
Copyright Notice If a physician wishes to copy limited passages from this book for patient use, this right is automatically granted without written permission from ICON Group International, Inc. (ICON Group). However, all of ICON Group publications have copyrights. With exception to the above, copying our publications in whole or in part, for whatever reason, is a violation of copyright laws and can lead to penalties and fines. Should you want to copy tables, graphs, or other materials, please contact us to request permission (E-mail:
[email protected]). ICON Group often grants permission for very limited reproduction of our publications for internal use, press releases, and academic research. Such reproduction requires confirmed permission from ICON Group International Inc. The disclaimer above must accompany all reproductions, in whole or in part, of this book.
iv
Acknowledgements The collective knowledge generated from academic and applied research summarized in various references has been critical in the creation of this book which is best viewed as a comprehensive compilation and collection of information prepared by various official agencies which produce publications on pneumonia. Books in this series draw from various agencies and institutions associated with the United States Department of Health and Human Services, and in particular, the Office of the Secretary of Health and Human Services (OS), the Administration for Children and Families (ACF), the Administration on Aging (AOA), the Agency for Healthcare Research and Quality (AHRQ), the Agency for Toxic Substances and Disease Registry (ATSDR), the Centers for Disease Control and Prevention (CDC), the Food and Drug Administration (FDA), the Healthcare Financing Administration (HCFA), the Health Resources and Services Administration (HRSA), the Indian Health Service (IHS), the institutions of the National Institutes of Health (NIH), the Program Support Center (PSC), and the Substance Abuse and Mental Health Services Administration (SAMHSA). In addition to these sources, information gathered from the National Library of Medicine, the United States Patent Office, the European Union, and their related organizations has been invaluable in the creation of this book. Some of the work represented was financially supported by the Research and Development Committee at INSEAD. This support is gratefully acknowledged. Finally, special thanks are owed to Tiffany Freeman for her excellent editorial support.
v
About the Editors James N. Parker, M.D. Dr. James N. Parker received his Bachelor of Science degree in Psychobiology from the University of California, Riverside and his M.D. from the University of California, San Diego. In addition to authoring numerous research publications, he has lectured at various academic institutions. Dr. Parker is the medical editor for health books by ICON Health Publications. Philip M. Parker, Ph.D. Philip M. Parker is the Eli Lilly Chair Professor of Innovation, Business and Society at INSEAD (Fontainebleau, France and Singapore). Dr. Parker has also been Professor at the University of California, San Diego and has taught courses at Harvard University, the Hong Kong University of Science and Technology, the Massachusetts Institute of Technology, Stanford University, and UCLA. Dr. Parker is the associate editor for ICON Health Publications.
vi
About ICON Health Publications To discover more about ICON Health Publications, simply check with your preferred online booksellers, including Barnes & Noble.com and Amazon.com which currently carry all of our titles. Or, feel free to contact us directly for bulk purchases or institutional discounts: ICON Group International, Inc. 4370 La Jolla Village Drive, Fourth Floor San Diego, CA 92122 USA Fax: 858-546-4341 Web site: www.icongrouponline.com/health
vii
Table of Contents FORWARD .......................................................................................................................................... 1 CHAPTER 1. STUDIES ON PNEUMONIA ............................................................................................. 3 Overview........................................................................................................................................ 3 The Combined Health Information Database................................................................................. 3 Federally Funded Research on Pneumonia .................................................................................... 5 E-Journals: PubMed Central ..................................................................................................... 148 The National Library of Medicine: PubMed .............................................................................. 175 CHAPTER 2. NUTRITION AND PNEUMONIA.................................................................................. 313 Overview.................................................................................................................................... 313 Finding Nutrition Studies on Pneumonia ................................................................................. 313 Federal Resources on Nutrition ................................................................................................. 316 Additional Web Resources ......................................................................................................... 317 CHAPTER 3. ALTERNATIVE MEDICINE AND PNEUMONIA ........................................................... 319 Overview.................................................................................................................................... 319 National Center for Complementary and Alternative Medicine................................................ 319 Additional Web Resources ......................................................................................................... 330 General References ..................................................................................................................... 334 CHAPTER 4. DISSERTATIONS ON PNEUMONIA ............................................................................. 335 Overview.................................................................................................................................... 335 Dissertations on Pneumonia...................................................................................................... 335 Keeping Current ........................................................................................................................ 336 CHAPTER 5. CLINICAL TRIALS AND PNEUMONIA ........................................................................ 337 Overview.................................................................................................................................... 337 Recent Trials on Pneumonia...................................................................................................... 337 Keeping Current on Clinical Trials ........................................................................................... 357 CHAPTER 6. PATENTS ON PNEUMONIA ........................................................................................ 359 Overview.................................................................................................................................... 359 Patents on Pneumonia ............................................................................................................... 359 Patent Applications on Pneumonia ........................................................................................... 368 Keeping Current ........................................................................................................................ 373 CHAPTER 7. BOOKS ON PNEUMONIA ............................................................................................ 375 Overview.................................................................................................................................... 375 Book Summaries: Federal Agencies............................................................................................ 375 Book Summaries: Online Booksellers......................................................................................... 376 The National Library of Medicine Book Index ........................................................................... 378 Chapters on Pneumonia............................................................................................................. 380 CHAPTER 8. MULTIMEDIA ON PNEUMONIA ................................................................................. 387 Overview.................................................................................................................................... 387 Video Recordings ....................................................................................................................... 387 Audio Recordings....................................................................................................................... 388 Bibliography: Multimedia on Pneumonia.................................................................................. 391 CHAPTER 9. PERIODICALS AND NEWS ON PNEUMONIA .............................................................. 395 Overview.................................................................................................................................... 395 News Services and Press Releases.............................................................................................. 395 Newsletter Articles .................................................................................................................... 399 Academic Periodicals covering Pneumonia ............................................................................... 402 CHAPTER 10. RESEARCHING MEDICATIONS................................................................................. 405 Overview.................................................................................................................................... 405 U.S. Pharmacopeia..................................................................................................................... 405 Commercial Databases ............................................................................................................... 407 Researching Orphan Drugs ....................................................................................................... 408
viii Contents
APPENDIX A. PHYSICIAN RESOURCES .......................................................................................... 413 Overview.................................................................................................................................... 413 NIH Guidelines.......................................................................................................................... 413 NIH Databases........................................................................................................................... 415 Other Commercial Databases..................................................................................................... 419 The Genome Project and Pneumonia ......................................................................................... 419 APPENDIX B. PATIENT RESOURCES ............................................................................................... 423 Overview.................................................................................................................................... 423 Patient Guideline Sources.......................................................................................................... 423 Associations and Pneumonia ..................................................................................................... 430 Finding Associations.................................................................................................................. 431 APPENDIX C. FINDING MEDICAL LIBRARIES ................................................................................ 433 Overview.................................................................................................................................... 433 Preparation................................................................................................................................. 433 Finding a Local Medical Library................................................................................................ 433 Medical Libraries in the U.S. and Canada ................................................................................. 433 ONLINE GLOSSARIES................................................................................................................ 439 Online Dictionary Directories ................................................................................................... 444 PNEUMONIA DICTIONARY..................................................................................................... 445 INDEX .............................................................................................................................................. 551
1
FORWARD In March 2001, the National Institutes of Health issued the following warning: "The number of Web sites offering health-related resources grows every day. Many sites provide valuable information, while others may have information that is unreliable or misleading."1 Furthermore, because of the rapid increase in Internet-based information, many hours can be wasted searching, selecting, and printing. Since only the smallest fraction of information dealing with pneumonia is indexed in search engines, such as www.google.com or others, a non-systematic approach to Internet research can be not only time consuming, but also incomplete. This book was created for medical professionals, students, and members of the general public who want to know as much as possible about pneumonia, using the most advanced research tools available and spending the least amount of time doing so. In addition to offering a structured and comprehensive bibliography, the pages that follow will tell you where and how to find reliable information covering virtually all topics related to pneumonia, from the essentials to the most advanced areas of research. Public, academic, government, and peer-reviewed research studies are emphasized. Various abstracts are reproduced to give you some of the latest official information available to date on pneumonia. Abundant guidance is given on how to obtain free-of-charge primary research results via the Internet. While this book focuses on the field of medicine, when some sources provide access to non-medical information relating to pneumonia, these are noted in the text. E-book and electronic versions of this book are fully interactive with each of the Internet sites mentioned (clicking on a hyperlink automatically opens your browser to the site indicated). If you are using the hard copy version of this book, you can access a cited Web site by typing the provided Web address directly into your Internet browser. You may find it useful to refer to synonyms or related terms when accessing these Internet databases. NOTE: At the time of publication, the Web addresses were functional. However, some links may fail due to URL address changes, which is a common occurrence on the Internet. For readers unfamiliar with the Internet, detailed instructions are offered on how to access electronic resources. For readers unfamiliar with medical terminology, a comprehensive glossary is provided. For readers without access to Internet resources, a directory of medical libraries, that have or can locate references cited here, is given. We hope these resources will prove useful to the widest possible audience seeking information on pneumonia. The Editors
1
From the NIH, National Cancer Institute (NCI): http://www.cancer.gov/cancerinfo/ten-things-to-know.
3
CHAPTER 1. STUDIES ON PNEUMONIA Overview In this chapter, we will show you how to locate peer-reviewed references and studies on pneumonia.
The Combined Health Information Database The Combined Health Information Database summarizes studies across numerous federal agencies. To limit your investigation to research studies and pneumonia, you will need to use the advanced search options. First, go to http://chid.nih.gov/index.html. From there, select the “Detailed Search” option (or go directly to that page with the following hyperlink: http://chid.nih.gov/detail/detail.html). The trick in extracting studies is found in the drop boxes at the bottom of the search page where “You may refine your search by.” Select the dates and language you prefer, and the format option “Journal Article.” At the top of the search form, select the number of records you would like to see (we recommend 100) and check the box to display “whole records.” We recommend that you type “pneumonia” (or synonyms) into the “For these words:” box. Consider using the option “anywhere in record” to make your search as broad as possible. If you want to limit the search to only a particular field, such as the title of the journal, then select this option in the “Search in these fields” drop box. The following is what you can expect from this type of search: •
Prognosis of Streptococcus Pneumoniae-Induced Hemolytic Uremic Syndrome Source: Pediatric Nephrology. 16(4): 362-365. April 2001. Contact: Available from Springer-Verlag. Service Center Secaucus, 44 Hartz Way, Secaucus, NJ 07094. (201) 348-4033. Summary: Streptococcus pneumoniae induced hemolytic uremic syndrome (HUS) is known to be a severe acute disease leading to death in one third of cases, but data regarding the long term followup are lacking. This article reports on a series of 11 patients with HUS induced by the bacteria Streptococcus pneumoniae; all patients had meningitis and pneumonia. Among 9 patients with a severe acute infectious disease, 3 died from meningitis (infection of the meninges, or outer membranes of the brain) and 1 from neurological sequelae after a partial recovery of renal (kidney) function. The mean
4
Pneumonia
duration of dialysis was 32 days in patients with acute renal failure (ARF) who survived the acute infectious period. Cortical necrosis (tissue death) was documented in five of six kidney specimens. Among the 7 surviving patients, 5 developed end stage renal disease (ESRD) between 4 and 17 years later. The authors note that S. pneumoniae induced HUS is a rare disease, and they recommend the use of a registry of patients, in order to follow prospectively a larger number of patients. 1 table. 21 references. •
Impact of Oral Diseases on Systemic Health in the Elderly: Diabetes Mellitus and Aspiration Pneumonia Source: Journal of Public Health Dentistry. 60(4): 313-320. Fall 2000. Contact: Available from American Association of Public Health Dentistry. 3760 SW Lyle Court, Portland, OR 97221. (503) 242-0712. Fax (503) 242-0721. E-mail:
[email protected]. Summary: Evidence is increasing that oral health has important impacts on systemic health. This article presents data from the third National Health and Nutrition Examination Survey (NHANES III) describing the prevalence of dental caries and periodontal diseases in the older adult population. The authors then evaluate published reports and present data from clinical and epidemiological studies on relationships among oral health status, chronic oral infections (including caries and periodontitis), and certain systemic diseases, specifically focusing on type 2 diabetes and aspiration pneumonia. Both of these diseases increase in occurrence and impact in older age groups. The NHANES III data demonstrate that dental caries (cavities) and periodontal diseases occur with substantial frequency and represent a burden of unmet treatment need in older adults. The authors found clinical and epidemiological evidence to support considering periodontal infection a risk factor for poor glycemic control in type 2 diabetes; however, there is limited representation of older adults in reports of this relationship. For aspiration pneumonia, several lines of evidence support oral health status as an important etiologic factors. Additional clinical studies designed specifically to evaluate the effects of treating periodontal infection on glycemic control and improving oral health status in reducing the risk of aspiration pneumonia are needed. Although the associations are complicated, there is evidence to support recommending oral care regimens in protocols for managing type 2 diabetes and preventing aspiration pneumonia. 8 tables. 71 references.
•
Implications of Oral Infections on Systemic Diseases in the Institutionalized Elderly with a Special Focus on Pneumonia Source: Annals of Periodontology. 3(1): 262-275. July 1998. Contact: Available from American Academy of Periodontology. Suite 800, 737 North Michigan Avenue, Chicago, IL 60611. (312) 787-5518. Fax (312) 787-3983. Website: www.perio.org. Summary: This article considers the implications of oral infections on systemic diseases in the institutionalized elderly; the author offers a special focus on pneumonia. The extent to which oral organisms cause systemic infections through hematogenous (through the blood) dissemination in this population is still unknown. The author hypothesizes that a more likely and common route of systemic infection by oral microorganisms is through aspiration of oropharyngeal fluids containing oral pathogenic microorganisms, which colonize the lower respiratory tract and cause pneumonia. Respiratory pathogens emerge in the dental plaque of elderly patients with very poor oral hygiene and severe periodontal disease. This is also a problem in
Studies
5
intensive care units in the hospital setting. Selective digestive decontamination, a technique involving the topical application of antimicrobials to reduce the risk of colonization of the respiratory tract, has been used to reduce the incidence of nosocomial pneumonia in the acute care setting of hospitals. This technique has not been employed in the nursing home setting. The author concludes by discussing the parameters of studying this problem, including ethical issues, and research design. 2 tables. 117 references. (AA-M).
Federally Funded Research on Pneumonia The U.S. Government supports a variety of research studies relating to pneumonia. These studies are tracked by the Office of Extramural Research at the National Institutes of Health.2 CRISP (Computerized Retrieval of Information on Scientific Projects) is a searchable database of federally funded biomedical research projects conducted at universities, hospitals, and other institutions. Search the CRISP Web site at http://crisp.cit.nih.gov/crisp/crisp_query.generate_screen. You will have the option to perform targeted searches by various criteria, including geography, date, and topics related to pneumonia. For most of the studies, the agencies reporting into CRISP provide summaries or abstracts. As opposed to clinical trial research using patients, many federally funded studies use animals or simulated models to explore pneumonia. The following is typical of the type of information found when searching the CRISP database for pneumonia: •
Project Title: 2-5A ANTISENSE INHIBITION OF RESPIRATORY SYNCTIAL VIRUS Principal Investigator & Institution: Cramer, Hagen; Ridgeway Biosystems, Inc. 9500 Euclid Ave, Nd-50 Cleveland, OH 44195 Timing: Fiscal Year 2001; Project Start 01-AUG-2001; Project End 31-JUL-2004 Summary: (Adapted from Applicant's Abstract): Respiratory syncytial virus (RSV) is a major cause of lower respiratory tract disease in infants, young children and the elderly, particularly those that are institutionalized. It is the most common cause of viral bronchiolitis and pneumonia in children, and outbreaks frequently reach epidemic proportions during the winter months, accounting for roughly 90,000 hospitalizations and 4,500 deaths per year. Gemini Technologies, Inc. is developing novel antisense chimeras for use in the treatment of RSV infections. These chimeras are comprised of an antisense component to the targeted viral RNA genome, while the 2-5A portion of the chimera attracts and activates RNase L, an endoribonuclease that can cleave the associated genomic RNA strand. In the phase I studies, we succeeded in synthesizing and testing a second generation anti-RSV chimera that had potent antiviral activity in cultured cells and in primates. Here we propose to carry this compound through more definitive animal studies, utilizing aerosol delivery to mimic the clinical application of this compound. In addition, we propose medicinal chemistry-based studies aimed at improving chimera synthesis, and preliminary toxicology studies. PROPOSED COMMERCIAL APPLICATION: NOT AVAILABLE
2
Healthcare projects are funded by the National Institutes of Health (NIH), Substance Abuse and Mental Health Services (SAMHSA), Health Resources and Services Administration (HRSA), Food and Drug Administration (FDA), Centers for Disease Control and Prevention (CDCP), Agency for Healthcare Research and Quality (AHRQ), and Office of Assistant Secretary of Health (OASH).
6
Pneumonia
Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: ACELLULAR VACCINES AGAINST FRANCISELLA TULARENSIS Principal Investigator & Institution: Conlan, Joseph W. Senior Research Officer; National Research Council of Canada Ottawa Kiaor6, Canada Ottawa, Timing: Fiscal Year 2001; Project Start 15-JUN-2001; Project End 30-APR-2006 Summary: (Provided by Applicant): The facultative intracellular bacterial pathogen, Francisella tularensis, can cause severe pneumonia and death following the inhalation of very small numbers of infectious particles. For this reason, F. tularensis is considered a primary biological warfare agent. Acquired host immunity against this pathogen is predominantly T-cell-mediated rather than humoral. An attenuated strain of F. tularensis is an effective live vaccine against virulent strains of the pathogen. However, this strain retains its virulence for mice, and might cause disease if administered to immunocompromised individuals. Thus, for mass-vaccination purposes, a defined fastacting acellular vaccine would be preferable to the current live vaccine. Our institute has developed a novel vaccine delivery technology based on liposomes manufactured from the total polar lipids of various Archaebacteria. These liposomes termed, archaeosomes, generate robust cell-mediated immune responses to model antigens entrapped within them, without the aid of any additional immune stimulants. Recently, we showed that a short peptide antigen of another intracellular pathogen, Listeria monocytogenes, packaged in archaeosomes, provides a high level of protective immunity against this pathogen in a murine listeriosis model after only a single vaccination. Because multiple studies indicate that the same host defenses are needed to combat F. tularensis and L. monocytogenes, it is likely that appropriate antigens of the former pathogen encapsulated in archaeosomes will provide effective acellular vaccines. This proposal will explore this possibility. It is expected that the findings from the proposed studies will be applicable to the development of acellular vaccines against other intracellular respiratory pathogens such as Mycobacterium tuberculosis, and Chlamydia pneumoniae. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: ACTG 254--PHASE II/III STUDY OF AT/AZ AS COMPARED TO TMP/SMX IN CHILDREN Principal Investigator & Institution: Vandyke, Russell B.; Tulane University of Louisiana New Orleans, LA 70118 Timing: Fiscal Year 2001 Summary: Pneumocystis carinii pneumonia (PCP) is the most common opportunistic infection reported in HIV-infected children. While trimethoprim-sulfamethoxazole (TMP/SMX) remains the drug of choice for PCP prophylaxis, drug sensitivity may limit its effective use; in addition, the efficacy of the most common alternative therapiesincluding dapsone and pentamidine has yet to be determined in infants and children. Atovaquone, an oral medication requiring only once daily administration, has demonstrated activity against P. carinii and Toxoplasma gondii, and has been shown to be both safe and with no defined adverse or toxic effects. Primary objectives of this multi-centered, two-armed, double blind, placebo controlled study will be to compare TMP/SMX and AT/AZ in the prevention of serious bacterial infections; determine and compare long-term safety and tolerance; and assess the likelihood of pharmacokinetic interaction between atovaquone and azithromycin in a subset of two to 18 year old patients.
Studies
7
Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: ACTG888: DISCONTINUING W/ANTIRETROVIRAL THERAPY
PCP
PROPHYLAXIS
IN
PTS
Principal Investigator & Institution: Goldman, Mitchell; Indiana Univ-Purdue Univ at Indianapolis 620 Union Drive, Room 618 Indianapolis, IN 462025167 Timing: Fiscal Year 2001 Summary: This abstract is not available. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: ADULT ACTG CENTRAL GROUP Principal Investigator & Institution: Benson, Constance A. Professor of Medicine; Social and Scientific Systems 7101 Wisconsin Ave, Ste 1300 Bethesda, MD 20814 Timing: Fiscal Year 2002; Project Start 01-JAN-1996; Project End 31-DEC-2004 Summary: (adapted from the application's abstract): The Adult AIDS Clinical Trials Group (AACTG) is a multicenter, multidisciplinary clinical trials group dedicated to the study of HIV pathogenesis and therapy. Since its inception in 1987, the AACTG has evolved into a cooperative group consisting of the Central Group (composed of the Office of the Group Chair, Executive, Scientific and Resource Committee, a state-of-theart laboratory network, a Community Constituency Group, and the Operations Center), 30 AIDS Clinical Trials Units (ACTUs) located at major academic medical centers, and the Statistical and Data Management Center. The AACTG has had an impact on elucidating the current understanding of AIDS pathogenesis and therapy, and has played a role in the development of novel trial designs and analysis strategies. AACTG clinical trials have helped define guidelines for the use of antiretroviral agents and for the prophylaxis and treatment of HIV- associated opportunistic complications. Over 200 manuscripts have been published by the AACTG describing this body of work since submission of the prior competing renewal application in 1995. Group productivity has been aided by collaborations with a wide variety of external investigators and laboratories, U.S. and international clinical trials networks, and members of the pharmaceutical and medical diagnostics industries. The AACTG proposes to build on its accomplishments with the goal of further reducing, and ultimately eliminating, HIVassociated morbidity and mortality. The applicants propose to undertake investigations in a structure that allows for a high degree of efficiency and flexibility in the design and implementation of a broad array of clinical trials with patient management principles, according to the applicant, which are reflective of contemporary clinical practice and designed to ensure the relevance of research findings. Over the next several years the Group proposes to address a number of issues including how best to: provide initial and subsequent treatment to maximally suppress HIV replication; provide optimum treatment strategies following treatment failure; develop approaches to individualization of therapy based on genotypic and phenotypic characteristics of the virus and/or host; eliminate reservoirs of HIV-1 in latently infected cells; ameliorate virologic, immunologic, pharmacologic, and behavioral factors (adherence) that contribute to treatment failure; incorporate new therapies and treatment strategies into future regimens; evaluate new strategies for enhancing immune reconstitution to HIV and OIs; and delay or prevent HIV disease progression, opportunistic complications, complications of therapy, and mortality. To accomplish this agenda, the Group requests funds for 35 ACTUs that are to be evaluated on objective performance criteria. New sites and laboratories have been added to the Group in order to provide additional expertise
8
Pneumonia
in virology, immunology, and pharmacology. The Group remains committed to enrolling women and minorities and to continuing support of the Minority AIDS Training Program. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: ADULT AIDS CLINICAL TRIALS UNIT Principal Investigator & Institution: Balfour, Henry H. Professor of Laboratory Medicine, Pathol; Lab Medicine and Pathology; University of Minnesota Twin Cities 200 Oak Street Se Minneapolis, MN 554552070 Timing: Fiscal Year 2001; Project Start 01-MAR-1992; Project End 31-DEC-2004 Summary: (adapted from the application's abstract): The Minnesota AIDS Clinical Trials Unit (ACTU) requests to continue to be a unit of the Adult AIDS Clinical Trials Group (AACTG). The Minnesota ACTU is committed to the Scientific Agenda of the AACTG, in which they have participated continuously since January 1, 1987. In addition to recruiting and retaining a cohort of new HIV-infected patients in clinical trials (estimated to be 85 patients in main studies and 54 patients in substudies annually), the Minnesota ACTU plans to contribute to the Group Scientific agenda with the following specific aims: (1) to correlate the quantity and replication competence of HIV at the cellular level in lymphoid tissue (LT), peripheral blood fractions and other compartments; (2) to develop more sensitive methods to detect HIV and apply these to selection of more effective therapies; (3) to define the natural history of cytomegalovirus (CMV) disease in the era of potent antiretroviral therapy and determine the best assays (virologic and immunologic) to monitor its clinical course (AACTG 360); (4) to identify and properly manage the patients who are at risk for complications of the dyslipidemias associated with potent antiretroviral therapy; (5) to identify resistant CMV strains and assess their pathogenicity; (6) to study relationships between the production of neurotoxins in plasma and cerebrospinal fluid of HIV-infected patients, neuronal loss as measured by proton magnetic resonance spectroscopy and the development or progression of HIV-associated dementia (HAD); and (7) to understand and characterize pharmacokinetic behavior, including drug-drug interactions, of antiretrovirals and other HIV-related drugs in biologic fluids. To help achieve these specific aims, the Minnesota ACTU has both Virology and Pharmacology Advanced Technology Laboratories (ATL). The Virology ATL is focusing on quantitation and characterization of HIV in lymphoid tissue and other body compartments. This laboratory also has expertise in HIV and CMV resistance. The Pharmacology ATL is developing assays for simultaneous determination of levels of protease inhibitors and measurement of intracellular antiretroviral anabolites. The Nebraska subunit has a special interest in neuroAIDS and has identified neurotoxins putatively responsible for pathology in HAD. The Iowa subunit has expertise in the detection of hepatitis C and will be collaborating in studies of the pathogenesis of coinfection with HIV and hepatitis C. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: ADULT AIDS CLINICAL TRIALS UNIT Principal Investigator & Institution: Bartlett, John A. Professor; Medicine; Duke University Durham, NC 27706 Timing: Fiscal Year 2001; Project Start 01-JAN-1996; Project End 31-DEC-2004 Summary: (adapted from applicant's abstract): The Duke University Adult ACTU has contributed to the ACTG scientific agenda over the past three years. The most notable contributions from Duke include the introduction of two pathogenesis-based ACTU
Studies
9
protocols (380 and A5049), and the integration of Duke investigators into the scientific leadership as the Chairs of five ACTG trials and as members of numerous ACTG scientific committees. Duke University contributions to the AACTG are facilitated by the clinical and basic science expertise in HIV infection at the Medical Center, and environment of collaboration in translational research. A Scientific Advisory Committee composed of basic and clinical scientists assists the Duke ACTU site investigators in the development of potential ACTG studies. The Duke University Adult ACTU has steadily increased its enrollment into ACTG studies, especially labor intensive scientifically rigorous trials, and studies enrolling treatment-naive subjects. In 1998, the unit enrolled 72 subjects into main ACTG studies and 44 subjects into ACTG substudies. As a result of these efforts and efficiency at the site, Duke ranked fourth among the 30 existing ACTUs in the lowest median cost per weighted accrual during 1997- 1998. The Duke ACTU also had the lowest loss to follow-up rate in the ACTG. The applicant proposes to make substantial contributions to longitudinal research such as the Longitudinal Linked Randomized Trial (ALLRT) protocol. Subjects enrolled through the Duke University Adult ACTU reflect the demographics of HIV infection in North Carolina. The recruitment of historically underrepresented persons is assisted by the efforts of the Community Advisory Board (CAB) and Outreach Core, the provision of comprehensive on-site primary care, the Women s Clinic, and a NIDA supplement to the ACTU which supports on-site substance abuse counseling. During the next five years, the Duke University Adult ACTU proposes to emphasize investigations into the cellular reservoir of HIV, immunologic recovery during antiretroviral therapy, the enhancement of HIVspecific immune responses, and the development of improved antiretroviral treatment strategies such as treatment intensification. The Duke ACTU also proposes to continue to enter 75 new patients into main ACTG studies and 20 new patients into ACTG substudies annually. Given the continuing referrals of newly diagnosed persons with HIV infection to Duke, the Duke University Adult ACTU plans to provide the opportunity for recruitment of these persons into ACTG studies of treatment initiation. The applicants anticipate that Duke will continue as an efficient, cost-effective ACTU that contributes to the ACTG scientific agenda. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: ADULT AIDS CLINICAL TRIALS UNIT Principal Investigator & Institution: Collier, Ann C. Assistant Professor; Medicine; University of Washington Seattle, WA 98195 Timing: Fiscal Year 2001; Project Start 30-JUN-1986; Project End 31-DEC-2004 Summary: (adapted from application's abstract): This application responds to NIH RFA NIAID-98-013. It describes the renewal application of the University of Washington (UW) Adult AIDS Clinical Trials Unit (AACTU). The purpose of the UW AACTU is to perform exemplary HIV/AIDS treatment research in support of the Adult AIDS Clinical Trials Group (AACTG) scientific agenda. UW AACTU was one of 14 original centers funded in 1986 to study therapies for HIV infection. The UW AACTU has made contributions to the AACTG through leadership and participation of its faculty in AACTG committees and protocols, accrual of 1758 patients into AACTG studies, and generation of high quality data. Since 1996, UW AACTU investigators have been members of 38 committees, subcommittees, and focus groups; Chair or Vice-chair for seven of these; Protocol Chair or Co-chair of 23 studies and substudies; and the UW AACTU has enrolled 419 patients in AACTG protocols. The UW AACTU application describes three specific aims: (1) contribute to the pathogenesis-based scientific agenda of the AACTG by providing scientific expertise and leadership in HIV disease,
10 Pneumonia
complications of HIV, neurology, immunology, women's health and outcomes; and provide technical expertise to support protocol-mandated procedures; (2) participate in AACTG clinical trials by maintaining the UW AACTUs infrastructure and its experienced staff; enroll 90 patients in main studies and 50 in substudies per year and follow them with a <5 percent loss-to-follow-up rate; and maintain high data quality, quality assurance programs, and a high standard of regulatory compliance; and (3) support special issues of relevance to the AACTG by enrolling patients representative of local demographics; continue an outreach program and partnerships with People of Color Against AIDS Network and Northwest Family Center to maximize enrollment of people of color and women; maintain links with the HIV-infected community, community-based organizations and their network of referring physicians; continue the UW AACTU Community Advisory Board, and provide opportunities for research training of women and minority investigators. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: ADULT THERAPEUTIC CLINICAL TRIALS PROGRAM FOR AIDS Principal Investigator & Institution: Eron, Joseph J. Associate Professor; Medicine; University of North Carolina Chapel Hill Office of Sponsored Research Chapel Hill, NC 27599 Timing: Fiscal Year 2002; Project Start 30-SEP-1987; Project End 31-DEC-2004 Summary: (adapted from the application's abstract): The applicants propose to continue their multidisciplinary multi-year research program, that will integrate institutional expertise in infectious diseases, neurology, ophthalmology, gynecology, pharmacology, immunology, retrovirology, herpes viruses, and numerous clinical resources in North Carolina. The main focus is the evaluation of novel therapies for HIV-infected persons. Clinical investigators at the UNC and two satellite units, Greensboro, and Charlotte will study new compounds active against HIV and associated infections, malignancies, and neurologic disorders in new patients and follow previously enrolled patients. This proposes to continue a high rate of accrual among minorities, women, and intravenous (I.V.) drug users. The trials will be of all Phases (I, II, and III) and types. Patients will be followed for in vivo evidence of study drug effects on HIV, Mycobacterium avium intracellular complex (MAC), cytomegalovirus (CMV), herpes simplex virus (HSV), and other opportunistic infections using the ACTG-certified retrovirology and immunology virus laboratory, as well as UNC hospital laboratories. Pharmacokinetics (PK) will be monitored in the General Clinical Research Center (GCRC) and Microbiology and Pharmacology Laboratories. Concepts for new protocols will originate by participation in the Executive, Neurology, and Complications of HIV, HIV Pharmacology and Immunology ACTG committees. The established scientific advisory board (SAB) also will be involved in concept development. The UNC group application has new proposals for many trials including the eradication of HIV, simplification of regimens, novel therapies, improving adherence and immune restoration. Outreach to the community may be accomplished through the community advisory boards (CAB) at each site, the website and through a statewide newsletter. Finally, low protocol costs may be maintained by cost sharing with NIH grants (GCRC, Pediatric ACTU, Center for AIDS Research (CFAR), as well as with UNC Hospitals, and the Departments of Medicine, Neurology, Ophthalmology, Microbiology and School of Pharmacy. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
Studies 11
•
Project Title: AIDS ASSOCIATED PLEURAL INFECTION Principal Investigator & Institution: Antony, Veena B. Professor; Medicine; Indiana Univ-Purdue Univ at Indianapolis 620 Union Drive, Room 618 Indianapolis, IN 462025167 Timing: Fiscal Year 2001; Project Start 15-JUL-1999; Project End 30-JUN-2004 Summary: Patients with AIDS continue to die predominantly as a result of respiratory infections. Bacterial empyema with pyogenic organisms is a common complication of pneumonia in patients with AIDS. Though multiple organisms can cause pleural infections in patients with AIDS, one of the commonest organisms to cause empyema is Staphylococcus aureus. It is the hypothesis of this proposal that recruited neutrophils represent important phagocytic cells involved in effective pleural antibacterial host defense in bacterial empyema. We have developed a model of bacterial empyema in CD4 knockout mice that mimics bacterial empyema in patients with AIDS. Pleural mesothelial cells play a critical role in neutrophil recruitment by the production of neutrophil activating and chemotactic chemokines MIP-2, and KC in our murine model of staphylococcal empyema CD4 depletion alters pleural neutrophil recruitment and bacterial clearance by inhibition the in vivo compartmentalized production of the chemokines. Macrophage inflammatory protein-2 (MIP-2) and KC (murine gro-alpha). The inhibitory effect of CD4 depletion is in part due to the relative imbalance between Th1 type Interferon Gamma (IFN-gamma) and Th2 type cytokines, Interleukin-10 (IL10). We will evaluate our hypothesis both in vivo and in vitro. Using an in vivo model of staphylococcal empyema in CD4, knockout mice, we will evaluate the regulation of MIP-2 and KC by 1TH and 2TH cytokines. In vitro, mesothelial cell responses to S. Aureus by release of neutrophil chemokines and their regulation will be studied. Understanding the mechanism of regulation of neutrophil recruitment to the pleural space may help us discern the pathophysiology of the fulminant bacterial empyema seen in patients with AIDS and may help develop therapeutic modalities that augment host defense responses. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: AIDS CLINICAL TRIALS Principal Investigator & Institution: Frenkel, Lisa M. Professor; Children's Hospital and Reg Medical Ctr Box 5371, 4800 Sand Point Way Ne, Ms 6D-1 Seattle, WA 98105 Timing: Fiscal Year 2001; Project Start 01-APR-1992; Project End 28-FEB-2003 Summary: This proposal responds to the National Institutes of Health NIAID RFA:AI96-OOl for renewal of the ongoing Pediatric AIDE Clinical Trial Group (PACTG), and specifically for the renewal of the Pediatric AIDS Clinical Trials Unit of the University of Washington/Children's Hospital and Medical Center of Seattle (UW PACTU). The UW PACTU began as a subunit of the UW Adult ACTU in 1989, became an independent PACTU in 1991, and is applying for renewal in conjunction with the Coordinating and Operations Center (CORC) headed by Stephen Spector, M.D. The UW PACTU has made major contributions to the PACTG through participation in trials and leadership of its faculty in protocol development, committee work and in contributions to the scientific agenda. The purpose of the UW PACTU is to perform exemplary clinical trials research in support of the PACTG. The proposal of the UW PACTU describes three specific aims: 1) To contribute to the scientific agenda of the PACTG by providing scientific leadership and proposing protocols aimed at understanding the viral pathogenesis of AIDS in relation to the prevention of perinatal (vertical) HIV-1 transmission; improving primary therapy of HIV-1 infection in children; improving treatment and prophylaxis of
12 Pneumonia
opportunistic infections; understanding immune recovery achieved when antiviral therapy is effective; and potential strategies for gene therapy. 2) To develop virologic and pharmacologic assays to better evaluate, predict and understand the course of HIV1 and related infections. 3) To continue to enroll subjects in PACTG protocols, to follow subjects according to protocol, with the production of high quality clinical and laboratory data, and in compliance with the high regulatory standard: imposed by the ACTG and DAIDS. This will include continued recruitment of pregnant women and children of color into protocols, and the maintenance of linkages with community-based organizations, the Community Advisory Board (CAB) of the UW's PACTU/AACTU, and the medical community of Washington, Wyoming, Alaska, Montana, Idaho (WAMI) and northern Oregon. This proposal describes the scientific contributions of UW PACTU investigators to the PACTG and the anticipated scientific contributions during the next four years. The infrastructure and organization of personnel is described, including plan develop a UW PACTU Subunit at Oregon Health Sciences University (OHSU). The structure and role of the CAB and the linkages with community based organizations are described. The PACTG site reports and regulatory evaluations of the UW PACTU which have generally been excellent are discussed. This proposal requests funds for the continuation of the successful UW PACTU. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: AIDS CLINICAL TRIALS GROUP - ACTU Principal Investigator & Institution: Feinberg, Judith T. Internal Medicine; University of Cincinnati 2624 Clifton Ave Cincinnati, OH 45221 Timing: Fiscal Year 2001; Project Start 30-SEP-1987; Project End 31-DEC-2004 Summary: (adapted from the applicantion's abstract): Since its inception in 1987, the University of Cincinnati (UC) ACTU has made contributions to the overall mission of the ACTG in a number of key areas. The UC ACTU has provided both scientific and administrative leadership especially in opportunistic infections, and more recently, in antiretroviral studies, HIV- associated neurologic diseases, research nursing, and study design. In the current cycle, the UC ACTU proposes to continue to perform a broad range of clinical trials and substudies to assure maximum UC ACTU contribution to the objectives of the ACTG research agenda. These include to translate the findings of basic research conducted at UC on immunopathogenesis of Pneumocystis carinii and other opportunistic pathogens that may help determine when and if prophylaxis can be discontinued safely in antiretroviral therapy responders. Also, to explore microbial and immunologic measures which define risk for the protection against Pneumocystis as a basis for adjunctive immune- based therapy and prophylaxis. In addition to study the pathogenesis and clinical significance of hepatitis C/HIV co-infection in the HARRT era, and use this knowledge to develop improved treatments. Another Aim is to continue to elucidate the underlying mechanisms in the neuropathogenesis of HIV infection, and exploit these mechanisms in the development of new therapeutic modalities for central nervous system HIV infection, including HIV dementia and multifocal leukoencephalopathy. The UC ACTU will also work to develop treatment strategies for the management of patients with discordant responses to current antiretroviral therapy and to develop simplified, potent treatment strategies, including the use of novel agents, to enhance antiretroviral adherence and therefore improve clinical outcome. The short and longer-term incremental cost of quality-adjusted life expectancy associated with various treatment strategies using utility assessment will also be studied. Finally, the UC ACTU proposes to evaluate whether an intensive educational intervention that is paced
Studies 13
by the patient yields improved short and long-term virologic suppression in naive patients. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: AIDS CLINICAL TRIALS UNIT Principal Investigator & Institution: Friedman, Harvey M. Professor; Medicine; University of Pennsylvania 3451 Walnut Street Philadelphia, PA 19104 Timing: Fiscal Year 2001; Project Start 01-APR-1992; Project End 31-DEC-2004 Summary: (adapted from the applicant's abstract): The University of Pennsylvania (Penn) ACTU consists of the main unit located at the Hospital of the University of Pennsylvania (HUP) and a subunit at the Veterans Administration Hospital (VAH) scheduled to open January 1999. This represents a change in the structure of the Penn ACTU since July 1998 when Thomas Jefferson University (TJU) was removed as a subunit. With this reorganization, funding has been redistributed enabling the addition of seven Penn scientists to the core group of investigators consisting of Drs. Friedman (Principal Investigator), MacGregor (Opportunistic Infections), Frank (antiretroviral therapy), Kolson (neuroAIDS/dementia), and Pomerantz (pathogenesis), the last serves as a consultant to our group. The new scientists include Drs. Gross (adherence to therapy), Holmes (quality of life), Rader (metabolic and lipoprotein abnormalities), Kimmel (risk factors for cardiac disease), Weissman (HIV immunology), Grossman (neuroimaging for AIDS dementia) and Jemmott (recruitment and retention of women and minorities). The HIV clinical program at Penn includes 750 patients cared for at HUP, 435 at the VAH, and 250 at Presbyterian Medical Center. Penn ID physicians are primary care providers for the HIV patients, which provides a link between the providers and the clinical research unit housed within the ID division. The demographics of the clinic population match those of the epidemic in Philadelphia; therefore, African Americans, women and IDU subjects (particularly with the addition of the VAH) have ready access to clinical trials. Approximately 60 percent of study patients come from the clinics while 40 percent are referred from physicians practicing throughout the Delaware Valley, enabling many patients to access HIV clinical trials. The investigators have credentials in basic and patient-oriented clinical research. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: AIDS OPPORTUNISTIC INFECTIONS DRUG DESIGN Principal Investigator & Institution: Borhani, David W.; Stanford University Stanford, CA 94305 Timing: Fiscal Year 2001 Summary: Pneumocystis carinii pneumonia (PCP) is the leading killer of patients with AIDS. Similarly, Toxomplasma gondii, a pervasive parasitic protozoan, causes significant morbidity and mortality among AIDS patients. Current treatment regimens for both P. carinii and T. gondii infections often produce severe side effects, leading to the cessation of therapy. It is widely recognized that new drugs having novel mechanisms of action are urgently needed for the treatment of PCP and toxoplasmosis. Building upon prior medicinal chemistry research, we have initiated two structurebased drug design programs to make improved inhibitors of T. gondii hypoxanthineguanine phosphoribosyltransferase (HGPRT), T. gondii dihydrofolate reductasethymidylate synthase (DHFR-TS) and P. carinii DHFR. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
14 Pneumonia
•
Project Title: ALCOHOL EFFECT ON SIV PRIMARY INFECTION AND OPPORTUNISTIC DISEASES Principal Investigator & Institution: Nelson, Steve; Louisiana State Univ Hsc New Orleans New Orleans, LA 70112 Timing: Fiscal Year 2001 Summary: Bacterial pneumonia substantially contributes to the morbidity and mortality among individuals abusing alcohol. The goal of this project is to elucidate the in vivo events that lead to impaired lung host defense against infection in acute and chronic alcohol-treated rats. We proposed that alcohol disrupts the normal evolution of proinflammatory cytokines elaborated by the alveolar macrophage (AM) during the course of an infectious challenge which leads to an acquired immunodeficient state. Our previous work has shown that alcohol suppresses AM expression of tumor necrosis factor-alpha (TNF), which is known to be a potent stimulus for the AM to produce granulocyte colony-stimulating factor (G- CSF). G-CSF is a cytokine that increases both the number and function of neutrophils (PMN). It is our hypothesis that alcohol-induced inhibition of AM-derived TNF directly contributes to the adverse effects of ethanol on PMN function and host defense by suppressing the normal autocrine amplification pathway responsible for macrophage G-CSF production. This proposal will test this hypothesis in a rat model and has 4 Specific Aims; 1) to characterize the effect of alcohol on cytokine responses to in vivo and ex vivo LPS challenge; 2) to delineate the mechanism(s) of alcohol-induced suppression of TNF and G-CSF; 3) to determine the role of endogenous G-CSF on the antibacterial defenses of the lung and PMN kinetic during an intrapulmonary infectious challenge; 4) to examine whether exogenously administered cytokines can reverse or attenuated the host defense deficits induced by alcohol. To accomplish these aims we will: a) examine the effect of alcohol dose on LPSinduced suppression of TNF and G-CSF both in vivo and ex vivo in isolated AM, the duration of this suppression, and whether depletion of TNF alters the in vivo and ex vivo LPS-induced G-CSF responses; b) determine if alcohol- induced increases in corticosterone contribute to the immunosuppressive effects of alcohol on lung host defense; c) examine the effects of an anti-G CSF antibody on pulmonary antibacterial defense and neutrophil function during an infectious challenge; d) determine if the administration of gamma-interferon and/or G-CSF attenuates the suppressive effects of alcohol on lung host defense. The identification of the basic mechanisms underlying alcohol-induced suppression of lung antibacterial defenses will increase our understanding of the host- cytokine network and may provide the foundation for innovative approaches in the treatment of these infections in susceptible patients. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: ALCOHOL MODULATION OF RECEPTOR SITES FOR HIV AND PRODUCTION OF CHEMOKINES Principal Investigator & Institution: Bautista, Abraham P. Scientist Review Administrator; Louisiana State Univ Hsc New Orleans New Orleans, LA 70112 Timing: Fiscal Year 2001 Summary: This proposal is based on the overall hypothesis that alcohol modulates the hepatic immune system at the plasma membrane and molecular levels by altering cell surface receptor expression (binding sites for HIV-1) and production of soluble mediators (chemokines) in hepatic non-parenchymal cells [NPC], i.e., Kupffer cells and sinusoidal endothelial cells. Specifically, acute or chronic alcohol regulates the expression of CD4, chemokine receptors and mannose-specific receptors on hepatic NPC
Studies 15
as a result of ethanol-induced alteration in plasma membranes on hepatic NPC. This event could also lead to enhanced intracellular production of H2O2 which in turn activates NF-kappaB. The nuclear translocation and activation of NF-kappaB, a transcription factor, enhances the expression of m-RNA and synthesis of alpha and betachemokines. These chemokines could potentially block the binding of HIV-1 or exacerbate its replication in CD4 lymphocytes. The HIV-1 gp120-induced production of beta-chemokines by hepatic NPC may also be modulated by alcohol. The liver is the major organ for microbial clearance and ethanol metabolism. Thus, hepatic cells become susceptible to these agents that could have an impact on the liver itself as well as on the overall homeostasis of the host. For example increased production of pro-inflammatory mediators by hepatic NPC which are the largest contributors of these agents, may also regulate functions of immunocompetent cells in other organs. Thus, based on these considerations, the following specific aims are proposed. Specific aim 1: To determine the effect of acute or chronic alcohol intoxication of hiv-1 GP120 binding, expression of mannose-specific receptors and CD4 on hepatic NPC. The internalization and degradation of HIV-1 gp120 by hepatic NPC will be examined. Specific aim 2: To determine the effect of acute or chronic alcohol intoxication on the intracellular production of H2O2, activation of NF-kappaB, m-RNA expression and secretion of alpha (CINC or IL-8) and beta (Rantes, MIP-1 alpha, MIP-1beta, MCP-1) chemokines in hepatic NPC. The biological activity of HIV-1 gp120 on beta-chemokine production will be assessed, as well as the role of endogenous and exogenous endotoxin on the above parameters (specific aims 1&2). The latter objective will test the hypothesis that chronic alcohol-mediated influx of LPS from the gut to the circulation is responsible, at least in part, for the regulation of hepatic NPC functions at the plasma membrane and molecular levels. Specific aim 3: To determine the effect of chronic alcohol intoxication on hepatic NPC functions, i.e., superoxide anion production, phagocytosis, chemokine and cytokine production, chemokine receptor (CXCR4 & CCR5) expression and SIV gp120 binding. This study will also examine chemokine-mediated SIV-1 replication in a simian model of SIV-1/AIDS. The overall regulation of the above processes by alcohol may further comprise susceptible individuals to HIV-1 infections and opportunistic pathogens associated with this viral infection. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: ALCOHOL, GLUTATHIONE, AND ALVEOLAR MACROPHAGE FUNCTION Principal Investigator & Institution: Burnham, Ellen L. Internal Medicine; Emory University 1784 North Decatur Road Atlanta, GA 30322 Timing: Fiscal Year 2003; Project Start 01-APR-2003; Project End 31-MAR-2008 Summary: (provided by applicant): Each year in the United States, there are an estimated 4 million cases of pneumonia, accounting for 600,000 hospitalizations with an annual cost of $23 billion. Alcohol is a common risk factor for the development of both community-acquired and nosocomial pneumonia. Presently, the mechanisms by which chronic alcohol abuse alters human pulmonary immunity and increases the likelihood of developing pneumonia are essentially unknown. We hypothesize that increased oxidative stress via glutathione (GSH) depletion leads to abnormal function and viability of human alveolar macrophages (AM), and subsequently impairs alveolar clearance of infectious particles leading to pulmonary infections. In this proposal, the impact of alcohol abuse on the development of pneumonia will be explored by examining the function and viability of AM obtained from two patient cohorts: individuals with a prior history of chronic alcohol abuse and critically ill patients with
16 Pneumonia
acute lung injury. Additionally, we will determine the efficacy of oral antioxidant replacement therapy on AM function in individuals with a prior history of chronic alcohol abuse. The goal of this research endeavor is effective medical therapy to decrease the risk of community-acquired and nosocomial pneumonia in the millions of individuals who chronically abuse alcohol. Dr. Ellen Burnham is presently a fellow in Pulmonary and Critical Care Medicine at Emory University. During the next five years, she will work with several investigators in the Emory Alcohol and Critical Care Clinical Research Program in order to develop necessary clinical and basic research skills. With the support of this proposal, Dr. Burnham will not only receive personal supervision from these established clinical and basic investigators, but will also enroll in the Clinical Research Curriculum Award (CRCA) program at Emory University and the Rollins School of Public Health, and obtain a Masters of Science in Clinical Research to further enhance her ability to perform high-quality research. The ultimate goal of this award is to develop an independent research career in "translational" investigation for Dr. Burnham, examining the systemic effects of alcohol abuse as it relates to pulmonary and critical care medicine. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: ALCOHOLISM: MODULATION & FUNCTION OF LEOCOCYTE SUBSETS Principal Investigator & Institution: Cook, Robert T. Professor; Pathology; University of Iowa Iowa City, IA 52242 Timing: Fiscal Year 2001; Project Start 01-JUL-1994; Project End 31-AUG-2006 Summary: (provided by applicant): Chronic alcohol abuse causes immune deficiency and an increase in manifestations of autoimmunity. Significant increases in pneumonia and other infectious diseases in alcoholics result in major morbidity and medical expense compared with non-abusing populations. Our work is part of a long-term strategy to define the alterations leading to the loss of normal immunologic function in the alcoholic. Others and we have shown previously that chronic alcoholics have activated T cells, activated monocytes, and selective lymphocyte subset loss. In experimental rodent models of alcohol administration, changes in splenic lymphocyte populations and function have been found, and a reduction in Th1 cytokine production such as IFN monocyte has been demonstrated in mice after short-term alcohol diets. In contrast, we have recently placed mice on longer-term alcohol, and agree that initial suppression of IFN monocyte does occur, but after 6 weeks, increasing activation is seen which is similar to the activation demonstrated in human alcoholics. Activation parameters in the chronic alcoholic mice include 1) increased CD4+ responsiveness to stimulation through the T cell receptor (TCR), with increased upregulation of CD40 ligand and other activation markers; 2) increased rapid production of IFN monocyte by both CD4+ and CD8+ T cells; 3) increased monocyte numbers, and up-regulation of the molecules involved in second signal transmission to T cells, CD80 and CD86. These findings in mice suggest that the innate immune system (especially monocytes) is first activated by chronic alcohol abuse, followed by activation of T cells by the activated monocytes. We will test this and other mechanisms of T cell activation and loss in several ways. We will: 1) evaluate the stimulatory effect of the monocytes of chronic alcoholic mice on the activation of their T cells; 2) determine whether there is a second signal requirement acting through CD28 for T cell activation in the alcoholic mice; 3) mimic bacterial translocation by exposure to defined substitutes for bacterial DNA, and determine whether this products alterations of the T cell balance (antigen-specific T cell loss, and Th1/Th2 skewing) in the alcoholic mice; and 4) continue the work in human
Studies 17
alcoholics by evaluation in restimulation assays, of Th1/Th2 skewing, and the effects of their activated monocytes on T cell proliferative activity after stimulation through the TCR. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: ALVEOLAR FACTORS IN UPTAKE OF LUNG SURFACTANT Principal Investigator & Institution: Wright, Jo Rae; Professor; Cell Biology; Duke University Durham, NC 27706 Timing: Fiscal Year 2003; Project Start 01-JUL-1994; Project End 30-JUN-2007 Summary: (provided by applicant): Pulmonary surfactant plays important roles in reducing surface tension at the air-liquid interface of the lung and in regulating lung host defense. In order to carry out these roles, a functional pool of adequate surfactant must be maintained by balancing the rates of secretion and clearance. Studies from our and other laboratories have shown that clearance in the normal lung occurs via reuptake and recycling by type II cells, and via degradation by both type II cells and macrophages. Recently we have focused on understanding the factors that affect surfactant metabolism in the injured or inflamed lung and have discerned that inflammatory cells and bacterial products contribute significantly to surfactant degradation. Our recent preliminary data show that Pseudomonas aeruginosa, an important pulmonary pathogen, degrades SP-A and SP-D and we have identified enzymes, including Pseudomonas elastase, that contribute to this process. In addition, our preliminary data suggest that neutrophils and activated macrophages contribute substantially to surfactant degradation. The hypothesis to be tested in this competitive renewal is that infection and inflammation result in release of degradative enzymes from bacteria and from newly recruited inflammatory cells that result in enhanced degradation and decreases in surfactant pool size. The decrease in the pool of functional surfactant leads to altered lung homeostasis, including decreased lung compliance and increased susceptibility to infection and inflammation. Five specific aims are proposed to test this hypothesis. Specific Aim 1 is to determine if bacterial enzymes degrade surfactant lipids and proteins in vitro. Specific Aim 2 is to determine the role of a newly described P. aeruginosa enzyme, Protease IV, in degrading surfactant. Specific Aim 3 is to investigate the functional consequences of degradation of surfactant by bacterial enzymes in vitro. Specific Aim 4 is to determine if surfactant is degraded in vivo. Specific Aim 5 is to investigate the role of activated macrophages and neutrophils in the degradation of surfactant. Results from these studies will help determine if these mechanisms contribute to the alterations in surfactant pool size that are observed patients with acute lung injury. We propose that degradation of surfactant by bacterial enzymes and cells recruited in response to bacterial infection represent a novel mechanism of pathogen adaptation and manipulation of the host response which would contribute to alterations in surfactant pool size and resulting lung injury. Significance: An understanding of the factors that regulate surfactant metabolism in lung injury and infection should contribute to development of therapies targeted at inhibiting surfactant degradation for treatment of surfactant deficiency of diseases such as ARDS and bacterial pneumonia. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: ALVEOLAR HOST DEFENSE TO PNEUMOCYTIS CARINII Principal Investigator & Institution: Martin, William J. Dean; Medicine; Indiana UnivPurdue Univ at Indianapolis 620 Union Drive, Room 618 Indianapolis, IN 462025167
18 Pneumonia
Timing: Fiscal Year 2001; Project Start 01-APR-2001; Project End 31-MAR-2006 Summary: (provided by the applicant): Pneumocystis carinii is the prototypical opportunistic pathogen in the lung. P. carinii pneumonia only occurs with profound immunosuppression that is often characterized by functional or absolute deficiencies in T and B lymphocytes. Alveolar macrophages (AMs) are the resident immunoregulatory cells of the alveolar spaces and are responsible for clearance of P. carinii organisms from the lung. The same factors that induce immunosuppression such as infections (HIV) or drugs (cytotoxic therapy or corticosteroids) directly and indirectly impair AM function and their ability to clear opportunistic infection such as P. carinii. Important immunomodulators that activate AM function include cytokines e.g. interferon-gamma (IFN-g) or tumor necrosis actor-a (TNF-a) are often deficient during immunodeficiency. Multiple studies have demonstrated the importance of T and B lymphocytes in the host response to P. carinii, often by reconstituting these cells into immunodeficient animals and restoring host defense. The critical role of the AM in the response is often assumed or ignored. We have developed new experimental approaches to assess the critical role of the AMs in vivo in alveolar host defense. This proposal will test the following hypothesis: Host susceptibility to infections such as P. carinii is due in part to deficiencies in AM function and factors that regulate AM function; conversely, correction of these defects will restore normal alveolar host response and control infection. The Specific Aims will include: I.To demonstrate that reconstitution of normal or activated AMs will restore local alveolar host defense in recipient SCID or immunodeficient mice; 2. To determine if reconstituted AM significantly enhance attachment/phagocytosis/killing of P. carinii and control of alveolar infection/pneumonia; 3. To determine the role of proinflammatory cytokines on the ability of reconstituted AMs to attach/phagocytose/kill P. carinii and to control alveolar infection/pneumonia; 4. To determine if ex vivo gene therapy to AMs corrects immune deficiencies in alveolar host defense and controls P. carinii alveolar infection/pneumonia. If successful, these studies may suggest it is possible to restore local alveolar host defense in an immunodeficient host despite ongoing systemic immunosuppression. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: ANALYSIS OF ASSOCIATION BETWEEN C. PNEUMONIAE AND MS Principal Investigator & Institution: Sriram, Subramaniam; Professor; Neurology; Vanderbilt University 3319 West End Ave. Nashville, TN 372036917 Timing: Fiscal Year 2001; Project Start 01-APR-2000; Project End 31-MAR-2003 Summary: Multiple sclerosis (MS) is an inflammatory, demyelinating disease of the central nervous system (CNS). Although the etiology of MS is not known, there is considerable indirect evidence to suggest the role of infectious agents in the development of the disease. While a viral agent is still strongly considered, efforts to defect a virus in patients with MS have failed. We present preliminary data which argue that Chlamydiae Pneumoniae may be a candidate pathogen in MS. This inference is based on: a) the presence of PCR products to major outer membrane protein (MOMP) gene of C. pneumoniae in the cerebrospinal fluid (CSF) of patients with secondary progressive MS but not in other neurologic disease controls (OND); b) the presence of antibody to C. pneumonia antigens in the CSF of MS patients; and c) the presence of chlamydial antigens in brain autopsy specimens of patients who have died of MS. C. pneumoniae belongs to a genus of intracellular pathogens that are infectious to humans and other vertebrates. C. pneumoniae are implicated in many chronic diseases,
Studies 19
including those presumed to be autoimmune. Chlamydiae cause chronic persistent inflammation in humans and other vertebrate animals and tissue injury in all cases appears to be immune mediated. Immune activation by C. pneumoniae includes induction of T cell response to heat shock proteins and production of pro-inflammatory cytokines. Our proposal sets out to meet the necessary criteria required to attribute a causal association between C. pneumoniae and MS. These would include the ability to detect the organism either directly by culture or by demonstrating the presence of C. pneumoniae DNA and mRNA and evidence of intracytoplasmic or organisms as proven by electron microscopy in the CNS tissue of patients with MS. Also, the presence of an immune response to C. pneumoniae that is contained within the CNS compartment will constitute strong circumstantial evidence of microbial infection. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: ANTI TUBERCULOSIS CANDIDATE VACCINE TESTING IN RHESUS MONKEYS Principal Investigator & Institution: Gormus, Bobby J.; Tulane University of Louisiana New Orleans, LA 70118 Timing: Fiscal Year 2001 Summary: Eight normal RM were inoculated with MTB via fiberoptic bronchoscope. Four received the less virulent H37Rv strain and four received the highly virulent Erdman strain via fiberoptic bronchoscope. Both monkeys that received the high dosage of H37Rv (6 X 106 cfu) developed extensive multifocal expansile and coalescing granulomas with broad central zones of necrosis, neutrophilic infiltration, and mineralization in the inoculated right lobe of the lung by 5 and 11 weeks (wk) postchallenge. Monkeys receiving the low dose of H37Rv (30 cfu) had granulomatous lesions in the bronchial lymph nodes 18 wk after infection. Lesions suggest that low doses of M. tuberculosis H37Rv are controlled, at least in the short term, by natural defenses in the simian lung and that challenge with higher doses of bacteria produces significant tissue response without evidence of septicemic spread. Two high dose (150 cfu) Erdman recipient monkeys developed extensive granulomatous pneumonia, pleuritis, and bronchial node necrosis with microgranulomas in the liver, kidney, and other sites in 7-9 weeks. The appearance of pneumonia and time course were roughly comparable to disease produced by high dose (>106) H37Rv. The 2 low dose Erdmaninoculated monkeys (15 cfu) remained clinically normal 9 weeks post-challenge and at 19 wk had minimal clinical manifestations, but fibrotic granulomatous pulmonary lesions with spread to other tissues. We conclude that chronic disease can be established by low dose Erdman inoculation with a wider distribution of lesions being produced compared to the H37Rv strain. FUNDING Base Grant, Venture Research PUBLICATIONS Didier PJ, Blanchard JL and Gormus BJ. Pulmonary Tuberculosis in Normal Rhesus Monkeys Produced by M. tuberculosis H37Rv. Am J Soc Trop Med Hyg 57:156, 1997 [Abstract]. Didier PJ, Blanchard JL and Gormus BJ. Chronic Tuberculosis Produced by Low Dosage of M. tuberculosis (Erdman) in Rhesus Monkeys. Am J Soc Trop Med Hyg 59:361, 1998. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: ANTIBODY EPITOPES OF PNEUMOCYSTIS IN HIV PATIENTS Principal Investigator & Institution: Daly, Kieran R. Internal Medicine; University of Cincinnati 2624 Clifton Ave Cincinnati, OH 45221 Timing: Fiscal Year 2003; Project Start 01-AUG-2003; Project End 31-JUL-2005
20 Pneumonia
Summary: (provided by applicant): Pneumocystis (Pc), a fungal opportunistic pathogen of humans, is the causative agent of Pneumocystis pneumonia (PcP), a leading cause of serious illness in immunocompromised people. As an alternative approach to treatment of PcP in HIV+ patients, which typically involves the long-term use of anti-Pc drugs, offers no protection from subsequent infections with Pc, and may lead to the acquisition of drug resistance by the microorganism, we propose to study antibody reactivity to Pc epitopes in HIV+ patients that did or did not have a previous bout of PcP. The Iong term goal is to identify epitopes for following Pc-specific immune reconstitution in HIV+ patients undergoing HAART. The overall goal of this proposal is to compare serum antibody recognition of the major surface glycoprotein (Msg) of Pc in patients that did or did not have a bout of PcP. Msg is a highly variable protein expressed on the surface of Pc which is recognized by the immune system, and may be involved in antigen switching and immune evasion. We will concentrate on the carboxy terminus of Msg (MsgC) which has previously been shown to differentiate between PcP+ and PcPpatients. The specific aims of this proposal are to define the spectrum of MsgC fragments that are recognized by human serum in health and PcP disease, and to identify individual antigenic epitopes found on disease relevant Msgs. We will determine if these epitopes are unique or cross-reactive with other variants of Msg, and will define the hierarchy of epitopes seen by individual patients. We will also study the frequency of immune recognition of the individual epitopes in different patient populations. We propose to identify the spectrum of MsgC fragments recognized by human serum by generating a phage display library expressing a diversity of MsgC fragments, and will use positive and negative phage selection to identify disease relevant MsgC fragments. These fragments will be studied for individual epitopes using a single chain variable region (scFv) antibody phage library. This library will be a set of monoclonal probes of human origin useful for identifying individual epitopes of MsgC. These newly identified epitopes will, in the long term, be used to probe immune reactivity in HIV+ patients undergoing HAART. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: APOPTOTIC T CELL CLEARANCE FROM MURINE LUNGS Principal Investigator & Institution: Curtis, Jeffrey L. Professor of Internal Medicine; Internal Medicine; University of Michigan at Ann Arbor 3003 South State, Room 1040 Ann Arbor, MI 481091274 Timing: Fiscal Year 2001; Project Start 01-MAY-1996; Project End 30-APR-2005 Summary: (Applicant's Abstract): Apoptotic T cells must be cleared efficiently by macrophages to prevent tissue damage, but ingestion of apoptotic cells causes macrophages to downregulate their own production of proinflammatory cytokines such as TNF and IL-8 and of chemokines. Hence, while ingesting apoptotic T cells during resolving pneumonia is beneficial, the same process could be immunosuppressive if pulmonary alveolar macrophages ingest dying T cells before or during encounters with pathogens. Indeed, studies funded by this project made the novel observation that many apoptotic lymphocytes are found in the lungs of mice. Thus, the lungs, a mucosal surface frequently exposed to pathogens, present a unique challenge in regulating macrophage clearance of apoptotic T cells while maintaining host defense. It is likely that this challenge is relevant both to the normal state, in which single alveolar macrophages encounter isolated apoptotic T cells, and when larger numbers of T cells die (e.g., following acute viral pneumonias and in chronic HIV infection). New preliminary data from this project suggest that ingestion of apoptotic T cells by lung macrophages is regulated, as an evolutionary adaptation, to minimize the
Studies 21
immunosuppressive effect that could otherwise result at this site of frequent pathogen exposure. The goal of this project is to define the molecular basis and significance of regulated phagocytosis of apoptotic T cells in the lungs. It will test the following hypotheses: that downregulated phagocytosis of apoptotic T cells by resident murine alveolar macrophages results both from altered adhesion of apoptotic T cells and from altered signal transduction relative to control peritoneal macrophages; that effective clearance of apoptotic T cells during resolving lung inflammation depends on acquisition of an ingesting phenotype, probably mostly by differentiation of recruited monocytes by inflammatory cytokines; and that ingestion of apoptotic T cells carries a risk of impaired lung host defense against bacterial and fungal pathogens. Both primary resident alveolar and peritoneal macrophages from normal mice, and two immortalized murine macrophage cell lines (MH-S and J774A.1) will be used. Techniques will include static adhesion and phagocytosis assays, specific enzyme inhibitors, immunoprecipitation, Western blotting, flow cytometry, and use of in vivo murine models of fungal (Cryptococcus neoformans) and bacterial (Staphylococcus aureus) pneumonia. It is anticipated that the results will provide important new information about immunoregulation that will be relevant to viral, bacterial, and fungal infections in normal and immunocompromised hosts, development of autoimmunity and lung fibrosis. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: APPROPRIATE PNEUMOCOCCAL VACCINATION IN INFANTS IN FIJI Principal Investigator & Institution: Mulholland, Edward K.; University of Melbourne Parkville 3052, Australia Parkville, Timing: Fiscal Year 2002; Project Start 30-SEP-2002; Project End 31-AUG-2005 Summary: (provided by applicant): Streptococcus pneumoniae (Pnc) is the leading vaccine preventable cause of serious infection in infants. The current Pnc conjugate vaccines are safe, immunogenic, and effective. However, the vaccine is very expensive (approximately USD $200/infant) so it is unlikely to be affordable for most developing countries. Moreover, as health care access in developing countries may be episodic and unreliable, many children do not receive either complete or timely vaccine courses. Therefore, it is important to investigate affordable and flexible ways to deliver this vaccine, which are safe and effective. A recent World Health Organization (WHO) / Global Alliance for Vaccines and Immunization (GAVI) meeting to address impediments to the introduction of these vaccines in developing countries recognized the need to evaluate other regimens of Pnc conjugate vaccine as an important research priority. This study has been deliberately formulated with that need in mind. The proposed site for this research is Fiji. Although health services are good, Pnc disease, particularly pneumonia, remains the commonest cause of childhood morbidity and mortality. Fiji has good vaccine coverage and was the first Pacific country to introduce Hib vaccine. The arrival of the new, expensive Pnc conjugate vaccine presents a dilemma for Fiji and many similar countries. The expense of this vaccine if used in the recommended 3 or 4-dose schedule would consume a large portion of the health budget. This study has two components, aimed at addressing these two issues:1. A phase 2 immunogenicity study (involving 750 infants) to evaluate regimens using reduced numbers of doses of Pnc conjugate vaccine, and using timing of dosing and combinations with polysaccharide (PS) vaccine that may be more suited to the epidemiology of Pnc disease in developing countries.2. An epidemiological study will measure the burden of invasive Pnc disease, pneumonia, and otitis media (OM) in Fiji.
22 Pneumonia
This will be part of a global effort to address these issues, and will be used to develop rapid assessment tools for these diseases in developing countries. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: AZITHROMYCIN AND CORONARY ARTERY DISEASE Principal Investigator & Institution: Grayston, J T. Professor of Epidemiology; Epidemiology; University of Washington Seattle, WA 98195 Timing: Fiscal Year 2001; Project Start 04-SEP-1998; Project End 31-JAN-2004 Summary: There is increasing evidence supporting a possible role for C. pneumonia in the pathogenesis of coronary atherosclerosis and its complications. This evidence stems from the results of seroepidemiologic studies, indicating an association between C. pneumonia seropositivity and coronary heart disease (CHD) and from microbiologic studies, indicating that C. pneumonia may be detected in a large proportion of atherosclerotic plaque specimens. The preliminary results of two human treatment trials, which have been recently published, suggest that treatment with antibiotics activate against C. pneumonia may be effective in secondary prevention of cardiovascular events. The strength of the evidence currently available in support of a role for C. pneumonia in the pathogenesis of atherosclerosis, and the magnitude of the potential public health importance of this finding, support further research involving clinical treatment trials of patients with atherosclerotic cardiovascular disease. The proposed study is a randomized, double-blind trial of azithromycin vs. placebo among adults with documented prevalence coronary artery disease. Patients will be treated for one year and followed for a mean of 3.75 years (range 3.0 to 4.5 years) for the composite primary study outcome of CHD death, non- fatal myocardial infarction, hospitalization for unstable angina, and requirement for revascularization procedures. Completed follow-up of 3500 subjects will provide 95 percent power to detect a 25 percent decrease, and 80 percent power to detect a 20 percent decrease, in the rate of the primary outcome in the treatment group, assuming a 6.5 percent per year event rate in the placebo group. Serologic testing for C. pneumonia will be performed on all subjects at enrollment and at intervals during the follow-up period for a random 25 percent of subjects. The results of this study will provide important information on the potential role of antibiotic therapy for the secondary prevention of complication of coronary artery disease. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: AZITHROMYCIN AND CORONARY EVENTS Principal Investigator & Institution: Cohn, Peter; State University New York Stony Brook Stony Brook, NY 11794 Timing: Fiscal Year 2001 Summary: This study is to determine whether the antibotic, azithromycin, decreases the risk of having a heart attack or other complication related to coronary artery disease in people with heart disease. Azithromycin is an antibiotic that is used to treat infections with a bacteria called Chlamydia pneumoniae. Some studies suggest that Chlamydia pneumoniae infection may be a risk factor for heart attacks and other complications related to coronary artery disease. Chlamydia pneumoniae is spread from person-toperson by sneezing and coughing (unlike a related bacteria, Chlamydia trachomatis, it is not a sexually transmitted disease). Studies show that people who have been infected with Chlamydia pneumoniae in the past have a higher chance of having a heart attack. Other studies show that Chlamydia pnreumoniae is present in the plaque, or material blocking the heart vessel, in many people with heart disease.
Studies 23
Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: RESPONSE
BACTERIAL
MODULATION
OF
LUNG
INFLAMMATORY
Principal Investigator & Institution: Russo, Thomas A. Associate Professor; Medicine; State University of New York at Buffalo 402 Crofts Hall Buffalo, NY 14260 Timing: Fiscal Year 2001; Project Start 01-JUL-2001; Project End 31-MAY-2005 Summary: (Unedited Applicant's Abstract): Gram-negative bacilli (GNB) are pathogens that are capable of causing severe, life-threatening pneumonia. More than 60 percent of nosocomial pneumonias are caused by GNB and associated mortality rates are often >50 percent. Over the last 10-15 years, there has been little improvement in outcome from this infection. As a result, this syndrome continues to cause significant morbidity and mortality and strongly contributes to the economic burden of our national health care system. The successful use of immune intervention in the treatment or modulation of infections has marked the beginning of a new era in the management of infectious diseases. There exists a delicate balance between an efficacious and injurious host defense response. An understanding of the host response in GNB pneumonia and how bacterial components affect this response will, in turn, lead to the development of rapid diagnostic tests that will enable the clinician to effectively utilize a variety of biologic modulators. It is also necessary to understand the relative role of bacterial components versus host factors in mediating damage to the lungs prior to therapeutic manipulations on which little is known. This information will enable us to appreciate the relative risk benefit ratio of altering the host response. Further, a more precise clarification of which host components are damaged is also needed. This knowledge may identify independent therapeutic interventions. Their global hypothesis is that surface components of GNB and/or secreted proteins differentially alter host antibacterial defenses and directly, and/or indirectly (by inflammatory mechanisms) promote lung injury. Preliminary data supports this hypothesis. These responses will have significant implications when attempting therapeutic immune interventions. The goals of this proposal are to determine the mechanisms by which the bacterial capsule and 0-specific antigen modulate neutrophil recruitment into the lungs in a diametrical manner and extend our evaluations on the relative roles of bacterial factors (e.g. hemolysin) and bacterially induced host response elements in directly mediating the pathogenesis of lung injury. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: BACTERIAL PHOSPHORYLCHOLINE AND PATHOGENESIS Principal Investigator & Institution: Weiser, Jeffrey N. Associate Professor; Microbiology; University of Pennsylvania 3451 Walnut Street Philadelphia, PA 19104 Timing: Fiscal Year 2001; Project Start 01-AUG-1999; Project End 31-JUL-2004 Summary: Description (Adapted from Applicant's Abstract): The bacterial cell surface is generally considered to be highly divergent from species to species. An exception to this rule is the expression of phosphorylcholine (ChoP). This unusual prokaryotic structure is now known to be exposed on the surface of the most common pathogens infecting the human respiratory tract; Haemophilus influenzae, mycoplasma, and Streptococcus pneumoniae. In addition, based on cross-reactivity to a MAb recognizing this structure, ChoP may be present on diverse phase-variable structures on N. meningitidis, N. gonorrhoeae, P. aeruginosa, and A. actinomycetemcomitans. We have defined the genetic basis of ChoP expression and the molecular mechanism
24 Pneumonia
controlling its phase variation in H. influenzae. This has allowed direct genetic analysis of clinical samples to show that the ChoP+ phase variants predominate on the mucosal surface of humans. The structure, however, is the target of innate immunity mediated by binding of C-reactive protein (CRP), which is bactericidal in the presence of complement. The focus of this proposal is to define the biological role of variants both with and without ChoP using H. influenzae as a prototype human respiratory tract pathogen. In Aim 1, we will determine whether switching to the ChoP- phenotype is required in natural H. influenzae infection (otitis media, pneumonia, bacteremia, and meningitis) to evade clearance by CRP and bactericidal anti-ChoP IgG. The ChoP phenotype in vivo will be determined by direct genetic analysis and compared to the local concentration of CRP and anti-ChoP antibody during infection. The local expression and concentration of CRP in the upper respiratory tract will be investigated. In Aim 2, we will determine how ChoP contributes to persistence on the mucosal surface. Genetically defined H. influenzae mutants with constitutive ChoP-on and ChoP-off phenotypes will be used to determine whether this host membrane-like structure contributes to (a) resistance to respiratory tract antibacterial peptides including LL-37 and tracheal antimicrobial peptide (TAP), and (b) colonization by functioning as a bacterial adhesin to host epithelial cells via putative ChoP ligands including GalNAcb 14Gal on the asialo-GM1 glycolipid and the platelet activating factor receptor. The blocking of complement mediated killing by naturally acquired secretory IgA recognizing ChoP will be explored as an explanation for the selection of the ChoP+ phenotype on the mucosal surface, despite the increased susceptibility of this phenotype to CRP and complement. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: PNEUMONIA
BACTERIAL
PREDICTORS
OF
SEVERE
NOSOCOMIAL
Principal Investigator & Institution: Hauser, Alan R. Microbiology and Immunology; Northwestern University Office of Sponsored Programs Chicago, IL 60611 Timing: Fiscal Year 2003; Project Start 01-JUL-2003; Project End 31-DEC-2007 Summary: (provided by applicant): The long-term objective of the proposed study is to better understand the pathogenesis of hospital-acquired pneumonia caused by Pseudomonas aeruginosa. The general strategy is to characterize the role of the P. aeruginosa type III secretion system in hospital-acquired pneumonia. This complex secretion pathway transports and injects four known effector proteins into host cells: ExoS, ExoT, ExoU (also known as PepA), and ExoY. Interestingly, clinical isolates differ in the combination of effector proteins they secrete. Recent studies are beginning to define the role of individual effector proteins in pathogenesis. Preliminary studies using bacterial mutants indicate that ExoS, ExoT, ExoU, and ExoY all have cytotoxic effects on mammalian cells in cell culture systems. ExoT, ExoU, and possibly ExoS contribute to virulence in animal models of pneumonia. In addition, ExoU secretion is associated with worse clinical outcomes in humans with hospital-acquired pneumonia. Together, these findings support an important role for type III effector proteins in the acute pneumonia, although the exact role of each effector protein and the mechanisms by which these proteins lead to the pathophysiological consequences of pneumonia remain to be defined and are the subject of this proposal. Our preliminary data suggest that type III secretion contributes to bacterial persistence, dissemination, and mortality as well as neutrophil killing and suppression of proinflammatory cytokine release in a mouse model of pneumonia. Further defining the role of individual effector proteins in these processes is crucial to our understanding of the pathogenesis of hospital-acquired
Studies 25
pneumonia caused by P. aeruginosa. It is hypothesized that specific effector proteins play an important role in the pathogenesis of hospital-acquired pneumonia, including the prevention of bacterial clearance by neutrophils. Furthermore, it is hypothesized that because of these effects secretion of specific effector proteins can be used as markers for strains associated with especially severe hospital-acquired pneumonia in human patients. Studies using both mice and humans will be performed to define the roles of these effector proteins in the pathogenesis of acute pneumonia, including modulation of the inflammatory response and resistance to neutrophil-mediated clearance, and to determine whether secretion of particular effector proteins serves as a marker for strains capable of causing especially severe disease in human patients with hospital-acquired pneumonia. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: BBA EFFECTS ON GEOGRAPHIC VARIATION IN POST-ACUTE CARE Principal Investigator & Institution: Lin, Wen-Chieh; Family and Community Medicine; University of Missouri Columbia 310 Jesse Hall Columbia, MO 65211 Timing: Fiscal Year 2003; Project Start 01-SEP-2003; Project End 31-AUG-2004 Summary: (Provided by Applicant): In response to the rapid growth in payments for post-acute care (PAC) services, Congress enacted Medicare reforms as part of the Balanced Budget Act of 1997 (BBA) for each PAC service. The reforms mandated a series of separate case-mix adjusted prospective payment systems, each with its own implementation timeline. In addition to the overall effects, the BBA's effects on PAC use varied substantially across geographic areas. For example, in the case of skilled nursing facility use from 1998 to 2000, the average change relative to 1996 for stroke patients was 2.7%.at the national level, but it ranged from -12% to 24% across regions (the nine United States Census Bureau divisions). This varied response raises concerns that the hospital discharge process may be driven by payment policy rather than by clinical needs and individual preferences. Furthermore, varied changes in PAC use across regions might lead to untoward consequences, such as early hospital readmission. As efforts continue to reform PAC services and payment systems, it is essential that policymakers understand how different payment mechanisms associate with geographic variation in PAC use. The proposed study seeks to: 1) analyze geographic variation in PAC use before and after the BBA changes; 2) explore whether utilization and cost have shifted among PAC settings and whether early hospital readmission has increased; and 3) investigate how the contributions of patient, hospital, and market area characteristics in explaining PAC use differ between pre- and post-BBA periods. We will analyze the Center for Medicare & Medicaid Services' 5% sample of Medicare claims data from 1996 to 2000 to study the initial effect of the BBA changes on geographic variation in PAC use. We will focus on six diseases associated with high PAC use: stroke, hip procedure, hip fracture, chronic obstructive pulmonary disease, pneumonia, and congestive heart failure. The selected diseases provide a contrast between rehabilitative and medical conditions. The stability, the degree, and the association of geographic variation in PAC use before and after the BBA changes will be examined. Shifts in utilization and costs will be presented as correlations between changes in PAC use, hospital length of stay, and early hospital readmission. Finally, we will estimate multinomial logit models to explore changes in contribution to explain PAC use by patient, hospital, and market area characteristics after the BBA changes. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
26 Pneumonia
•
Project Title: BIOLOGY OF PCRV Principal Investigator & Institution: Wiener-Kronish, Jeanine P. Professor; Anesthesia and Perioperative Care; University of California San Francisco 500 Parnassus Ave San Francisco, CA 94122 Timing: Fiscal Year 2001; Project Start 01-MAY-2000; Project End 30-APR-2005 Summary: Nosocomial pneumonia is the second most common nosocomial infection and the leading cause of death from infection acquired in the hospital. P. aeruginosa is the most frequent gram negative bacteria involved in nosocomial pneumonia, and nosocomial pneumonias associated with P. aeruginosa infections have up to a 60% mortality despite appropriate antibiotic treatment. Also patients who are chronically infected with P. aeruginosa (i.e.: cystic fibrosis, HIV patients and bronchiectasis patients) become resistant to antibiotics and may die from their4 infections. Thus, there is an urgent need for novel treatments of P. aeruginosa infections. The long-term objectives of this grant are to determine the cell biology of a Pseudomonal protein, PcrV. PcrV is part of the bacterial type III secretory system; PcrV is involved in the translocation of bacterial toxins by P.aeruginosa into eukaryotic cells. It is also highly homologous to LcrV, a Yersinia protein also involved in the translocation. of that bacteria's toxins into eukaryotic cells. Antibodies to LcrV can protect animals from infections caused by Y. pestis and other Yersinia strains. Yet, although there are similarities between LcrV and PcrV, there are also important differences in the roles of LcrV compared to PcrV in the regulation of toxin secretion in the two strains. Therefore, PcrV warrants independent investigation. This group has shown that PcrV is accessible to antibody neutralization, that antibody attachment to PcrV blocks the translocation of the Pseudomonal toxins into eukaryotic cells and that antibody to PcrV protects animals infected with virulent P. aeruginosa from lung injury, sepsis and death. Therefore, therapies targeting PcrV appears clinically useful. Finally, many virulent gram negative bacteria utilize the type III secretory system which delivers bacterial toxins into eukaryotic cells. These gram negative bacteria, including enteropathic E. coli, Yersinia, Salmonella, produce bacterial proteins and structures similar to those found in P.aeruginosa. Therefore, understanding the mechanism of PcrV's role in bacterial translocation into eukaryotic cells may help in the development of other therapies targeting this widespread gram negative bacterial secretory system. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: BODY TEMPERATURE AND REGULATING HOST DEFENSES Principal Investigator & Institution: Hasday, Jeffrey D. Professor; Medicine; University of Maryland Balt Prof School Baltimore, MD 21201 Timing: Fiscal Year 2001; Project Start 01-MAR-1999; Project End 28-FEB-2003 Summary: Fever is a key element of the initial response to infection. In general, fever is associated with improved survival during infections, but the mechanisms of its protective effects are largely unknown. We hypothesize that the increase in core temperatures that occurs during febrile illnesses is essential for optimal orchestration of the host defenses. Our overall research objective is to determine the mechanisms through which increases in core temperature during fever influence morbidity and showed that increases in core temperature to febrile levels enhances the early cytokine responses to bacterial endotoxin (LPS), a non-replicating agonist. We have taken advantage of the partial ectothermic nature of young (8-10 week old) mice to develop a method to passively maintain core temperatures at febrile (39-40 degrees Celsius) or afebrile (36.5- 37.5 degrees Celsius) levels during infections. We will use this model to
Studies 27
directly determine the following potential effects of core temperatures changes in mice infected with Klebsiella pneumoniae, a clinically relevant and virulent bacterial pathogen: (1) determine if febrile core temperatures enhance containment and reduce dissemination of K. pneumoniae peritonitis; (2) determine if increasing core temperature to febrile levels enhances collateral tissue injury during K. pneumoniae peritonitis; (3) evaluate the potential roles of altered TNFalpha expression or tissue responsiveness to TNFalpha; and (4) determine if an increase in core temperature in core temperature to febrile levels is required for optimal orchestration of the host response and survival in K. pneumoniae pneumonia. The results of the proposed research will provide important information about the mechanisms through which changes in core temperature regulate host defenses. Because technology is available to modify body temperature, the results of the proposed experiments can be rapidly translated to the clinical area. Understanding the role of core temperature in regulating host defenses may lead to new protocols for managing body temperature during infections and may identify novel modalities for treating and preventing septic shock. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: BRONX/LEBANON PEDIATRIC ACTU Principal Investigator & Institution: Bakshi, Saroj S.; Bronx-Lebanon Hosp Ctr (Bronx, Ny) 1276 Fulton Ave New York, NY 10456 Timing: Fiscal Year 2001; Project Start 11-MAR-1992; Project End 28-FEB-2002 Summary: The Bronx Lebanon Hospital Center (BLHC) Pediatric AIDS Clinical Trial Unit (ACTU) has been very productive site of the Pediatric AIDS Clinical Trials Group (ACTG) since initiation of funding in 1992. It is located in an HIV epicenter in New York City and is the only funded PACTU in the Bronx. In the past seven years, the combined BLHC Division of Women and Children's HIV Services has provided comprehensive, integrated medical and psychosocial to 600 HIV exposed children and is now caring for 380 HIV infected. The major strength of the BLHC PACTC lies in its ability to recruit and retain large numbers of HIV infected children and pregnant women into protocols as demonstrated by past performance. Clinical care is integrated with research programs including a CDC funded Maternal-Infant Transmission Study (MITS) and the Pediatric AIDS Foundation Ariel Project. As with our performance in the PACTG, we have exceeded targeted accrual in each of these studies. The target for the first study year of this proposal is 94 participants which exceeds the minimum requirements stated in the RFA. The recent expansion and renovation of our clinical space has created an environment in which the PACTG obligations can be met with sensitivity. The site has implemented an extensive and comprehensive data quality assurance plan which has resulted in excellent data management summaries as per the DAIDS. The staff of the BLHC- PACTU is contributing to the development and implementation of the scientific mission of the PACTG. Therefore, the BLHC PACTU is an excellent site to continue as a participant in the scientific agenda of the PACTG. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: C3-BINDING AND -DEGRADING PROTEINS IN S. PNEUMONIAE Principal Investigator & Institution: Hostetter, Margaret K. Professor and Director; Pediatrics; Yale University 47 College Street, Suite 203 New Haven, CT 065208047 Timing: Fiscal Year 2002; Project Start 23-SEP-2002; Project End 22-SEP-2004 Summary: (provided by applicant): Streptococcus pneumoniae remains a leading cause of morbidity and mortality in community acquired respiratory infections. The third
28 Pneumonia
component of complement, C3, stands as the central mediator of host defense in susceptible patients who lack anti-capsular antibody. Over the past 5 years, we have identified two C3-degrading enzymes from S. pneumoniae: CppA, which degrades the C3 beta-chain; and PhpA, which cleaves the C3 alpha-chain into previously unrecognized fragments. Neither proteinase has any homolog in the database, and both are expressed by a wide variety of encapsulated clinical isolates. Intranasal immunization of mice with recombinant rCppA reduced nasopharyngeal colonization with a serotype 3 organism. Immunization of mice with rPhpA significantly reduced bacteremia and increased survival; in separate experiments, immunization with rPhpA was more effective than the serotype 3 conjugate vaccine in reducing nasopharyngeal colonization. In addition to the protective effects of CppA and PhpA in vivo, cppA- and phpA- mutants are more susceptible to C3-mediated opsonophagocytosis in vitro than is the isogenic parent. This revised proposal focuses on the mechanisms by which CppA and PhpA enable S. pneumoniae to elude C3-mediated killing in blood and lung. In Specific Aim One, we will characterize the mechanism of proteolysis by which CppA degrades the C3 beta-chain using chromogenic substrates and standard protease inhibitors. Truncation constructs expressed in Lactococcus lactis will be used to map the active site. A cppA- mutant in an encapsulated serotype 4 will be constructed. Specific Aim Two will focus on PhpA, a 79 kDa proteinase that cleaves the C3 alpha-chain into novel fragments of 97 and 83 kDa. Possible biologic activities of these C3 fragments in inhibiting C3 or neutrophils will be assayed. Biochemical techniques will be employed to understand how full-length PhpA liberates an internal 20 kDa polypeptide that appears to account for the majority of C3-cleaving activity. A phpA- mutant in an encapsulated serotype 4 will be constructed. Specific Aim Three will use a standard killing assay and a double mutant to test for additive or synergistic effects of CppA and PhpA. Other opsonins in blood (fibronectin) and lung (surfactant protein A) will be assessed as potential substrates for CppA and PhpA. Specific Aim Four will employ cppA- and phpA- mutants in the encapsulated strain to understand whether the effects of CppA and PhpA on C3-mediated killing contribute to virulence in a rabbit model of pneumonia and bacteremia. This revised proposal will define the role of two potent immunogens in pneumococcal pathogenesis. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: CARET-CHLAMYDIA PNEUMONIA AND RISK OF LUNG CANCER Principal Investigator & Institution: Goodman, Gary E. Associate Professor; Fred Hutchinson Cancer Research Center Box 19024, 1100 Fairview Ave N Seattle, WA 98109 Timing: Fiscal Year 2001; Project Start 01-JUL-1994; Project End 31-MAY-2004 Summary: This abstract is not available. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: CCSP IN INNATE DEFENSE AGAINST LUNG VIRAL INFECTION Principal Investigator & Institution: Harrod, Kevin S.; Lovelace Biomedical & Environmental Res Environmental Research Inst Albuquerque, NM 87185 Timing: Fiscal Year 2001; Project Start 20-AUG-2000; Project End 31-JUL-2004 Summary: The present application seeks to determine the role of Clara cell secretory protein (CCSP) in modulating host responses to viral infection in vivo. The lung is continually exposed to inhaled pathogens; yet, in healthy individuals, it remains remarkably free from infection. CCSP is an abundant protein of the lung airway fluid, and may have anti- inflammatory properties. Thus, CCSP may constitute an important
Studies 29
component of the innate immune system of the lung. CCSP is decreased in the lungs of smokers and patients with ARDS, suggesting a role for CCSP in the modulation of host inflammatory responses. Viral infection is a major cause of lung disease in humans, especially children. To directly determine the role of CCSP in vivo, gene-targeted mice lacking CCSP (CCSP -/-) were generated. These mice survive normally, with no apparent abnormalities. However, recent experiments demonstrate that CCSP -/- mice are susceptible to pulmonary adenoviral infection. CCSP - /-mice following adenoviral infection have increased infiltration of inflammatory cells early during the course of viral-induced inflammation. The infiltrating inflammatory cells consist predominantly of neutrophils. Cytokine and chemokine production is also increased in the lungs of CCSP -/- mice following adenoviral infection, coinciding with the infiltration of inflammatory cells into the lung. These results suggest that CCSP alters the host response to pulmonary adenoviral infection in vivo and may constitute an important mechanism of innate defense in the lung. The present application tests the hypothesis that CCSP modulates host responses through the regulation of lung phagocyte function and augments viral clearance during infection. To determine the role of CCSP in viral innate defense, experiments will determine if CCSP alters phagocyte activation and function in vivo following adenoviral infection. Viral uptake and killing will be assessed in the lungs of CCSP -/- mice following adenoviral infection to determine the role of CCSP in viral clearance. Temporal studies of recombinant CCSP (rCCSP) administration to CCSP -/- mice will determine the role of CCSP in modulating the initiation and resolution of viral-induced lung inflammation. CCSP expression will be restored in CCSP -/- mice through the development of CCSP transgenic mice, and subsequently bred into the CCSP -/- mouse model to assess the spatial relationship of CCSP expression in altering host defense to lung viral infection. This application will determine the role and delineate mechanisms by which CCSP provides innate immunity to viral infection in the lung. Such data may be useful in designing treatment and prevention of viral pneumonia. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: CD-18 DEPENDENT/INDEPENDENT WBC RESPONSES IN THE LUNG Principal Investigator & Institution: Doerschuk, Claire M. Professor of Pediatrics and Pathology; Pediatrics; Case Western Reserve University 10900 Euclid Ave Cleveland, OH 44106 Timing: Fiscal Year 2003; Project Start 01-AUG-1994; Project End 31-MAY-2008 Summary: (provided by applicant): Neutrophil emigration into the lungs can occur through at least two different pathways depending upon the stimulus, one that requires the CD11/CD18 adhesion complex, and one that does not. Our studies provide evidence that mice deficient in the NF-kappaB p65 (Rel A) subunit, mice deficient in both TNF R1 and IL-1R1, or mice with blockade of ICAM-1 have defects in E. coli-induced CD18dependent emigration. In contrast, mice deficient in the leukocyte non-receptor Src tyrosine kinases Lyn, Fgr, and Hck, in the small GTPase Rac2, or in interferon-(IFN-g) have defects in S. pneumoniae-induced CD18-independent but not E. coli-induced CD18-dependent emigration. Moreover, exogenous IFN-( switches CD18-dependent to CD18-independent emigration, whereas genetic deficiency of IFN-( switches CD18independent to CD18-dependent emigration. Studies comparing gene expression during these bacterial pneumonias also provided many new ideas. Our goal is, to understand the mechanisms, through which CD18-dependent and CD18-independent adhesion pathways are elicited and function; and to identify ways of modulating the acute
30 Pneumonia
inflammatory process to benefit the host. Our working hypothesis is that neutrophil emigration occurs through CD11/CD18-dependent pathways when early stages of host defense result in nuclear translocation of NF-kappaB, production of TNF-alpha and IL-1, and increased expression of ICAM-1 on pulmonary capillary endothelial cells, while CD11/CD18- independent mechanisms are selected when IFN-( is produced and the leukocyte Src kinases Lyn, Fgr, and Hck and the small GTPase Rac2 are activated. The proposed Aims will test this hypothesis and examine the role of each of these required molecules in the mechanisms of neutrophil emigration. Aim 1 will determine the role of NF-(B -mediated gene transcription and the function of TNF-alpha and IL-1 in CD18dependent and -independent neutrophil emigration. Aim 2 will determine the role of IFN-g in CD18- independent emigration. Aim 3 will determine the role of Lyn, Fgr, and Hck and of Rac2, and the functional relationships between these molecules and IFN-g in neutrophil recruitment and function. Aim 4 will determine the functional role of molecules identified by gene microarray technology to be differentially expressed in S. pneumoniae but not E. coli pneumonia. These studies will help to elucidate the molecular mechanisms of neutrophil recruitment and identify potential targets for therapy. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: CD8 T CELL DEPENDENT DAMAGE IN PNEUMOCYSTIS PNEUMONIA Principal Investigator & Institution: Harmsen, Allen; Professor and Head; Veterinary Molecular Biology; Montana State University (Bozeman) Bozeman, MT 59717 Timing: Fiscal Year 2001; Project Start 01-JUL-2000; Project End 30-JUN-2005 Summary: (from applicant's abstract): During Pneumocystis carinii pneumonia (PCP) in CD4 depleted mice, P. carinii specific CD8 T cells shift from a protective T1-type to a nonprotective and deleterious T2-type response. This detrimental response of cytotoxic T cells is further down regulated by interferon gamma and subsequent NO production. This general hypothesis will be addressed through three specific aims. First, Harmsen and colleagues will investigate the antigen specificity of CD8 T cells as they accumulate in the lungs of CD4 T cell-depleted mice during PCP. They will further investigate the role of class I MHC antigens in the activation of these cells. Next, they will determine the roles of interferon gamma and iNOS-dependent NO production in mediating the effects of CD8 T cells during PCP. Under the final aim, they will determine the mechanisms by which CD8 T cells damage the lung during PCP. They will investigate both the roles of T-cell derived perforin and recruited neutrophils in mediating this CD8 dependent lung injury. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: CELLULAR MECHANISMS THAT CONTROL SIV & DEVELOPMENT OF P* Principal Investigator & Institution: Clements, Janice E. Professor; Comparative Medicine; Johns Hopkins University 3400 N Charles St Baltimore, MD 21218 Timing: Fiscal Year 2003; Project Start 19-SEP-2003; Project End 31-AUG-2008 Summary: (provided by applicant): HIV establishes infection in lung during acute infection. However, virus replication appears to be controlled after acute infection, and HIV interstitial pneumonia does not develop until the late stages of infection prior to the development of AIDS. The goals of these studies are to elucidate the mechanism that regulates acute HIV/SIV replication in the lung and cells in the bronchoalveolar lavage
Studies 31
and to establish a testable model for control of HIV/SIV replication in the lung. Using an SIV/macaque model of HIV pneumonia in which all infected animals develop interstitial pneumonia and AIDS by 3 months, we demonstrated that there is viral replication in the lung during acute infection that is controlled during the asymptomatic infection, but virus replication resurges during the late stages of disease when there are lymphocytic infiltrates in the lung and pneumonia. Because active virus replication continued in the periphery during this time, these findings suggested the existence of a mechanism in the lung that mediates down-regulation of acute HIV/SIV replication. Alveolar macrophage is the predominant cells in the lung productively infected with HIV/SIV. Because HIV replication in macrophages requires C/EBP sites in the HIV LTR, we considered the possibility that negative regulation of C/EBP-dependent transcription is integral to the mechanism suppressing acute HIV/SIV replication in the CNS. Consistent with this notion is the ability of IFNbeta to inhibit active HIV transcription via induced expression of a dominant-negative isoform of C/EBPbeta. Based on preliminary studies demonstrating up-regulated expression of IFNbeta and the dominant-negative isoform of C/EBPbeta in the lung, our hypothesis is that acute virus replication in the lung is controlled by IFNbeta and increased expression of the dominant-negative form of C/EBPbeta in macrophages. Resurgent virus replication in the lungs during terminal disease is the result of increased influx of CXCR3+/CD8+ cells, decreased inhibition by the dominant-negative form of C/EBPbeta protein due to and increased activation of NF-kappaB in macrophages. Intervention with exogenous IFNbeta during asymptomatic infection will inhibit influx of CXCR3+ CD8+ cells, maintain the control of HIV transcription by the dominant-negative form of C/EBPbeta protein and inhibit resurgent virus activation in the lung and the development of associated lesions. These studies will be supported by our collaborators, Dr. William Bishai, an expert in AIDS and M. tuberculosis, in humans, and Dr. Christopher Karp, an immunologist who has studied HIV and Multiple Sclerosis and is actively involved in therapeutic treatment of MS patients in INFbeta. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: CELLULAR TUBERCULOSIS
NECROSIS
INDUCED
BY
MYCOBACTERIUM
Principal Investigator & Institution: King, C Harold. Medicine; Emory University 1784 North Decatur Road Atlanta, GA 30322 Timing: Fiscal Year 2002; Project Start 15-SEP-2002; Project End 14-SEP-2003 Summary: (provided by applicant): A key step in the pathogenesis of M tuberculosis is its ability to cause caseating necrosis, parenchymal lung destruction, and cavity formation, which develop into the characteristic necrotizing bronchointerstitial pneumonia and bronchiolitis of tuberculosis. M tuberculosis is cytotoxic to epithelial cells in vitro, and we have shown that this cytotoxicity is associated with cell membrane permeation to lactose dehydrogenase and is mediated by necrosis of lung epithelial cells after infection with virulent mycobacteria (Dobos, K. M., Quinn, F. D. and King, C. H. 2000, Infect. Immun. 68:6300-6310). Interestingly, the attenuated M bovis BCG does not induce necrosis in this epithelial cell model suggesting that necrosis is related to the virulence of mycobacteria. Our working hypothesis is that M tuberculosis possesses factors that cause necrosis. We intend to identify the genes that encode or synthesize such factors and determine their functions. Towards this goal, we have been successful in isolating two such (necrosis-deficient) mutants with insertions into genes that have no known function by screening a transposon library of the Erdman strain of M tuberculosis (TN5370) for mutants that have lost their ability to cause cell membrane
32 Pneumonia
permeation and necrosis. Both nec mutants possess extremely interesting phenotypes when grown in mice. The first mutant (necA) appears to be highly attenuated for growth and virulence in SCID mice. This is an important result as it suggests that we have identified a gene whose product either directly causes necrosis or induces necrosis and thus should enhance our understanding of tuberculosis pathogenesis. Interestingly, the second mutant (necB) appears to kill SCID mice more rapidly than the parental strain. We intend to characterize these mutants, characterize the functions of the gene products, and extend this mutant isolation strategy to identify a large battery of mutants defective for necrosis of host cells. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: CHEMOKINE AND CHEMOKINE RECEPTORS IN IPF Principal Investigator & Institution: Hogaboam, Cory M. Associate Professor; University of Michigan at Ann Arbor 3003 South State, Room 1040 Ann Arbor, MI 481091274 Timing: Fiscal Year 2002; Project Start 26-DEC-2001; Project End 30-NOV-2006 Summary: (Applicant's Abstract) Interstitial lung disease (Il-D) encompasses a group of pulmonary inflammatory disorders that are characterized by excessive tissue injury and progressive fibrosis. Clinical and laboratory evidence suggest that ILD is a consequence of a poorly regulated pulmonary inflammatory process because of the persistence of one or several inflammatory signals. Recent experimental data suggest that the lung fibroblast is not a bystander during chronic inflammatory responses in the lung, rather this structural cell has a very specialized role in the recruitment and regulation of immune cells that infiltrate the interstitial space. The role of the fibroblast during ILD has expanded because of the recent recognition that this cell markedly increases the generation of chemotactic proteins (chemokines) and directly responds to these factors through the expression of high-specialized chemokine receptors. Chemokines affect both the proliferation and synthetic capacity of pulmonary fibroblasts. Although increased chemokine levels during ILD have been reported, little is known about changes in the chemokine and chemokine receptor expression in the fibroblast during ILD, nor is it known whether the temporal pattern of expression of chemokine receptors by these cells may aid in differentiating the various pathologically distinct types of ILD or success of ILD treatment. Thus, the overall aim of this proposal is to characterize the pattern of chemokine and chemokine receptor expression associated with non-specific interstitial pneumonia (NSIP)-cellular, NSIP-fibrotic, usual interstitial pneumonia (UIP)-discordent, and UIP-cordent in open lung biopsies (OLB), fibrotic foci and cultured fibroblasts from OLB and transbronchial biopsies. The following specific aims will be addressed using powerful new techniques including TAQMAN quantitative polymerase chain reaction (PCR) and laser capture microscopy: 1) to characterize the chemokine and chemolcine receptor profile in OLB from patients at the time of ILD diagnosis, and specifically identify the chemokine receptor profile in fibrotic foci from histological samples. 2) to characterize the chemokine and chemokine receptor profile in fibroblasts cultured from open lung biopsies at the time of ILD diagnosis. 3) to examine changes in the chemokine and chemokine receptor profile in cultured transbronchial biopsy fibroblasts at defined intervals after initial ILD diagnosis and during a defined ILD treatment regimen. Taken together, these studies entail an examination of the expression of chemokines and their receptors in OLB, fibrotic foci and cultured lung fibroblasts at the time of diagnosis and during ILD treatment. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
Studies 33
•
Project Title: CHIMERIC VIRUS VACCINES FOR P. AERUGINOSA INFECTIONS Principal Investigator & Institution: Staczek, John; Professor; Microbiology and Immunology; Louisiana State Univ Hsc Shreveport P. O. Box 33932 Shreveport, LA 71103 Timing: Fiscal Year 2003; Project Start 01-JUL-1998; Project End 31-MAR-2007 Summary: (provided by applicant): Pseudomonas infection is an underappreciated cause of morbidity and mortality. Nosocomial infections can be life-threatening in immunocompromized populations, cancer patients, the elderly, and patients with cystic fibrosis. Physicians try to protect patients with antibiotic therapy, but the bacteria quickly develop antibiotic resistance. A complementary approach to antibiotic therapy is therefore urgently needed, and one such approach is vaccination. Our long-range goal is to develop vaccines that protect against Pseudomonas lung infection. We have developed two effective outer membrane protein F (OprF)-based vaccines that protect against both nonmucoid and mucoid Pseudomonas phenotypes. These vaccines are called F/I and F/HG. The F/I vaccine consists of three biolistic inoculations of naked DNA sequences for the fusion protein OprF/l. The F/HG vaccine uses a prime-boost strategy with two biolistic inoculations of naked DNA-oprF sequences followed by an intramuscular booster containing the chimeric influenza virus HG10-11. Each vaccine appears to induce a polarized immune response. The F/I vaccine induced antibodymediated immunity (AMI) while F/HG induced cell-mediated immunity (CMI). Insufficient information is available regarding the immune mechanisms whereby Pseudomonas infection is controlled or how Pseudomonas vaccines work. AMI in pulmonary Pseudomonas infection is believed to be important, but the definitive mechanism for clearance is unknown. We propose to define the mechanisms of antibody protection by identifying antibody isotypes and serum cytokines in infected and F/Iimmunized mice that are immune-intact or immune-deficient. Likewise, the role of CMI in Pseudomonas pneumonia is poorly understood. Our F/HG vaccine will allow us to define the mechanism(s) of Pseudomonas-specific, cell-mediated protection in the lungs of infected and immunized mice that are immune-intact or immune-deficient. Defining these mechanisms will allow us to rationally modify immune responses to protect more effectively against pulmonary Pseudomonas infection. As researchers delineate the immune responses to pulmonary Pseudomonas infection in humans, we will be uniquely positioned to modify our vaccines to induce specific Th-1 or Th-2 responses. These rationally designed vaccines tested in a pulmonary chronic infection model will provide guiding principles to prevent and treat more effectively Pseudomonas pneumonia in humans. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: CHLAMYDIA ATHEROSCLEROSIS
PNEUMONIAE
AND
MACROPHAGES
IN
Principal Investigator & Institution: Byrne, Gerald I. Professor & Chairman; Medical Microbiol & Immunology; University of Wisconsin Madison 750 University Ave Madison, WI 53706 Timing: Fiscal Year 2001; Project Start 15-FEB-1999; Project End 31-JAN-2004 Summary: (Adapted from the Applicant's Abstract): Chlamydia pneumoniae, a causative agent in human community acquired pneumonia, also has been implicated in a variety of sequelae associated with chronic disease and re-exposure to the organism. One important sequel associated with C. pneumoniae infection is the development of atherosclerotic lesions that define the pathology of cardiovascular disease in people.
34 Pneumonia
Cardiovascular disease due to atherogenic processes is a major health problem in most of the world, accounting for about 50% of all deaths. It is clear that vascular injury is crucial in the development and progression of atherosclerosis and that this injury can result from a variety of causes, including infection. Several lines of evidence support the hypothesis that C. pneumoniae infection is linked to the development of atherosclerosis. Initially, seroepidemiological evidence was generated to establish a relationship between C. pneumoniae and cardiovascular disease. Subsequently, evidence for the presence of the organism in atherosclerotic lesions was obtained using either direct antigen detection methods or probes specific for C. pneumoniae nucleic acids. In addition, the organism has been isolated from an aortic lesion and grown in cell culture. Finally, two pilot secondary prevention antibiotic treatment trials have provided evidence to suggest that treatment of C. pneumoniae in individuals with coronary heart disease significantly reduces cardiac events in treated versus placebo administered populations. Thus, although the association of C. pneumoniae and atherosclerosis is well-established, existing data do not prove an etiology or pathogenic role for the organism in disease, although both rabbit and murine animal models have been developed to determine if C. pneumoniae is causally associated with development or progression of atherosclerotic lesions in vivo. Activation and modification of mononuclear phagocyte function is associated with atherosclerotic lesion development. Characteristic changes include development of cholesteryl ester-laden monocytes (foam cells) and oxidation of lipids to form tissue-damaging derivatives. The hypothesis to be tested here is that infection of human monocytes, monocyte-derived macrophages or murine monocyte cell lines with C. pneumoniae results in changes in macrophage morphology and function that are consistent with a role for C. pneumoniae in the pathogenesis of atherosclerosis. This hypothesis will be tested by determining if C. pneumoniae causes mononuclear phagocytes to form foam cells in the presence of low density lipoprotein (LDL) or other cholesterol-containing serum lipoprotein complexes. Studies also will be conducted to determine if C. pneumoniae contributes to the oxidative modification of LDL and molecular characterization of C. pneumoniae antigens involved in these processes will be identified. Finally, a murine model will be developed to provide in vivo correlates to cell culture observations. Results will help establish links between C. pneumoniae infection and the atherosclerotic disease process. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: CHLAMYDIA SIGNIFICANCE
PNEUMONIAE
ANTIGENS
OF
BIOLOGICAL
Principal Investigator & Institution: Campbell, Lee A. Professor; Pathobiology; University of Washington Seattle, WA 98195 Timing: Fiscal Year 2002; Project Start 01-APR-1998; Project End 31-MAR-2007 Summary: (provided by the applicant): Chlamydia pneumoniae is a human respiratory pathogen that causes 5 percent to 10 percent of pneumonia, bronchitis, and sinusitis. Virtually everyone is infected in his or her lifetime and reinfection is common. Infection is difficult to treat even with sensitive antibiotics. Chronic infection is common and has been associated with asthma, reactive airway disease, Reiter's syndrome, erythema nodosum, and sarcoidosis. The potential public health impact of infection with this pathogen is underscored by the association of C. pneumoniae with atherosclerosis and related clinical manifestations such as coronary heart disease, carotid artery stenosis, aortic aneurysm, claudication, and stroke. If C. pneumoniae infection plays a role in atherogenesis, there will be an urgent need to facilitate diagnosis and develop strategies for intervention and prevention. The overall goal of this proposal is two fold. First, C.
Studies 35
pneumoniae specific antigens that are recognized during human infection will be exploited to facilitate serodiagnosis and identify putative vaccine candidates. The second goal is to define chlamydial/host cell interactions that lead to entry and survival of C. pneumoniae in host cells relevant to atherosclerosis. The specific focus will be on the interaction of the chlamydial glycan moiety with carbohydrate binding receptors on the host cell. Importantly, infection of epithelial cells can be inhibited with N-linked high mannose type oligosaccharide, the major component of the glycan. The novel hypothesis to be tested is that C. pneumoniae enters through the mannose-6 phosphate receptor by binding to the site involved in transport of phosphomannosylated residues to the lysosome and this differs from C. trachomatis, which utilizes the mannose receptor. The ultimate goals of these studies are to identify C. pneumoniae specific antigens to facilitate laboratory diagnosis and virulence factors playing a role in pathogenesis to guide vaccine development or develop anti-adhesive strategies for prevention of infection. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: COLUMBIA-ADARC AIDS CLINICAL TRIALS UNIT Principal Investigator & Institution: Hammer, Scott M. Director; Medicine; Columbia University Health Sciences New York, NY 10032 Timing: Fiscal Year 2001; Project Start 01-JAN-2000; Project End 31-DEC-2004 Summary: (adapted from the application's abstract): The overall goal of this application is the formation of a clinical site within the Adult AIDS Clinical Trials Group (AACTG) which will effectively execute studies designed to improve the understanding and treatment of HIV disease. This site, a linkage of the Columbia Presbyterian Medical Center (Columbia) with the Aaron Diamond AIDS Research Center (ADARC) will be designated the Columbia-ADARC AIDS Clinical Trials Unit. Columbia will serve as the main unit and ADARC as the sub-unit in this collaboration of two institutions already scientifically linked by the recently awarded Center for AIDS Research (CFAR) grant. The intent is to bring together extensive and complementary clinical trials and basic investigative expertise to facilitate execution of the Group's scientific agenda. A Columbia-ADARC unit may possess the elements necessary to successfully carry out a diverse array of pathogenetically and strategically based clinical trials in a demographically diverse population. The specific aims of this application are: (1) to establish a clinical trials unit that has the capability to conduct studies which advance the knowledge of HIV pathogenesis and treatment. Specifically, this unit will be dedicated to further the AACTG's research agenda through active accrual to protocols sponsored by the scientific committees of the Group; (2) to recruit and retain a diverse population of HIV infected persons in AACTG trials who reflect the affected population in Manhattan, particularly Northern Manhattan, a region which has been severely affected by the HIV epidemic and one that is representative of the penetrance of the epidemic into the inner cities. This will be achieved through recruitment of patients from a large primary care base and broad regional referral network; and (3) to promote the Group's scientific mission by active participation in AACTG protocols and committees by Columbia-ADARC investigators. This will include sharing of new technologies that enhance the sophistication of patient monitoring and thereby generate new hypotheses to test in the context of AACTG trials. Thus, the Columbia-ADARC ACTU will be an active participant in the Group's mission to improve the health of HIV infected individuals and set standards for treatment of HIV disease. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
36 Pneumonia
•
Project Title: CONST OF VACCINE CTR: PNEUMONIA, FLU Principal Investigator & Institution: Lucas, Alexander H. Senior Research Immunologist; Children's Hospital & Res Ctr at Oakland Research Center at Oakland Oakland, CA 94609 Timing: Fiscal Year 2002; Project Start 01-MAY-2002; Project End 30-APR-2003 Summary: (provided by applicant): This application seeks funds from the National Center for Research Resources (NCRR) to support construction of the CIVD being established at the CHORI. The Center will consist of new laboratories, core facilities and office spaces suitable to house the research, research training and research support activities of several integrated scientific programs. The investigators who will occupy the Center conduct molecular, cellular and clinical studies in the inter-related areas of immunobiology, infectious diseases, pathogenesis, vaccine development and vaccine evaluation. As a group, the CIVD investigators have 18 extramural awards with total direct costs in year 2001 that exceed $3 million of which 75 percent derives from the National Institutes of Health (NIH). Dr. Dan Granoff will be the Scientific Director of the Center. Dr. Alexander Lucas, Deputy Director of Medical Research at CHORI, is the Principal Investigator (PI) and will be responsible for the space utilization and the administrative management of the Center. CHORI has made a substantial financial commitment to this project and has designated the CIVD as a high priority in its Strategic Plan. Approximately 8,000 sq. ft. of undeveloped shell space will be used for construction of the CIVD. The Center will provide interactive laboratory and office spaces as well as specialized shared core facilities, such as a Biosafety Level 3 (BSL3) facility and a DNA clean room for polymerase chain reaction (PCR) assembly. Construction of the CIVD will expand investigators' research capabilities, promote programmatic interaction and growth, increase training opportunities, and permit recruitment of additional scientists. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: CORE -- IMMUNIZATION AND PNEUMONIA DISPARITIES RESEARCH Principal Investigator & Institution: Zimmerman, Richard K.; University of Pittsburgh at Pittsburgh 350 Thackeray Hall Pittsburgh, PA 15260 Timing: Fiscal Year 2002; Project Start 30-SEP-2002; Project End 29-SEP-2007 Summary: CORE ABSTRACT NOT PROVIDED Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: CORE--CLINICAL Principal Investigator & Institution: Martinez, Fernando J.; University of Michigan at Ann Arbor 3003 South State, Room 1040 Ann Arbor, MI 481091274 Timing: Fiscal Year 2002; Project Start 26-DEC-2001; Project End 30-NOV-2006 Summary: (Applicant's Abstract) The mission of the Clinical Core is to provide the personnel, facilities, and organizational structure necessary to generate the clinical database and patient specimens for Projects 6, 2 and 7. These resources will support individual protocols within the Center, facilitate interactions between investigators, and provide a cohesive framework for the formulation, execution, and data analysis of clinical research projects. The clinical protocols are designed to approximate the best available strategies for diagnostic assessment and therapy for subsets of idiopathic interstitial pneumonias (11P), including idiopathic pulmonary fibrosis (usual interstitial
Studies 37
pneumonia, UIP) and nonspecific interstitial pneumonia (NSIP). The specific aims are to: Manage the clinical studies involving patients with UIP and NSIP including: (a) Identify eligible patients and coordinate patient flow from the Fibrotic Lung Disease Network (FLDN) physicians to the University of Michigan Health System (UN4HS) for initial evaluation (b) Obtain informed consent, enroll patients, collect clinical data (physiologic testing, scoring chest roentgenograms and high resolution computed tomography) (c) Select the biopsy site based on HRCT findings, communicate this to thoracic surgeons at the UMHS and at FLDN sites; coordinate the interpretation of histologic, samples by collaborating pathologists (d) Manage outpatients on prednisone, prednisone/azathiopnine and zileuton at UMBS or the FLDN Procure Tissues and cells for individual investigators including: (a) Performing bronchoalveolar lavage and transbronchial biopsies at appropriate time points (b) Coordinate procurement of surgical lung biopsy specimens at LTMHS or at the FLDN and deliver specimens to appropriate SCOR investigator at the UNIHS Provide data management services to individual investigators including: (a) Organizing and managing the clinical database, advisino on study design, sample size calculation and selection of appropriate outcome variables (b) Assisting with statistical applications and data analysis. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: CORE--CLINICAL Principal Investigator & Institution: Shasby, D Michael. Professor; University of Iowa Iowa City, IA 52242 Timing: Fiscal Year 2001; Project Start 01-SEP-2001; Project End 31-AUG-2002 Summary: While there are some optimistic reports, the mortality for ARDS remains near 50%. Of the patients who die, one half survive beyond the first three days. In these patients who survive more than 3 days, signs of persistent lung and systemic inflammation are associated with increased mortality. Early autopsy series detected a large number of unsuspected cases of bacterial infection of the lung in persons dying with ARDS. In more recent clinical studies culture of bronchoscopic samples from live patients without clinical signs of pneumonia have not yielded a high prevalence of results that meet strict criteria for pneumonia. However, a large fraction of samples did contain bacteria and the prevalence of samples with bacteria increased with time on the ventilator. In addition to bacterial colonization of the lung itself, translocation of bacteria across the intestinal wall occurs in severely ill patients, and especially those with shock. The use of broad spectrum antibiotics in patients with ARDS limits the sensitivity of strict quantitative culture criteria to accurately quantify the bacterial burden in ARDS patients. We hypothesize that a significant portion of the persistent acute inflammation present in the lungs of ARDS patients derives from bacteria which colonize the lung surfaces and/or translocate into the blood stream. In the case of bacteria which translocate into the blood stream the primed lung becomes the subject of a response similar to the Shwartzman phenomenon. Recent studies have not detected high levels of lung colonization or blood stream invasion by bacteria because of the ubiquitous use of broad spectrum antibiotics. We will measure bacterial burden in the lung and blood stream of ARDS patients using PCR for bacterial DNA, the sensitivity of which is not as limited by the presence of antibiotics. We will determine if the bacterial burden in the lung and blood as an independent predictor of mortality and if it correlates with indices of acute inflammation. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
38 Pneumonia
•
Project Title: CTRS FOR EDUCATION AND RESEARCH ON THERAPEUTICS (CERTS) Principal Investigator & Institution: Strom, Brian L. Professor of Medicine and Pharmacology; Medicine; University of Pennsylvania 3451 Walnut Street Philadelphia, PA 19104 Timing: Fiscal Year 2001; Project Start 01-SEP-2000; Project End 31-AUG-2003 Summary: There remain enormous gaps in the information available to the public about the effects of their drugs, and in the application of that information to optimizing prescribing and thereby improving the risk/benefit balance from drugs. Centers for Education and Research on Therapeutics (CERTs) offer the opportunity to address many of these deficits, and this proposal goes a long way toward filling that gap. In particular, we propose to: 1. Establish a CERT with a coordinated infrastructure, including: a. Logistical support, including faculty time and core staff; b. Governance, including regular coordination and business meetings; c. Programmatic coordination, including linkage of the pharmacoepidemiology skills of the Center for Clinical Epidemiology and Biostatistics (CCEB) with the pharmacoeconomics skills of the Leonard Davis Institute of Health Economics, the experience in patient -oriented research of the General Clinical Research Center; basic science laboratories interested in evaluating the molecular mechanisms of drug effects; and the social science skills of non-biomedical researchers in other parts of the University; d. Regularly scheduled educational conference series; e. Active participation in the national network of CERTs; and f. A pilot research grant program targeted at the development of R01 quality grants and proposals. 2. Testing and building the capabilities of the current Penn ambulatory drug use evaluation program as a laboratory, expanding it to broader populations; 3. Improve the use of antibiotics locally and nationally, with studies leading to grant funding for larger scale efforts, as well as formal dissemination of evidence-based data both known and to be known. The initial studies will: a. evaluate techniques to reduce the use of antibiotics for acute bronchitis in the outpatient setting b. evaluate the impact of antimicrobial formulary interventions at different hospitals on the resistance patterns of extendedspectrum beta-lactamase- producing Escherichia coli and Klebsiella species; c. simulate data, in order to expand the use of meta-analysis to study rare adverse outcomes from antibiotics; d. study the effects of tetracycline used to treat acne in a dermatology clinic on antibiotic resistance patterns; and e. study the use of the GPRD Database to explore the epidemiology of drug -resistant pneumococcal pneumonia 4. Conduct an extensive education program, including: i) a Masters in Clinical Epidemiology (MSCE) and PhD pharmacoepidemiology fellowship training program; ii) opportunities for MSCE and PhD students in epidemiology and biostatistics to use existing in-house databases to answer new questions, to participate in ongoing research, and to develop new research projects; iii) courses for university physicians housestaff, nurses, and nursing students; iv) courses for pharmacists and pharmacy students; v) courses for medical students; and vi) a degree credit course in pharmacoepidemiology for MSCE students. 5. Organize and formally disseminate the results of our work, consisting of: publications and presentations for the Scientific/Professional community; ii) the FDA, AHCPR, other CERTs, etc. and iii) the public, building on the dissemination program of the Leonard Davis Institute of Health Economics. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
Studies 39
•
Project Title: CYSTEINE PRESENTATION
PROTEASES
IN
MHC
CLASS
II
ANTIGEN
Principal Investigator & Institution: Chapman, Harold A. Professor; Medicine; University of California San Francisco 500 Parnassus Ave San Francisco, CA 94122 Timing: Fiscal Year 2001; Project Start 01-JAN-1993; Project End 31-DEC-2002 Summary: (Adapted from the applicant's abstract): Presentation of foreign antigens by MHC class II gene products is a central arm of immunity. The process of MHC class IIdependent antigen presentation involves several discrete steps mediated by proteolytic enzymes: generation of peptides for their subsequent presentation as antigens in peptide complexes with MHC alpha/beta dimers and the stepwise breakdown of the class IIassociated molecular chaperone, the invariant chain (Ii). Degradation of Ii promotes loading of MHC class II alpha/beta with newly formed peptides. A single protease, cathepsin S, was recently found to be essential to the process of Ii breakdown and efficient MHC class II peptide loading. These studies are aimed at elucidating the mechanisms by which cathepsin S promotes antigen presentation and at understanding the consequences of inhibition of cathepsin S on MHC class II function. Toward that end, cellular models of antigen presentation in which the activity of cathepsin S, and other cysteine proteases can be manipulated have been developed. Ii resistant to cleavage of cathepsin S will be generated by site-directed mutagenesis and the function of mutant Ii assessed in vitro and in vivo. The importance of cathepsin S in vivo to MHC class II-dependent immune responses, including allergic pulmonary reactions, will be tested by creating a selective, systemic deficiency of cathepsin S with low molecular weight protease inhibitors. And finally, mice with targeted disruption ("knockout") of the cathepsin S gene are being generated in order to assess the consequences of longstanding cathepsin S deficiency on MHC class II function and to provide a fertile background on which to search for additional proteases important to antigen presentation. These studies should provide new information on the basic events important to MHC class II peptide loading and establish whether there is a clear rationale for therapeutic inhibition of cathepsin S to suppress inflammation in lung diseases promoted by MHC class II-dependent immune reactions such as asthma, hypersensitivity pneumonitis, and transplant rejection. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: CYTOKINE PNEUMOCYSTIS
CONTROL
OF
HOST
SUSCEPTIBILITY
TO
Principal Investigator & Institution: Beck, James M. Associate Professor; Internal Medicine; University of Michigan at Ann Arbor 3003 South State, Room 1040 Ann Arbor, MI 481091274 Timing: Fiscal Year 2001; Project Start 30-SEP-1997; Project End 31-AUG-2003 Summary: An improved understanding of the factors contorlling host susceptibility to Pneumocystis carinii could provide novel therapeutic modalities directed against this opportunistic pathogen. Our laboratory utilizes immunodeficient mouse models of P. Carinii pneumonia to study susceptibility to this organism, modeling the immune deficits present in HIV-infected individuals. Using these immunodeficient mouse models of P. Carinii pneumonia, we confirmed the roles of both CD4+ and CD8+ T cells in host defense against P. Carinii. Both CD4+ and CD8+ T cells are likely to control susceptibility to P. Carinii by elaboration of cytokines. Recent information shows that both of these T cell subsets can express either Th1 or Th2 cytokine repertoires. In an increasing number of model systems, it is apparent that the balance between
40 Pneumonia
susceptibility and defense does not depend on single cytokines with isolated actions. Rather, coordinated responses, precisely modulated in intensity and in sequence, control susceptibility. In preliminary data presented in this application, we characterize Th1 and Th2 cytokine production in the lungs of immunocompetent and immunodeficient mice after P. Carinii inoculation. We demonstrate differential, time-dependent patterns of cytokine production in vivo. Furthermore, we have successfully used mice deleted of specific cytokine genes ("knockout" mice) to examine suceptibility to P. Carinii in vivo. Based o these data, we hypothesize that coordinated Th1 and Th2 responses are required for successful defense against p. Carinii, requiring early Th2-like responses and late Th1-like responses. There are four specific objectives: (1) to determine the cellular sources of cytokines responsible for successful defense against or susceptibility to P. Carinii in vivo; (2) to determine whether cytokine blockade can alter defense against or susceptibility to P. Carinii in vivo; (3) to isolate P. Carinii-specific CD4+ T cells with specific cytokine profiles in vitro and to determine whether these cells maintain their cytokine profiles in vivo; and (4) to determine whether reconstitution with CD4+ T cells of defined repertoire alters susceptibility to infection in vivo. These powerful animal models allow us to test the roles of cytokines in control of susceptibility to P. Carini using in vivo approaches that model human P. Carinii pneumonia. Ultimately, these studies can be extended to develop therapeutic strategies directed against this important opportunistic pathogen. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: CYTOKINES IN RADIATION LUNG INJURY Principal Investigator & Institution: Blackstock, Arthur W. Associate Professor Radiation/Oncology; Radiation Oncology; Wake Forest University Health Sciences Winston-Salem, NC 27157 Timing: Fiscal Year 2002; Project Start 05-JUL-2002; Project End 30-JUN-2004 Summary: (provided by applicant): Non small cell lung cancer (NSCLC) is the leading cause of cancer related deaths in the United States. Traditional radiotherapy delivered with standard fractionation to standard doses is ineffective at sterilizing the primary tumor and results in local control rates of 20-40 percent. The overall outcome for patients with inoperable NSCLC is a five year survival rate of less than 10 percent. Advances using combined modality therapy and altered radiation fractionation schedules have resulted in modest improvements in survival, although local and distant failure rates remain high. There is increasing evidence that pro-inflammatory cytokines (chemokines) can be induced in response to ionizing radiation. Macrophage inflammatory protein 1-alpha (MIP-1alpha) appears to be an important cytokine mediator of pulmonary inflammation and injury. Growing preclinical and clinical data suggest a potential relationship between serum MIP-1alpha levels and the risk of lung injury following thoracic radiation. A pilot study to determine the clinical significance of MIP-1alpha levels in patients receiving thoracic radiation will be evaluated in this study. A phase I/II trial has been initiated to determine the toxicity of induction/concurrent chemotherapy and 3-dimensionally planned - thoracic radiation therapy for patients with locally advanced NSCLC. In conjunction with this clinical trial, we will collect and analyze pre-treatment, weekly (during treatment) and post-treatment MIP-1alpha levels. Our specific aims are to: Ia) define the temporal changes in MIP-1alpha levels over the course of therapy and in follow-up to ascertain if these changes are predictive for the clinical development of radiation pneumonitis, Ib) define these same temporal changes in MIP-l-alpha and ascertain if they are predictive for the clinical development of pulmonary fibrosis, and II) discern if the temporal changes in MIP-1alpha can be
Studies 41
correlated with the lung volume irradiated, changes in pulmonary function after therapy or overall clinical outcome. By determining that changes in MIP-1alpha levels correlate with the acute and chronic lung injuries associated with thoracic irradiation, we may more rationally develop and incorporate their use in future clinical trials employing thoracic radiation therapy. Even further, understanding the temporal expression of MIP-1alpha during thoracic radiation may allow the future utilization of anticytokine reagents, e.g. antibodies, receptor and synthesis blockers during treatment. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: DATA INFORMATICS
MINING
AND
MODEL
BUILDING
IN
MEDICAL
Principal Investigator & Institution: Buchanan, Bruce G. Professor; Computer Science; University of Pittsburgh at Pittsburgh 350 Thackeray Hall Pittsburgh, PA 15260 Timing: Fiscal Year 2001; Project Start 01-MAY-1999; Project End 30-APR-2003 Summary: Our long-term goal is to assist biomedical scientists by extracting and codifying new knowledge from large biomedical databases routinely by computer. As large collections of data become more readily accessibly, the opportunities for discovering new information increase. We propose here to work toward this goal by extending our prior research on machine learning in two important directions: (1) codification of disparate pieces of knowledge into a coherent model (model building), and (2) discovery of new information in medical databases (data mining). Machine learning programs find classification rules (or decision trees or networks) that separate members of a target class from other individuals. They have emphasized predictive accuracy, with some attention to tradeoffs between accuracy and cost of errors or between accuracy and simplicity. We propose a framework in which these, and other, tradeoffs are explicit and the criteria by which tradeoffs are made are available for modification. We also include semantic considerations among the criteria to control the internal coherence of models. "Data mining" is a recently-coined term for using computers to explore large databases, with a goal of discovering new relationships but usually with no specific target defined at the outset. In addition to accuracy, simplicity, coherence, and cost, a program that purports to discover new relationships must be able to assess novelty. We propose to measure the extent to which proposed relationships are novel by comparing them against existing knowledge in the domain of discourse, and to look for unusual rules (and other relations) that would be very interesting if true. The computer program we are primarily building on, RL, is a knowledge- based learning program that learns classification rules from a collection of data. RL has been demonstrated to be flexible enough to allow guidance from prior knowledge, and powerful enough to learn publishable information for scientists working in several different domains. Both parts of the research will requires extending the RL system in new ways detailed in the research plan, which are consistent with the overall design philosophy of the present system. We will primarily work with data already collected on pneumonia patients with with which we have considerable. We will test the generality of the criteria used to evaluate models and discoveries with a Baynesian Net learning. We will test the generality of the generality of the criteria used to evaluate models and discoveries with Bayesian Net learning system, K2. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: DELIVERY OF CLINICAL PREVENTIVE SERVICES Principal Investigator & Institution: Buchwald, Debra; University of Colorado Hlth Sciences Ctr Uchsc at Fitzsimons Aurora, CO 800450508
42 Pneumonia
Timing: Fiscal Year 2001 Summary: American Indians and Alaska Natives (AI/ANs) are especially susceptible to respiratory diseases. According to Indian Health Service statistics, influenza/pneumonia is the 6th leading cause of death among all AIs and the 4th among Native elders. Moreover, mortality increases markedly with age; for persons greater than or equal to 65 years, mortality due to AI/ANs are not available, minority populations receive influenza (IV) and pneumococcal (PV) vaccinations at substantially lower rates than whites. Since minority adults utilize preventive services loss, present for care at more advanced stages of disease, and have greater morbidity and mortality than higher income individuals, AI/AN elders are at risk for not obtaining IV and PV. In this regard, our pilot work with urban Native elders in a primary care practice found that only 31% and 21%, respectively, in accordance with published guidelines. Thus, the Specific Aims of this project are to: 1) compare the effectiveness of "usual care" to 2 patient-targeted interventions in promoting immunizations among AI/AN elders at a large urban health center (either receipt of culturally appropriate educational materials addressing knowledge, attitudes, and beliefs informed by focus groups or an incentive); 2) assess the effectiveness of provider-targeted peer feedback versus usual care in increasing vaccination rates; and 3) examine patient-related factors influencing receipt of immunizations. To accomplish this we will conduct a randomized, controlled, clinical trial to assess improvement in IV and PV rates among an elderly AI/AN clinic population. During Year 1, focus groups will help develop culturally appropriate educational materials determine the incentive, as well as facilitate an understanding of reasons for non-adherence to guidelines. In Year 2, eligible Native elders will receive culturally appropriate educational materials, an incentive, or usual care. In Year 3, a physician- targeted feedback intervention will consist comparisons to rates of peer administration of IV and PV. During Years 4 and 5, we will complete the data collection and analysis, than meet with health leaders from 5 Northwest tribes to evaluate the feasibility of putting into practice the successful portions of the planned intervention in local reservation-based communities. These objectives are consistent with the Healthy People 2000 National Health Promotion and Disease Prevention Objectives to achieve IV and PV coverage rates of greater than or equal to 60% among community-dwellers aged greater than or equal to 65 living and high-risk populations. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: DETECTING ASPIRATION ASSOCIATED WITH TUBE FEEDINGS Principal Investigator & Institution: Metheny, Norma A. Dorothy A. Votsmeier Professor; None; St. Louis University St. Louis, MO 63110 Timing: Fiscal Year 2002; Project Start 01-AUG-1999; Project End 31-MAY-2005 Summary: (provided by applicant) The ultimate goal of the proposed study is to increase the safety of mechanically ventilated (MV) tube-fed patients. This group is at high risk for aspiration of regurgitated gastric contents with deleterious consequences including transient hypoxemia, chemical pneumonitis, and potentially life-threatening nosocomial pneumonia. Efforts are made in practice settings to detect aspirations early so that interventions can be initiated to prevent morbidity and mortality. However, clinicians are unsure about how to accomplish this since currently available bedside methods to detect aspirations are unreliable. A laboratory method of detecting aspirations based on pepsin was tested in an animal model in the current study (8/1/997/31/02) and found to be highly sensitive and specific. Preliminary studies have indicated that the laboratory assay can detect pepsin (a proxy for the aspiration of gastric contents) in tracheal secretions suctioned from critically ill tube-fed patients. To
Studies 43
determine the extent to which pepsin in tracheal secretions predicts the development of pneumonia, daily Clinical Pulmonary Infection Scores will be calculated. Another problem in the management of tube-fed MV patients is uncertainty about how to assess for significantly slowed gastrointestinal (GI) motility, a condition that predisposes to aspiration. Especially problematic is difficulty in determining when indicators of slowed GI motility, such as large GI residual volumes, are of sufficient magnitude to warrant temporary withholding of feedings. As a result feedings are often withheld unnecessarily, leading to significantly reduced caloric intake. Therefore, another aim of the proposed study is to identify the signs of slowed GI motility that are most predictive of aspirations of gastric contents. Additional aims are to examine the effect of risk factors for aspiration on the detection of pepsin in tracheal secretions as well as the effect of risk factors for pneumonia on the development of pneumonia. The proposed work is a prospective, descriptive study of 680, critically ill, tube-fed patients who will be monitored 24 hours a day for the first 3 days of tube feedings to assess for: pepsin in suctioned tracheal secretions, signs of GI intolerance to tube feedings (large GI residual volumes, absence of bowel sounds, and presence of vomiting), and risk factors for aspiration and pneumonia. In addition, Clinical Pulmonary Infection Scores will be calculated daily for the first 4 days of tube feedings. Patients will be recruited from 5 intensive care units at a Level I trauma center. Data collection will occur over a 24month period and the data will be analyzed by logistic regression and multiple linear regression. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: DETECTION OF PULMONARY ASPIRATION USING PULSE OXIMETRY Principal Investigator & Institution: Edwards, Sharon J. None; St. Louis University St. Louis, MO 63110 Timing: Fiscal Year 2001; Project Start 01-MAY-2001 Summary: Mechanically ventilated patients are at high-risk for frequent small- volume aspirations of regurgitated gastric contents with potentially harmful consequences (e.g., pneumonia). Detection of micro-aspirations is a major clinical problem since the two most commonly used methods for this purpose (observing for dye and glucose in suctioned tracheobronchial secretions) have questionable sensitivity and specificity. The purpose of this study is to determine the extent to which a commonly used apparatus (pulse oximetry) can be used to detect micro-aspiration in an animal model. A pulse oximeter (a NONIN 8600 MV) will be applied to the animal's shaved tail and readings made at baseline and every 15 minutes for a period of 6 hours. The sample will consist of 30 anesthetized New Zealand White rabbits who are undergoing forced microaspiration of a solution of human gastric juice and dye-stained enteral formula. Since the presence of fiber in an enteral formula is likely to increase airway obstruction, two types of formulas will be analyzed, fiber-free and fiber-containing. There will be 12 rabbits placed in each formula group and 6 rabbits used as a control group (which will receive forced micro-aspirations of 0.9% normal saline). This sample size achieves a power of 80% at an alpha level of.01. Detection of aspiration will be considered to have occurred if there are 2 or more decreases in oxygen saturation >3% below baseline. The analysis of the proposed hypotheses will include a z-test to compare the proportion of experimental animals in which aspiration is detected by pulse oximetry. A 2 x 3 x 8 repeated measures analysis of covariance and planned comparisons will also be used to analyze relationships between the variables. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
44 Pneumonia
•
Project Title: DETERMINANTS OF UREAPLASMA-MEDIATED NEONATAL LUNG INJURY Principal Investigator & Institution: Viscardi, Rose M. Associate Professor; Pediatrics; University of Maryland Balt Prof School Baltimore, MD 21201 Timing: Fiscal Year 2002; Project Start 01-JUL-2002; Project End 30-JUN-2004 Summary: (provided by applicant): Respiratory tract colonization with Ureaplasma urealyticum (Uu) in preterm infants is a highly significant risk factor for Bronchopulmonary Dysplasia (BPD). In a prospective cohort of infants less than 32 wk gestation, 50 percent mod-severe BPD, 29 percent mild BPD, and 19 percent non-BPD subjects were Uu tracheal aspirate (TA) positive. Five of six (83 percent) infants who were TA Uu positive and serum or CSF PCR positive had BPD, suggesting invasiveness of the organism may be associated with increased pulmonary pathogenicity. However, invasive disease alone was not significantly associated with BPD, suggesting local immunomodulatory effects of Uu in the lung are required to develop BPD. We previously observed that Uu respiratory tract colonization in preterm infants was associated with greater levels of the pro-inflammatory cytokines tumor necrosis factor (TNF) and interleukin (IL)-1B in TA during the first week of life. In vitro studies of cultured preterm monocytes, Uu serovar 3 alone stimulated TNF and IL-8, and, in combination with bacterial endotoxin (LPS) augmented LPS-induced TNF release, but blocked LPS-induced IL-6 release. We used a clinical Uu isolate (biovar 2) to develop the first non-neonatal mouse model of Uu pneumonia. While these mice develop little detectable illness and minimal signs of lung injury, Uu infection caused a biphasic influx of neutrophils peaking 24h and again 14d after inoculation, and of macrophages peaking 48h and 14-28d after inoculation. Our long-term objective is to determine how Uu modulates the pulmonary immune response alone and in the presence of coinflammatory stimuli. The specific aims of this proposal focus on the central hypothesis that the Uu serovars; differ in their ability to promote the development of BPD due to differences in capacity to augment the pulmonary inflammatory response. The specific aims are: 1) determine whether the risk for BPD is Uu biovar or serovar specific by PCR typing of archived TA isolates, blood and CSF samples from preterm infants with and without BPD, and 2) characterize pathologic properties of TA Uu isolates from BPD and nort-BPD infants using our cell culture and murine Uu pneumonia models. These studies will provide new insights into how certain serovars contribute to the prolonged inflammatory process in BPD. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: DEVELOPMENT AND CHARACTERIZATION OF CD14 DEFICIENT MICE Principal Investigator & Institution: Freeman, Mason W. Chief; Massachusetts General Hospital 55 Fruit St Boston, MA 02114 Timing: Fiscal Year 2001; Project Start 15-FEB-2001; Project End 31-JAN-2006 Summary: (Adapted from the applicant's abstract): CD14 is a 55 kDa glycosyl phosphatidylinositol-linked protein that is also present in a soluble form in serum. CD14 binds lipopolysaccharides (LPSs) derived from the outermost layer of Gram-negative bacteria and activates a signaling cascade that results in the production of inflammatory cytokines that include tumor necrosis factor alpha, interleukin-6, and interleukin-1. This response has been shown to be important in the pathogenesis of septic shock following Gram- negative septicemia. Recent data have also suggested that a similar response may play a role in accelerating atherosclerotic plaque development and in enhancing the
Studies 45
formation of the macrophage foam cell, the histologic hallmark of the early atheroma. Several lines of evidence also implicate this pathway in the pathogenesis of PID, a leading cause of infertility in the developed world, and in the phagocytosis of apoptotic cells, an essential event in tissue remodeling and development. Investigators working on inflammatory bowel disease, periodontal disease, and a variety of inflammatory pulmonary disorders have also postulated an important role for CD14 in these conditions. Given the widespread interest in understanding the contributions of CD14 to normal physiology and pathologic conditions, the applicant's laboratory has generated homologous recombinant mice lacking this protein. This grant application proposes to generate a breeding colony of these animals and to distribute these mice to the many investigators that have requested them. These investigators, working on diseases supported by a diverse group of NIH Institutes, can then utilize these animals in experiments that explore the biological processes in which CD14 activity has been implicated. In addition to developing the breeding colony of CD14 deficient mice, this application proposes to characterize the utility of these animals as models for diseases that represent major human health problems in which the principal investigators of the grant have established research efforts. Thus, the CD14 deficient animals will be bred into mouse strains that are susceptible to atherosclerosis in order to explore the role of Chlamydial infections in the pathogenesis of cardiovascular disease. In addition, CD14null mice will also be used to explore the role of the endotoxin signaling pathway in mouse models of PID. This work is intended to broaden the applicability of CD14 deficient mice to research involving acute and chronic inflammatory disease and to make a critical animal resource available to the investigative community at large. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: DEVELOPMENT OF NOVEL ANTIFUNGAL ANTIPC NATURAL PRODUCTS Principal Investigator & Institution: Avery, Mitchell A. Associate Professor; Medicinal Chemistry; University of Mississippi University, MS 38677 Timing: Fiscal Year 2001; Project Start 01-JUN-1999; Project End 31-MAY-2003 Summary: (Adapted from Applicant's Abstract): The development of a new drug candidate for the treatment of Pneumocystis carinii pneumonia and azole-resistant Candida albicans, and the identification of one or more potential new therapeutic targets in these OI pathogens is proposed. Pseudolaric Acid B (PLAB), a diterpene acid isolated from the bark of a Chinese medicinal plant, Pseudolarix kaempferi, is proposed as a lead compound for the development of a new class of antipneumocystic and antifungal agents. PLAB appears to exert its antifungal activity and antipneumocystic activity by a novel mechanism of action involving a previously unrecognized therapeutic molecular target in these AIDS-related OI pathogens. To accomplish the objectives of new drug development and validation of the proposed new therapeutic target(s), pharmacophore-based tools for drug design by synthesis and bioassay are proposed. Parallel mechanisms of action studies are also proposed. Specifically, these goals will be met by completing ongoing studies directed towards the total synthesis of PLAB using methods that will also provide for construction of analogs not available by semi-synthesis (including carbon-14 labeled PLAB for use in mechanism of action studies); by preparing through semi-synthesis, PLAB analogs from PLAB and PLAC, both of which are in the process of being isolated from bulk quantities of Pseudolarix amabilis; by evaluating all prepared PLAB analogs for in vitro and in vivo inhibition of P. carinii and other fungal OI pathogens and for inhibition/activation of specific molecular targets; by determining the mechanism of action of PLAB and its active
46 Pneumonia
analogs by correlating effects on specific molecular targets with whole cell inhibitory effects; and, utilizing data derived above to design mechanism-based inhibitors/ activators of a specific therapeutic target. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: EARLY PULMONARY HOST DEFENSE IN M. TUBERCULOSIS INFECTIO Principal Investigator & Institution: Sherman, David R. Senior Scientist; Pediatrics; University of Washington Seattle, WA 98195 Timing: Fiscal Year 2003; Project Start 30-SEP-1999; Project End 31-JUL-2004 Summary: Although a lung is a portal of entry for this M. tuberculosis and chronic pneumonia is the most common disease caused by M. tuberculosis infection, the specific nature of the pulmonary host response to this pathogen is relatively unknown. The central goal of the studies outlined in this proposal is to determine whether components of the early pulmonary immune response are critical determinants for resistance or susceptibility to disease caused by M. tuberculosis. The specific aims will address the role of TNF-alpha, beta chemokines and the B7/CD28/CTLA4 costimulation pathway in the initiation and amplification of the pulmonary host response to aerosol infection with M. tuberculosis. Preliminary studies using transgenic mice with a local inhibition of TNF-alpha in the lung (SPCTNFRIIFc mice) indicate that blockade of TNF-alpha selectively in the lung results in early deaths, severe lung pathology and an alteration of antigen specific immunity. These studies also indicate that transgenic mice with local inhibition of the immune response in the lung are a useful model to study pulmonary host defense. Further studies are proposed to compare the response that develops in the lung vs. regional lymph nodes in wildtype and SPCTNFRIIFc mice. To investigate the role of beta chemokines in the pulmonary host defense, transgenic mice that secrete a virally encoded inhibitor of all chemokines has been generated. The phenotype of these mice will be determined then used to investigate the role of beta chemokines in the initiation of the pulmonary host response to M. tuberculosis. To investigate the role of the B7/CD28/CTLA4 costimulation pathway in the initiation and amplification of the pulmonary host response to M. tuberculosis, transgenic mice that secrete an inhibitor of the B7/CD28/CTLA4 co stimulation pathway will be generated, characterized then used in experiments examining the immune response to M. tuberculosis. To determine the relative importance of the intrapulmonary component of the immune response vs the systemic immune response, in each of the project specific aims, mice will be included with both local inhibition of the immune response and systemic inhibition. In the studies examining the pulmonary host response to M. tuberculosis, infections will occur via the aerosol route because inhalation is the usual route of infection in humans. The primary endpoints will include bacterial burden, lung histology, survival and the phenotypic and functional characteristics of the immune response. The proposed studies should advance the existing knowledge of the specific nature of the pulmonary immune response to M. tuberculosis, will directly test the role of these mediators in host defense against M. tuberculosis, suggest important targets for novel therapies and elucidate role of specific mediators of the host immune response that are critical for the induction of an antigen specific immune response by candidate vaccines. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
Studies 47
•
Project Title: EFFECT OF ZINC SUPPLEMENTATION ON PNEUMONIA IN CHILDREN Principal Investigator & Institution: Fataki, Maulidi R.; Muhimbili University Coll of Health Scis of Health Sciences Dar Es Salaam, Timing: Fiscal Year 2003; Project Start 15-SEP-2003; Project End 31-AUG-2006 Summary: (provided by applicant) Randomized trials carried out elsewhere in the developing countries have shown that dietary zinc supplementation in apparently healthy children reduces pneumonia incidence by 41%, however, all the studies that were analyzed had looked at the efficacy of zinc supplementation on the incidence of pneumonia during a prospective follow-up period and none had looked at the effect of zinc supplements on an episode of respiratory disease during the course of treatment. We propose to undertake a randomized, double blind, placebo-controlled trial to examine whether daily oral supplement of 10 mg of elemental zinc will reduce severity of respiratory disease among children admitted at Muhimbili National Hospital, Dares Salaam, Tanzania with radiographically confirmed pneumonia. Six hundred children aged between 6 months and 5 years who will be admitted because of radiologically confirmed pneumonia and whose parents/caretakers will give consent will be recruited during a 3-year study period and will be randomly assigned to receive either daily zinc supplements or placebo and the outcome between the two groups will be closely monitored and documented to determine any beneficial effects of zinc supplements on the course of hospital treatment of pneumonia with duration of hospital stay, fever, rapid respiratory rate and hypoxia as endpoints of interest After discharge from hospital each patient will be followed for duration of 6 months, once every month at study clinic at Muhimbili National Hospital to determine the effect of zinc supplements on growth patterns using increment in weight and height as endpoints. Baseline laboratory investigations to determine serum zinc levels, hematological profile and on consent HIV status will be done and a repeat of serum zinc levels will be done at the end of 6 month follow-up period for each child. At the end of the study appropriate statistical tests will be done to analyze the effects between the two study groups and dissemination of the information will be done. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: EFFECTS OF TOBACCO SMOKE ON AIRWAY BACTERICIDAL ACTIVITY Principal Investigator & Institution: Di, Yuan-Pu P. Environ & Occupational Health; University of Pittsburgh at Pittsburgh 350 Thackeray Hall Pittsburgh, PA 15260 Timing: Fiscal Year 2002; Project Start 18-SEP-2002; Project End 31-JUL-2005 Summary: (Taken from the Investigator's Abstract) Environmental stresses such as microorganisms and toxic chemicals have profound effects on lung injury and pulmonary disease. Airway bacterial infection has been associated with various lung diseases such as pneumonia, cystic fibrosis, and tuberculosis. Tobacco smoke (TS) is known to induce pulmonary diseases such as emphysema and lung cancer and has effects on the host defense mechanism against pathogens, but the molecular mechanisms by which this occurs is not completely understood. The long-term goal of this proposal is to investigate the functional characteristics of a novel airway specific gene, DD4, its regulation and its potential role in health and human lung diseases that relate to tobacco smoke. The human DD4 gene is specifically expressed in serous cells of submucosal glands where bactericidal proteins such as lysozyme and lactoferrin are secreted. This novel gene has exhibited significant response to promoting agents of
48 Pneumonia
mucous cell differentiation such as UTP and retinoids, as well as to several mediators of inflammation and proliferation such as tumor necrosis factor-alpha (TNF-alpha) and epidermal growth factor (EGF). Of potential significance, the candidate?s preliminary studies revealed that DD4 has antibacterial properties and that its secretion varied dramatically between different lung diseases. In addition, the candidate?s laboratory also observed that human DD4 MRNA expression is elevated upon TS stimulations in both time and dose dependent manner. The objective of this application is to elucidate effects of TS on the regulatory mechanism of DD4?s gene expression and to examine DD4?s function after TS exposure both in vitro and in vivo. The central hypothesis to be tested is that DD4 is a secreted bactericidal protein that plays a role in airway defense mechanisms against pathogens. The rationale behind this research is that modulation (such as TS exposure) of the secretary DD4 protein is one means of directly affecting host defense response against human airway infection. Therefore, regulation of DD4 gene expression and protein secretion in response to pathological stimuli must be understood before the mobilization of host defenses and the pathogenesis of airway diseases that are related to DD4 can be fully appreciated. To accomplish the objectives of this application, they will pursue three specific aims: (1) to characterize the bactericidal activity of DD4; (2) to elucidate the regulatory mechanism of TS exposure on DD4?s bactericidal function; (3) to evaluate DD4?s antibacterial effect in vivo. At the completion of this research, the candidate expects to have determined the bactericidal potency of DD4 and the regulation by TS of the antibacterial defense mechanism of DD4. The candidate expects that regulation of DD4 will prove to be related, at least in part, to the inflammatory response and tobacco smoke exposure. Finally, the candidate may obtain a better understanding of the pathogenesis of bacterial infections in certain lung diseases under effects of tobacco smoke, and the development of new therapeutic strategies. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: EFFECTS OF TRAUMATIC STRESS ON GASTRIC SECRETIONS Principal Investigator & Institution: Mercer, David A.; University of Texas Hlth Sci Ctr Houston Box 20036 Houston, TX 77225 Timing: Fiscal Year 2001 Summary: Over the last decade, the Trauma Research Center has explored the role of the gut in the pathogenesis of multiple organ failure (MOF). It is our working hypothesis that the gut is a source of pro-inflammatory mediators in early MOF and serves as a reservoir for pathogens and toxins in late MOF. This research proposal contends that the stomach becomes a reservoir for bacteria during traumatic stress because inhibition of gastric acid secretion occurs with resultant loss of natural bactericidal activity. The inevitable bacterial overgrowth in the stomach may play a significant role in the development of nosocomial pneumonia which occurs in 10%- 65% of IC patients and is associated with case fatality rates ranging from 13-55%. The current research proposal is designed to identify mechanisms regulating inhibition of gastric acid secretion during traumatic stress cause inhibition of gastric acid secretion by the gastric H/K-ATPase, the enzyme responsible for acid secretion, via changes in gut peptide (somatostatin and gastrin) expression which are nitric oxide and prostaglandin sensitive. To address this hypothesis, we will utilize the mesenteric ischemia/reperfusion model as well as the LPD model in rats, because of their abilities to mimic the syndrome of MOF. The specific aims to prove or disprove this hypothesis are as follows. The first aim will be to elucidate the effects of traumatic stress induced experimentally with lipopolysaccharide (LPS( and mesenteric ischemia/reperfusion, on
Studies 49
gastric acid secretion. The second aim will evaluate the effects of traumatic stress on the gastric H/K-ATPase. The third aim will determine whether gut peptide (i.e. gastrin and somatostatin) expression is altered following traumatic stress. The fourth aim will examine the role of nitric oxide synthase in traumatic stress induced changes in gastric secretion. The fifth aim will assess whether cyclooxygenase expression modifies gastric secretion following traumatic stress. The results of this research proposal will clarify the mechanisms regulating inhibition of gastric acid secretion during traumatic stress and may allow identification of new therapeutic strategies that could ultimately prevent or decrease the likelihood of developing nosocomial pneumonia in patients with or at high risk for MOF. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: ELDERLY POLYSACCHARIDE
IMMUNE
RESPONSE
TO
PNEUMOCOCAL
Principal Investigator & Institution: Westerink, Ma J. Medicine; Medical College of Ohio at Toledo Research & Grants Admin. Toledo, OH 436145804 Timing: Fiscal Year 2001; Project Start 01-APR-2000; Project End 31-MAR-2005 Summary: Infection is one of the leading causes of morbidity and mortality in the elderly. Streptococcus pneumoniae is the organism most commonly isolated from elderly patients with pneumonia. Increased susceptibility to infections that occur in the elderly has been attributed to deteriorating health, decreased pulmonary function and a functional decline of the immune system. The immune system is unique in that it may be manipulated to achieve a desirable response. Studies in aged mice demonstrate both quantitative and qualitative changes in the immune response to T-independent type 2 (TI-2) antigens. Reports indicate age related loss of affinity, fine specificity and protective immunity are associated with a molecular shift in V gene usage and changes in cytokine profile. Studies of the in vivo immune response in elderly have been limited to vaccine efficacy studies and quantitative analysis of the magnitude and duration of the post-vaccination antibody response. The results of these studies suggest that despite adequate quantitative immune response the elderly show decreased vaccine efficacy. Current knowledge concerning the aging immune response to TI-2 antigens is mostly based on animal models and may not be applicable to humans. Human studies are fragmented and address quantitative and qualitative immune response as separate issues. We propose to study and characterize the immune response to S. pneumoniae capsular polysaccharide in the elderly. We will focus on both quantitative and qualitative changes in the immune response on molecular and functional levels. The quantitative immune response, isotype and IgG subclass, will be correlated with opsonophagocytic activity. We hypothesize that the discrepancy between the quantitative and qualitative immune response in the elderly results from altered V region sequence. We will characterize the immunoglobulin gene usage pattern and V-DJ joint diversity of the antibody response to pneumococcal polysaccharides (PPS) of serotypes 4 and 14 in elderly and young adults. This will be accomplished by gene family specific ELISA and by isolating single responding cells and determining the sequence of the V chains. Second, we propose to evaluate the influence of soluble regulatory factors on the aging immune response. The reconstituted SCID mouse model will be used to study the aging human B cell response to PPS 4 and 14 in a controlled cytokine environment allowing us to differentiate altered response intrinsic to the B cells versus altered responses secondary to environmental factors such as cytokines. The results of these studies will form the essential baseline for the rational development of vaccine and adjuvant strategies for the elderly.
50 Pneumonia
Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: ELR-CXC CHEMOKINES IN LUNG ANTIBACTERIAL HOST DEFENSE Principal Investigator & Institution: Standiford, Theodore J. Professor; Internal Medicine; University of Michigan at Ann Arbor 3003 South State, Room 1040 Ann Arbor, MI 481091274 Timing: Fiscal Year 2002; Project Start 01-DEC-1996; Project End 30-NOV-2005 Summary: (provided by applicant): Bacterial pneumonia is the second most common cause of hospital-acquired infection, and is leading cause of death among all nosocomial infections. Innate, or natural immunity, is the principal pathway for effective elimination of bacterial organisms from the lung. While ELR-CXC chemokines have been shown to be expressed during the generation of Th1 cell-mediated immune responses against intracellular microbial pathogens, the contribution of this family of chemokines to innate immunity against common gram-positive and gram-negative bacterial pathogens is unknown. We have focused this competitive renewal on ELRCXC chemokines, as our preliminary observations indicate that the in-vivo depletion of selected ELR-CXC chemokines substantially impairs bacterial clearance and survival of mice with pneumonia due to Klebsiella pneumoniae. It is the hypothesis of this proposal that ELR-CXC chemokines are integral components of the innate neutrophildependent immune response against gram-negative bacterial infection of the lung. A murine model of Klebsiella pneumonia will be employed to achieve the following specific aims: 1) to determine the time course of expression and cellular sources of ELRCXC chemokines and their common receptor (CXCR3) during the evolution of gramnegative bacterial pneumonia; 2) to determine the contribution of ELR-CXC chemokines and their receptor to leukocyte recruitment, proinflammatory cytokine expression, bacterial clearance, survival in Klebsiella pneumonia using specific neutralizing antibodies or knockout mice; 3) to determine the effect of IP-10 or MIG administration/transgenic expression on proinflammatory cytokine expression, bacterial clearance, and survival in murine Klebsiella pneumonia in-vivo and on alveolar macrophage effector cell function in-vitro; and 4) to identify endogenous signals that regulate the expression of ELR-CXC chemokines during the evolution of Klebsiella pneumonia in-vivo and in isolated lung cells in-vitro. Elucidation of specific cellular and molecular mechanisms of lung antibacterial host defense, in conjunction with the use of novel gene therapy approaches will provide important insights into the treatment of patients with serious multi-drug resistant bacterial infections of the lung. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: ENTERAL VS IV FEEDING: EFFECT ON MUCOSAL IMMUNITY Principal Investigator & Institution: Kudsk, Kenneth A. Surgery; University of Wisconsin Madison 750 University Ave Madison, WI 53706 Timing: Fiscal Year 2002; Project Start 01-FEB-1998; Project End 31-MAR-2006 Summary: Hospital acquired pneumonia costs up to 2 billion dollars per year in the United States, and any inexpensive therapy which reduces this septic complication could greatly impact health care costs. Enteral feeding significantly reduces the complications of pneumonia compared with intravenous (IV-TPN) feedings by 60-70 percent in trauma patients. Our experimental and clinical work implicates previously unrecognized defects in mucosal immunity which develop when the intestinal tract is not stimulated with enteral feeding or when surrogates of enteral feeding are not
Studies 51
provided. The principal specific immunologic defense at mucosal surfaces is secretory IgA produced by the mucosal-associated lymphoid tissue (MALT). The principal anatomic site for immunologic sensitization of Peyer's patches within the small intestine. Adhesion molecules direct unsensitized immunocytes through the Peyer's patches where these lymphocytes are sensitized and change their own surface integrins. They are then directed to both intestinal and extraintestinal sites, such as the respiratory tract, where they produce IgA against those antigens. The antibody binds to bacteria, preventing their attachment and their ability to infect. This proposal focuses on how route and type of nutrition affects the expression of the specific adhesion molecules, modified MAdCAM-1, unmodified MAdCAM-1, and ICAM-1 which are important in directing unsensitized immunocytes into Peyer's patches. The proposal tests the hypothesis that interaction between these adhesion molecules and their ligands on naive T and B cells are critical in maintaining mucosal immunity in both intestinal and extraintestinal sites. The proposal is designed to test the hypothesis that inhibition of these interactions recreates the defects in in vivo mucosal defenses that are induced when enteral feeding is not provided. It also focuses on previous observations that a specific immunocyte fuel, glutamine, and the enteric nervous system neuropeptide, bombesin, can act as surrogates for enteral feeding and exert beneficial effects upon the MALT in IV-TPN-fed animals by upregulating MAdCAM-1 and ICAM- 1 expression. The experiments are designed to confirm that IgA is a critical element of specific immunity and respiratory defenses against pneumonia with in vivo experiments. These experiments use a monoclonal antibody produced by a hybridoma cell line which is specific for polysaccharide antigen(s) found on a high percentage of clinical isolates of Pseudomonas aeruginosa. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: ENVIRONMENTAL AND MOLECULAR EPIDEMIOLOGY OF P CARINII Principal Investigator & Institution: Vermund, Sten H. Professor; Medicine; University of Alabama at Birmingham Uab Station Birmingham, AL 35294 Timing: Fiscal Year 2001; Project Start 15-AUG-1998; Project End 30-APR-2004 Summary: Despite the recent declines in incidence Pneumocystis carinii pneumonia (PCP) remains the leading cause of mortality among those individuals diagnosed with AIDS. Although antimicrobial compounds are available for treatment and prophylaxis, many individuals fail to respond to treatment, develop infections in spite of prophylaxis, or have serious toxicity from the available medications. Controlling the source of infection could lead to lower PCP incidence. However, due to research limitations from the lack of an in vitro culture system for Pneumocystis carinii (PC), the source of transmission remains unknown. Previously, the prevailing assumption was that reactivation of a latent infection with PC occurs in severely immunosuppressed individuals. However, recent studies indicate that PC has a limited persistence in immunocompetent persons implying that PCP results from de novo acquisition of the organism during periods of immunosuppression. Furthermore, animal studies have demonstrated airborne transmission of PC between immunosuppressed rodents, and clinical studies have suggested airborne patient-to-patient transmission. The Investigator proposes to determine if the horizontal transmission of PC from infected to susceptible humans is possible and if this mode of transmission contributes significantly more than other possible airborne environmental sources to the occurrence of PCP in susceptible persons. In order to accomplish these goals the Investigator plans to use a recently developed molecular assay that detects human PC DNA as well as a typing
52 Pneumonia
system that can track strain types from patient to environment. Further, the Investigator proposes to develop and validate an RT-PCR assay to assess the viability of PC organisms once collected from the environment. Using these molecular tools, the researchers will characterize the occurrence of viable human PC in the home and hospital environment, identify potential sources, and determine the influence of seasonal factors and indoor climate conditions on the presence, persistence, and viability of this organism. The long-term objective of this research is to prevent the transmission of PC in the health care as well as the home setting, thereby reducing the risk of PC infection among immunosuppressed individuals. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: EPITHELIAL INFLAMMATION
CELL
GENE
EXPRESSION
IN
AIRWAY
Principal Investigator & Institution: Brasier, Allan R. Professor; Internal Medicine; University of Texas Medical Br Galveston 301 University Blvd Galveston, TX 77555 Timing: Fiscal Year 2001; Project Start 01-SEP-2000; Project End 31-AUG-2003 Summary: (Adapted from applicant's abstract): The human pathogen respiratory syncytial virus (RSV) induces mucosal inflammation by replication in the airway epithelium. In particular, severe lower respiratory tract infection (pneumonia and bronchiolitis) with RSV produces inflammatory mononuclear cell recruitment, airways remodeling and post-infectious airway hyper-reactivity (asthma). We and others have shown that RSV replication is a potent inducer of CC- and CXC-type chemokine synthesis, chemokines that play an important role in the subsequent immune response. Here we will comprehensively pursue our observations that lower respiratory tract cells produce greater amounts of eosinophilic CC chemokines than do upper respiratory tract cells. We hypothesize that the pathogenesis of RSV-induced respiratory tract inflammation is partly due to the consequence of cell type- dependent effects on inducible gene expression where lower respiratory tract cells express a different profile of inflammatory genes. Three aims pursued in this project are: (1) we will apply cDNA microarrays to profile the pattern of inflammatory gene expression in RSV-infected lower airway epithelial cells. From this, we will establish a database of constitutive and RSV-inducible immune response genes. We will identify those genes whose expression is activated directly by virus or indirectly (through paracrine factors); (2) we will compare the patterns of RSV-inducible genes in tracheal and upper airway epithelial cells with that of lower respiratory tract cells to establish whether there are distinct patterns of inducible gene expression; and (3) we will identify genes induced following infection with clinical RSV isolates of the two major groups (A and B) associated with mild or severe disease to determine whether there are strain-dependent effects of RSV on epithelial gene expression. This multidisciplinary approach uses specific expertise in molecular biology, immunology and computational biology to systematically characterize the expression of inflammatory gene networks in RSV-infected epithelial cells. These studies are aimed at advancing our understanding of pathogen-induced mucosal inflammation and identifying gene targets whose activity can be modulated by therapeutic agents. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: FOCUS Principal Investigator & Institution: Carson, Jeffrey L. Richard C. Reynolds Professor of Medicin; Medicine; Univ of Med/Dent Nj-R W Johnson Med Sch Robert Wood Johnson Medical Sch Piscataway, NJ 08854
Studies 53
Timing: Fiscal Year 2003; Project Start 01-SEP-2003; Project End 31-AUG-2008 Summary: (provided by applicant); Red blood cell transfusions are an extremely common medical intervention in both the United States and worldwide; over 11 million units are transfused in the United States. Between 60% and 70% of all blood is transfused in the surgical setting. Despite the common use of red blood cell transfusions, the threshold for transfusion has not been adequately evaluated and is very controversial. A decade ago the standard of care was to administer a peri-operative transfusion whenever the hemoglobin (Hgb) level fell below 10 g/dl (the "10/30 rule"). Concerns about the safety of blood, especially with respect to HIV and hepatitis, and the absence of data to support a 10 g/dl threshold led to current standard of care today to administer blood transfusions based on the presence of symptoms and not a specific Hgb/hematocrit level. However, there are no randomized clinical trials in surgical patients that have tested the efficacy and safety of withholding blood until the patient develops symptoms or the "10/30" approach to transfusion. Patients with underlying cardiovascular disease are at greatest risk of adverse effects from reduced Hgb levels. We propose to conduct a multi-center randomized trial to test if a more aggressive transfusion strategy that maintains postoperative Hgb levels above 10 g/dl improves patient outcome as compared to a more conservative strategy that withholds blood transfusion until the patient develops symptoms of anemia. Eligible patients for the trial will have undergone surgical repair for a hip fracture and have a postoperative Hgb level below 10 g/dl within three days of surgery. Only patients with cardiovascular disease will be entered into the study. Patients will be randomized to one of the two transfusion strategies. The 10 g/dl threshold strategy will use enough red blood cell units to maintain Hgb levels at or above 10 g/dl through hospital discharge. Symptomatic transfusion strategy patients will receive red blood cell transfusions for symptoms of anemia, although transfusion is also permitted but not required if the Hgb level falls below 8 g/dl. Outcomes will include functional recovery (primary outcome: ability to walk ten feet across a room without human assistance at 60-days postrandomization), long-term survival, nursing home placement, and postoperative complications (death in hospital or within 30 days, pneumonia, myocardial infarction, thromboembolism, stroke, delirium). We will randomize 2,600 patients from 25 centers over a 3.5-year period. This will allow us to detect a 16% relative risk reduction in the loss of ability to walk independently with power about 0.90. A pilot study in 84 patients demonstrated the feasibility of the study. Ambulation at 60 days is known to be highly predictive of ultimate functional outcome as well as of mortality at one year. Because inability to walk again has such important implications for quality office, and because, unfortunately, it is a common problem, it far outweighs the remote chance of viral infection or other complications from transfusion in these elderly patients. Also, this study will measure the frequency and 95% confidence intervals of the medical errors that are important in this patient population and are poorly documented in the literature. The medical errors that will be measured are: transfusion errors (blood transfusion to the wrong patient, mislabeling of samples for type and cross match, use of whole blood instead of packed red cells), failure to use thromboembolism prophylaxis, incorrect antibiotic prophylaxis, wrong site surgery and femoral shaft fracture. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: FUNCTIONAL SENESCENCE OF INNATE IMMUNITY AND PNEUMONIA Principal Investigator & Institution: High, Kevin P. Internal Medicine; Wake Forest University Health Sciences Winston-Salem, NC 27157
54 Pneumonia
Timing: Fiscal Year 2003; Project Start 15-SEP-2003; Project End 31-AUG-2004 Summary: #14 Functional Senescence of Innate Immunity and Pneumonia Risk in Older Adults.With advancing age, there is a general waning of immune competence collectively termed immune senescence. Previously, immune senescence was felt to primarily affect only the adaptive immune system (e.g. B and T cell responses, delayed typehypersensitivity), the hallmark of which is recognition of specific antigens with memory responses. However, recent data suggest innate immunity is also profoundly affected. Innate immunity does not depend on prior exposure to a specific antigen, but recognizes general patterns of microbial products (e.g. microbial lipoproteins, DNA, peptide sequences). Two important components of innate immunity are profoundly impaired with advanced age, even in the absence of significant co-morbidity. First, phagocytic function (the ability to engulf bacteria) of polymorphonuclear neutrophils (PMNs) is markedly reduced in older adults. This correlates with lower cell surface expression of CD16, an important receptor through which PMNs recognize the Fc portion of immunoglobulin and phagocytose bacteria. Second, very recent animal studies have shown impaired expression of Toll-like receptors (TLRs) and reduced cytokine production after stimulation of TLRs by specific ligands. Human studies are needed to determine if this is true in older humans. Little is known about the relationship between immune senescence, particularly senescent nnate immunity, and the risk of acquiring infections in older adults. The major goals of this proposal are to provide important pilot data to assist in designing of future studies of immune senescence, and to test our general hypothesis that senescent innate immunity contributes to the risk of infection in older adults. Using standard methods of flow cytometry and ELISA cytokine assays within an ongoing study of community-acquired pneumonia (CAP) in older adults, the specific aims are: 1) Determine whether innate and adaptive immune senescence occur in the same individuals or are independent phenomena; 2) Determine the intra-individual variation of innate immune senescence parameters (PMN phagocytosis and CD16 expression, and TLR expression and function) in older adults with and without CAP; and 3) Determine whether there is an association between CAP and senescent innate immunity. These data are essential to design meaningful studies using the case-control method, the most effective means of studying the link between immune senescence and infection risk. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: GASTRIC FEEDING TUBES: PATIENT/FAMILY/PROVIDER VIEWS Principal Investigator & Institution: Carey, Timothy S. Professor of Medicine; Medicine; University of North Carolina Chapel Hill Office of Sponsored Research Chapel Hill, NC 27599 Timing: Fiscal Year 2001; Project Start 01-SEP-2000; Project End 28-FEB-2003 Summary: We propose a two and a half year prospective study of predominantly older individuals with neurologic diseases, head and neck cancer, and severe medical illness who receive gastric feeding tubes. We wish to define the outcomes of this treatment from a patient and caregiver perspectives. The number of gastrostomy feeding tubes used for the Medicare population has grown rapidly, more than doubling during the past decade. The diseases that cause dysphagia also shorten life expectancy, and cause other deficits in cognitive, physical and social functioning. Nutrition, hydration, and the social context of eating are fundamental elements of comfort care for these patients near the end of life. Feeding is a primary act of care giving and nurture, yet tube feedings have become a form of life- sustaining treatment fraught with ethical implications for patients and caregivers. Previous studies have emphasized medical outcomes of this
Studies 55
procedure. No prior study has examined outcomes of this treatment from the patient and caregiver perspective. Our overall aims are: 1. Describe the expectations of patient, family, health care providers regarding the benefits of gastric feeding tubes on: patient longevity, patient functioning, likelihood of hospitalization for pneumonia. 2. Compare perceived benefits of gastric feeding tubes at the time of placement to perceived benefits such as outcomes of survival, functional status and pneumonia at 3 and 6 month followup, from the perspectives of patient, family and health care providers, including physicians and nurses. 3. Describe the true outcomes of patient survival, pneumonia incidence and functional status among those who survive for 3 and 6 months after insertion of the feeding tube. We will recruit 200 patients receiving gastrostomy from two North Carolina hospitals: a university tertiary care center, and a large community hospital. Interviews will be conducted with physicians, nurses, family caregivers and patients shortly following the procedure with follow-up interviews at 3 and 6 months. The interview will include assessment of functional status, perceived benefit, and expectations regarding longevity and future function. These multiple perspectives on the use of gastrostomy tubes will allow a much more complete portrait of the benefits and limitations of this increasingly utilized supportive therapy at the end of life. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: GENDER-BASED OUTCOME DIFFERENCES IN NOSOCOMIAL PNEUMONIA Principal Investigator & Institution: Evans, Heather L. Surgery; University of Virginia Charlottesville Box 400195 Charlottesville, VA 22904 Timing: Fiscal Year 2002; Project Start 01-SEP-2002 Summary: (provided by applicant): Controversy exists regarding the effect of gender on differences in surgical infectious disease outcomes. Previously, our laboratory reported that the gender-based difference in mortality was greatest among critically ill patients who developed nosocomial pneumonia. Therefore, the proposed prospective, observational cohort study will concentrate on these hospital-acquired infections, stratifying patients not only by gender, but also by estrogen-status. Based on evidence that women who develop nosocomial pneumonia are at higher risk for death, especially if they are elderly, we hypothesize that estrogen-rich pre-menopausal women will be least likely to develop nosocomial pneumonia, while post-menopausal women will have the highest mortality. Thus, we hope to confirm our earlier findings of the incidence and mortality related to nosocomial pneumonia, and to further evaluate three areas of potential gender differences to account for the disparate outcomes: diagnosis, treatment and immune response. We believe that these areas are not only influenced by sex-based biologic and physiologic features, but also social factors. In the future, these data may lead to methods that facilitate either prevention, or earlier diagnosis and more efficacious treatment of nosocomial pneumonia, a disease which accounts for a substantial proportion of the lethal infections in surgical patients. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: GENE DISCOVERY FOR PNEUMOCOCCAL OTITIS MEDIA Principal Investigator & Institution: Pettigrew, Melinda M. Epidemiology and Public Health; Yale University 47 College Street, Suite 203 New Haven, CT 065208047 Timing: Fiscal Year 2003; Project Start 01-JUL-2003; Project End 30-JUN-2006 Summary: (provided by applicant): Otitis media (OM) is the most common bacterial infection in the United States among young children for which medical care is sought,
56 Pneumonia
and Streptococcus pneumoniae strains are the leading cause of bacterial OM. These gram-positive diplococci colonize the respiratory tract in up to 50% of healthy children and only cause disease under special circumstances. Recent genomic sequencing projects and advancements in molecular biology have resulted in the identification of numerous putative virulence factors. These factors have mainly been studied in the context of invasive pneumococcal diseases such as pneumonia, or have been studied in one or a few laboratory strains. While more virulence factors remain to be discovered, the new challenge is to identify which of these many factors warrant further study, to link these factors specifically to OM pathogenesis, and to estimate the relative importance of these virulence factors among the S. pneumoniae strains in circulation. This project is built on the observation that S. pneumoniae strains differ in their ability to cause disease, and that these differences are likely due to genetic differences between strains that extend beyond the polysaccharide capsule. The goal of this project is to identify genes associated with pneumococcal OM and to evaluate the relative frequency of pneumococcal virulence genes among a collection of isolates obtained from healthy children and children with clinical disease. A four step interdisciplinary approach utilizing techniques of molecular biology and epidemiology will include: 1. Selection of S. pneumoniae strains for genomic subtraction with the highest potential to identify genes associated with OM. 2. Identification of DNA sequences (sPCR fragments) unique to strains causing OM (tester strains) and absent in strains from healthy carriers (driver strains) using genomic subtraction. 3. Epidemiologic screening of a large collection of isolates from healthy children and children with OM, meningitis, pneumonia, or bacteremia using sPCR fragments. 4. Identification of genes associated with sPCR fragments important for OM pathogenesis and description of their biological and clinical characteristics. Discovery of additional factors involved in streptococcal OM will facilitate the development of new strategies for the control and prevention of this important disease. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: GENETIC ANALYSIS OF GBS ADHERENCE TO FIBRONECTIN Principal Investigator & Institution: Tamura, Glen S.; Children's Hospital and Reg Medical Ctr Box 5371, 4800 Sand Point Way Ne, Ms 6D-1 Seattle, WA 98105 Timing: Fiscal Year 2001; Project Start 15-AUG-1998; Project End 31-JUL-2003 Summary: GBS adherence to epithelial cells may play an important role in pathogenesis of GBS pneumonia. I propose that GBS adherence to epithelial cells is mediated, at least in part, by GBS adherence to fibronectin. I have isolated four transposon mutants with single insertions which show decreased adherence to fibronectin; 3/4 of these show decreased adherence to epithelial cells. One mutant has been tested in a neonatal rat model of pulmonary colonization, and shows a significantly decreased ability to persist in the lungs of neonatal rats at 24 hours. I have cloned the transposon insertion sites from two of these mutants. One mutant contains a mutation in a gene which shows significant homology to ABC transporters, while the other contains a mutation immediately upstream of a gene with homology to multiple surface receptors. Disruption of the ABC transport gene by plasmid insertional mutagenesis demonstrates that this gene is required for maximal fibronectin adherence. I propose to study the role of GBS adherence to fibronectin in the pathogenesis of neonatal pneumonia and sepsis. I propose to clone the transposon insertion sites of the additional two mutants, and to create targeted mutations in genes of interest as well as complement mutants to confirm the role of the transposon insertion in the phenotype. Using this strategy, I propose to clone the structural gene for the fibronectin adhesin. If necessary, I will create additional
Studies 57
fibronectin adherence mutants. The role of these genes will be further studied in the mouse model of neonatal pulmonary colonization. These studies will establish a role for fibronectin adherence in the pathogenesis of GBS disease. The role of these putative adhesin genes will then be tested after hyperexpression of the adhesin gene by blockade of binding of GBS to fibronectin with both the cloned adhesin and antisera to the adhesin. These studies will allow for identification of the structural gene(s) for fibronectin adhesin(s). Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: GENETIC AND INFLAMMATORY MARKERS OF SEPSIS Principal Investigator & Institution: Angus, Derek C. Anestheslgy/Critical Care Med; University of Pittsburgh at Pittsburgh 350 Thackeray Hall Pittsburgh, PA 15260 Timing: Fiscal Year 2001; Project Start 01-APR-2001; Project End 31-MAR-2005 Summary: (Verbatim from the Applicant's Abstract): Sepsis, a diffuse inflammatory response to infection, occurs in over 450,000 cases per year in the US and frequently progresses to organ dysfunction and death. Although experimental studies using cells and animals have greatly improved our understanding of the pathophysiology of sepsis, there remains a remarkable paucity of biochemical and genetic data regarding the natural history of this important public health problem. In particular, there is a need for better markers of sepsis and outcome and a more rigorous evaluation of the complex relationships among the many genetic, inflammatory, and clinical factors that appear to influence the development and outcome of sepsis. Because pneumonia is the most common cause of sepsis, patients with this infection represent an excellent clinical model for studying sepsis in a relatively homogeneous population. We propose to study a large cohort of patients (n=2,703) with community-acquired pneumonia (CAP). Our study will be "piggy-backed" onto a multicenter trial of alternative hospital quality improvement initiatives that is already funded and slated to begin enrolling patient's early in 2001. In addition to collecting detailed clinical data, we will carry out careful genetic analyses, focusing on allelic variations in the coding or noncoding regions of genes whose products are important in the expression and/or regulation of the inflammatory response. We will also obtain measurements over time of the plasma concentrations or cell surface expression of several key inflammatory molecules. We will determine the influence of specific polymorphisms on the development, course and outcome of pneumonia and sepsis. We will test whether genetic predisposition to an exuberant inflammatory response protects against infection yet also increases risk for adverse systemic effects and outcome. We will compare genetic data from patients with results obtained from a cohort of healthy controls (n=300). We will test several existing hypotheses regarding the association of circulating inflammatory molecules with outcome. We will use time-varying regression analyses and probabilistic networks to explore in new detail relationships among genetic polymorphisms and the inflammatory response in sepsis. Finally, we will construct and evaluate two sets of clinical decision tools: i.) clinical risk prediction rules that incorporate genetic and inflammatory response variables with existing clinical factors, and; ii.) a state-transition simulation model of the course of sepsis that allows time-dependent estimates of the effects of alternative treatment decisions. This study will generate: new and valuable information regarding existing lines of inquiry and laboratory investigation; new hypotheses arising from the use of time-dependent modeling; and new clinical decision tools that have immediate and practical value for designing clinical trials and improving patient care. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
58 Pneumonia
•
Project Title: GENETIC DETERMINANTS OF PATHOGENICITY IN LEGIONELLA Principal Investigator & Institution: Tompkins, Lucy S. Professor; Microbiology and Immunology; Stanford University Stanford, CA 94305 Timing: Fiscal Year 2001; Project Start 01-MAR-1991; Project End 31-JAN-2003 Summary: (Adapted from the applicant's abstract): Legionella pneumophila is a facultative intracellular pathogen that grows inside protozoans in fresh water sources. Susceptible humans may develop a fulminant pneumonia called Legionnaires disease following inhalation of contaminated water aerosols. This opportunistic pathogen contributes significantly to community-acquired and nosocomial pneumonia infection rated and is associated with serious morbidity and mortality. During human infection, and in animal models, virulent L. pneumophila elicits a cellular immune response, including recruitment and activation of macrophages, which serve as the primary cellular target for entry and subsequent growth and the production of specific cytokines. A series of prior studies has demonstrated that the outcome of the interaction with macrophages depends upon the expression of L. pneumophila genes, some of which may be regulated by intracellular environmental signals. Only a few genes that apparently are involved in this interaction have been discovered, and the definitive role of any of these in the pathogenesis of infection and disease in unknown. Studies on a L. pneumophila mutant that lacks the capacity to produce protease strongly suggest that virulence was attenuated in an animal model, and furthermore, that this effect might be directly related to impairment of the host s immune response, including cytokine production. Other studies demonstrated that prior growth of laboratory passaged strains in Acanthamoeba enhanced the invasiveness of L. pneumophila into macrophages. This was associated with the expression of new polypeptides. The specific aims of the proposal are to: 1) further define the contribution of the protease protein to L. pneumophila pathogenesis and host immune response: and 2) detect and define the role of new genes, not yet discovered, that are involved in intracellular growth in eukaryotic cells. Dr. Tompkins propose to study the cell biology of he interaction of macrophages with wild-type strains and mutants to characterize and define the steps in intracellular growth governed by each gene product. She will also use two new genetic selection methods to isolate and identify new genes involved in intracellular growth. Thus, the proposal incorporates novel molecular and genetic methods and utilizes contemporary microscopy techniques, including laser confocal microscopy, to further define and characterize the cell biology of Legionella in eukaryotic cells. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: GENETIC RISK FACTORS FOR PNEUMONIA IN SLE PATIENTS Principal Investigator & Institution: Freemer, Michelle M. Medicine; University of California San Francisco 500 Parnassus Ave San Francisco, CA 94122 Timing: Fiscal Year 2003; Project Start 15-JUL-2003 Summary: (provided by applicant): Systemic lupus erythematosus (SLE) can be a severely disabling disease and may affect any portion of the respiratory tract. The most frequent lung disease in SLE patients is pneumonia. It constitutes a major source of morbidity as well as mortality in these patients. While many of the clinical factors predisposing SLE patients to infections have been investigated, the genetic risk factors for pneumonia have not been thoroughly examined. The University of California, San Francisco (UCSF) Lupus Genetics Project, represents a well-characterized, ethnically diverse cohort of patients. Furthermore, the availability of genotype analysis for these patients provides an ideal opportunity to determine the impact of genetic
Studies 59
polymorphisms on SLE patients' risk of developing pneumonia. Interestingly, prior investigators have identified genetic risk factors for infections in healthy populations that correspond to some of the polymorphisms associated with the development of SLE Evaluation of the relationship between pneumonia and these polymorphisms in an SLE population will yield insight into whether the genetic risk factors identified in healthy hosts also account for the high infection rate observed in SLE patients. This information has significant clinical implications regarding SLE patients' need for immunization and antibiotic prophylaxis. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: GENETICS PNEUMOPHILA
OF
IRON
ACQUISITION
BY
LEGIONELLA
Principal Investigator & Institution: Cianciotto, Nicholas P. Professor; Microbiology and Immunology; Northwestern University Office of Sponsored Programs Chicago, IL 60611 Timing: Fiscal Year 2001; Project Start 01-APR-1995; Project End 31-MAR-2004 Summary: (Adapted from the Applicant's Abstract): Legionella pneumophila, the etiologic agent of Legionnaires' disease, is a significant cause of both communityacquired and nosocomial pneumonia. This gram-negative bacterium is an intracellular parasite of human alveolar macrophages and aquatic protozoa. Although critical for intracellular survival, the mechanisms used by L. pneumophila for iron acquisition have remained largely unknown. However, recent biochemical and genetic studies have uncovered four Legionella strategies for iron uptake. First, a potentially novel siderophore was discovered in the supernatants of virulent strains. The detection of this iron chelator required the universal CAS assay and was strain and culture dependent, explaining the previous negative results. Second, they identified an iron-regulated gene that encodes an analog of aerobactin synthetases and promotes intracellular replication, suggesting the existence of a second L. pneumophila siderophore. Third, the analysis of a mutant that was defective for intracellular infection and virulence revealed a gene (ira216) encoding a di/tripeptide transporter. The reduced ability of this mutant to acquire intracellular iron suggests that L. pneumophila imports iron-loaded peptides during macrophage infection. Finally, another iron acquisition and infectivity mutant appears to lack an ABC- transporter (ira225), which is similar, but not identical, to other bacterial systems that assimilate unchelated iron. This grant renewal will define more precisely the nature of these pathways. Upon demonstration that the siderophores are expressed within infected host cells, a set of mutants will be used to ascertain the role of the iron chelators in intraphagosomal growth. Mass spec and NMR will define the structure of the purified siderophores. CAS and Csaky assays as well as Southern hybridizations will determine whether these iron scavengers are peculiar to the pathogenic Legionella species, as preliminary data suggest. Next ira216 and ira225 mutants will be assessed for reduced abilities to grow in defined media where iron is provided as either iron-loaded peptides or ferric citrate. Conversely, the cloned genes will be examined for the abilities to enhance the iron assimilation of E. coli uptake mutants. To gauge the total number of iron uptake systems that operate intracellularly, double mutants, e.g. Sid-, ira216 negative strain, will be analyzed for iron and infectivity defects. Taken together, the proposed experiments will offer greater insight into Legionella pathogenesis as well as intracellular parasitism and microbial iron acquisition in general. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
60 Pneumonia
•
Project Title: GENOME ANALYSIS OF STREPTOCOCCUS AGALACTIAE Principal Investigator & Institution: Tettelin, Herves' S. Associate Investigator; Institute for Genomic Research Rockville, MD 20850 Timing: Fiscal Year 2001; Project Start 30-SEP-2001; Project End 29-SEP-2003 Summary: (provided by applicant): Group B streptococci (GBS) or Streptococcus agalactiae are weakly beta-hemolytic, facultatively anaerobic Gram-positive cocci, which have emerged over the past 50 years as the most significant bacterial cause of neonatal sepsis, pneumonia, and meningitis. GBS account for 30-50 percent of neonatal bacterial infections and increases in adult GBS infections have also been noted. This demonstrates that GBS infections remain an important public health problem. We propose to sequence the 2.1 Mb genome of S. agalactiae serotype Ia strain A909 using a genome-wide random shotgun approach. We will then use the final assembled sequence and its complete annotation to perform detailed comparative genomics analyses between serotype Ia and other organisms causing pneumonia and meningitis. These analyses will allow to identify virulence determinants shared by all organisms or specific to individual ones. These determinants will be related to Drs. Jones and Rubens? experiments on signature tagged mutagenesis and TnphoZ translational fusion (identification of secreted proteins) mutant libraries constructed through transposon insertions in strain A909. Regions where transposons inserted will be aligned to the genome sequence to identify the genes affected. A subset of the mutants conserved across serotypes will be analyzed in the rat sepsis model to evaluate their virulence. This collaborative effort will provide extensive preliminary data for future proposals relevant to understanding the pathogenesis of S. agalactiae infections. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: GLOBAL PATHOGENESIS
REGULATORY
INTERACTIONS
IN
BACTERIAL
Principal Investigator & Institution: Akerley, Brian J. Microbiology and Immunology; Microbiology and Immunology; University of Michigan at Ann Arbor 3003 South State, Room 1040 Ann Arbor, MI 481091274 Timing: Fiscal Year 2002; Project Start 01-JUN-2002; Project End 31-MAY-2007 Summary: (provided by applicant): Haemophilus influenzae efficiently and chronically colonizes the human nasopharyngeal mucosa, and is capable of causing invasive disease including otitis media, pneumonia, and, more rarely, meningitis. A number of factors involved in H. influenzae virulence have been identified in the pre-genomic era. Taking advantage of the genome sequence and the advent of new technologies, such as global expression profiling, we intend to advance understanding of critical virulence characteristics of this organism. Lipopolysaccharide (LPS) structural modifications are essential virulence determinants for H. influenzae. Using expression profiling with DNA microarrays, complemented by classical approaches, we have recently uncovered a previously unappreciated link between redox regulation and LPS modifications in H. influenzae. In addition, we have isolated a mariner transposon insertion mutation in H. influenzae that disrupts redox control over one such modification (addition of a phosphorylcholine epitope, termed ChoP, to the LPS) and also results in a pronounced colonization defect in an animal model of H. influenzae infection. These observations are of potential significance for in vivo modulation of the LPS structure by environmental signals. We propose to use such signaling and regulatory mutants generated in our laboratory to examine the role of redox signaling in controlling virulence genes in H. influenzae. Global genomic approaches we have developed for
Studies 61
studies of H. influenzae will facilitate our analysis of how LPS modifications are modulated in response to environmental conditions. We will also determine whether other genes that play a role in pathogenesis are coregulated, inversely regulated, or constitutively transcribed under the varied redox conditions that affect LPS modification. We believe that these studies will provide important insights into the relationship between physiological adaptations to the host environment and the coordinated production of bacterial cell-surface structures critical for interactions with host cells or for evading the immune response. Specifically, we will: 1. Characterize the redox control mechanisms involved in the regulation of the ChoP cell surface LPS modification. 2. Investigate the role of signaling pathways in H. influenzae in the context of epithelial cell interactions and in a model of respiratory tract infection. 3. Examine coordinate regulation of virulence factors by redox signaling systems. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: GUIDELINES INTERVENTION
ADHERENCE
AFTER
CLINICAL
PATHWAY
Principal Investigator & Institution: Dykes, Patricia C. None; Columbia University Health Sciences New York, NY 10032 Timing: Fiscal Year 2002; Project Start 07-FEB-2003 Summary: (provided by applicant): Heart failure is a major public health problem that increases the vulnerability of older Americans. While adherence to practice guidelines is clearly linked with positive patient outcomes, studies to date demonstrate that practitioner adherence with core recommendations of practice guidelines is deficient. Currently a gap exists in the literature regarding strategies to promote interdisciplinary adherence to these guidelines. The overall goal of the proposed research is to study an innovative strategy to promote interdisciplinary guideline adherence and positive patient outcomes in patients diagnosed with heart failure. The aims of this study are to: 1) examine interdisciplinary adherence to core recommendations of the AHA/ACC clinical practice guidelines before and after implementation of an automated clinical pathway model and 2) compare patient outcomes before and after implementation of an automated clinical pathway model, integrated with core AHA/ACC guideline recommendations. Two samples of 150 consecutive patients age 65 or older, admitted to the proposed setting with a primary diagnosis of heart failure will be studied, 150 preand 150 post-implementation of the automated pathway. Similarly, two groups of 150 consecutive patients age 65 or older admitted to the proposed setting with a primary diagnosis of Pneumonia will be used as a nonequivalent comparison group without an automated pathway intervention. Clinician adherence and selected patient outcomes will be compared between treatment and control groups pre and post pathway using analysis of variance models. The study findings will provide the foundation for more extensive research programs whose findings could be generalized to larger patient populations and health care organizations. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: GUT EPITHELIAL APOPTOSIS IN SHOCK AND SEPSIS Principal Investigator & Institution: Coopersmith, Craig M. Surgery; Washington University Lindell and Skinker Blvd St. Louis, MO 63130 Timing: Fiscal Year 2002; Project Start 01-JUL-2002; Project End 30-JUN-2006 Summary: Sepsis and noninfectious inflammation lead to organ dysfunction and death in greater than 230,000 people annually in the United States alone. Recent studies
62 Pneumonia
demonstrate that sepsis and noninfectious inflammation induce excess intestinal epithelial apoptosis in both animal models of critical illness and in human autopsy studies. The central hypothesis of this new laboratory is that increased gut epithelial apoptosis is detrimental in critical illness, and that decreasing levels of cell death will improve experimental survival. Since previous descriptive studies showing elevated intestinal epithelial apoptosis in sepsis and noninfectious inflammation cannot distinguish whether altered gut apoptosis has a functional significance in critical illness, the first aim of this investigation is to demonstrate that inhibiting gut epithelial apoptosis through mechanistically distinct strategies decreases mortality in diverse models of critical illness. Gut epithelial apoptosis will be selectively targeted using transgenic mice that overexpress Bcl-2 in their intestinal epithelium. Gut-directed caspase inhibitors will also be utilized. These apoptosis- inhibition strategies will be complemented with a novel apoptosis-acceleration strategy using the antilymphocyte antibody, anti-CD3 which causes a 40-fold induction of gut epithelial apoptosis. Mechanisms that may underlie the survival advantage conferred by a decrease in gut apoptosis will be investigated as well. Gut permeability studies will be performed using the ex vivo everted gut sac model on transgenic animals that overexpress intestinal Bcl-2 and their control littermates after induction of sepsis or noninfectious inflammation and. Interactions with the immune system will be assessed by the development of mice that simultaneously overexpress Bcl-2 in their intestinal epithelium but are deficient for Tand B- lymphocytes (Rag-1 mice). Throughout these studies, four models of critical illness will be utilized varying the site of injury (intraabdominal vs. lung) and type of infection (polymicrobial vs. monomicrobial). Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: HARLEM AIDS TREATMENT GROUP-'CPCRA' Principal Investigator & Institution: El-Sadr, Wafaa M. Chief, Division of Infectious Diseases; Medicine; Columbia University Health Sciences New York, NY 10032 Timing: Fiscal Year 2001; Project Start 30-SEP-1989; Project End 31-MAR-2005 Summary: (adapted from application's abstract): The HIV/AIDS epidemic currently affects African Americans, Latinos, women and injection drug users, populations that have traditionally been underrepresented in HIV clinical trials. Alarmingly, while the rate of HIV/AIDS is 10.4 per 100,000 among whites, it is 83.7 and 37.7 per 100,000 among African Americans and Latinos, respectively. The Harlem AIDS Treatment Group (HATG) was established in 1989 with the primary goal of providing access to HIV trials for persons of color, women, and injection drug users. It was recognized, however, that accomplishing this goal would be challenging due to the legacy of mistrust of research and the many social needs of the population. In spite of these challenges, through concerted educational efforts, the building of community support, the recruitment of a talented and committed staff and the provision of the research in the context of state-of-the-art care, HATG has been able to achieve its goals. A total of 957 participants have been enrolled in 27 CPCRA studies with 1,436 separate enrollments including 65.3 percent African American, 15.7 percent Latino, 31.7 percent women and 41.1 percent with a history of injection drug use. Through the, outreach and tracking systems, the provision of support services and the devotion of the participants to their care, HATG has had a 97 percent retention rate. The accomplishments of HATG are firmly embedded in the success of its Community Advisory Board, which has been a vibrant venue for community input and whose functions are solidly linked to unit activities. HATG investigators have made significant contributions to the CPCRA science by providing leadership in the study of tuberculosis, P. carinii pneumonia,
Studies 63
funga1 infections, and nutrition/metabolic complications. Their efforts have culminated in multiple publications and presentations. HATG expects to follow at a minimum 270 participants in trials at Harlem Hospital Center, the Renaissance Health Care Network, Jacobi Medical Center and the St. Vincent's Comprehensive HIV Center. Overall, HATG sites provide care to more than 4,000 persons living with HIV, predominantly African Americans, Latinos, women and injection drug users. This population spans the spectrum of HIV disease and includes a substantial group with recently recognized HIV infection who are antiretroviral naive. All HATG site investigators have the expertise, experience and commitment to make substantial contributions to the CPCRA science in adherence, metabolic/nutrition, opportunistic infection prophylaxis and hepatitides. They also are committed to the conduct of large long-term studies as a means of answering key questions in HIV management that cannot be answered through shorter trials. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: HIV SURVEILLANCE AFFECTS MACROPHAGE FUNCTION Principal Investigator & Institution: Wewers, Mark D. Professor; Internal Medicine; Ohio State University 1800 Cannon Dr, Rm 1210 Columbus, OH 43210 Timing: Fiscal Year 2001; Project Start 30-SEP-1998; Project End 31-AUG-2003 Summary: Bacterial pneumonia remains one of the most common complications of HIV infections. In spite of our growing understanding of the pathogenesis of the immune deficiency associated with HIV infection, the factors that predispose HIV+ individuals to pneumonia remain obscure. For example, the risk of pneumonia for HIV infected individuals is 6 fold higher than for HIV-individuals. This risk can only partially be explained by lower blood CD4 counts. Our preliminary experiments demonstrate that the lung CD4 counts remain normal in the face of falling peripheral counts when compared to HIV uninfected subjects. However, CD8+ lymphocytes are markedly increased in the lung, a hallmark of HIV infection. These cytotoxic CD8+ lymphocytes (CTLs) are believed to function to suppress viral replication. In this context, the primary defense against bacterial infections in the lung is provided by alveolar macrophages which are also the prime source of HIV in the lung. Since macrophage HIV infection is enhanced by inflammatory events, we have hypothesized that 1) initiation of antibacterial function by lung macrophages induces local HIV replication, and 2) as a consequence of this increase in viral burden, lung CTLs may be signaled to suppress this viral replication. This suppression of virus may in the process suppress macrophage antibacterial function. We therefore, propose to test these hypotheses by studying the macrophage's ability to phagocytose opsonized particles. We will evaluate lung macrophages from HIV infected individuals and normal controls to test whether opsonized phagocytosis induces viral replication in the macrophage. As a corollary we will determine whether CTLs can impair macrophage phagocytosis. These in vitro experiments will be corroborated by studies of lung macrophages taken at the time of bacterial pneumonia. Together these experiments will improve our understanding of how the innate immune defense against bacteria is affected by attempts to suppress HIV in macrophages. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: HIV-RELATED ORAL DISEASES AMONG WOMEN IN HARARE Principal Investigator & Institution: Greenspan, John S. Professor; Stomatology; University of California San Francisco 500 Parnassus Ave San Francisco, CA 94122
64 Pneumonia
Timing: Fiscal Year 2002; Project Start 15-AUG-2002; Project End 31-JUL-2005 Summary: (provided by applicant): As part of the last competing renewal application of the parent program project P01-DE07946 (PI: John Greenspan), we sought to address emerging problems concerning the oral manifestations of HIV/AIDS. To date, our research has focused on HIV-infected populations in the US. However, we are proposing, as part of the present FIRCA application, to expand our study of the role and significance of oral manifestations of HIV infection to a setting that thus far has been understudied: sub-Saharan Africa. Because biologic assays to measure HIV disease progression are rarely accessible in sub-Saharan African countries due to prohibitive cost, other less expensive means of monitoring disease progression are needed. In US populations, visual inspection of the mouth and diagnosis of selected oral mucosal lesions have been found to be good predictors of HIV disease progression. If the predictive role of oral examination can be confirmed in sub-Saharan Africa, this would provide an important new tool for clinicians and public health specialists in this setting with respect to initiation of certain prophylactic drug regimens (such as tuberculosis or pneumocystis pneumonia prophylaxis) or anti-retrovirals. Midion Chidzonga, currently a Fogarty trainee supported by the "AIDS International Training and Research Program" Fogarty grant (2D43 TW00003-11; PI: Art Reingold; UCSF PI for the oral component in Zimbabwe: Caroline Shiboski) is conducting a cross-sectional study among HIV-infected and non-infected women in Zimbabwe to estimate oral mucosal disease prevalence in relation to HIV serostatus in this population. In collaboration with Dr. Chidzonga, we are hereby proposing to conduct a longitudinal study by expanding this ongoing crosssectional study among Zimbabwean women. Our objectives are 1) to estimate oral mucosal disease incidence in relation to known immunologic marker of HIV disease progression (CD4 lymphocyte count); and 2) assess the sensitivity and specificity of detecting oral mucosal lesions by visual inspection of the mouth by trained nurses in a family planning/gynecology clinic in the sub-Saharan African setting. To address these objectives, we will conduct follow-up oral examinations at 6-month intervals on 225 HIV-positive participants who are being recruited into our cross-sectional study from an ongoing parent cohort study. Each participant would be seen at 6-month intervals over a 3-year period as part of the proposed study. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: HOST AND VIRAL FACTORS IN SIV PNEUMONIA Principal Investigator & Institution: Zink, M C. Professor; Comparative Medicine; Johns Hopkins University 3400 N Charles St Baltimore, MD 21218 Timing: Fiscal Year 2001; Project Start 30-SEP-1997; Project End 31-AUG-2002 Summary: Tropism of HIV for macrophages contributes to primary HIV pneumonia whereas replication in lymphocytes leads to immunosuppression and secondary opportunistic infections. The two main forms of primary HIV-induced pneumonia are lymphocytic interstitial pneumonia (LIP) and diffuse infiltrative lymphocytosis syndrome (DILS), and individuals with these conditions survive longer and have fewer opportunistic infections than those who do not. Like HIV, SIV replicates in both CD4+ lymphocytes and monocytes/macrophages, but is mainly detected in cells of macrophage lineage in the lung. Specific strains of SIV cause lesions in the lungs of juvenile macaques that resemble HIV lymphoid interstitial pneumonia, and macaques with these lesions also survive longer. This application proposes a multidisciplinary approach to identify viral and host factors that contribute to pulmonary disease. The hypothesis to be tested in these studies is that while many viral strains enter the lung in infected blood, only certain macrophage-tropic strains establish themselves in
Studies 65
pulmonary tissue, possibly related to expression of specific viral co-receptors in the lung. It also hypothesized that the lymphocytic pneumonia is indicative of effective immunologic restraint of macrophage-tropic viral burden and thus improved prognosis. For these studies, macaques will be inoculated with SIV and euthanized during the initial stage of viral replication (3 weeks p.i.), during the stage of clinical quiescence (3 months p.i.), and during terminal clinical diseases. 1) Pulmonary and systemic immune responses, pulmonary lesions, and viral load will be measured in these macaques to determine at what stage of infection lymphocytic interstitial pneumonia appears, whether lymphocytic interstitial pneumonia is indicative of effective pulmonary antiviral immune responses, and whether the effectiveness of pulmonary immune responses predicts outcome of infection. 2) The levels of expression of pro-inflammatory molecules (cell adhesion molecules, chemokine receptors, chemokines, and cytokines) in lung tissue and bronchoalveolar cells will be measured throughout SIV infection and correlated with pulmonary and peripheral viral load with host immune responses. 3) The viral strains and genotypes that replicate productively in lungs of animals infected with SIV will be identified to determine if specific virus strains are associated with the development of LIP. Replication of viruses isolated from the lung of infected macaques in primary cultures of peripheral blood-derived macrophages and alveolar macrophages will be measured. Virus isolates from lung will be characterized for co-receptor usage (chemokine receptors) to determine if differences exist between macrophage-tropic viruses isolated from the peripheral blood and the lung. 4) The cytokines, chemokines, and chemokine receptors that are expressed in alveolar macrophages and peripheral blood-derived macrophages infected with different strains of virus will be identified. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: HOST CELL DETERMINANTS IN PSEUDOMONAS PNEUMONIA Principal Investigator & Institution: Mostov, Keith E. Professor; Anatomy; University of California San Francisco 500 Parnassus Ave San Francisco, CA 94122 Timing: Fiscal Year 2001; Project Start 30-SEP-1995; Project End 31-MAR-2004 Summary: (Adapted from the Applicant's Abstract): In immunocompromised and other severely ill patients, Pseudomonas aeruginosa (PA) causes an acute pneumonitis, which has an extremely high fatality rate. Improved methods for prevention and therapy are urgently needed. An in vitro model of PA infection using polarized Madin-Darby canine kidney (MDCK) cells or cultured lung epithelial cells mimics many important features of in vivo pneumonia. Live Pseudomonas organisms added to the apical surface of these cultures attach to and kill the cells. These foci of infection spread centripetally. The current proposal will study the host cell factors that determine susceptibility to Pseudomonas pneumonia using these in vitro model systems. There are four aims in this study: to investigate how modification of cell polarity affects virulence; to identify the receptors for PA and how their regulation affects bacterial interaction; to determine the pathway for internalization of PA organisms; and to examine the role of the actin cytoskeleton in interaction of PA with cells. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: HOST RESPONSE TO POST-OPERATIVE PNEUMONIA Principal Investigator & Institution: Knight, Paul R. Professor and Vice Chairman; Anesthesiology; State University of New York at Buffalo 402 Crofts Hall Buffalo, NY 14260 Timing: Fiscal Year 2001; Project Start 01-JUL-2001; Project End 31-MAY-2006
66 Pneumonia
Summary: (Verbatim from the Applicant's Abstract): Anesthesia/surgery predisposes the patient to develop nosocomial pneumonia by mechanisms that are not completely defined. The presence of a viral respiratory tract infection (RTI) during anesthesia/surgery further complicates the host antibacterial response. Evidence from our laboratory has demonstrated anesthesia/surgery induces changes in cytokine response (e.g., TNFalpha, MIP-2, IFNgamma), leukocyte recruitment, and lung injury to influenza RTI. These responses are also critical to innate host defenses against bacterial pathogens. Our focus is to examine cellular mechanisms during a viral RTI that predispose the host to a post-surgical bacterial pneumonia. We hypothesize that anesthesia/surgery will change host responses differently during distinct periods in the course of a viral RTI by altering expression of pro- and antiinflammatory cytokines, thereby decreasing antibacterial defenses. Aim #1 will assess the effects of anesthesia/surgery during influenza on bacterial clearance, inflammatory cell influx, and cytokine expression an Escherichia coli challenge. We predict that laparotomy during influenza will promote the relative expression of MCP-1 and IL-10 over TNFalpha, MIP-2, and IFNgamma. Aim #2: will assess ex vivo the combined effect of laparotomy and influenza on a) LPS stimulated aMphi cytokine expression and phagocytic activity, and b) the ability of in vitro antiMCP-1, antiIL-10, or IFNgamma administration to improve M dysfunction. We postulate that laparotomy during influenza will alter aMphi regulatory functions and decrease effector functions as a result of selective enhancement of expression anti-compared to proinflammatory cytokines. Finally, in Aim #3, we will examine the contribution of endogenous cytokines in the suppression of antibacterial defenses following laparotomy during influenza by selective cytokine manipulations. Bacterial clearance, inflammatory cell influx, and cytokine levels will be assessed. We anticipate that neutralization of IL-10 or MCP-1, administration of IFNgamma, or increased TNFalphaexpression will improve antibacterial host defenses following laparotomy during physical signs of influenza. These studies will examine mechanisms that lead to alterations in bacterial clearance post-surgically following a viral RTI, assess the pathogenesis of post-surgical pneumonia in general, and suggest immune adjuvant strategies to prevent this complication. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: HOST VIRUS INTERACTION AND GENE EXPRESSION Principal Investigator & Institution: Banerjee, Amiya K. Chairman; Cleveland Clinic Foundation 9500 Euclid Ave Cleveland, OH 44195 Timing: Fiscal Year 2002; Project Start 01-FEB-1992; Project End 31-MAY-2007 Summary: (provided by applicant): The long term goal of this renewal grant application is to understand the molecular mechanism of host-virus interactions and gene expression of human parainfluenza virus, type 3 (HPIV3), an important human pathogen which targets lung epithelial cells of the respiratory tract of infants and children leading to acute bronchiolitis, pneumonia and croup. Effective vaccines or antivirals to combat HPIV3 infection are currently unavailable. Our primary goal is to gain insight into some specific host-virus interactive processes which include, (b) identification and characterization of the cell surface receptors of epithelial cells (a) the role of actin binding protein, beta catenin in the transcription ability of HPIV3 ribonucleoprotein (RNP) complex and (c) regulation of expression of major histocompatibility complex II induced by HPIV3 which may play an important role in cellular immunity leading to infection-related damage to lung epithelium. We also propose to continue our studies in understanding the structure and function of the RNA
Studies 67
polymerase, L and P proteins, of HPIV3, especially with regard to the role of phosphorylation of P protein and identification and characterization of the functional domains of L and P proteins. Finally, we wish to exploit reverse genetics using the infectious cDNA of HPIV3 constructed in our laboratory to study phenotypic characteristics of some distinctive cis-regulatory mutants. The studies proposed in this application have the potential to gain deeper insight to various host-virus interactive pathways, which may eventually lead to rational designing of antivirals, vaccines, and expression vectors. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: HOW CD2 AND CD28 DETERMINE SUSCEPTIBILITY TO P. CARINII Principal Investigator & Institution: Green, Jonathan M. Assistant Professor; Internal Medicine; Washington University Lindell and Skinker Blvd St. Louis, MO 63130 Timing: Fiscal Year 2002; Project Start 15-MAY-2002; Project End 30-APR-2004 Summary: (Provided by the applicant): Loss of CD4+ T cell number or function may render individuals susceptible to opportunistic infection such as P. carinii pneumonia (PCP). This is exemplified by Human Immunodeficiency Virus infection, but also complicates other diseases in which normal immune cell function is perturbed. Although both observational and experimental data indicate that the CD4+ T cell is a critical determinant of the outcome of infection with Pneumocystis, the precise manner in which this effect is exerted is less clear. In addition to direct effector function, CD4+ T cells influence the function of other cells such as B cells, macrophages and cytolytic T cells through both soluble mediators as well as via direct intercellular interactions. Derangement in any of these elements of the immune response may lead to increased susceptibility to opportunistic infection. T cell activation is determined not only by engagement of the T cell antigen receptor, but also by theengagement of other receptors, termed costimulatory receptors. CD2 and CD28 are two well-described costimulatory molecules. Mice deficient in CD2 have little discernible phenotype on examination of T cell function. T cells from CD28-deficient mice have reduced proliferative responses and cytokine secretion. as well as impaired survival, but previously have not been noted to be susceptible to opportunistic infection. We have generated mice deficient in both CD2 and CD28. These mice have a profound defect in T cell activation despite normal lymphocyte numbers and distribution. Furthermore, the CD2/CD28 double deficient mice spontaneously develop and succumb to infection with P. carinii. Mice deficient only in CD28 do not develop P. carinii following co-housing with infected animals, yet are susceptible if inoculated intratracheally. The defined genetic defect that results in defective T cell function despite normal T cell number provides us with a novel opportunity to examine the role of T cells response to P. carinii. Furthermore, the differential susceptibility of CD28-deficient mice to naturally acquired infection vs direct inoculation allows us to examine how route of infection influences the host response. To address this, we propose the following two specific aims: 1 ) Characterize the response of costimulation deficient mice to infection with Pneumocystis carinii. The experiments proposed in this aim will provide quantitative data defining the susceptibility of the costimulation deficient mice and the characteristics of the immune response mounted against them. 2) Determine if reconstitution of specific cellular elements enable clearance of P. carinii infection in costimulation deficient mice. In this aim we will restore specific aspects of the host response by adoptive transfer into the costimulation deficient mice to dissect what required elements of the host response are lacking in the costimulation deficient mice. Although the observation of severe P. carirzii pneumonia in the double knockout mice was unexpected, these mice provide us with a powerful tool to examine
68 Pneumonia
the role of costimulatory molecules in defense against this important opportunistic pathogen. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: IDENTIFICATION OF S. PNEUMONIAE VIRULENCE FACTORS Principal Investigator & Institution: Joyce, Elizabeth A. Microbiology and Immunology; Stanford University Stanford, CA 94305 Timing: Fiscal Year 2002; Project Start 01-SEP-2002 Summary: (provided by applicant): Streptococcus pneumoniae, is the primary cause of invasive bacterial disease in children and the elderly. This organism infects the lung with devastating consequences. Worldwide, over 5 million children under the age of 5 die of S. pneumoniae-acquired pneumonia each year. S. pneumoniae is also responsible for more than 12 million cases of middle ear and sinus infections annually. Given its impact on public health, surprisingly few virulence determinants have been described, and little is known about how these factors are regulated in pneumococci. There is a growing body of evidence suggesting that the regulation of a number of virulence factors depends on the cell density of the pneumococci (Quorum Sensing; QS). Using microarray analysis, I will investigate, on a genome-wide scale, the role of QS regulation in S. pneumoniae pathogenicity under conditions of in vitro broth culture, in vitro cell culture, and ultimately in two pneumococcal animal models of infection. I hope the results of this approach will contribute to a much more comprehensive molecular description of S. pneumonia/host relationship and the diseases. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: IL-17 AND KLEBSIELLA PNEUMONIA Principal Investigator & Institution: Shellito, Judd E. Professor; Medicine; Louisiana State Univ Hsc New Orleans New Orleans, LA 70112 Timing: Fiscal Year 2002; Project Start 01-MAY-2002; Project End 30-APR-2007 Summary: The long-term objective of this project is to understand interactions between cellular and soluble factors in host defense against bacterial pneumonia. Preliminary data from our laboratory indicate that deposition of bacteria (Klebsiella pneumoniae) into the lungs of mice stimulates the release of one such soluble factor- the lymphocytederived cytokine, Interleukin-17 (IL-17). Additional experiments in IL- 17 receptor "knock-out" mice show increased mortality and impaired neutrophil recruitment after K. Pneumoniae challenge. In this project, we will test the experimental hypothesis that IL17 released from lung T-lymphocytes amplifies the host response to bacterial infection through stimulated release of C-X-C chemokines for neutrophils and enhanced release of other proinflammatory cytokines. In Specific Aim 1, we will localize IL-17 to CD4+ and CD8+ T- lymphocytes in the interstitium or alveolar space at serial intervals after bacterial challenge using flow cytometry and laser capture microdissection. In Specific Aim 2, we will show that IL-17 enhances host release of CXC chemokines and recruitment of neutrophils in response to K. Pneumoniae. We will utilize IL-17 receptor knock-out mice and mice administered a neutralizing IL-17 receptor/FC fusion construct by gene transfer. In Specific Aim 3, we will investigate the interactions between IL-17 and other pro-inflammatory and anti-inflammatory cytokines released into lung tissue in response to K. Pneumoniae. These experiments will focus on TNFalpha, IL-12, IFN-gamma, and IL-10. In Specific Aim 4, we will upregulate IL-17 in lung tissue with gene transfer of the murine IL-17 gene using an adenoviral vector and demonstrate increased bacterial clearance and enhanced recruitment of neutrophils. The
Studies 69
results of these experiments will provide new information on how IL-17 participates in host defense against bacterial pneumonia and may lead to novel approaches to augment immune function in the immunocompromised host. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: IMMUNE RESPONSES DURING MEASLES VIRUS INFECTION Principal Investigator & Institution: Griffin, Diane E. Professor & Chair; Molecular Microbiol and Immun; Johns Hopkins University 3400 N Charles St Baltimore, MD 21218 Timing: Fiscal Year 2003; Project Start 01-DEC-1985; Project End 31-DEC-2007 Summary: (provided by applicant): Measles remains a major cause of morbidity and mortality worldwide due to problems with delivery, acceptance and timing of measles immunization. An additional contributor to the continued failure of measles control may be the epidemic of human immunodeficiency virus (HIV) in developing countries, particularly sub-Saharan Africa, where many of the measles deaths occur. The primary complications of measles are pneumonia, otitis media, diarrhea and post-infectious encephalomyelitis and the effect of measles virus (MV) on the immune system is important in the development of these complications. Delayed type hypersensitivity skin test responses, natural killer cell activity and mitogen-induced proliferative responses are depressed and plasma IgE is increased for weeks after infection. At the same time, the immune response is effective in clearing virus from tissue and in establishing lifelong immunity to reinfection. Our studies of measles in the US and Peru have determined: (i) that monocytes, epithelial cells and endothelial cells are the primary sites of MV replication in vivo; (ii) that there is immune system activation during the period of "immune suppression"; and (iii) that type 2 cytokines are the predominant T cell cytokines expressed late in the response to MV. In vitro studies have shown that MV interaction with CD46 suppresses production of IL-12 by macrophages and that MV infection of B cells synergizes with IL-4 to induce IgE class switching. Recent studies in Zambian children have shown that concurrent HIV infection slows clearance of MV, that many children have baseline skewing of cytokine responses toward production of IL-5, and that measles transiently, but profoundly, suppresses HIV replication. To define the role of host immune responses during measles and the effect of concurrent HIV infection on these responses, we propose the fol]owing specific aims: 1. To determine the effects of MV infection on antigen presenting cells in vivo and in vitro and the consequences of these effects for the immune response. 2. To determine the role of CD8 T cells in MV clearance and the effect of concurrent HIV infection on this role. 3. To determine the roles of different CD4 and CD8 T cell populations in production of cytokines at various times during measles and the effect of concurrent HIV infection on these roles. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: IMMUNOLOGY OF BACTERIAL PNEUMONIA IN HTLV-II INFECTION Principal Investigator & Institution: Jarvis, Gary A.; Northern California Institute Res & Educ San Francisco, CA 941211545 Timing: Fiscal Year 2001; Project Start 01-MAR-2000; Project End 28-FEB-2003 Summary: (Adapted from the Applicant's Abstract): This projects seeks to understand the immunologic basis for the epidemiological outcome observation of an increased incidence of bacterial pneumonia in HTLV-II-infected blood donors. In a study of
70 Pneumonia
persons with both HTLV-II seropositivity and intravenous drug use, an increased risk for bacterial pneumonia compared to patients with neither risk was found. A similar finding of increased risk for bacterial pneumonia in HTLV-II-infected individuals was observed in a clinical outcome analysis of blood donors who participated in a Retroviral Epidemiological Donors Study. Since the cell tropism of HTLV-II infection includes CD4+ and CD8+ T cells, B cells and monocytes, the investigators will determine whether HTLV-II infection predisposes to bacterial pneumonia by creating immune dysfunction in these cells which are known to be critical for natural protection against pneumococcal pneumonia, the most common cause of bacterial pneumonia in individuals with immune dysfunction. Studies planned for the next five years address the immune status of HTLV-II-infected persons. HTLV-II-infected and -uninfected individuals will be vaccinated with the pneumococcal 23-valent polysaccharide vaccine, and their qualitative and quantitative antibody responses will be investigated by determining the isotype and IgG subclass distribution, concentration, avidity and opsonic function of specific pneumococcal capsular antibodies. The same individuals will also be vaccinated with tetanus toxoid protein antigen as a control for antibody response to a separate class of antigen, and their antibody responses measured. The effect of HTLV-II infection of T cells on the proliferative and antibody-secreting functions of B lymphocytes will be tested. CD4+ and CD8+ T cells will be isolated from HTLV-II-infected persons using immunobeads, co-cultivated with normal B lymphocytes, and the functional activity of the B cells assessed using mitogen stimulation and ELISA antibody quantitation assays. Levels of B cell regulatory cytokines produced by infected and uninfected T cells will be measured by ELISA. Levels of immune response markers IL2 receptor on CD8+ T cells, and CD21 and CD35 on B cells will be determined by flow cytometry. The phagocytic and bactericidal function of PMN and of human macrophages derived from the monocytes from HTLV-II-infected individuals will be tested and compared to the function of those cells from uninfected persons. Human CD4+ and CD8+ T cells will be isolated using immunobeads and quantities of macrophage and PMN regulatory cytokines produced by HTLV-II-infected and -uninfected T Cells will be measured by ELISA. The effect of HTLV-II infection of human T cells on cytokine-dependent activation of macrophages and PMN will be studied using functional assays of pneumococcal phagocytic killing. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: IMMUNOREACTIVE MACROMOLECULES OF COCCIDIOIDES CELL TYPES Principal Investigator & Institution: Cole, Garry T. Professor and Chairman; Microbiology and Immunology; Medical College of Ohio at Toledo Research & Grants Admin. Toledo, OH 436145804 Timing: Fiscal Year 2002; Project Start 01-SEP-1986; Project End 31-MAR-2007 Summary: (provided by applicant): Coccidioidomycosis is a fungal respiratory disease which is endemic to desert regions of the Southwestern U.S. The most common clinical presentation is self-limited pneumonia, although the fungus is also capable of establishing systemic infections in immunocompetent individuals. The pivotal arm of host defense against coccidioidal infection is T cell mediated immunity. The T helper 1 (Th1) subset of T cells secretes cytokines that activate macrophages which contribute to protection, while Th2 cells secrete cytokines that stimulate B cells to produce antibodies which seem to provide little protection against the mycosis. A correlation exists between resistance/susceptibility to Coccidioides immitis infection and the profile of cytokine response elicited in mice. It has been shown that administration of interleukin (IL-12) to
Studies 71
susceptible BALB/c mice either before or after intraperitoneal challenge promoted the production of interferon (IFN-gamma) and significantly reduced the fungal burden in these animals compared to controls. Evidence has also been presented that upregulation of IL-10 expression, which inhibits stimulation of the Th1 pathway of immune response, can exacerbate susceptibility to coccidioidal infection in certain strains of inbred mice. Our central hypothesis is that the virulence phenotype of C. immitis is the result of in vivo expression of multiple genes, the products of which contribute to colonization of host tissue, modulation of host immune response to the advantage of the pathogen, and maintenance of a persistent inflammatory response which can result in host tissue damage. The major goal of the proposed project is to develop a fundamental understanding of the influence of selected antigens of C. immitis upon the stimulation of innate immune cells and production of specific cytokines and chemokines that activate either a Th1 or Th2 immune response. The specific aims of the project are focused on studies of four C. immitis gene products, three of which appear to contribute to the initiation and metastasis of the infection, and one which stimulates host protection against coccidioidal infection. We have outlined a multifaceted approach to the evaluation of the impact of these four gene products on the course of disease development. We suggest that the results of these studies will significantly advance our understanding of the pathogenesis of C. immitis. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: IMMUNOSENESCENCE AND CHLAMYDIA PNEUMONIAE Principal Investigator & Institution: Fresa, Kerin L. Pathology, Microbio/Immunology; Philadelphia College of Osteopathic Med 4170 City Ave Philadelphia, PA 19131 Timing: Fiscal Year 2001; Project Start 01-MAY-2001; Project End 30-APR-2004 Summary: (the Applicant's Abstract): With increasing age, there is increased incidence and severity of infectious diseases, including pneumonia, meningitis and sepsis, as well as many non-infectious diseases including cancers, heart disease, Alzheimer' s disease and other dementias. The obligate intracellular bacterial parasite Chlamydia pneumoniae is an established pathogen for respiratory infection. Recent evidence from a number of laboratories suggests that C. pneumoniae may be a factor in the pathogenesis of a number of non-respiratory diseases including Alzheimer's disease and atherosclerosis. It has been repeatedly hypothesized that increased incidence of infectious and other diseases with age may be the result of age alterations in the immune system, particularly in cell mediated immune reactions. It is well established that T cell function, as measured in vivo by delayed type hypersensitivity reactions and in vitro as proliferative responses to antigenic or mitogenic stimulation, both decline with age. While infection with C. pneumoniae as well as other Chlamydial species induces production of antibodies, recent evidence suggests that cell mediated immune mechanisms play a key role in recovery from infection as well as immunopathology associated with Chlamydial infection. It has not been established whether old animals are able to clear infection by C. pneumoniae or remain chronically infected. It also remains unknown whether the immune response, particularly the cell-mediated immune response, to acute chlamydial infection is altered with age. Finally, the extent to which the cell-mediated immune response to Chlamydia, or lack thereof, contributes to the pathogenesis of diseases such as atherosclerosis or Alzheimer's disease is entirely speculative. We propose here to begin to address these issues in a mouse model. The working hypothesis is that the cellular immune response against C. pneumoniae declines with age. The Specific Aims of this project are: 1) To assess whether aging is associated with alterations in the clinical course of experimental intranasal infection of
72 Pneumonia
mice by C. pneumoniae; and 2) To assess whether there are age-associated changes in the immune response to C. pneumoniae. Specifically, we will examine proliferative responses, generation of cytotoxic T cells, and production of Th1 associated cytokines (IL-2 and IFN-g). Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: IMPROVING ANTIBIOTIC USE IN ACUTE CARE SETTINGS Principal Investigator & Institution: Gonzales, Ralph; Assistant Professor; Medicine; University of California San Francisco 500 Parnassus Ave San Francisco, CA 94122 Timing: Fiscal Year 2003; Project Start 07-AUG-2003; Project End 31-JUL-2007 Summary: (Provided by the Applicant) The emergence and rapid rise in antibiotic resistance among common bacteria are adversely affecting the clinical course and health care costs of community-acquired infections. Because antibiotic resistance patterns are strongly correlated with antibiotic use patterns, reductions in unnecessary antibiotic use are critical components of efforts to combat antibiotic resistance. Among humans, the vast majority of unnecessary antibiotic prescriptions are used to treat acute respiratory tract infections (ARIs) that have a viral etiology. Although the rate of antibiotic prescribing for ARIs by office-based physicians in the U.S. has decreased about 16% from its peak in 1997, the rate of antibiotic prescribing in acute care settings (e.g., emergency departments and urgent care centers), which account for 1 in 5 ambulatory antibiotic prescriptions in the U.S., has shown only a modest decline (6%) during this period. Translation of lessons from intervention studies in office-based practices is needed to improve antibiotic use in acute care settings. We propose to conduct a randomized controlled trial of a quality improvement program consisting of physician education (educational seminar, practice guidelines, performance feedback, and decision support tools) and patient education (waiting room print and audiovisual materials) in 8 VA hospital urgent care clinics and 8 non-VA hospital emergency departments. Non VA study sites will be identified from an existing research network of hospital emergency departments--EMNet. VA urgent care clinic sites will be selected among academically affiliated hub facilities. Preliminary studies suggest that a rapid, bedside c-reactive protein test on a fingerstick blood specimen can help classify adults at very low risk, and at high risk, for community-acquired pneumonia. In a second phase of the study, we propose to evaluate the incremental impact of a c-reactive proteinbased diagnostic algorithm to improve antibiotic prescribing behavior. Specific Aim 1: To evaluate the impact of a multidimensional (patient, system, clinician) intervention on appropriate antibiotic use for adults with acute respiratory tract infections-- identifying factors that influence successful translation across VA and non-VA hospital acute care settings. Specific Aim 2: To evaluate the impact of a rapid diagnostic test for c-reactive protein on antibiotic use for adults with acute cough illness when added to a multidimensional intervention. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: INFECTION AND CARDIOVASCULAR DISEASE Principal Investigator & Institution: Davidson, Michael; Medstar Research Institute Hyattsville, MD 20783 Timing: Fiscal Year 2001; Project Start 01-APR-1999; Project End 30-JUN-2003 Summary: Recent studies have associated evidence of Chlamydia pneumoniae infection with coronary and carotid atherosclerosis and evidence of increased infection with cytomegalovirus (CMV) in patients developing restenosis or with atherosclerosis.
Studies 73
Several other common pathogens have been less consistently associated with atherosclerosis. Altered parameters of inflammation and hemostasis have been identified as prognostic factors of myocardial infarction and have been linked as possible pathogenetic mechanisms. Recent studies have indicated that peripheral blood mononuclear cells (PBMC) from patients with coronary artery disease frequently called Chlamydia pneumoniae DNA and stimulation of PBMCs can reflect an unsuccessful host cellular immune response to CMV associated with elevated C-reactive protein (CRP). This proposed study is both a nested case-cohort study and a nested cohort analysis within the Strong Heart Study (SHS), an ongoing cohort study of 4,549 American Indians. This study will utilize previously collected specimens, baseline data, and the planned ultrasound measurement of carotid wall thickness (IMT) in SHS participants. Within the initial SHS cohort, 400 definite cases of incident myocardial infarction, coronary heart disease, and stroke will be compare with 400 control individuals with no such diagnoses and matched for age, gender, and residence. Their prior serum specimens will be analyzes for Chlamydia pneumoniae-specific IgG, IgM antibody, for cytomegalovirus-specific IgG antibody, and for CRP. In addition, assays will be performed for antibodies to Helicobacter pylori, hepatitis A virus, (HAV) and herpes simplex virus (HSV) type 1 and 2. Correlations will be made with baseline parameters of lipids, coagulation, and adjusted for potential confounding variables of tobacco use, pneumonia, and altered pulmonary function. An additional analysis of a subcohort, the above 400 controls, will be performed looking at the outcome of their carotid IMT, a parameter of subclinical atherosclerosis, in relation to serologic results indicating a prior exposure to CMV, Chlamydia pneumoniae, and/or other pathogens approximately 8 years preceding ultrasound testing. Both case-control and cohort analysis will be stratified by levels of hemostasis and inflammation, including CRP, fibrinogen, Lp(a), and plasminogen- activator inhibitor-1. A separate nested substudy performed on PBMCs, prospectively collected from 80 cases and 80 controls, will examine the host T-cell proliferative response to CMV and other pathogens in relation to disease and also search for a chronic persistent infection with Chlamydia pneumoniae evidence by DNA detection. Thus, this study will assemble a prognostic profile of infectious, inflammatory, and hemostatic factors and provide a foundation for possible future primary prevention trials. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: INHALED PARTICLES AND HOST DEFENSE IN THE PRIMED LUNG Principal Investigator & Institution: Kobzik, Lester; Associate Professor; Environmental Health; Harvard University (Sch of Public Hlth) Public Health Campus Boston, MA 02460 Timing: Fiscal Year 2003; Project Start 07-JUL-2003; Project End 31-MAY-2008 Summary: (provided by applicant): The Problem: Hospital admissions for pneumonia are increased by elevated air particle levels. The mechanism(s) underlying particle effects on lung infection are unknown, but may reflect increased incidence of infection, increased severity of infection, or both. Hypothesis: The pathogenesis of the pneumococcal pneumonia (the most common variety and the disease we will study) suggests three possible mechanisms for particle effects: enhancement of lung cell 'receptors' used by bacteria for initial adhesion, damage to antimicrobial function of host cells (AMs and PMNs), and exaggerated inflammation in established infection leading to worse signs and symptoms. Hence, the central thesis of this research is that oxidant components of air particles mediate 1) dysfunction of host defenses against infection
74 Pneumonia
(incidence) and 2) increased inflammation in extant pneumonia (severity). Experimental Plan: Aim 1 will measure expression and function of pneumococcal 'receptors' (e.g., PAF receptor) used by pneumococcal for initial adhesion after exposure to concentrated ambient particles (CAPs) or control particles. Aim 2 will determine effects of air particles on pulmonary inflammation before and after onset of pneumococcal pneumonia. The hypothesis to be tested is that particles cause enhanced release of cytokine mediators by primed AMs, leading to increased inflammation and ultimately oxidant damage to both AM and PMN In vivo and in vitro studies will measure release of pro-inflammatory cytokines, cell influx and viability and severity of pneumonic inflammation. Aim 3 will test the hypothesis that particle exposure inhibits bacterial clearance via oxidantdependent damage of anti-microbial functions of AMs and PMNs. Component analysis will be performed using a panel of CAPs samples to provide links of particle constituents (e.g., metals, organics, endotoxin) with biologic effects. Rotated factor analysis will be used to correlate source types with CAPs toxicity. Specific intracellular oxidant pathways will be identified by measurement of oxidant production, intracellular levels of antioxidants, and the effect of a panel of anti-oxidants and other inhibitors. Significance: This research is relevant to the public health question of how inhaled particles cause pulmonary health effects and to the pathophysiology of lung host defense against environmental agents. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: INNATE MECHANISMS OF MYCOPLASMAL KILLING BY ALVEOLAR MAC Principal Investigator & Institution: Hickman-Davis, Judy M. Anesthesiology; University of Alabama at Birmingham Uab Station Birmingham, AL 35294 Timing: Fiscal Year 2001; Project Start 01-JUL-1999; Project End 30-JUN-2004 Summary: I graduated from Emory University in 1987 and then spent 2 years as a research assistant in the Department of Pediatric Biochemistry at Emory Hospital. My research experience at Emory prompted me to study animal medicine and I received the D.V.M., cum laude from the University of GA in 1993. At UAB I have received excellent training in laboratory animal medicine, and molecular and Cellular Pathology (Ph.D. December 1998; mentor, Dr. Lindsey). My dissertation research has produced a number of important advances in understanding pulmonary antimycoplasmal defenses applicable to human disease. This SERCA provides the ideal setting for my desired maturation into an independent comparative medicine scientist. Mycoplasma pneumoniae is a leading cause of pneumonia and extrapulmonary disease in humans. C57BL mice are highly resistant and C3H mice are highly susceptible to Mycoplasma pulmonis and are excellent models of the human disease. I have shown that the alveolar macrophage (AM) is the key cell in resistance of C57BL mice, and surfactant protein A (SP-A) mediates the killing of mycoplasmas by C57BL AMs in vitro through the production of reactive oxygen-nitrogen species. Furthermore, my results suggest for the first time that AM nitric oxide derived species, but not reactive oxygen species, are essential for killing mycoplasmas in vivo and in vitro. My aims for the 01-03 years are: (1) Determine the molecular mechanism(s) responsible for SP-A mediate mycoplasmal killing by C57BL AMs in vivo and in vitro, and (2) Identify the mechanism responsible for the defect in SP-A mediated killing by susceptible C3H AMs in vivo and in vitro. My tentative plan for the 04-05 years is to investigate the mechanism by which reactive species damage and effect killing of mycoplasmas, and the pathophysiologic sequelae of mycoplasmal injury to alveolar epithelium in vivo. My career will emphasize the development of models and the investigation of immunologic mechanisms for
Studies 75
resistance/susceptibility to bacterial pneumonias, utilizing transgenic and other methodologies. Thus, I plan to perform experiments in vivo, to show the relevance of my findings in human disease, and in vitro to identify the basic mechanisms. This SERCA with Dr. Matalon (lung physiology, biochemistry) as advisor and Drs. Lindsey (mycoplasmal diseases, lung defenses) and Wood (molecular genetics, transgenics) as co-advisors provides a unique and extremely stimulating environment, ideal for my desired maturation into an independent scientist focused on the development of models for pneumonic processes. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: INTERFERON-ALPHA/BETA PATHOGENESIS
IN
RESPIRATORY
VIRUS
Principal Investigator & Institution: Durbin, Joan E. Associate Professor; Children's Research Institute 700 Children's Dr Columbus, OH 43205 Timing: Fiscal Year 2001; Project Start 01-MAR-2001; Project End 28-FEB-2005 Summary: Respiratory syncytial virus (RSV) is a major cause of lower respiratory infections in infants and the elderly. Bronchiolitis and pneumonia caused by RSV are the primary reasons for the hospitalization of infants under 6 months of age. The initial infection often occurs in the presence of maternal antibodies and reinfections occur throughout life. To date, efforts to develop a safe and effective vaccine have failed. Progress in RSV vaccine development has been hampered by the legacy of enhanced, even fatal, illness in vaccinated children during trials of a formalin- inactivated, alumprecipitated whole virus vaccine in the mid 1960s. The lack of a clear understanding of vaccine-augmented RSV disease still stands in the way of clinical trials of new vaccines in RSV naive infants. Our laboratory has demonstrated enhanced RSV and influenza disease in strains of knockout mice that are unable to respond to IFN-alpha/beta (IFNalpha/beta Receptor-/-) or IFN-alpha/beta and IFN-gamma (Stat1-/- ). The pathology of primary virus infection in these mutant animals resembles that seen following RSV challenge of mice previously immunized with the formalin-inactivated whole virus vaccine (FI-RSV) with exacerbated, eosinophilic inflammation and a Th-2-like cytokine pattern. In this proposal we will test our hypothesis: that poor IFN- alpha/beta induction by RSV may help to explain the induction of Th-2 biased immunity by the FIRSV vaccine preparation. The specific aims of this proposal are: 1) Characterization of exacerbated disease in response to RSV infection in Stat1-/- mice. 2) Analysis of T cell lines derived from RSV immune WT and mutant animals. 3) Alteration of RSV pathology by priming in the presence of IFN- alpha/beta. 4) Development of a vaccine strategy promoting strong induction of IFN- alpha/beta. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: INTERSTITIAL TRANSPLANTATION
PNEUMONIA
AFTER
BONE
MARROW
Principal Investigator & Institution: Cohen, Donald A. Professor; Microbiology Immunology, and Molecular Genetics; University of Kentucky 109 Kinkead Hall Lexington, KY 40506 Timing: Fiscal Year 2001; Project Start 17-SEP-1999; Project End 31-JUL-2003 Summary: This abstract is not available. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
76 Pneumonia
•
Project Title: INVASION GENE AND VIRULENCE OF LEGIONELLA Principal Investigator & Institution: Cirillo, Jeffrey D. Assistant Professor; Veterinary & Biomedical Scis; University of Nebraska Lincoln 14Th and R Sts Lincoln, NE 68588 Timing: Fiscal Year 2001; Project Start 01-JUL-1997; Project End 30-JUN-2002 Summary: (Adapted from the applicant's abstract): Legionella pneumophila causes the severe and sometimes lethal pneumonia termed Legionnaire's disease. Legionnaire's disease has been shown to arise in individuals that undergo prolonged exposure to aerosols from domestic water supplies that contain Legionella. The first evidence that air-handling devices were the source of infection stems from a confirmed Legionella epidemic in 1976. There have recently been a large number of infections that have arisen aboard cruise ships as well. Approximately 15% of all domestic water supplies are thought to contain Legionella. It has been found that Legionella replicates almost exclusively intracellularly during infection and in the environment. Thus, Legionella must enter a eukaryotic cell in order to survive and the genes involved in entry should be critical for production of disease. The investigator's recent data indicate that Legionella grown in an environmental host, the amoebae Acanthamoeba castellani, are approximately two to four logs more invasive for host cells than bacteria grown in the standard laboratory medium. Electron microscopic examination of entry has shown that a novel mechanism, termed "coiling phagocytosis", is responsible for bacterial uptake. This mechanism appears to result in enhanced survival of Legionella after entry into activated macrophages. Taken together, these studies indicate that a key factor in the production of virulent Legionella in water supplies is growth within the appropriate environmental host, without which the investigator hypothesizes that human infections will most likely not occur. The specific aims of the current proposal are to: 1) isolate and characterize the genes involved in invasion and 2) determine the involvement of these genes in virulence of Legionella. Through an examination of the mechanisms of entry and the factors that regulate it, the investigator hopes to further the understanding of how Legionella causes disease as well as provide insight into novel methods for disease prevention. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: INVASION OF THE ALVEOLAR EPITHELIUM BY PSEUDOMONAS Principal Investigator & Institution: Zaas, David W. Pathology; Duke University Durham, NC 27706 Timing: Fiscal Year 2003; Project Start 01-APR-2004 Summary: (provided by applicant): Pseudomonas aeruginosa (Pa) is a major cause of morbidity and mortality in patients with nosocomial pneumonia and patients with cystic fibrosis. Although usually considered an extracellular pathogen, Pa may be able to enter respiratory epithelial cells in order to avoid host defenses. Caveolae are lipid rich domains present on the plasma membranes of a wide range of cell types including the alveolar epithelium that can function as an alternative pathway of endocytosis. We hypothesize that the virulence of Pa may be in part due to its ability to live intracellularly within the alveolar epithelium. Pa may co-opt the pathway of caveolaemediated endocytosis as a mechanism invading type I pneumocytes. This work is important because interventions aimed at reducing the morbidity and mortality of Pa must be refined by a better knowledge of the mechanisms by which Pa avoids host defenses. Specific Aims: I) Expose primary cell cultures of rat type I-like pneumocytes to several strains of Pa to screen for the ability of Pa to invade the alveolar epithelium. 2) Determine the role of caveolae in the uptake of Pa by examining the cellular invasion of
Studies 77
type I-like pneumocytes by previously identified invasive strains of Pa. 3) Examine the specific role of caveolin-I in the endocytosis of invasive strains of Pa. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: IRAK FAMILY FUNCTION IN BACTERIAL INFECTION Principal Investigator & Institution: Thomas, James A. Pediatrics; University of Texas Sw Med Ctr/Dallas Dallas, TX 753909105 Timing: Fiscal Year 2002; Project Start 01-MAY-2002; Project End 30-APR-2007 Summary: Infection represents one of the most fundamental threats to host integrity. When bacterial pathogens breach an epithelial barrier, the host innate immune system detects the attack and triggers a response to contain and eliminate the invader. Cellular sensors, such as macrophages and dendritic cells, detect pathogen through receptors that recognize bacterial macromolecules. These cells then mount a proinflammatory reaction that leads to cellular responses that contain and eliminate the infection. Thus, the innate immune response contains both afferent (pathogen-sensing) and efferent (proinflammatory) limbs. The Toll/IL-1 signal transduction pathway mediates both arms of this innate response to infection. This conserved signaling cascade consists of the proteins MyD88, the interleukin-1 receptor-associated kinase (IRAK) family of molecules (IRAK, IRAK2, and IRAK-M) and the tumor necrosis factor associated factor 6. It processes signals from at least 10 Toll-like receptors (TLRs) and three IL-1 receptor family members (IL-1, IL-18, and Ti/ST2), distributing them to multiple downstream targets, including NF-kB and several mitogen activated protein kinase cascades. We have genetically deleted IRAK, the primary proximal kinase in this pathway, in mice. IRAK-deficient animals and macrophages exhibit impaired responses to lipopolysachharide (LPS), peptidoglycan (PGN), lipotechoic acid (LTA), and CpG DNA, bacterial molecules that activate the afferent arm of innate immunity through TLR4 and TLR2. These mice also exhibit attenuated proinflammatory (efferent) responses due to disrupted IL-1 and IL-18 signaling. The overall objective of this proposal is to determine IRAK function in the host response to Gram-negative and Gram-positive infections. Aim 1 is to determine the role of IRAK in the acute inflammatory response to Gram-negative and Gram-positive infections. We will subject IRAK- deficient macrophages and mice to increasingly complex models of these infections, using toxin challenges, stimulation with nonreplicating bacteria, and Klesiella pneumoniae and Staphylococcus aureus pneumonia. Aim 2 is to isolate IRAK function genetically to either the TLR4 or IL1receptor pathway by generating IRAK/IL-121 and IRAK/TLR4 double knockout animals and comparing the responses of double and single KO macrophages and mice to LPS stimulation, nonreplicating K. pneumoniae, and K. pneumoniae pneumonia. Aim 3 is to determine the contributions of IRAK2 and IRAK-M to residual TLR signaling in IRAK-deficient cells, as deletion of IRAK impairs, but does not completely abrogate signaling. These studies should provide fundamental new information about the role of IRAK in the innate immune response to acute bacterial infection and may eventually lead to the development of strategies to modulate deleterious aspects of this response. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: ISOLATION AND CHARACTERIZATION OF GBS VIRULENCE GENES Principal Investigator & Institution: Clancy, Kathryn A.; Children's Hospital and Reg Medical Ctr Box 5371, 4800 Sand Point Way Ne, Ms 6D-1 Seattle, WA 98105 Timing: Fiscal Year 2001; Project Start 01-AUG-2001
78 Pneumonia
Summary: Group B streptococci (GBS) are the leading cause of human neonatal pneumonia, sepsis and meningitis in the United States. The high incidence of infant mortality associated with GBS infection has led to a significant research effort focused on GS pathogenesis and the identification of virulence-related factors. However, the characteristics of GBS that are critical to the virulence of this pathogen and disease progression largely remain unknown. The long-term goals of this proposal are to gain a better understanding of the molecular basis for BS virulence in the human host and to identify important protein targets for the development of preventative and therapeutic measures such as vaccines and novel antimicrobials. Specifically, the aims of this proposal are to isolate putative virulence proteins from GBS and investigate the role of these proteins in the disease process. Gene fusion technology using alkaline phosphatase as a reporter enzyme will be employed to isolate secreted proteins from GBS, which are thought to be enriched for factors that participate in bacterial-host cell interactions, and have been shown to contribute to bacterial virulence in other microbial systems. Bacterial strains deficient for the putative protein effectors will be constructed and examined in vivo animal sepsis and infection models, which, in concert with in vitro cell-culture adherence and invasion assays, will help to characterize the function of the identified proteins and their importance in disease. The isolation of putative protein effectors from GBS is hoped to help identify future targets for therapeutic studies and development to provide treatment and protection against GBS infection. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: JOHNS HOPKINS ADULT AIDS CLINICAL TRIALS UNIT Principal Investigator & Institution: Flexner, Charles W. Associate Professor; Medicine; Johns Hopkins University 3400 N Charles St Baltimore, MD 21218 Timing: Fiscal Year 2001; Project Start 01-JAN-2000; Project End 31-DEC-2004 Summary: (adapted from applicant's abstract): Johns Hopkins University has had an ACTU since its inception in 1986. The Unit is administratively within the Division of Infectious Diseases as a component of the Johns Hopkins HIV Care Program, but it is configured to make maximum use of relevant institutional resources with investigators from multiple departments and divisions including Pharmacology, Neurology, Ophthalmology, Gynecology, Pathology and Internal Medicine. The Hopkins ACTU has provided leadership to the ACTG scientific agenda and has provided HIV clinical trials to Baltimore, a city that ranks ninth among metropolitan areas in AIDS rates. The performance record for the last grant cycle shows average enrollment, data performance and a rank of No. 3 in scientific contributions. Assets of this ACTU include leadership and scientific expertise in virology (B. Jackson), immunology (H. Lederman, T. Quinn, R. Bollinger), quality of life assessment (A. Wu), neurology (J. McArthur), pharmacology (C. Flexner), CMV retinitis (D. Jabs), and mycobacteriology (R. Chaisson). This unit has a subunit in the prison system, has developed an ACTG study of tuberculosis in Haiti and has high enrollment of injection drug users and African-Americans. This application proposes to continue a scientific portfolio that has depth and diversity to support the ACTG scientific agenda and a clinical trials program that includes good data performance and the enrollment of high priority participants. All current investigators will continue in their present roles as will the three advanced technology laboratories. Three new investigators, Dr. R. Siliciano (latent reservoirs of HIV), Dr. Richard Moore (HIV outcomes, cost and cost effectiveness), and Dr. David Thomas (hepatitis C coinfection) will be added. Preference will be given to protocols that reflect emphasis areas of the Hopkins ACTU, especially pharmacology, neurology, immunology, mycobacteriology, hepatitis C, long-term outcomes (quality of life and cost analyses)
Studies 79
and simplified ART regimens (to better serve the patients). There will be emphasis on enhanced enrollment with a new peer recruiter and a new subunit to increase the catchment area. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: LETHAL PNEUMOCOCCUS
SYNERGISM
BETWEEN
INFLUENZA
AND
Principal Investigator & Institution: Mccullers, Jonathan A. Assistant Member; St. Jude Children's Research Hospital Memphis, TN 381052794 Timing: Fiscal Year 2001; Project Start 01-APR-2001; Project End 31-MAR-2004 Summary: (provided by applicant): The K08 Award will provide an opportunity for the applicant to extend his virology training in the area of viral-bacterial interactions and to develop new expertise in pneumococcal pathogenesis in the setting of prior viral infection. These skills will enable the applicant to achieve his long term career goals by becoming a fully independent research scientist who can translate observations made at the bench into therapeutics and interventions at the bedside. Epidemiologic evidence suggests that there is a lethal synergism between influenza A virus and Streptococcus pneumonias accounting for excess mortality (average 20,000 influenza-related deaths per year in the US) during influenza epidemics. However, the pathogenic mechanisms underlying this interaction are poorly understood, and the lack of a suitable animal model of pneumonia following infection with both organisms has hampered study. The goal of the proposed research plan is to determine the role of receptor alterations engendered by influenza virus infection in the pathogenesis of pneumococcal pneumonia. A newly developed murine model of dual infection will be used to examine the relationships of timing and of infectious doses of influenza virus and pneumococcus to morbidity and mortality. Influenza viruses with different pathogenic features in the mouse will be utilized to determine how cytokine expression varies with different viruses. Expression of receptors permissive for pneumococcal adherence and invasion will be examined in the context of cytokine expression following influenza virus infection, and a correlation to development of pneumonia and in the murine model of dual infection will be made. Identification of specific pneumococcal proteins involved in this synergistic interaction will provide drug and vaccine targets for future intervention in human disease and death caused by pneumococcal superinfection following influenza. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: LINGUAL MECHANICAL FUNCTION DURING SWALLOWING Principal Investigator & Institution: Gilbert, Richard J. Mechanical Engineering; Massachusetts Institute of Technology Cambridge, MA 02139 Timing: Fiscal Year 2003; Project Start 12-SEP-2003; Project End 31-AUG-2006 Summary: (provided by applicant): The human tongue is an intricately configured muscular organ that plays a vital role during the physiological act of swallowing. During normal deglutition, the tongue first configures, then propels the ingested bolus from the oral cavity retrograde to the pharynx. From a clinical perspective, disorders of lingual function are exceedingly common in the elderly, in association with common neurological diseases, such as stroke, Parkinson's disease, and dementia, and are responsible for impaired nutrition and increased risk of aspiration pneumonia in these patient populations. Notwithstanding, there is minimal understanding of the way in which lingual muscular structure contributes to physiological function. The study of
80 Pneumonia
lingual mechanics has long been hampered by the complex myoarchitecture of the tissue and its material properties. As a result, mechanical function cannot be determined solely from global changes of shape, but necessitates the study of intramural dynamics. Our overall hypothesis is that the tongue functions as a muscular hydrostat, a unique structure in the human body, with the ability to both create motion and to provide the skeletal support for that motion. In order to test this hypothesis in the setting of human swallowing, we have considered the tongue from the perspective of a material continuum, and have thus depicted the tissue in terms of local fiber organization and strain. This project will study the quantitative relationship between three-dimensional myoarchitecture and regional mechanics during human swallowing. Our experimental approach uses non-invasive nuclear magnetic resonance imaging techniques to discern patterns of myoarchitecture and regional mechanics in vivo. In Specific Aim 1, the threedimensional myoarchitecture of the tongue will be studied through the depiction of the local second order diffusion tensor derived from magnetic resonance imaging. In Specific Aim 2, the quantitative relationship between muscle fiber architecture and regional strain in association with swallowing will be determined by linkage of the structural measures with tagged magnetization. In Specific Aim 3, the regional mechanical adaptation to varying bolus volume and viscosity will be studied through combined diffusion tensor and tagged magnetization imaging under varying load conditions. This project should result in an improved understanding of structurefunction relationships for the human tongue, and related human muscular hydrostats. It is anticipated that this understanding will result in novel hypotheses of pathological lingual function for patients with oropharyngeal dysphagia. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: LIPOPEPTIDE VACCINE TO PREVENT HCMV INFECTION AFTER BMT Principal Investigator & Institution: Diamond, Don J. Professor and Head, Laboratory of Vaccin; City of Hope Helford Building Duarte, CA 910103000 Timing: Fiscal Year 2001; Project Start 01-APR-1998; Project End 31-JAN-2003 Summary: (Applicant's Abstract) A complication of the recovery phase after BMT is cytomegalovirus (HCMV) infection. Therapy using gancyclovir prophylaxis has decreased the mortality from HCMV infection in allogeneic BMT recipients. However side-effects which include delayed immune reconstitution limit its effectiveness in reducing overall mortality from BMT. Studies from several laboratories have indicated that control of CMV infection in BMT recipients is dependent on a strong cytotoxic T lymphocyte (CTL) response which is targeted mainly against the viral matrix protein pp65, and to a lesser degree against pp150. An adoptive immunotherapy strategy using CTL has proved successful but is impractical for general use in BMT centers. The applicant will develop an alternative strategy that uses small peptide fragments from the CTL viral target proteins pp65 and pp150 in the form of a vaccine as a means to simulate CTL in vivo. The vaccine is a peptide composed of a CTL epitope combined with a peptide which stimulates a T helper (TH) response and is lipidated on the amino terminus. He will first evaluate several different structural forms of the vaccine containing the HLA-A0201 restricted CTL epitope from pp65 and several different TH epitopes in a transgenic HLA-A2.1 mouse model. He will evaluate which of the vaccine molecules provide the strongest and longest-lived immunity by comparing the degree of lysis in vitro of human fibroblasts infected with HCMV mediated by murine splenic effector CTL. Based on the results of murine immunizations, a Phase I dose-escalating and safety trial will be conducted in asymptomatic HCMV seropositive human
Studies 81
volunteers with a lipidated HLA-A0201 restricted CTL vaccine. Additional vaccines including those with 2 or 3 CTL epitopes will also be evaluated in human volunteers in a Phase I trial. In order to test whether the vaccine, which enhances CTL against HCMV in healthy volunteers, is also capable of protecting against infection, a Phase II trial will be conducted in HCMV seropositive BMT donors and recipients. BMT donors will be vaccinated according to a protocol determined by the Phase I trial and their HLAmatched siblings who undergo BMT will be monitored for the ability to resist viremia and/or pneumonia brought about by HCMV infection. Success of this protocol will be determined by the avoidance of gancyclovir post-BMT and reduction of early and late HCMV infection in the BMT recipient. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: LOS ANGELES PEDIATRIC AIDS CONSORTIUM Principal Investigator & Institution: Bryson, Yvonne J. Professor; Pediatrics; University of California Los Angeles 10920 Wilshire Blvd., Suite 1200 Los Angeles, CA 90024 Timing: Fiscal Year 2001; Project Start 30-SEP-1988; Project End 28-FEB-2002 Summary: This is a renewal of the Pediatric ACTG unit for the Los Angeles area. The LAPAC consists of 7 clinical study sites (UCLA Med. Ctr., Childrens Hosp., of LA, Harbor-UCLA, Mem. Med. Ctr. Long Beach, Cedars-Sinai Med. Ctr., Martin Luther King Jr. Hosp., and Kaiser Perm. Med. Group). This consortium has successfully worked together for the past eight years and has enrolled a significant number of HIV infected women, children and adolescents representing 79% ethnic minorities and other disenfranchised populations into AGTG trials (n=336). UCLA is the main administrative data entry, coordinating and laboratory site with a well integrated network and infrastructure at our subsites. We have established effective liaisons with an LA County surveillance study, community health centers for HIV screening of pregnant women, a county- wide social service network for HIV+ children, community representatives and a pediatric Community Advisory Board. All centers provide primary care for HIV infected children and adolescents and three are also designated perinatal centers, which can enroll HIV+ pregnant women into clinical trials with liaisons for continued care and access to clinical trials. This consortium provides clinical care for 80% of the HIV exposed or infected children in LA (n=424) and is a catchment area for 75,000 of the deliveries. Our unit has made major scientific contributions both in the design and implementation of the overall pediatric/perinatal scientific agenda including studies to enhance the knowledge of pathogenesis and to significantly reduce perinatal transmission, to develop new methods of early diagnosis in infected infants, to provide insight into the actors associated with disease progression in infants and children and to improve the treatment and quality of lives of infected children and adolescents. We have a very strong record in advancing the science, providing leadership and also contributing to the productivity of the national pediatric effort. We plan to enroll a minimum of 50 patients/yr into clinical trials with an emphasis on perinatal and phase I/II studies, and to follow 87 continuing patents. We plan to enroll 28 new HIV infected pregnant women and/or newborns, 14 HIV infected children or adolescents into primary therapy and 8 into studies of opportunistic infections. Our goals are integrated into the scientific agenda and include the reduction of perinatal transmission to <2%, early aggressive treatment of infants during primary infection and the evaluation of new potent combination therapies to evince and prolong the lives of children(adolescents already infected with HIV. We will also enhance our outreach to identify HIV+ pregnant women and adolescents for entrance into clinical trials. Our core and developmental
82 Pneumonia
laboratories in both virology and immunology have the capability to provide new innovative assays to enhance the overall scientific agenda and support the clinical trials. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: LUNG DRUG DELIVERY WITH CARBON DIOXIDE AEROSOL INHALERS Principal Investigator & Institution: Hansen, Brian N.; Aerophase, Inc. 401 Mountain View Ave Longmont, CO 80501 Timing: Fiscal Year 2001; Project Start 09-MAR-2001; Project End 31-AUG-2001 Summary: (Adapted from the Investigator's Abstract): The chlorofluorocarbon (CFC) propellants currently being used in metered dose inhalers for pulmonary drug delivery are being phased out due to their high ozone depletion potential. An international pharmaceutical industry consortium has proposed that the zero-ozone depletion potential hydrofluoroalkane (HFA) propellants will replace CFCs in metered dose inhalers. There remain, however, crucial reasons to find other drug aerosolization alternatives. Potential problems with the HFA propellants include toxicity, incompatibility with devices, incompatibility with FDA approved inhaler surfactants and reduced bioavailability of some drugs. The investigators have patented a method for the pulmonary aerosol delivery of pharmaceuticals using supercritical fluid carbon dioxide as an inhaler propellant, and have demonstrated its potential usefulness in vivo in several laboratory studies. The investigators have designed a number of inhaler prototypes that use carbon dioxide as a propellant and are seeking funding for additional research and development of these devices. This technology has several advantages including zero-ozone depletion potential propellant, low toxicity of carbon dioxide, and the ability to administer to the lungs lipophilic drugs which cannot currently be delivered by any other method. The investigators propose to improve and thoroughly test a new form of metered dose inhaler which uses carbon dioxide as a propellant. PROPOSED COMMERCIAL APPLICATION: 1. This ozone-friendly technology may replace existing MDI propellants. 2. Aerosol delivery of antibiotics may reduce death from pneumonia. 3. This inhaler may prove to be better than needle injection of insulin. 4. This is an excellent surfactant delivery system to reduce acute lung injury. 5. This may deliver drugs that cannot be administered by any other method. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: LUNG FIBROSIS: TREATMENT AND MYOFIBROBLAST CONTROL Principal Investigator & Institution: Schwarz, Marvin I. Professor of Medicine; National Jewish Medical & Res Ctr and Research Center Denver, CO 80206 Timing: Fiscal Year 2001; Project Start 05-SEP-2001; Project End 31-JUL-2006 Summary: (Applicant's Abstract) In Project 5 we propose to define the role of the fibroblastic foci and myofibroblast presence in IPF/UIP pathogenesis, to test an antiproliferative therapy for this disorder, and develop surrogate markers which predict outcome. Because of its antiproliferative properties and antagonism of transforming growth factor-beta-1 (TGF-b1) functions in vitro, as well as TGFb-1 driven myofibroblast generation, we propose to study the efficacy of interferon gamma (IFN) (subcutaneous and inhaled) in idiopathic pulmonary fibrosis/usual interstitial pneumonia (IPF/UIP). In the recently initiated phase III trial, we will define surrogate markers of outcome; to include dyspnea scores, physiologic tests, quantitative image analysis of the high resolution computed tomographic images, and fibroproliferative biomarkers. Recently, we were instrumental in organizing an NHLBI workshop which proposed systematic
Studies 83
evaluation of several available novel therapeutic agents that could abrogate the fibroproliferative response. Myofibroblast apoptosis, proliferation, clonality and structure of fibroblastic foci will be compared to bronchiolitis obliterans organizing pneumonia (BOOP), a disease whose positive outcome exceeds IPF/UIP. Gene expression patterns of whole IPF[UIP lung will be analyzed by microarray and compared to normals and BOOP to determine differences and characteristic patterns. Microdissection of fibroblastic foci in IPF1UIP and Masson's bodies of BOOP will be performed. Based on this and utilizing laser capture microdissection BOOP will be performed to determine diagnostic patterns. The goal is to determine gene expression patterns of IPF/UIP and BOOP, which predict clinical behavior and are typical for that particular disease. We will also determine within the IPFIUIP group which genes reflect a bad vs. improved prognosis and the differential gene expression pattern between Fibroblastic foci (IPF/IJIP) and Masson's bodies. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: LYMPHOCYTE/EPITHELIAL REMODELING
INTERACTIONS
IN
MUCOSAL
Principal Investigator & Institution: Basbaum, Carol B.; University of California San Francisco 500 Parnassus Ave San Francisco, CA 94122 Timing: Fiscal Year 2001 Summary: The epithelium of chronically inflamed airways is characterized by mucus hypersecretion and shows 2 relevant adaptations: (a) mucous cell metaplasia, whereby individual epithelial cells differentiate to express mucin and (b) epithelial remodeling whereby the entire epithelial tissue layer becomes convoluted, invading connective tissue to form mucous crypts and glands. To identify molecular mechanisms underlying these changes requires the use of biochemical markers. Mucin can be considered a marker for mucous metaplasia as mucous differentiation is dependent on mucin gene expression. Metalloproteinases can be considered markers for epithelial remodeling as morphogenetic processes requiring connective tissue degradation are dependent on these enzymes. Seeking stimuli potentially controlling mucin and metalloproteinase expression in the inflamed airway we tested the effect of lymphocyte-derived cytokines. Product of both mixed lymphocyte reactions and fluid from asthmatic airways stimulated expression of the two markers at the RNA level. Experiments described below indicate that the Th2 cell mediator IL-9 is a major mucin stimulus in asthmatic airway fluid and that the T cell surface marker OX-47 (EMMPRIN) strongly stimulates metalloproteinases 1 and 9. Based on these relationships, we hypothesize that activated T cells in inflamed airways control mucous metaplasia and epithelial remodeling via IL9 and EMMPRIN. Specific aim 1 will use mutant mice to determine which lymphocyte populations are required for M. pulmonis-induced mucin (Muc 5ac) and metalloproteinase (MMP-9) gene activation. Specific aim 2, using chemical inhibitors, dominant negative mutants and chimeric IL-9 receptor constructs, will test the hypothesis that IL-9 stimulates MUC5 AC in human bronchial epithelial cells via intersecting JAK-STAT and MAPK signaling pathways. Specific aim 3, using biochemical inhibitors, dominant negative mutants and a novel mutagenesis approach, will test the hypothesis that EMMPRIN stimulates MMP-1 in human fibroblasts via a p38-dependent mechanisms and will identify key elements of EMMPRIN-MMP signaling. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
84 Pneumonia
•
Project Title: MACROPHAGE ELASTASE IN HOST DEFENSE Principal Investigator & Institution: Shapiro, Steven D.; Brigham and Women's Hospital 75 Francis Street Boston, MA 02115 Timing: Fiscal Year 2002; Project Start 01-APR-2002; Project End 31-MAR-2006 Summary: (provided by applicant): Matrix metalloproteinases (MMPs) are a group of matrix degrading enzymes whose aberrant or excessive expression can lead to a variety of tissue destructive diseases. Less is known about the normal physiologic functions of MMPs. We present data that macrophage elastase (MMP-12) is the only MMP that has direct antimicrobial activity. MMP-12 acts within the lung macrophage as the first line of defense against microbes within the alveolar space. MMPs are well known for their roles in promoting tumor progression. However, with the discovery of angiostatin, an antiangiogenic proteolytic fragment of plasminogen, it became clear that proteinases can be involved in limiting tumor growth. We present evidence that MMP-12 plays a major role in limiting tumor growth within the lung. This property might have clinical importance since at least 6 phase 3 trials using MMP inhibitors for cancer therapy and two for arthritis were stopped last year related to this under-appreciated property of certain MMPs to limit tumor growth. To further define the role of macrophages and MMP-12 in host defense against bacteria and tumors in the lung, we propose to: 1. Test the hypothesis that MMP-12 represents a novel macrophage-mediated intracellular antimicrobial agent. We provide preliminary data that MMP-12-/- mice have a poorer outcome in response to S. aureus pneumonia, MMP-12-/- macrophages have impaired intracellular killing of S. aureus, and show that MMP-12 has direct antimicrobial capacity. This activity is independent of catalytic capacity and involves the non-catalytic C-terminal domain. Studies are proposed to define the spectrum of bacteria influenced by MMP-12. We will also define the structural components of MMP-12 responsible for this activity. 2. We will extend the hypothesis that MMP-12 interferes with tumor growth via inhibition of angiogenesis and further define potential mechanisms of action. We provide preliminary data that MMP-12 is required to maintain dormancy of Lewis lung cell carcinoma (LLC) metastases. This activity appears related to inhibition of angiogenesis. This is not merely due to generation of angiostatin. Additional antiangiogenic protein fragments play a role, and we postulate that MMP-12 also interferes with MMP-2-mediated promotion of tumor growth. MMP-12 might do this by cleavage of MMP-2 as well as by competition with MMP-2 for endothelial cell and tumor cell binding through its C-terminal domain. 3. We will determine the role of macrophages in lung development, bacterial infection, and tumor progression. We will take advantage of MMP-12 macrophage specific expression and complete generation of diphtheria toxin (DT) "knock-in" to the MMP-12 locus. We hypothesize that this will result in mice deficient in lung (and peritoneal) macrophages, and that these mice will undergo normal lung development. If this hypothesis is correct, then the mice will be used to study the requirement of macrophages in host defense and inflammation. If the mutation is lethal or not fully deficient in pulmonary macrophages, then lung-specific transgenic mice will be used to inducibly express DT in lungs of mature mice. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: MEASUREMENT & BIOTERRORISM PREPAREDNESS: AN IMPACT STUDY Principal Investigator & Institution: Loeb, Jerod M. Vice President; Joint Commission/Accredit Hlthcare Orgs of Healthcare Organizations Oakbrook Terrace, IL 60181 Timing: Fiscal Year 2002; Project Start 30-SEP-2002; Project End 29-SEP-2006
Studies 85
Summary: This proposal describes two distinct but complementary projects designed to improve the performance of health care organizations on a broad scale. The first project relates to performance measurement- an indicator-based approach to measuring quality of care. The goal of the performance measurement project is to demonstrate the impact of evidence-based performance measurement on health care quality across hospitals in the United States. Specifically, the study will examine the ability of nationally implemented performance measures to influence those processes of hospital care that have direct bearing on improved patient outcome. This project will be based on hospital core performance measures that have been introduced as part of the Joint Commission's ORYX initiative in the areas of congestive heart failure, acute myocardial infarction, community-acquired pneumonia and pregnancy. The usefulness of performance measures for improving health care quality will be addressed within a multidimensional framework, including perception of value, action taken, and the impact of intervention. The second project, under the supplemental funding option noted in the RFA, addresses an essential element of overall preparedness of health care organizations for a bioterrorism event- namely establishing strong linkages to relevant community entities. The overall goal of this project is to assess improvements in linkages between health care organizations, the public health infrastructure, and emergency response entities in the wake of multiple influences such as implementation of revised Joint Commission emergency management standards, occurrence of national events and provision of federal funding for bioterrodsm preparedness. Using a mailed survey with on-site verification, we propose to evaluate change over time on linkage related items consistent across previous surveys, conduct a comprehensive cross sectional assessment of existing linkages, assess health care organization preparedness activities over the last five years, and identify exemplary practices related to linkages. The sample will consist of two types of health care organizations: a nationally representative sample of accredited hospitals and a convenience sample of accredited community health centers. The Joint Commission is uniquely positioned to conduct these projects because of its national stature and leadership role in the measurement and oversight of health care quality and its ability to influence change through consensus. Together, these projects aim to provide information about the overall usefulness of performance measurement to improve care and to identify opportunities and effective strategies for improving coordination and communication among key entities responding to bioterrorism events. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: MECHANISM OF ACTION OF ANTIBODY TO PSPA Principal Investigator & Institution: Briles, David E. Professor; Microbiology; University of Alabama at Birmingham Uab Station Birmingham, AL 35294 Timing: Fiscal Year 2003; Project Start 01-AUG-1984; Project End 31-OCT-2007 Summary: (provided by applicant): Streptococcus pneumoniae is one of the largest causes of death by infectious disease of the elderly worldwide. It is also one of the greatest causes of death among very young children in developing countries. Although the polysaccharide-protein conjugate vaccine is effective at protecting children from bacteremia and sepsis, protection is restricted to the included capsular types. The vaccine is only partially protective against otitis media and its potential for herd immunity is limited. Moreover, the conjugate vaccine is more than 100-fold too expensive for widespread use in the developing world. One way to improve this vaccine, or possibly replace it, would be to use protection-eliciting cross-reactive proteins of pneumococci. Several such proteins have been identified, and one, PspA, has reached clinical trials. PspA is required for full virulence of pneumococci in mice and
86 Pneumonia
antibodies to it are protective against sepsis, pneumonia, and carriage. Antibody to PspA can enhance the clearance of pneumococci from the blood of infected animals, and it appears to be able to increase complement deposition on the pneumococcal surface in vitro. Antibodies to PspA promote the attachment of pneumococci to phagocytes, but have not been found to be opsonic (even in the presence of complement) for phagocytosis and killing in vitro. To obtain a better understanding of how antibodies to PspA promote protection in vivo, we will examine several of their known biologic effects in detail. Our investigations will include in vitro conditions that are as close as possible to those in vivo. Investigations of a panel of protective and non-protective monoclonal antibodies, all of which will react with native PspA, will allow us to determine which biologic assays are relevant to in vivo protection. We will also map the epitopes that elicited the monoclonal antibodies. Identification of the in vivo mechanism by which antibody to PspA protects should enable development of a valid surrogate assay for protection, and should improve our understanding of pneumococcal disease. Our analyses of the protection-eliciting and non-protection-eliciting epitopes on PspA should make it possible to design even better PspA vaccines in the future. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: MECHANISM PNEUMONIAE
OF
CAPSULAR
TRANSFORMATION
IN
S
Principal Investigator & Institution: Nesin, Mirjana; Pediatrics; Weill Medical College of Cornell Univ New York, NY 10021 Timing: Fiscal Year 2001; Project Start 01-JUL-1997; Project End 30-JUN-2004 Summary: Streptococcus pneumonia is one of the most common invasive bacterial pathogens in children. The increase( incidence of pneumococcal diseases has been complicated by the appearance of multidrug resistant isolates, low levels of serotypespecific antibodies in young children and the absence of routine, effective immunization. Understanding the mechanisms of acquisition and spread of multidrug resistant microorganisms and their interaction with the immune system during colonization and invasion in order to design novel approaches for therapy of these infections is the long term career goal of this candidate. In the sponsor's laboratory the applicant has been studying the molecular epidemiology of penicillin resistant, pediatric isolates of S. pneumonia. Results of these studies have lead to the hypothesis that multidrug resistant defenses through capsular transformation. The proposed project would involve creating mutants in the genes for the capsular of S. Pneumonia and clarifying the mechanisms by which capsular transformation occurs in vivo. Information about this process improve our understanding of the strategies pneumococci have developed for colonization and infection and the essential criteria for successful immunization and therapy. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: MECHANISM OF PSEUDOMONAS MEDIATED EPITHELIAL CELL DAMAGE Principal Investigator & Institution: Engel, Joanne N. Associate Professor; Medicine; University of California San Francisco 500 Parnassus Ave San Francisco, CA 94122 Timing: Fiscal Year 2001; Project Start 01-JUN-1998; Project End 31-MAY-2003 Summary: (Adapted from the applicant's abstract): P. aeruginosa is one of the most virulent opportunistic pathogens of man. The morbidity of P. aeruginosa infections results from the ability of the bacterium to colonize previously injured or disrupted epithelial cell layers, cause further epithelial cell damage, and in many cases, gain access
Studies 87
to other tissues or the blood stream. To dissect these steps, the investigators make use of a recently developed in vitro and a recently developed animal model of acute pneumonia in which localized cytotoxicity in a polarized epithelial cell line grown in vitro correlates with virulence in this animal model of acute pneumonia. These events do not appear to depend on previously identified virulence factors with the possible exception of exoenzyme S. In preliminary work, they carried out a genetic screen of transposon mutants of a cytotoxic and animal-virulent human isolate of P. aeruginosa (PA103) to identify genes that mediate this localized cytotoxicity. In this grant, the investigators will explore the role revealed by each of these mutants in localized cytotoxicity in an in vitro epithelial cell model of P. aeruginosa-mediated epithelial cell damage and will test them in an animal model of acute pneumonia. Specifically, (i) They will investigate the site of action, function and structure/function relationship, regulation, cellular substrates, and virulence in an animal model of acute pneumonia of the putative novel cytotoxin (PepA) they have discovered. (ii) They hypothesize that either invasion is necessary for and precedes cytotoxicity or that these two events are mutually exclusive. They will test these hypotheses by genetic and pharmacological approaches. (iii) Their initial results demonstrate that while functional pili are necessary for P. aeruginosa-mediated epithelial cell damage in vitro, this function is independent of their ability to bind to the apical surface of MDCK cells. They propose experiments to test further confirm these results. (iv) They postulate that the role of pili in function in cytotoxicity is to allow bacteria to aggregate before binding the apical surface, to move along the surface of epithelial cells by twitching motility, or to transduce the signal that initiates contact-mediated secretion of the putative effectors of cytotoxicity by type III secretion. To test these hypotheses, they will employ time-lapse videomicroscopy to examine the ability of the bacteria to aggregate prior to mediating cell injury, they will use genetic approaches to determine whether twitching motility can be separated from cytotoxicity, and they will test whether pili function to transmit the signal that host cell binding has occurred, leading to contact-mediated type III secretion of PepA. From these studies will come novel targets for anti-Pseudomonal therapies and a better understanding how this bacterium colonizes and injures epithelial cells. In addition, the study of the complex interplay between P. aeruginosa and the host epithelium may reveal new insights into epithelial cell biology. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: MECHANISMS OF IPS AFTER ALLOGENEIC BMT Principal Investigator & Institution: Ferrara, James L. Professor of Internal Medicine and Pedia; Internal Medicine; University of Michigan at Ann Arbor 3003 South State, Room 1040 Ann Arbor, MI 481091274 Timing: Fiscal Year 2001; Project Start 15-SEP-1995; Project End 30-NOV-2004 Summary: Almost half of the pneumonias after allogeneic bone marrow transplant (BMT) are non infectious in origin, and are referred to as idiopathic pneumonia syndrome (IPS). During the first cycle of funding of this grant the authors have used well defined mouse models to investigate IPS pathophysiology after allogeneic BMT. Significant progress has been made in identifying two interrelated pathways of lung injury: (1) host antigen-non-specific inflammatory effectors, including endotoxin (LPS) and TNF which are linked through a gut-liver-lung axis; and (2) host antigen specific T cell effectors which home to the pulmonary interstitium and cause pneumonitis. In this first competing renewal of the grant, the investigators propose to investigate further the mechanisms of IPS lung injury using these well defined allogeneic BMT mouse models and to explore novel approaches to the prevention of
88 Pneumonia
such injury. The Specific Aims are: 1) to analyze the contribution of inflammatory effectors to IPS lung injury after allogeneic BMT, 2) to analyze the contribution of T cell effectors to IPS by injury after allogeneic BMT, and 3) to analyze the mechanisms of chronic lung injury after allogeneic BMT. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: MECHANISMS OF LEUKOCYTE RECRUITMENT DURING IPS AFTER BMT Principal Investigator & Institution: Cooke, Kenneth R. Pediatrics & Communicable Dis; University of Michigan at Ann Arbor 3003 South State, Room 1040 Ann Arbor, MI 481091274 Timing: Fiscal Year 2003; Project Start 11-JUL-2003; Project End 30-JUN-2007 Summary: (provided by applicant): Pulmonary dysfunction remains a frequent and potentially fatal complication following allogeneic hematopoietic stem cell transplantation (SCT). Almost half of the pneumonias that occur in this setting are noninfectious in origin and are referred to as idiopathic pneumonia syndrome (IPS). We have developed mouse models of IPS in order to examine the pathophysiologic mechanisms responsible for this process. Significant progress has been made in identifying roles for donor derived T cells and accessory cells (monocytes/macrophages/neutrophils) in the development of IPS These findings are significant because they support a paradigm shift away from identifying IPS solely as a clinical syndrome and toward understanding IPS as a process in which the lung is a target of two distinct, but inter-related pathways of immune mediated injury. However, the mechanisms by which leukocytes traffic to the lung during IPS have not been explored. Initial studies demonstrate that chemokine ligands and receptors that are responsible for leukocyte migration to inflamed tissue are associated with IPS, but a mechanistic relationship between chemokines and recruitment of cells to the lung during IPS remains to be determined. Extensive preliminary data support a central hypothesis that links enhanced chemokine expression and leukocyte infiltration to the lung with systemic inflammation that occurs after allogeneic SCT and proposes that the sequential influx of cells is causally rather than temporally related; modification of the local chemokine milieu by infiltrating leukocytes will directly contribute to the recruitment of subsequent effector populations. Preliminary data will confirm that donor lymphocyte effectors are recruited to the lung first and are followed by donor accessory cell subsets. This sequential influx of cells follows, and then correlates with, increased expression of corresponding chemokine ligands and receptors respectively. This proposal will use established mouse SCT models to test this hypothesis. The specific aims of this proposal will investigate the following chemokine receptor:ligand pairs and their contribution to the recruitment of lymphocytes, macrophages and neutrophils to the lung during the development of IPS: SA1: CCR5 / RANTES (CCL5) and MIP-1alpha (CCL3) --> Th1 lymphocytes --> days 7-21 SA2: CXCR3 / IP-10 (CXCL10) and Mig (CXCL9) SA3: CCR2: / MCP-1 (CCL2) --> monocytes/macrophages -> days 14-28 SA4:CXCR2 / KC and MIP-2 (CXCL1) --> neutrophils --> days 21 to 42 Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: MECHANISMS OF LUNG INJURY FOLLOWING AUTOLOGOUS BMT Principal Investigator & Institution: Folz, Rodney J. Associate Professor; Medicine; Duke University Durham, NC 27706
Studies 89
Timing: Fiscal Year 2003; Project Start 01-AUG-2003; Project End 31-JUL-2007 Summary: (provided by applicant): Lung toxicity following high dose chemotherapy (HDC) and bone marrow transplantation (BMT) or hematopoietic stem cell support develops in up to 70% of patients, with the most severe form of toxicity, termed idiopathic pneumonia syndrome (IPS), accounting for up to 40% of non-graft versus host disease related deaths. We have described a lung toxicity syndrome that occurs following HDC and autologous bone marrow transplant (autoBMT) that we termed delayed pulmonary toxicity syndrome (DPTS). DPTS may be an early form of IPS, is a risk factor for increased mortality, and manifests as an interstitial pneumonitis no sooner than 4 to 6 weeks following autoBMT (mean onset 11 weeks). To begin to better understand its pathogenesis, we developed a novel HDCIautoBMT mouse model of lung toxicity that shows remarkable similarity to the human condition. Based on clinical and bronchoalveolar lavage studies of patients undergoing HDC/autoBMT and our mouse model, we hypothesize three specific mechanisms the development of DPTS. First, HDC induces an intense oxidative stress resulting in both lung tissue injury and increases in monocyte chemo attractant protein-1 (MCP-1). Second, in response primarily to MCP-1 (and MIP-1a), pulmonary inflammatory cells are recruited into the lung, which possess antigen presenting cells (APC) features and may further stimulate a T cell lymphocyte response. Finally, fibroblast growth factors, like FGF-2, initiate a lung repair and fibrotic response. We plan to test these hypotheses by utilizing mouse strains that 1) overexpress and under express (knockout) antioxidant enzymes, 2) overexpress MCP-1, and 3) are deficient in CCR2. Additional studies designed to characterize the pulmonary inflammatory cells, determine their activation status, and their ability to stimulate T cells will be performed. Finally, we plan to identify BALF growth factors responsible for the development of restrictive lung. This proposal should provide new insights into the pathophysiology of lung injury following autologous bone marrow transplant and provide the basis for future clinical studies to prevent or treat this serious pulmonary complication. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: MIAMI ADULT AIDS CLINICAL TRIALS GROUP, AACTG Principal Investigator & Institution: Fischl, Margaret A. Associate Professor; Medicine; University of Miami Box 016159 Miami, FL 33101 Timing: Fiscal Year 2001; Project Start 01-APR-1992; Project End 31-DEC-2004 Summary: (adapted from application's abstract): The Miami ACTU has been a member of the AACTG since its inception and has contributed to a number of AACTG studies that led to the approval of seven antiretroviral drugs and numerous HIV treatment strategies including lower and alternative dosing schedules for all three classes of antiretroviral agents, early treatment intervention, combination therapies with dual NRTIs and triple-drug therapy. The Miami ACTU has also actively participated in the Virology Laboratory Subcommittee working groups with an active role in the standardization of a PBMC culture assay for determining drug susceptibility, the assessment of interlaboratory concordance of DNA sequencing analysis of HIV RT, and the development of a consensus sequencing protocol to detect drug resistant mutations. This unit has also been involved with the Surrogate Markers Subcommittee with an active role in the assessment of plasma cytokines and soluble markers, cytotoxic Tlymphocyte activity, lymphocyte proliferation and advanced flow cytometry, and defining and validating immunologic markers as surrogate markers independent of CD4 and HIV RNA. Finally, this unit has contributed to the Pharmacology Committee with the evaluation of targeted- concentration control studies and the correlation of
90 Pneumonia
drug exposure with treatment response and failure parameters. The Miami ACTU will actively participate in HIV Disease RAC efforts and provide expertise to address study treatment strategies for initial therapy, treatment options for virologic failure and utilization of phenotypic and genotypic assessments to direct subsequent therapy and treatment intensification. The Miami ACTU will also bring expertise in the areas of hepatitis B and C pathogenesis and treatment, metabolic complications of HIV-1 protease inhibitor pathogenesis and treatment, HIV dementia pathogenesis and treatment and peripheral neuropathy pain assessment, Kaposi sarcoma (KS) pathogenesis, intensive immunologic monitoring and definition, and validation of immunologic determinants of treatment response. The Miami ACTU plans to enroll 100 subjects per year across AACTG studies and 70 patients into AACTG substudies, including but limited to Compartmental, Virology, Viral Dynamics, Pharmaceuticals, Metabolic, Neurologic, Women's Health and Adherence and Outcomes substudies. With a support system in place for the long-term follow-up of patients, the Miami ACTU anticipates to enroll approximately 80 patients into the ALLRT study (ACTG 5001) over a 2-year period. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: MICROARRAY DETERMINANTS IN COMMUNITY-ACQUIRED PNEUMONIA Principal Investigator & Institution: Wood, Kelly; University of Pittsburgh at Pittsburgh 350 Thackeray Hall Pittsburgh, PA 15260 Timing: Fiscal Year 2003; Project Start 01-MAY-2003; Project End 30-APR-2008 Summary: (provided by applicant): I am a junior faculty member in the Department of Critical Care Medicine at the University of Pittsburgh. I am trained in Pulmonary and Critical Care Medicine and have a Masters of Health Science degree in clinical research. My short-term goal is to become expertly trained in clinical research of the critically ill, specifically focusing on the integration of emerging knowledge of the biology of critical illness with advances in clinical research, biostatistics, and data management. My longterm goal is to bring a new level to critical care medicine where an individual's pathophysiologic response to illness is used to predict outcome and guide care. Under the tutelage and mentorship of Dr. Angus (sponsor) and key consultants, I have developed a set of formal coursework, directed reading and tutorials that will form the educational and training core necessary to achieve my goals. This training and education will take place in the Department of Critical Care Medicine, the Department of Biostatistics in the Graduate School of Public Health, the Center for Human Genetics and integrative Biology at the University of Pittsburgh Medical Center, and at the adjacent Carnegie Mellon University. My research project, "Microarray Determinants in Community-Acquired Pneumonia (CAP)" is designed to both provide important new information and provide an important educational opportunity complimenting the other components of my training and education. CAP is a major public health problem, frequently fatal in the elderly. The proposed study will perform a high throughput genetic analysis of elderly Caucasian males with pneumococcal CAP using microarray technology. Two substudies will occur. The first substudy is designed to develop a mortality risk prediction that distinguishes survivors and non-survivors, who are phenotypically similar, from a pre-existing database of stored whole blood samples (n=50). The second substudy involves the recruitment of a prospective inception cohort (n=50) of elderly white males with pneumococcal pneumonia. The value that provocation testing (with pneumococcal vaccine) has in providing additional information with regard to predicting clinical outcome will be explored. This second
Studies 91
substudy will also serve as a validation cohort for the model developed in the first substudy. This proposed study will generate a new predictive tool of clinical outcome based on gene expression analysis in the narrowly defined, homogeneous cohort of elderly Caucasian males with CAP and potentially identify genes not previously known to be involved in the immune response to infection. Information will also be generated regarding the pathophysiology of infection and possible points of early intervention with medical therapy that may alter the course of the disease process. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: MIF AND THE HOST RESPONSE TO INFECTION Principal Investigator & Institution: Bucala, Richard J. Professor; Internal Medicine; Yale University 47 College Street, Suite 203 New Haven, CT 065208047 Timing: Fiscal Year 2003; Project Start 01-JUN-1998; Project End 31-JAN-2008 Summary: (provided by applicant): Overwhelming infection can lead to massive endorgan damage and death, which is a clinical condition known as septic shock. Current concepts of septic shock pathogenesis emphasize the role of innate immunity and excessive inflammatory cytokine production. Under normal circumstances, these responses are carefully regulated so that the infectious agent is eliminated without causing life-threatening tissue damage. Inhibition of inflammatory cytokines has been studied as a way to treat septic shock, however therapies directed at mediators such as TNF alpha and IL-I have not shown clinical benefit, and in fact have worsened outcome in some studies. We have discovered that macrophage migration inhibitory factor (MIF) is an important mediator of innate immunity and upstream regulator of inflammatory cytokine production. Anti-MIF protects from shock caused by live bacteria in the same models of infection that have demonstrated either a null or a detrimental effect of antiTNF alpha therapy. Interference with MIF action thus offers potential therapeutic advantages that have not been observed with previous anti-cytokine interventions. The objective of this application is to understand the mechanism by which MIF contributes to the overwhelming inflammatory response that produces shock. Our central hypothesis is that septic shock is the result of genetic predisposition to overproduction of MIF, coupled with M1F activation of cells by binding to the surface protein, CD74. We have formulated this hypothesis on the basis of our studies showing, first, that antiMIF prevents shock in relevant models of bacterial sepsis, second, that MIF is encoded by a functionally polymorphic gene, and third, that MIF initiates signal transduction by binding to CD74. The rationale for this proposed research is that once it is known how MIF expression leads to septic shock, then new and selective approaches for therapeutic intervention may be devised. We will test our hypothesis by pursuing the following three specific aims: 1) Define the Frequency of the Low and High Expression M/f Alleles in Patients with Pneumonia, and Determine if the High Expression Alleles are Associated with Septic Shock. Our working hypothesis is that high expression M/f alleles wilt be over-represented in patients with pneumonia who develop shock. 2) Define the Mechanism of MIF Signal Transduction. Our working hypothesis is that CD74 transduces MIF signals by recruiting an additional protein(s) into the signaling complex. 3) Determine the Biological Significance of the MIF-CD74 Interaction. Our working hypothesis is that anti-CD74 mAb and soluble CD74 protein (sCD74) will protect mice from lethal septic shock. The proposed research is innovative because it capitalizes on two recent and potentially unifying findings, a polymorphism in the M/fgene that affects its level of expression, and a cell surface protein (CD74) that mediates MIF signal transduction. These results will be significant because they will
92 Pneumonia
provide a better understanding of the molecular pathways responsible for the development of sepsis in susceptible individuals. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: MK-0826 VS CEFTRIAXONE FOR PNEUMONIA Principal Investigator & Institution: Dunbar, Lala; Tulane University of Louisiana New Orleans, LA 70118 Timing: Fiscal Year 2001 Summary: MKC-0826 is a recently developed investigational antibiotic drug that has been shown in laboratory tests to have a strong inhibitory effect on the growth of bacteria. Ceftriaxone sodium, a marketed drug has been approved by the Food and Drug Administration (FDA) for the treatment of complicated lower respiratory infections, including pneumonia. The purpose of this study is to determine whether MK-0826 is equivalent to ceftriaxone (an established cephalosporin with a prolonged serum half-life) for the treatment of community acquired pneumonia in adults with a positive Gram stain. The primary goal is comparison of clinical efficacy, secondary and tertiary goals are comparisons of safety and microbiologic effects. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: PNEUMONIA
MODIFIABLE
RISKS
FOR
NURSING
HOME
ACQUIRED
Principal Investigator & Institution: Quagliarello, Vincent J.; Yale University 47 College Street, Suite 203 New Haven, CT 065208047 Timing: Fiscal Year 2002; Project Start 30-SEP-2002; Project End 31-JUL-2003 Summary: (provided by applicant): The purpose of this pilot/exploratory study is to identify and validate modifiable risk factors for nursing home acquired pneumonia that are amenable to a targeted prevention strategy. The underlying premise is that nursing home acquired pneumonia is a multifactorial geriatric syndrome with modifiable risk factors amenable to prevention. Under the standard disease model of pneumonia, the invading infectious organism is the focus of diagnosis and treatment. However, under the multifactorial geriatric syndrome model, the invading organism is the precipitating event which is superimposed upon a set of modifiable predisposing factors that make the individual vulnerable to infection with the invading organism. The specific aims of this pilot/exploratory study are to identify modifiable risk factors for nursing home acquired pneumonia in a development cohort of elderly residents (age > 65 years) housed in three New Haven area nursing homes, and to test the validity of the identified risk factors in an independent cohort of elderly residents housed in two additional New Haven area nursing homes. To accomplish these aims, baseline demographic and clinical data are being collected from enrolled residents, and surveillance for the primary outcome (radiographically documented pneumonia) is conducted three times per week for 12 months following enrollment. Bivariate and multivariable Cox modeling will identify modifiable risk factors that have an independent association with the development of pneumonia. Pneumonia is the leading cause of death in elderly nursing home residents, and it results in considerable morbidity and healthcare expenditures since it is a major cause of transfer to acute care facilities. The long term implication of this study is that identification and validation of modifiable risk factors for nursing home acquired pneumonia will facilitate the development of a targeted prevention strategy that can be tested and ultimately placed
Studies 93
into practice to reduce the incidence of pneumonia in this vulnerable population of older Americans. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: MODULATION OF CYTOKINE NETWORKS IN MYCOPLASMA PNEUMONIA Principal Investigator & Institution: Simecka, Jerry W. Associate Professor; Molec Biology & Immuno; University of North Texas Hlth Sci Ctr Fort Worth, TX 761072699 Timing: Fiscal Year 2003; Project Start 01-JUL-2003; Project End 30-JUN-2005 Summary: (provided by applicant): The broad, long-term objective of the parent grant (5 R01 AI42075-04) and this project is to determine the immune and inflammatory responses that have an impact on the pathogenesis of and protection from mycoplasma respiratory disease. In the parent grant, the hypothesis is that T helper cells play a central role in determining the balance between helpful and harmful immunologic responses in murine mycoplasma respiratory disease. Furthermore, this balance is mediated by T cell subsets whose activity is modulated by regulatory cytokines, such as IL-4 and IFN-gamma. In fact, Th cells are proinflammatory while CD8+ T cells were found to unexpectedly dampen the inflammatory disease due to mycoplasma infection. In addition, the results demonstrate that IFN-gamma plays a novel but an important regulatory role in innate immunity against mycoplasma. These results indicate that the immune mechanisms involved in this disease are complex and require a broader understanding of the regulatory cytokines produced during disease pathogenesis and their regulation by T cells and cytokines. Thus, the current studies are proposed to establish whether a broader, more exploratory approach to analyze production of cytokines can facilitate our understanding their modulation and their potential role in mycoplasma respiratory disease. The Specific Aims address the following questions: 1) What cytokines are produced in lungs of normal or IFN-gamma deficient mice at different stages of mycoplasma disease?; and 2) What is the impact of CD4+ and CD8+ T cells on pulmonary cytokine production? The methods to be used in this exploratory approach are to first monitor cytokine mRNA production using array technology, and those cytokine mRNAs, shown modulated using arrays, will be further analyzed for their levels of expression and for experimental variations using real-time RT- PCR analysis. Furthermore, cytokine protein arrays will be developed to assess their production in a microarray format; once established tissue homogenates and cell culture supernatants to do this, we will develop assays using pre-existing antibodies to capture and detect cytokine protein in an array format. Thus, by analysis of a broad number of cytokines, clusters of cytokines with similar and/or contrasting regulatory properties should be identified that are associated with disease progression for further functional analysis. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: MOLECULAR AND FUNCTIONAL STUDIES OF H INFLUENZAE PILI Principal Investigator & Institution: Gilsdorf, Janet R. Professor of Pediatrics; Pediatrics & Communicable Dis; University of Michigan at Ann Arbor 3003 South State, Room 1040 Ann Arbor, MI 481091274 Timing: Fiscal Year 2001; Project Start 01-JAN-1991; Project End 31-MAR-2003 Summary: (Adapted from the applicant's abstract): Haemophilus influenzae (Hi) are significant cause of respiratory tract infections, including sinusitis, otitis media,
94 Pneumonia
bronchitis, and pneumonia. The first step in the development of Hi infections is colonization of nasopharyngeal tissues, which depends on the ability of Hi to adhere to nasopharyngeal cells. To this end, Hi have evolved pili that bind to gangliosidecontaining receptors on epithelial cells and human red cells. Hi pili are complicated structures composed of at least three proteins, including HifA (the major pilus subunit), HifD (whose function is poorly defined), and HifE which contains the actual epithelial cell adhesin. The long-term goal of this project is to identify strategies to interfere with Hi adherence and, thus, prevent Hi infections. This goal will be met through understanding the underlying mechanisms by which the HifE adhesin of Hi mediates adherence to human tissue. Specific Aim I is designed to identify the receptor binding domain(s) of HifE through three approaches: 1. To analyze the amino acid sequences of HifE from Hi respiratory and invasive strains for conserved regions; 2. To identify epitopes defined by monoclonal antibodies that interfere with pilus mediated Hi binding to erythrocytes and epithelial cells; 3. To construct mutations in candidate receptor binding domain(s) by alanine-replacement and to test the function of the mutants in adherence assays. Specific Aim II is designed to compare the receptor binding domain(s) of Hi strains (biotype IV and biogroup aegyptius strains) that occupy unique niches within humans and may possess distinctive receptor binding domains. Specific Aim III is designed to identify tissue specificity of the receptor binding domain(s), by testing in competitive inhibition assays the binding of receptor binding domain mutants to a variety of human epithelial cells and by determining the role of the pilus stalk in binding specificity. Specific Aim IV is designed to identify the immunogenic potential of the receptor binding domain(s). Rabbit antisera will be raised to the domains and binding of the antibodies to HifE assessed by whole cell dot blot assays, Western blot assays, and immunoelectron microscopy. The receptor binding domain antibodies will be tested for their ability to interfere with the adherence of piliated Hi to human erythrocytes and respiratory cells. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: PNEUMONIA
MOLECULAR
EPIDEMIOLOGY
OF
HUMAN
P.
CARINII
Principal Investigator & Institution: Huang, Laurence; Medicine; University of California San Francisco 500 Parnassus Ave San Francisco, CA 94122 Timing: Fiscal Year 2003; Project Start 01-JUL-2003; Project End 30-JUN-2007 Summary: (provided by applicant): This is a resubmission of a K23 grant application that is designed to enable Dr. Laurence Huang to acquire additional clinical research training and to develop a research program that will allow him to become an independent and successful clinical investigator. The plan emphasizes didactic training in clinical epidemiology, molecular methods in clinical research, and advanced statistical analysis techniques, which he will gain through completion of a Master's Degree Program in Clinical Research. This didactic training will be coupled with the opportunity to spend time in the laboratories of his scientific collaborators so that he may gain practical insights into the new and highly promising molecular techniques he proposes to use to examine the epidemiology and transmission of human Pneumocystis carinii pneumonia. These studies will involve the close collaboration of scientists from the CDC, NIH, and several university-based laboratories. and will be conducted under the guidance of his two co-mentors: Philip Hopewell, MD, one of the world's foremost experts in the molecular epidemiology of tuberculosis, and Dennis Osmond, PhD, a leading HIV/AIDS epidemiologist and biostatistician. Although the transmission of Pneumocystis carinii between mammals of the same species has been convincingly
Studies 95
demonstrated in the laboratory, it is unproven whether a similar clinical model exists for human disease. In addition, it is debated whether PCP in humans develops solely from reactivation or of a latent infection acquired early in childhood or also from acquisition of a new infection due to a recent exposure. The proposed research plan will determine whether P. carinii and immune responses to P. carinii can be detected in household and hospital contacts living with and caring for HIV-infected patients with PCP and, if P. carinii is detected, whether the P. carinii genetic sequence from a contact matches that from the patient with PCP. This information will be used to develop future studies to examine whether PCP can result from acquisition of a new infection. Since PCP remains a leading cause of the moribiity and mortality in HIV-infected and other immunocompromised persons, insights into its epidemiology and transmission may have profound implications for clinical management and disease prevention. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: MOLECULAR PATHOLOGY OF PNEUMOCYSTIS PNEUMONIA Principal Investigator & Institution: Lee, Chao-Hung; Professor; Pathology; Indiana Univ-Purdue Univ at Indianapolis 620 Union Drive, Room 618 Indianapolis, IN 462025167 Timing: Fiscal Year 2001; Project Start 30-SEP-2001; Project End 31-JUL-2005 Summary: Alveolar macrophages from Pneumocystis carinii-infected hosts are defective in phagocytosis, and the expression of the transcription factor GATA-2 in these cells is severely down-regulated. Introduction of a GATA-2-specific antisense oligonuceotide into alveolar macrophages from normal uninfected animals also resulted in a decrease in the phagocytic activity of these cells. In this proposed study, experiments will be performed to further investigate the role of GATA-2 in alveolar macrophage phagocytosis. A GATA-2 expression vector will be introduced into alveolar macrophages from P. carinii-infected hosts to investigate whether GATA-2 overexpression could correct the defect. To further understand the involvement of GATA-2 in P. carinii pathogenesis, genes that are regulated by GATA-2 in monocytes will be identified. DNA microarrays will be probed with labeled cDNA from wild type and GATA-2 knockout monocytes. The hybridized microarrays will then be analyzed to determine which genes are regulated by GATA-2. Experiments will also be performed to determine whether genes such as those encoding MMR, MIP-1alpha, MCP-1, IL6 and TNF-alpha that are associated with functions of alveolar macrophages are regulated by GATA-2. The mechanisms by which P. carinii causes down regulation of GATA-2 in alveolar macrophages will be explored. Normal alveolar macrophages will be incubated directly or indirectly with live or dead P. carinii organisms to determine whether a P. carinii protein is responsible for down regulation of GATA-2 transcription leading to a reduction in the phagocytic activity of alveolar macrophages. Proteins such as vitronectin, fibronectin, surfactant proteins A and D, and P. carinii major surface glycoprotein, which are known to interact with alveolar macrophages during P. carinii infection, will also be examined. These proteins will be incubated either alone or in combination with normal macrophages to determine whether they have any effect on GATA-2 down regulation. Different fractions of bronchoalveolar lavage fluids from P. carinii-infected lung will also be tested. Any P. carinii or host protein that is found to have the ability to down regulate GATA-2 expression will be identified by sequencing a portion of the protein. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
96 Pneumonia
•
Project Title: MOLECULAR PATHWAYS OF HOST SUSCEPTIBILITY TO LEGIONELLA Principal Investigator & Institution: Dietrich, William F. Assistant Professor; Genetics; Harvard University (Medical School) Medical School Campus Boston, MA 02115 Timing: Fiscal Year 2002; Project Start 15-FEB-2002; Project End 31-JAN-2007 Summary: Legionella pneumophila is a significant human lung pathogen that is responsible for many community- and hospital- acquired cases of pneumonia. An important part of the pathogenesis of Legionella infection is its ability to grow inside of macrophages. Interestingly, different inbred strains of mice exhibit differences in the permissiveness of their macrophages for the intracellular replication of Legionella, and these differences have been attributed to genetic differences in one of the mouse Neuronal Apoptosis Inhibitory Protein (Naip) genes. The goals of this project are to: Establish the identity of the Naip gene and its mutations that are responsible for the differences in Legionella permissiveness, and to study the function of the Naip proteins by identifying critical interacting proteins that participate in its molecular function. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: MUNC18 PROTEINS IN AIRWAY MUCUS HYPERSECRETION Principal Investigator & Institution: Dickey, Burton F. Professor and Chairman; Medicine; Baylor College of Medicine 1 Baylor Plaza Houston, TX 77030 Timing: Fiscal Year 2003; Project Start 01-APR-2003; Project End 31-MAR-2007 Summary: (provided by applicant): Airway mucus forms a protective layer against inhaled particles and pathogens. However, excessive mucus secretion in response to inflammatory stimuli can lead to airflow obstruction. Mucus hypersecretion can be divided into two distinct stages: metaplasia of an epithelial layer that consists predominantly of ciliated and Clara cells into a layer that consists predominantly of mucus-secreting goblet cells; this is followed by regulated secretion of mucus from the metaplastic epithelium. At a molecular level, secretory metaplasia involves expression of genes encoding three sets of proteins: secretory products; components of an exocytic machinery; and signal transduction pathways connecting extracellular secretory signals to exocytic membrane fusion. Secreted macromolecules and signal transduction pathways are subjects of intensive study, but little is known about the exocytic machinery. Munc18 proteins are ubiquitous components of the exocytic machinery of secretory cells. Their absence leads to a complete failure of secretion, and their overexpression also impairs secretion. Together, these data indicate the critical role played by Munc18 proteins and suggest that their expression is tightly regulated. We have found that Munc18B is highly upregulated in metaplastic airway epithelium of mice, and that its promoter region contains elements known to respond to inflammatory stimuli. We propose to suppress expression of Munc18B to test the protective and pathophysiologic roles of mucus secretion in models of allergic and infectious lung inflammation in mice, and to analyze the control of Munc18B expression in mice and humans to gain insight into the molecular pathogenesis of mucus metaplasia. Aim 1: Further characterize the cellular biology of Munc18 proteins in the regulation of airway mucus secretion in murine and human cells. Aim 2: Analyze the protective and pathophysiologic roles of mucus hypersecretion in murine models of allergic asthma and bacterial pneumonia by reducing the capability of airway goblet cells to secrete mucus through reduction of Munc18B expression. Aim 3: Identify critical cis-acting DNA elements and transcription factors that control expression of the Munc18B gene in metaplastic airway epithelium of mice. Aim 4: Confirm the importance of cis-acting
Studies 97
DNA elements and transcription factors that control expression of the Munc18B gene in airway secretory metaplasia of humans. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: MUTANTS FOR CELL ADHESION MOLECULES Principal Investigator & Institution: Beaudet, Arthur L. Professor and Chair; Molecular and Human Genetics; Baylor College of Medicine 1 Baylor Plaza Houston, TX 77030 Timing: Fiscal Year 2001; Project Start 01-JUL-1991; Project End 31-DEC-2001 Summary: (Adapted from the Investigator's Specific Aims): The overall goals of this project are to use genetic strategies to study the role of leukocyte and endothelial cell adhesion molecules in normal biology and in disease processes. Five Specific Aims are proposed: (1) Develop mutations in all three mouse selectin genes. (2) Perform phenotypic evaluation of knockout mice, including routine pathology, leukocyte counts, peritonitis, pneumonia, delayed type hypersensitivity reactions, and intravital microscopy. (3) Investigate the pathogenesis of psoriasis-like skin disease in CD18 deficient mice, specifically searching for a modifier gene or genes using a genomic-wide linkage strategy. (4) Develop cell-specific and inducible mutations using the loxP/Cre recombinase system, including an endothelial cell-specific mutation for VCAM-1 and an inducible mutations for ICAM-1. (5) Evaluate the role of adhesion molecules in the pathogenesis of atherosclerosis using apolipoprotein E-deficient mice. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: MYCOPLASMA PNEUMONIAE - AIRWAY INTERPLAY Principal Investigator & Institution: Baseman, Joel B. Professor & Chair; Microbiology and Immunology; University of Texas Hlth Sci Ctr San Ant 7703 Floyd Curl Dr San Antonio, TX 78229 Timing: Fiscal Year 2001; Project Start 01-APR-2000; Project End 31-MAR-2005 Summary: The epithelial lining of air spaces of the human respiratory system provides a crucial barrier between inspired gas and pulmonary blood flow. By virtue of its large surface area, delicate membranes and anatomic location, the epithelial barrier is vulnerable to damage by inhaled toxic substances and attack by infectious agents. The cell wall-less bacterium, Mycoplasma pneumoniae (whose genome is completely sequenced), is a common bacterial pathogen of the human respiratory tract. It causes a range of acute and chronic illnesses, including tracheobronchitis, pneumonia and other airway pathologies as well as extrapulmonary manifestations, such as joint, CNS and cardiovascular involvement. This microorganism exhibits a flask-like appearance and adheres to respiratory cell surfaces via a unique tip-like terminal organelle. In general, bacterial adherence is a complex process involving multiple interactions and molecular cross-talk between the microbe and target cell. We have been investigating mechanisms of cytadherence of M. pneumoniae and other mycoplasmas, and our recent studies indicate that various components in the airway microenvironment contribute to mycoplasma-respiratory cell interactions and subsequent tissue colonization. Delineating the role of such environmental components in the infectious process of mycoplasmas, particularly M. pneumoniae, is a major objective of this proposal. We will focus on understanding how fibronectin (FN) and surfactant protein A (SP-A) influence the mycoplasma-airway cell interplay, as these host proteins exist abundantly in the respiratory tract. These proteins play several roles including i) modulating alveolar macrophages in enhanced phagocytosis of invading bacteria; and ii) assisting bacteria (particularly FN) in binding to non-phagocytic cells. We have discovered the presence of
98 Pneumonia
FN- and SP-A binding proteins in M. pneumoniae, and we intend to clarify the role of these proteins as mediators of mycoplasma- airway cell interactions. Thus, the proposed study is expected to provide new insights concerning mycoplasma parasitic mechanisms which, together with the existing knowledge base concerning mycoplasma cytadherence, will broaden our overall understanding of mycoplasma pathogenesis and virulence determinants. Ultimately, these studies should identify new therapeutic strategies to control mycoplasma infections in humans. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: NATURAL CONTROL OF M AVIUM IN SAIDS Principal Investigator & Institution: Didier, Peter J.; Tulane University of Louisiana New Orleans, LA 70118 Timing: Fiscal Year 2001 Summary: The objectives of this pilot project are to establish the source of Mycobacterium avium infection in SIV-infected monkeys, characterize immune correlates of disease, and determine the feasibility of vaccination to prevent opportunistic infection of SAIDS animals with M. avium. The incidence of M. avium infection (MAI) in the SAIDS colony has increased from undetectable levels in 1988 to 18-25% in recent years. This opportunistic infection produces diarrhea, cachexia, and sometimes pneumonia in severely immunocompromized monkeys with remarkable similarity to MAI in children with AIDS. We detect M. avium by culture and PCR and characterize isolates from the environment (soil and water) and monkeys by molecular fingerprint analysis. To date, isolates from the environment rarely infect deep tissues of monkeys. In vitro testing of monkey macrophages demonstrates that cells co-infected with SIV and a common strain of pathogenic M. avium found in our monkey colony produces higher than expecte d levels of virus. Protein components of our pathogenic strain are being characterized. We have demonstrated that animals infected with SIV and severely immunodeficient can be infected with our pathogenic strain (MavK128) while inoculation with a human strain of M. avium (Serovar 4) fails to infect immunodeficient monkeys. In a pilot study vaccination of four animals with sonicated M. avium prior to SIV-infection failed to protect them from challenge with MavK128 but lesions contained more lymphocytes than expected. Future studies could look for promising formulations of M. avium and adjuvant that might provide protection against opportunistic infection. FUNDING Venture Research PUBLICATIONS Greenberg SS, Xie JM, Kolls J, Mason C, Didier P. Rapid induction of mRNA for nitric oxide synthase II in rat alveolar macrophages by intratracheal administration of Mycobacterium tuberculosis and Mycobacterium avium. Proc Soc Exp Bio Med, 209:46-53, 1995. Didier P, Ramesh G, Newman G, Maslow J. Detection of M. avium by PCR in rhesus monkeys. [Abstract #2486]. FASEB J, 10(6):A1431, 1996. Brar I, Didier P, Murphey-Corb M, Newman GW, Maslow JN. Prevalence of Mycobacterium avium complex (MAC) infection in SIV infected monkeys. [Abstract]. Infectious Diseases Society Meeting, September 1996, New Orleans, LA. Brar I, Didier P, Murphey-Corb M, Maslow JN. Epidemiology of Mycobacterium avium complex (MAC) infection in simian immunodeficiency virus (SIV) infected rhesus monkeys. [Abstract #655], p185, 4th Conference on Retroviruses and Opportunistic Infections, Washington, DC, January 2226, 1997. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
Studies 99
•
Project Title: NEONATAL INHALED NITRIC OXIDE Principal Investigator & Institution: Ehrenkranz, Richard A.; Yale University 47 College Street, Suite 203 New Haven, CT 065208047 Timing: Fiscal Year 2001 Summary: This abstract is not available. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: NEW AGENTS FOR PNEUMOCYSTIS CARINII PNEUMONIA Principal Investigator & Institution: Huang, Tien L.; Xavier University of Louisiana Box 121-C New Orleans, LA 70125 Timing: Fiscal Year 2001 Summary: Pneumocystis carinii pneumonia (PCP) is the most common serious opportunistic infection in patients with acquired immunodeficiency syndrome (AIDS) and as a major cause of mortality in these patients. Pentamidine is one of the drugs of choice widely used for the treatment of AIDS-related PCR despite its high incidence of serious side effects. Therefore, the is a critical need for more effective and less toxic antiPCP agents. Pentamidine is a flexible molecule and can assume a number of interconvertible conformations. The precise mechanism of anti-PCP action of pentamidine is unknown. We hypothesize that the conformational flexibility of pentamidine allows it to bind to different macromolecules and this may account at least in part, for the therapeutic as well as toxic actions of the drug. It may therefore, be possible to separate these actions by a conformation-biological activity relationship study. To test these hypothesis, we propose to conduct the following studies: a) design and synthesize new conformationally restricted analogues related to pentamidine; b) determine the pKa values of the synthesized compounds; c) evaluate the compounds for in vitro anti-PCP activity and toxicity in an animal model of the disease; e) study the interactions of the proposed pentamidine analogues with DNA using molecular modeling techniques and by measuring thermal denaturation temperatures. The information gained will be valuable not only in determining the mechanism(s) of action of the pentamidine analogues, but may also result in the development of a more effective and safer anti-PCR agent. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: NITROUS OXIDE AND WOUND INFECTIONS Principal Investigator & Institution: Sessler, Daniel I. None; University of Louisville University of Louisville Louisville, KY 40292 Timing: Fiscal Year 2003; Project Start 01-FEB-2003; Project End 31-JAN-2007 Summary: (provided by applicant): Nitrous oxide remains the most commonly used anesthetic and has been given to several billion patients. In vitro, even brief exposure to nitrous oxide inactivates methionine synthetase, which reduces induction of enzymes required for immune function. Nitrous oxide also reduces chemotactic migration by monocytes. However, nitrous oxide improves neutrophil chemotaxis and facilitates oxygen radical formation, and may therefore augment the efficacy of oxidative killing by neutrophils - the primary defense against pathogenic bacteria. Preliminary results in 200 patients suggest that the beneficial effects of nitrous oxide on wound healing outweigh its toxicities. We will thus test the hypothesis that the incidence of postoperative wound infection will be less in patients given 60% nitrous oxide than in those given 60% nitrogen during elective colon surgery. We propose to study up to 1000
100 Pneumonia
patients undergoing elective colon resection. Perioperative antibiotic, anesthetic, fluid, and oxygen management will be set by protocol. Patients will be anesthetized with isoflurane in 40% inspired oxygen, with the remaining ventilatory mixture randomly assigned as nitrous oxide or nitrogen. Surgical wounds will be evaluated daily by a physician blinded to group assignment. Wounds will be considered infected when they meet CDC criteria or pus is detected and they are culture-positive for pathogenic bacteria. As a secondary outcome, incidence of nosocomial pneumonia in the two groups will be determined. Results will be analyzed by Fisher Exact and unpaired, twotailed t-tests; P < 0.05 will be considered statistically significant. We anticipate showing that substituting nitrous oxide for nitrogen reduces the incidence of surgical wound infection. Confirming our hypothesis would thus allow clinicians to make a minor modification in anesthetic practice that might reduce the incidence of a complication responsible for considerable perioperative morbidity and cost. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: NON CD4 HOST DEFENSE AGAINST P CARINII PNEUMONIA Principal Investigator & Institution: Kolls, Jay K. Professor of Pediatric; Medicine; Louisiana State Univ Hsc New Orleans New Orleans, LA 70112 Timing: Fiscal Year 2001; Project Start 01-JAN-1999; Project End 31-DEC-2002 Summary: Despite current strategies to treat HIV infection and its complications, Pneumocystis carinii pneumonia (PCP) remains a common clinical problem. Although there is a well-known relationship between CD4+ lymphocyte count and the risk of PC infection, the role of mononuclear phagocytes, CD8+ cells, NK cells, and their secreted cytokines in host defense against this infection are far less clear. As it is unknown at the present time, whether highly active antiretroviral therapy will result in long term immune reconstitution in patients with AIDS, understanding non-CD4+ T cell dependent host defense mechanisms operative in opportunistic infections may be critical. Among CD4+ T cell derived cytokines, interferon-gamma (IFN-g) is likely to play a key role in host defense against PC infection. Lymphocytes exposed to PC organisms or the major surface glycoprotein of PC in vitro elaborate IFN and lymphocytes recovered from HIV-infected individuals are deficient in IFN-g production. Preliminary studies from our laboratory demonstrate that overexpression of IFN-g in the lung, using adenoviral-mediated lung delivery of the murine IFN cDNA, (AdIFN) enhances clearance of PC in normal mice, and eradication of infection in mice depleted of CD4 lymphocytes, with a monoclonal antibody. Moreover, this augmented host response is associated with a significant increase in lung CD8+ T-cells. Furthermore, AdIFN fails to eradicate PC infection in scid mice which lack both T and B cells, suggesting that overexpression of IFN is not solely through macrophage activation and/or NK cells. We hypothesize that IFN is critical to host defense against PC and that overexpression of IFN in the lungs of mice depleted of CD4+ T cells will substitute for CD4+ T-lymphocytes, and mediate clearance of PC pneumonia through a CD8 T-celldependent mechanism. We will test this hypothesis with the following Specific Aims. Specific Aim 1. Our hypothesis predicts that overexpression of IFN-g will enhance recruitment of inflammatory cells and permit clearance of P. carinii in CD4-depleted mice. Specific Aim 2. Our hypothesis predicts that AdIFN induces the recruitment of CD8+ T cells, specifically of the Tc1-like phenotype, in CD4-depleted mice challenged with P. carinii. Specific Aim 3. To elucidate cytokine and cytotoxic mechanisms of CD8+ T cell mediated clearance of P. carinii in CD4-depleted mice. These studies will investigate non-CD4 dependent host defenses utilizing a novel form of immunotherapy against an important opportunistic pathogen. The results of these studies will not only
Studies 101
aid us in further understanding lung host defenses, but also may lead to novel methods of therapy for opportunistic infections. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: NOVEL ANTI-BACTERIAL THERAPY FOR GRAM NEGATIVE PNEUMONIA Principal Investigator & Institution: Murthy, Kanneganti; Director of Molecular Biology; Inotek Pharmaceuticals Corporation 100 Cummings Ctr, Ste 419E Beverly, MA 01915 Timing: Fiscal Year 2001; Project Start 01-SEP-2001; Project End 28-FEB-2003 Summary: (provided by applicant):In spite of aggressive antibiotic therapy and supportive care, gram negative pneumonia remains a major cause of death and prolonged hospitalization. To address this unmet need, Inotek is developing an antibody-based strategy that targets flagellin, a critical virulence factor of motile gram negative pathogens. Flagella is required for effective bacterial invasion of epithelium. Moreover, flagellin is a highly potent trigger of NF-kappa B activation and proinflammatory gene expression, and thus may contribute to the excessive deleterious host response to regional infection. Both active and passive immunization strategies that target the N-terminal domain of flagellin reduce mortality in LD9O-100 murine models of Serratia marcescens induced acute pneumonia to less than 10 percent. This level of protection is associated with a 90 percent reduction in bacterial cfu in the lung, a 95 percent decrease in pulmonary neutrophil infiltration, and a 50 percent reduction in the incidence of bacteremia. Because the N-terminus is highly conserved, immune responses are cross-protective against a broad spectrum of gram negative pathogens. The central objective of the Phase I SBIR is to obtain proof of principle that anti-N-terminal flagellin mAb's are protective in vivo against a broad spectra of lethal infection.We will test the in vivo protective action of 14 proprietary murine mAb's in a murine model of acute gram negative bacterial pneumonia produced by intratracheal bacterial inoculation of E. coil. Specific outcome variables will include: 1) Pharmacodynamic profile; 2) Therapeutic window of opportunity; and 3) Spectrum of activity against Pseudomonas aeruginosa, Serratia marcescens, and Enterobacter cloacae. In a follow-on Phase II SBIR, we will use the peptide corresponding to the lead epitopes identified in Phase I in order to produce a human mAb.We will then advance the lead mAb technology towards commercialization by 1) optimizing in vitro yield and purity, 2) characterizing in vivo half-life, and 3) performing safety and tolerance studies in two species. These milestones will provide a foundation for IND submission and the first clinical trials of a human anti-flagellin broad-spectrum mAb. PROPOSED COMMERCIAL APPLICATION: Since there are no marketed anti-inflammatory agents that are safe and effective for the adjunctive therapy of gram negative pnenmocda, it is difficult to predict the future market size and trend. We anticipate, based upon the numbers of hospitalized patients with severe pneumonia, that the market exceeds that for sepsis. Thus, a very conservative estimate of the domestic market may be $200-400 million per annum. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: NOVEL PRODRUGS FOR TREATMENT OF OPPORTUNISTIC INFECTIONS Principal Investigator & Institution: Allen, James L.; Immtech International, Inc. 150 Fairway Dr, Ste 150 Vernon Hills, IL 60061 Timing: Fiscal Year 2001; Project Start 30-SEP-1996; Project End 31-AUG-2002
102 Pneumonia
Summary: The long-range goal is to develop new drugs to treat important AIDS-related opportunistic infections and tropical parasitic diseases. STTR Phase I studies confirmed the hypothesis that diamidoxime prodrugs are readily absorbed after oral administration, then metabolized to active diamidines, with excellent antimicrobial activity and reduced host toxicity. Phase I research identified a lead candidate prodrug, DR 289 that is highly active orally in rodent models of P. carinii and African trypanosomiasis, with markedly reduced toxicity compared to pentamidine. The objective in Phase II is to synthesize sufficient quantities of DB289 to perform formal preclinical toxicity and further pharmacological studies required to support IND filing for Phase I clinical trials. The immediate goal is to apply for FDA approval to begin human clinical trials as an orally active agent to treat P. carinii pneumonia. PROPOSED COMMERCIAL APPLICATION: NOT AVAILABLE Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: NUTRITION, IMMUNITY & HEALTH STATUS OF ELDERLY ECUADORA* Principal Investigator & Institution: Meydani, Simin N. Professor of Nutrition & Immunology; None; Tufts University Boston Boston, MA 02111 Timing: Fiscal Year 2002; Project Start 15-JUL-2002; Project End 30-JUN-2005 Summary: (provided by applicant)This research will be done primarily in Ecuador as an extension of NIA grant 1 R01 AG13975, May 1997- April 2003 "Vitamin E and Infection in the Elderly." The overall goal of the parent grant is to determine the role of nutrients on immune response and resistance to infectious diseases in the elderly. Specifically, the objectives include evaluations of the effect of one year supplementation with vitamin E on: 1) incidence of respiratory infections (RI), total number of sick days, and antibiotic use, 2) in vivo and in vitro indices of cell-mediated and humoral immune responses, and 3) incidence of other infections, hospitalization, transfer to skilled nursing home facilities, and death. We intend to expand the goals of this grant by determining the relationship between nutritional status, immune response and health status in Ecuadorian elderly. In so doing, we will in part utilize the infrastructure of a related NIH grant, 1 R01HD 38327-0 1 A1, "Vitamin A and Zinc: Prevention of Pneumonia (VAZPOP) Study, Jan 2000-Dec 2004. This latter project is studying the potential benefits of vitamin A and/or zinc for the prevention of pneumonia and diarrheal diseases in malnourished children in Ecuador. The number of elderly is increasing both in developed and developing countries. Age-associated physiological, psychological, social, and economic changes adversely affect the nutritional and immunological status of older individuals. These changes are often reflected in poor health and a reduced quality of life. Infections, particularly respiratory infections, are prevalent in the elderly, and contribute significantly to their morbidity and mortality as well as to the associated costs of heath care. Micronutrient supplementation has been proposed as a cost-effective intervention to improve immune response and reduce morbidity and mortality in the elderly. Because of the higher prevalence of nutritional deficiencies and infectious diseases in developing countries such as Ecuador, the interaction between nutrition, immune response, and infectious diseases can be more efficaciously determined in these countries. Such information would be of great value to developing countries, because, despite the increasing number of elderly in these countries, very little is known about the nutritional and immunological status of their elderly and their impact on the health of the older population. Thus the specific aim of this proposal is to determine the nutritional, immunological, and health status of the elderly population living in the VAZPOP study area (poor northwestern suburb) of Quito. Nutritional status will be
Studies 103
assessed by obtaining dietary intake, selected nutrient analysis, and anthropometrics measurements. Immunological status will be assessed using delayed type hypersensitivity skin test (DTH), cellular profile, and a whole blood assay to determine lymphocyte proliferation and selected cytokine production. Health status will be determined using health questionnaires. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: ORAL CARE AND RESPIRATORY PATHOGEN COLONIZATION Principal Investigator & Institution: Akca, Ozan; Anesthesiology; University of Louisville University of Louisville Louisville, KY 40292 Timing: Fiscal Year 2003; Project Start 15-JUL-2003; Project End 30-APR-2005 Summary: (provided by applicant): Ventilator-associated pneumonia (VAP) causes significant morbidity and increases health care cost. Identical bacteria have been cultured from the mouth and sputum of VAP patients suggesting that the oropharynx of critically ill patients becomes colonized with respiratory pathogens that are aspirated into the lungs. Antimicrobial rinsing reduces surface bacteria in the oropharynx, but does not remove plaque, which can serve as a reservoir of bacteria for recolonizing the entire oropharynx. Removing dental plaque may thus reduce recolonization following antibacterial rinse. A national survey of oral care practices in American intensive care units indicates that usual oral care consists primarily of swabbing the teeth and mouth with foam toothettes and rinsing with alcohol-free mouthwash. Foam swabbing is not effective in plaque removal and may not remove respiratory pathogens. Plaque removal with manual toothbrushing is effective but is performed once a day or less often by approximately 80% of ICU nurses. We will therefore test the hypothesis that mechanical removal of dental plaque combined with antimicrobial oral rinse significantly reduces respiratory pathogen colonization when compared usual to oral care plus swabbing with a placebo solution or the antimicrobial agent chlorhexidine. Seventy-five patients expected to be on a ventilator for more than 48 hours will be recruited for this study. Patients will be randomly assigned to: 1) Control: twice daily swabbing of the oropharynx with placebo in addition to usual oral care; 2) Chlorhexidine: twice daily swabbing of the oropharynx with chlorhexidine in addition to usual oral care; 3) Chlorhexidine/brushing: twice daily swabbing of the oropharynx with chlorhexidine followed by brushing of the teeth with a powered toothbrush with simultaneous suctioning and finally another swabbing with chlorhexidine. Research personnel who are unaware of patient assignment will collect plaque scores and microbial samples from all patients at baseline and every three days until extubation or day 15. The primary outcome will be the colonization by respiratory pathogens of microbiological samples taken from the teeth, mucosa, and sputum, Secondary outcomes will be dental plaque scores, endotracheal tube colonization and development of VAP. Data and confounding factors will be quantitatively analyzed. This study will serve as a basis for future multi-site clinical trials that will: 1) validate the effectiveness of dental hygiene as another measure to prevent VAP; 2) evaluate cost effectiveness; and 3) evaluate mortality. Reducing respiratory pathogen colonization in the mouth could significantly reduce the morbidity and cost of VAP. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: ORAL CARE INTERVENTION IN MECHANICALLY VENTILATED ADULTS Principal Investigator & Institution: Munro, Cindy L. Adult Health Nursing; Virginia Commonwealth University Richmond, VA 232980568
104 Pneumonia
Timing: Fiscal Year 2002; Project Start 01-MAR-2002; Project End 28-FEB-2007 Summary: (provided by applicant) Pneumonia is the leading cause of death from nosocomial infections. Intubation and mechanical ventilation greatly increase the risk of bacterial ventilator-associated pneumonia (VAP). Growth of potentially pathogenic bacteria in dental plaque of critically ill patients provides a nidus of infection for microorganisms that have been shown to be responsible for the development of VAP. Since these organisms are concentrated in dental plaque, removal of organisms form the oral cavity by oral care interventions is a theoretically attractive method to reduce the risk of development of VAP. However, evidence-based protocols for oral care of mechanically ventilated patients are not available. Thus, we propose a prospective, randomized clinical trial to test the effects of three oral care interventions (mechanical, MECHI; pharmacologic, PHARMI; and combination, mechanical plus pharmacologic, COMBI) in reducing the risk of developing VAP. The primary aim of this study is to test the effects of mechanical, pharmacologic and combination (mechanical plus pharmacologic) oral care interventions on dental plaque, oral microbial flora and oral immunity in critically ill mechanically ventilated adults. Secondary aims are to1) examine the effects of mechanical, pharmacologic and combination (mechanical plus pharmacologic) oral care interventions on development of VAP in critically ill mechanically ventilated adults; and 2) describe any differential effects of mechanical and pharmacologic oral care interventions on the development of VAP in specific patient populations (medical, surgical, and neurologic critically ill patients). A total of 456 subjects will be randomly assigned to 4 groups (control, MECHI, PHARMI, COMBI) in order to attain an adequate sample size of 300 subjects. The effects of interventions will be examined using a between-subjects 22 factorial design. A two-factor analysis of variance will be used to conduct significance tests, including tests of the effect of each intervention (MECHI, PHARMI, and COMBI) on the outcomes of dental plaque (UMOHI score), oral immunity (salivary IgA and lactoferrin), oral flora (semi-quantitative culture), and development of VAP (CPIS score). Results of the study have the potential to positively affect patient well-being, morbidity, mortality and health care costs. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: P CARINII PNEUMONIA--IMMUNOPATHOGENESIS OF LUNG INJURY Principal Investigator & Institution: Gigliotti, Francis; Professor; Pediatrics; University of Rochester Orpa - Rc Box 270140 Rochester, NY 14627 Timing: Fiscal Year 2001; Project Start 30-SEP-1997; Project End 31-AUG-2003 Summary: Pneumocystis carinii produces a life-threatening pneumonia in patients who are immunocompromised. It is especially prevalent among patients with AIDS. While the hallmark of P. carinii pneumonia (PCP) is hypoxia, the type and extent of lung injury produced by P. carinii has never been defined or characterized. The goal of this proposal is to define and begin to characterize the pulmonary insult resulting from PCP. This will be accomplished by completing the following specific aims: 1) to determine the extent and means by which P. carinii directly contributes to injury and altered lung function in the absence of a host immune response, i.e., in a SCID mouse; 2) to determine the extent and mechanism by which the host inflammatory response contributes to the pathophysiological changes that occur in PCP; and 3) to determine whether manipulation of the host inflammatory response can ameliorate the pathophysiological sequelae of PCP. Preliminary experiments show that the host inflammatory response itself contributes significantly to the overall pulmonary injury in a SCID mouse model of PCP. Using the most modem molecular/cellular and
Studies 105
physiologic techniques, including assessment of lung compliance in a ventilated living mouse, this proposal will test the hypothesis that the pathogenesis of PCP is the result of both the direct effect of P. carinii on the lung and the effect of the P. carinii-driven host inflammatory response. This will be done by carefully manipulating various aspects of the inflammatory response to determine the effect on lung injury. If this hypothesis is proven correct, the information gained from the proposed studies can be utilized to develop new therapeutic modalities to improve the morbidity and mortality resulting from PCP. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: P INFLAMMATION
CARINII-EPITHELIAL
INTERACTIONS
MEDIATE
Principal Investigator & Institution: Wright, Terry W. Assistant Professor of Pediatrics; Pediatrics; University of Rochester Orpa - Rc Box 270140 Rochester, NY 14627 Timing: Fiscal Year 2001; Project Start 30-SEP-1999; Project End 31-AUG-2004 Summary: Pneumocystis carinii produces life-threatening pneumonia (PCP) in immunocompromised patients. Importantly, the clinical severity of PCP often correlates more closely with a patient's ability to mount an inflammatory response against P. carinii than with organism burdens. Alveolar epithelial cells (AECs) interact closely with P. carinii, and the important role of these cells in initiating inflammatory responses is becoming increasingly recognized. The hypothesis of this proposal is that AECs play a critical role in the initial detection and recognition of P. carinii in the alveolar compartment, and that the interaction of P. carinii with the alveolar epithelium stimulates chemokine secretion, and signals the recruitment of inflammatory cells specifically to sites of infection. When immune function is restored to P. carinii-infected SCID mice, T lymphocytes and macrophages are recruited only to sites of infection. In addition to clearing infection, this inflammatory response also results in "bystander" injury to the lung. Our preliminary data extends these observations by demonstrating that beta-chemokines and the beta-chemokine receptors CCR1 and CCR2 are highly expressed in vivo after reconstitution of infected SCID mice, and after inoculation of immunocompetent mice. In addition, we show that the specific attachment of P. carinii to AECs, in vitro, simulates the secretion of TNF-alpha and beta-chemokine gene expression. The specific aims of this proposal are designed to: 1) characterize the ability of P. carinii stimulated AECs to secrete chemokines, and induce the chemotaxis of CD4+ T cells. 2) determine whether CD4+ T cells are required for the early chemokine signals at the alveolar surface following in vivo exposure to P. carinii. 3) determine the role of beta-chemokines in cell recruitment and in resistance to P. carinii by utilizing CCR1 and 2 knockout mice. 4) determine the role of CCR1 and CCR2 in T cell recruitment, organism clearance, and lung injury in a well-characterized model of P. carinii-induced pulmonary inflammation. The goal of this proposal is to understand the inflammatory response to P. carinii so that strategies may be developed to circumvent the lung injury that results from the host response to P. carinii. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: PATHOGENESIS OF A NOVEL HANTAVIRUS FROM LABORATORY RATS Principal Investigator & Institution: Simmons, Joe H. Laboratory Animal Medicine; University of Missouri Columbia 310 Jesse Hall Columbia, MO 65211 Timing: Fiscal Year 2001; Project Start 01-APR-2001; Project End 31-MAR-2006
106 Pneumonia
Summary: (Adapted from the applicant's abstract): Dr. Simmons, the candidate for this SERCA, is a highly qualified young investigator who has achieved a MS in chemistry, a DVM and residency certification in laboratory animal medicine. He is a candidate for a PhD in veterinary pathobiology with an expected graduation date of summer semester 2001. During the course of the SERCA, Dr. Simmons will obtain additional training that will allow him to develop into an independently funded research investigator. To develop his scientific skills, Dr. Simmons will participate in a variety of research training opportunities, including an in-depth research project, scientific meetings, seminars and journal clubs relevant to his area of research, and specialized topical courses at the Cold Spring Harbor Laboratory. Further, Dr. Simmons will receive additional training via collaboration with Dr. Connie Schmaljohn of the US Army Medical Research Institute of Infectious Diseases. He will present his research findings at national scientific meetings, and he will publish his findings in peer reviewed journals. Preliminary results from this SERCA will be used to pursue additional extramural grant funding during year 5 of the granting period. The focus of Dr. Simmons' research project is a novel hantavirus that was recently isolated from laboratory rats with interstitial pneumonia. Preliminary serologic analysis indicates that this novel hantavirus is widespread in laboratory rodents in North America and Europe with approximately 8% of rats infected. Further study of this novel agent is warranted because hantaviruses are potentially zoonotic, subclinical viral infections of laboratory rodents can invalidate research data, and infected rats may represent a critically needed animal model of human hantavirus diseases. The short-term goals of this grant application are to characterize this novel rat hantavirus (RRV), to initiate studies to determine its pathogenesis in rats and to describe the rat's inflammatory cell and cytokine responses to RRV. The long term goal is to develop the RRV-infected rat into a rodent model of human hantavirus diseases. Dr. Riley's laboratory provides a unique environment for this project as it is the only laboratory that has isolated and cultured this novel hantavirus. Further, the UM Research Animal Diagnostic and Investigative Laboratory is an internationally respected rodent diagnostic laboratory with specialized handling facilities and expertise in the infectious diseases of rodents necessary to complete this project. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: PATHOGENESIS OF KLEBSIELLA AIRWAY INFECTIONS Principal Investigator & Institution: Clegg, Steven; Professor; Microbiology; University of Iowa Iowa City, IA 52242 Timing: Fiscal Year 2003; Project Start 01-APR-2003; Project End 31-MAR-2008 Summary: (provided by applicant): The opportunistic pathogen, Klebsiella pneumoniae, is responsible for a significant number of pulmonary infections in compromised individuals. The ubiquity of antibiotic resistant strains, particularly those producing extended-spectrum beta-lactamases, presents a serious clinical problem among groups such as hospitalized individuals and chronic alcoholics. The pathogenesis of Klebsiella airway infections has not been studied to any great extent and the investigation of the production of virulence determinants has essentially focused upon the role of capsules as antiphagocytic factors. The mouse has been extensively used as a model of airway infections due to K. pneumoniae primarily to investigate host cell responses. Also, epidemiologic observations suggest that specific capsular serotypes (e.g. K2) are most frequently associated with pulmonary infections. However, our preliminary data indicate that not all K2-positive isolates are virulent in the mouse model of infection. Therefore, although the capsule is most likely to be an antiphagocytic factor and prevent efficient killing of the bacteria in vivo, additional factors are necessary to establish
Studies 107
airway infections with subsequent invasion of the bloodstream. We propose to identify and confirm the role of previously unknown virulence factors that mediate airway infections due to K. pneumoniae. Three techniques; signature-tagged mutagenesis, subtractive hybridization and in vivo gene expression technology will identify these determinants. The murine model of Klebsiella infection will be used to demonstrate the role of putative virulence factors during infection. The three approaches are complementary and have been used to investigate virulence in many different types of pathogens. Since very little is known about the virulence factors of K. pneumoniae, it is anticipated that these studies will provide information on new and novel virulence factors produced by these bacteria. Fundamental to devising new therapeutic approaches to opportunistic infections will be an understanding of the virulence factors produced by this group of organisms. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: PATHOGENESIS OF LUNG INJURY IN LUNG AND PERITONEAL SEPSIS Principal Investigator & Institution: Martin, Thomas; University of Washington Seattle, WA 98195 Timing: Fiscal Year 2001 Summary: Problem. This project will investigate the cellular and molecular events that link local infection in a primary body space with systemic consequences and injury to distant organs. The major hypothesis is that a three compartment model best explains the responses of humans to bacteria and their products. In this model, bacteria enter an initial compartment (e.g., lungs or abdominal cavity), and local interactions between bacteria and host effector systems govern whether bacteria are effectively eliminated. When first compartment responses are ineffective, responses occur in the second "systemic" compartment. When the second compartment responses are severe, responses occur in the third compartment (distant organs). In the lungs these responses include injury to the epithelial barrier and sustained loss of function. We will investigate important questions that relate to understanding this model. The major long-term goal is to understand how responses in the second and third compartments can be minimized without adversely affecting bacterial elimination in the first compartment. Specific Aims. 1) to investigate the "first compartment" responses in the lungs and the peritoneal cavity, in order to determine why the "first compartment" responses differ in each of these two sites; 2) to investigate the critical inter-relationships between the first compartment and the second compartment inflammatory responses; 3) to investigate the mechanisms by which injury occurs to the lung epithelium in the third compartment; 4) to investigate strategies that will protect the third compartment without adversely affecting antibacterial responses in the first compartment. Experimental approach. We will study rabbits with pneumonia or peritonitis due to E. coli, and follow them for up to 24 hours after infection. Responses in the first compartment will be compared with systemic physiologic and inflammatory response variables, and measurements of functional and anatomic integrity of the third compartment (lungs). New strategies to protect the third compartment without compromising antibacterial defenses in the first compartment will be investigated. Significance. These studies will provide information about the relationship between local and systemic responses and lung injury in sepsis, and will help to determine whether the best approach to prevention and treatment of septic complications is to focus on the specific organism (e.g., better antibiotics), or on interfering with the host response (e.g., better anti-inflammatory therapy), or both. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
108 Pneumonia
•
Project Title: PATHOGENESIS OF VIRAL PROLIFERATIVE BRONCHIOLITIS Principal Investigator & Institution: London, Lucille; Associate Professor; Microbiology and Immunology; Medical University of South Carolina 171 Ashley Ave Charleston, SC 29425 Timing: Fiscal Year 2001; Project Start 01-JAN-1999; Project End 31-MAR-2003 Summary: (Adapted from the applicant's abstract): Bronchiolitis obliterans with organizing pneumonia (BOOP) is a term for a long observed, but unclassified pattern of acute lung injury. In humans, BOOP is characterized by fibrosis of small airways with fibrous extension into the alveolar spaces with preservation of alveolar ducts and walls. It is frequently associated with a peribronchiolar organizing pneumonia. The lesions may also be accompanied by lipid-laden foamy alveolar macrophages trapped in the air spaces by the fibrosis and by a T cell rich lymphocytic interstitial infiltrate in the regions of the lung directly affected by the lesion. Also, necrosis and sloughing of epithelial cells has been observed and is thought to result in the partial alveolar collapse seen in human BOOP. While BOOP can be associated with documented viral and bacterial infections, many cases are not associated with known causes and are thus classified as idiopathic. Little is known concerning the pathogenesis and treatment of BOOP since no animal models were available for this disorder. The investigators are the first to establish an experimental animal model for this disease. In this model, CBA/J mice infected with reovirus serotype 1/strain Lang develop BOOP lesions which closely resemble the histopathological picture of human BOOP. In addition, the development of BOOP lesions in CBA/J mice is virus strain specific. The central hypothesis of this proposal is that "Disruption of the epithelial basement membrane determines the susceptibility to fibrosis". The investigators propose to characterize the host and/or viral factors (both immune and non-immune cellular populations) that result in initiation of damage to the basement membrane and relate these finding to the development of fibrosis. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: PEDIATRIC AIDS CLINICAL TRIALS GROUP Principal Investigator & Institution: Flynn, Patricia M. Member, Dept of Infectious Diseases; St. Jude Children's Research Hospital Memphis, TN 381052794 Timing: Fiscal Year 2001; Project Start 01-MAR-1992; Project End 28-FEB-2002 Summary: A pediatric AIDS Clinical Trials Unit (PACTU) is proposed for St. Jude Children's Research Hospital with subunits at the University of Tennessee, (Le Bonheur Children's Medical Center and The Med), the Methodist Hospital and Vanderbilt University Medical center. The objective is to support the scientific agenda of the coordinating and Operations Center (CORC) proposed by Spector et al. and the NIAID) HIV/AIDS research agenda set forth in 1995. The team off the proposed PACTU includes well established academic specialists in pediatric and adult infectious diseases, immunology, pharmacology, virology, pharmaceutical science, pediatric neurology, psychology, neonatology, fetal and maternal medicine, vaccinology, oncology and gene transfer- based therapy. Each of the three children's hospitals have ongoing clinics for pediatric AIDS and the hospitals provide three separate obstetrical and neonatal programs with experience in maternal and infant AIDS. Over the past five years the St. Jude PACTU has demonstrated excellence as an innovative, productive, interactive site for the AUG program of the NIAID). We now plan to build on the existing program by addition of esteemed colleagues, state-of-the-art facilities and expanded clientele of HIV-infected infants, children and women at Vanderbilt University. This, in turn, provides access for all HIV- infected children throughout Tennessee and its seven
Studies 109
bordering states to ACTG protocols and experimental drugs and vaccines. The high density population of African-Americans in the mid-South and the rapid increase of HIV infection in adolescents of this group assure an ample sample of HIV-infected pregnant women and their infants, as well as non- pregnant adolescents for study. Because of the strength of our experience in pharmacology, phrmacokinetics and new drug development we intend to take a major role in phase I and I/II studies of new compounds. A second major emphasis will be on HIV-infected adolescents because of unique features of these older pediatric patients, the prevalence of these individuals in our catchment area and our well established collaboration with specialists in internal medicine who share our, interest in AIDS research. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: PEDIATRIC AIDS CLINICAL TRIALS GROUP Principal Investigator & Institution: Gershon, Anne A. Professor; Pediatrics; Columbia University Health Sciences New York, NY 10032 Timing: Fiscal Year 2001; Project Start 01-SEP-1993; Project End 28-FEB-2002 Summary: This application is for continuation of a Pediatric AIDS Clinical Trials (ACTU) at Columbia University, for years 10-14 of the project. The Unit has two components, the main unit at Babies Hospital, in the Women and Children's Care Center (WCCC) and a subunit Incarnation Children's Center (ICC) a residential center that provides respite, hospice and clinical care for HIV infected children many of whom are in foster care. This ACTU is located is located in the Upper West Side of New York City in a geographic location of high prevalence of HIV infection, especially in women and children. The PIs and other researchers are seasoned investigators in AIDS clinical trials and each is a full time member of the faculty at Columbia University College of Physicians and Surgeons. There is a Pediatric HIV-certified ACTG virology laboratory on site. At Babies Hospital the interweaving of staff involved in NIH-supported HIV studies of viral transmission of HIV from women into their offspring (WITS) and ACTG clinical trials provides a unique opportunity for rollover of patients from one HIV study into another, thus resulting in a high level of access to women and children in ACTG protocols. The representative patient population served by the two institutions are largely impoverished, from minority groups, and socially disadvantaged. For the past five years, staff at the Babies Hospital and ICC have worked together synergistically to enroll a large number of patients into ACTG protocols. On average, we have enrolled 18 new HIV-infected children into protocols annually in the past. We have also enrolled many children into multiple protocols so that over the past 9 years our patient accrual has been more than 250 enrollments. In the current year we have already enrolled have more patients above out originally planned accrual. With the local presence of the WITS study and a newly forged relationship with Harlem Hospital Department of Obstetrics, we anticipate significantly greater enrollment of HIV-infected women into perinatal studies. Based on our past performance at what we believe has been an outstanding level of regarding accrual, data management, compliance with regulatory requirements, and significant contributions to the research agenda of the ACTG, we are respectfully requesting that our unit be funded in order to perform future research studies. Our plans for the future are to concentrate our efforts on perinatal studies and Phase 1 primary antiretroviral studies in women, infants and children. We further hope to establish a program for adolescents. We will also participate to the fullest of our resources in protocols that address means to prevent and treat opportunistic infections and to record information regarding long term outcomes of HIV-infected patients. We believe that our ACTU provides significant access to patients and in turn offers an
110 Pneumonia
outstanding an outstanding level of medical competence, an outstanding staff whose aim is not only to provide compassionate medical care to HIV-infected patients but also to perform meaningful and useful research on prevention and treatment of HIV. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: PEDIATRIC AIDS CLINICAL TRIALS UNIT Principal Investigator & Institution: Borkowsky, William; Professor of Pediatrics; Pediatrics; New York University School of Medicine 550 1St Ave New York, NY 10016 Timing: Fiscal Year 2001; Project Start 30-SEP-1988; Project End 28-FEB-2003 Summary: The New York University Medical Center Department of Pediatrics plans to continue its goal o providing excellent care and perform outstanding research for children, adolescents, and pregnant women part of the AIDS Clinical Trials Group. This goal will he accomplished by contributing to the scientific agenda established by the Coordinating and Operations Center and utilizing a Statistical and Data Management Center to collect and analyze the data resulting from the proposed studies. We also plan to provide clinical and laboratory expertise which will help elucidate mechanisms of pathogenesis. Although he participation of Minority groups will be encouraged, this group currently comprises 80% of our ongoing patient base. It is our goal to perform studies to prevent perinatal transmission of HIV with antiretroviral drugs, immunebased therapies such as vaccines and passive immunotherapy, and newly formulated genetic therapies. We also expect to modify the HIV- related illnesses of those already infected with HIV by using emerging new antiretrovirals or by using established drugs in different combinations, performing pharmacokinetic analyses as required. In addition to interventions directed at the HIV agent itself, we expect to intervene with agents which may prevent the development of serious infections which result from the immunodeficient state of the child and adolescent or to modify the course of already ongoing disease with these or other agents, including vaccines. It is expected that these goals will be achieved from patient resources present in Bellevue Hospital well as through an already established Consortium of health care providers present in Lower Manhatten and in Staten Island. This effort will also be helped by established links to previously funded community resources, our community advisory board, and by our own local General Clinical Research Center. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: PERCUTANEOUS RESPIRATORY ASSIST CATHETER Principal Investigator & Institution: Federspiel, William J. Associate Professor/Director; Chemical and Petroleum Engr; University of Pittsburgh at Pittsburgh 350 Thackeray Hall Pittsburgh, PA 15260 Timing: Fiscal Year 2002; Project Start 01-APR-2002; Project End 31-MAR-2006 Summary: The objective of this proposal is to develop a percutaneous respiratory assist catheter (PRAC) that can be inserted into the venous system to provide supplemental breathing support, independent of the lungs, for patients requiring short- term (less than 1-2 weeks) respiratory assistance. The PRAC will be designed for percutaneous insertion into a peripheral vein and placement in the central venous system, where it will be exposed to all the blood returning to the heart. The PRAC will incorporate a cylindrical bundle of microporous hollow fiber membranes woven as a fabric that is wrapped around a balloon. The balloon is pulsed with helium and enhances gas exchange by pumping blood past the hollow fibers at velocities much greater than would otherwise exist in the vena cava. The specific aims of the project are to: 1. Fabricate candidate
Studies 111
PRAC devices with insertional diameters of 25-28 Fr (8-9 mm) and evaluate the functional mass transfer characteristics in an in-vitro test loop. We will establish how the gas exchange performance of the PRAC depends on key operating and design parameters. 2. Evaluate and optimize balloon pulsation in the PRAC to improve gas exchange. We will principally explore changes in balloon geometry and balloon pulsation mode, and we will use flow visualization, local gas tension measurements, and computational simulations to help guide our design development. 3. Perform acute calf implants of the PRAC to assess the gas exchange functionality in-situ and any adverse anatomical, physiological and biocompatibility effects associated with shortterm implantation. We will also evaluate the hemolysis potential of candidate PRAC designs in-vitro using bovine blood in a bench flow loop. Our target is a percutaneous assist catheter that can provide 75- 85 ml/min of extrapulmonary CO2 removal at normocapnia and that could be used as an adjuvant or replacement to existing therapy for patients with acute lung failure (ARDS, pneumonia) or acute on chronic lung failure (COPD with exacerbation). Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: PHARMACOKINETICS OF GREPAFLOXACIN & CIPROFLOXACIN IN LUNG Principal Investigator & Institution: Bascom, Rebecca; Pennsylvania State Univ Hershey Med Ctr 500 University Dr Hershey, PA 17033 Timing: Fiscal Year 2001 Summary: The purpose of this study is to determine the concentration of the antibiotic Grepafloxacin (Raxar) or Ciprofloxacin (Cipro) in the lung after taking a single dose. Both drugs are used for treating lung infections such as pneumonia and acute exacerbations of chronic bronchitis caused by bacteria that are resistant to many antibiotics. The greater the amount of antibiotic that is deposited at the site of the infection, the faster the bacteria is eliminated and the course of treatment is shorter. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: PHEROMONE SIGNALING IN PNEUMOCYSTIS CARINII Principal Investigator & Institution: Thomas, Charles F.; Mayo Clinic Rochester 200 1St St Sw Rochester, MN 55905 Timing: Fiscal Year 2002; Project Start 01-MAR-2002; Project End 28-FEB-2005 Summary: (provided by applicant): Pneumocystis carinii is an opportunistic fungal pathogen which causes severe pneumonia in patients with impaired immunity such as patients with AIDS. The life cycle of P. carinii is poorly understood. In fungi related to P. carinii, nutrient deprivation and dessication are the major stimuli for the release of pheromone mating factors which activate a mitogen-activated protein kinase (MAPK), resulting in mitotic cell cycle arrest, conjugation and meiosis, and increased pathogenicity. MAPK is the essential molecule in the pheromone-induced signal transduction cascade which controls these events. As an essential molecule regulating an organism's life cycle, MAPK activity is highly regulated. Dual phosphorylations are requiring for activation, and variable MAPK activity and expression are restricted to certain life cycle forms. Our initial studies indicate that P. carinii possesses a MAPK which is closely related to fungal pheromone-induced MAPKs. We hypothesize that the pheromone-induced mitogen-activated protein kinase (MAPK) signal transduction cascade regulates cellular differentiation and proliferation of P. carinii organisms. As an essential component in the life cycle of fungi, investigation of the P. carinii MAPK will
112 Pneumonia
result in an enhanced understanding of the P. carinii life cycle, pathogenicity, and lead to development of novel therapeutic agents to treat P. carinii pneumonia. To evaluate these hypotheses, we will undertake several parallel investigations. MAPK activity and expression in separated life cycle forms will be accessed to determine whether P. carinii MAPK is differentially regulated over the P. carinii life cycle. We will identify and characterize the P. carinii pheromone receptors and separate P. carinii mating types by FACS. We will access whether nutrient deprivation, hypoxia, or temperature changes results in mitotic cell cycle arrest leading to meiosis and formation of the cyst, and whether inhibitors of the MAPK cascade block these effects. We will also investigate if isolated mating types undergo haploid mitosis or if mixing of mating types is essential for meiosis and formation of the cyst. Through these investigations, we hope to gain important insights into the life cycle regulation and pathogenicity ofP. carinii. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: PLATELET CELL ADHESION MOLECULES Principal Investigator & Institution: Furie, Bruce; Chief, Coagulation Unit; Beth Israel Deaconess Medical Center St 1005 Boston, MA 02215 Timing: Fiscal Year 2001; Project Start 01-DEC-1994; Project End 30-NOV-2003 Summary: P-selectin is a cell adhesion molecule that resides in the storage granules of platelets and endothelial cells. Upon cell stimulation, the protein is translocated to the plasma membrane where it functions as a leukocyte receptor for PSGL-1 on neutrophils and monocytes. The current application represents a continuation of studies of the biology of P-selectin and PSGL-1. Since PSGL-1 has been shown to bind to all selectins, the kinetic and equilibrium binding of soluble PSGL-1 to soluble P-selectin, E-selectin and L-selectin will be analyzed by fluorescence spectroscopy. During the past grant period, we have prepared a PSGL-1 deficient mouse by homologous recombination and have completed the initial characterization. Cells from this mouse will be used to establish the physiologic role of PSGL-1 in selectin function by comparing the interaction of PSGL-1 (-/-), (+/-) and (+/+) leukocytes with P-selectin, E- selectin and Lselectin under rolling conditions in a parallel plate ex vivo assay using neutrophils and T lymphocytes. The PSGL-1 deficient mouse and double knockout mice including PSGL1 null/P-selectin null mice, PSGL-1 null/E-selectin null mice and PSGL-1 null/Lselectin null mice will be employed in model systems to determine the physiologic function of PSGL-1. Pathologic processes to be studied include models of non- immune mediated and T-cell mediated skin inflammation, leukocyte rolling following trauma and TNF, experimental glomerulonephritis, chemical peritonitis, bacterial pneumonitis, thrombosis, atherosclerosis, wound healing and platelet rolling. To understand the molecular basis of signal transduction and effector function induced by platelet activation or P-selectin binding to the P-selectin ligand on leukocytes, the induction of Ca2+ flux in platelets by PSGL-1 via P-selectin will be analyzed. Furthermore, binding of cytoplasmic tails of P-selectin and PSGL-1 to cytoplasmic signalling proteins in platelets and monocytes respectively will be examined using dimer constructs of cytoplasmic tails. If these studies indicate that PSGL-1 and ESL-1 are not physiologically critical counterreceptors for E-selectin or that there is evidence for another P- selectin ligand, we propose to expression clone a novel E-selectin ligand from a leukocyte library prepared from WEHI cells and a novel P-selectin ligand from a library prepared from neutrophils isolated from the PSGL-1 null mouse. The putative ligands will undergo characterization of their full length cDNAs and comparison of their predicted amino acid sequences with that of the PSGL-1, ESL-1 and GlyCAM-1. These studies will
Studies 113
contribute to our understanding of the physiologically relevant receptors and counterreceptors that define cell-cell interaction during inflammation. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: PNEUMOCYSTIS CARINII IN CONTINOUS AXENIC CULTURE Principal Investigator & Institution: Clarkson, Allen B. Associate Professor; Medical/Molecular Parasitology; New York University School of Medicine 550 1St Ave New York, NY 10016 Timing: Fiscal Year 2001; Project Start 01-JUN-1999; Project End 31-MAY-2004 Summary: (Adapted from Investigator's Abstract) Pneumocystis carinii is also a very poorly understood fungal pathogen and P. carinii pneumonia (PcP) remains one of the most common opportunistic infections associated with AIDS despite effective antiretroviral therapy, improved PcP treatment protocols and widespread PcP prophylaxis. The greatest obstacle in P. carinii research has been the inability to culture this organism other than in short term systems, generally with a co-cultured mammalian cell line. This laboratory has obtained continuous axenic growth of both rat- and human-derived P. carinii.The overall goal of this project is to develop this culture system further and use it to study P. carinii. Conditions will be established allowing for optimal growth in culture. Temperature and pH optima will be determined. Validation will be sought for the supplements now added to the culture medium and other supplements will be tested. Supplement concentrations will be optimized. Minimum medium exchange rates for optimal growth will be determined. A method of growing a P. carinii culture from a single cell will be developed. Cultured P. carinii will be characterized with reference to morphology, movement, and aspects of cell physiology such as respiration and polyamine metabolism. A library of 50 isolates of human-derived P. carinii will be obtained using bronchoalveolar lavage fluid from patients with P. carinii pneumonia. These isolates will be studied in vitro for sensitivity to the combination of trimethoprim + sulfamethoxazole (the mainstay for both treatment of and prophylaxis against P. carinii pneumonia) and to atovaquone (a commonly used alternative drug). In these isolates, we will determine critical sequences in the sulfamethoxazole target enzyme (dihydropteroate synthase) gene and the atovaquone target enzyme (cytochrome b) gene. An attempt will be made to correlate drug sensitivity, gene sequence and patient response to determine if there is resistance to this drug combination in human P. carinii. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: PNEUMOCYSTIS CARINII PNEUMONIA MODEL IN RHESUS MACAQUES Principal Investigator & Institution: Norris, Karen A. Associate Professor; Molecular Genetics & Biochem; University of Pittsburgh at Pittsburgh 350 Thackeray Hall Pittsburgh, PA 15260 Timing: Fiscal Year 2001; Project Start 30-SEP-1999; Project End 31-AUG-2003 Summary: Pneumocystis carinii pneumonia is a primary cause of morbidity and mortality in immunocompromised patients, with particularly high infection rates in patients with acquired immunodeficiency syndrome (AIDS). Studies of the pathophysiology of Pneumocystis carinii pneumonia (PCP), host immune responses, and molecular characterizations of the organism have relied on animal models because of the lack of continuous in vitro culture systems. Although these animal models have been useful in producing information regarding the nature of the organism and the complex host-parasite interaction, the relevance to human PCP has been questioned
114 Pneumonia
since they generally involve broadly immunosuppressed animals. In addition, much evidence has been accumulated that demonstrates host species specific phenotypic and genotypic variation. For these reasons, the development of a reproducible, nonhuman primate model of PCP which mimics the disease seen in AIDS would provide several advantages for studying the pathogenesis of PCP and the molecular aspects of host species variations in a model most closely related to humans. Simian immunodeficiency virus (SIV) infected rhesus macaques develop spontaneous PCP, and preliminary evidence suggests that this occurs when peripheral CD4+ T cells counts falls below approximately 30 percent of the total T cells. The occurrence of PCP in SIV infected animals is not predictable due to individual host variability, environmental factors, and the variability in the course of the SIV infection. The primary goals of this study are to develop a reproducible PCP infection in immunocompromised, SIV infected rhesus macaques and to use this model to characterized the phenotypic and genotypic variation of simian derived P. carinii. It is our hypothesis that this model will most closely resemble PCP in AIDS and that the simian P. carinii will be most closely related to human P. carinii at the molecular level. To test these hypotheses, we propose to develop a PCP model by initiating a P. carinii infection in SIV infected rhesus macaques. The P. carinii infection will be initiated in monkeys when the SIV -induced decline in peripheral CD4+ T cells reaches 30 percent of the total peripheral blood T cells. Various manifestations of the disease progression will be monitored and simian P. carinii will be recovered for molecular and antigenic characterizations. These studies will address the question of similarities between simian and human P. carinii and determine the relevance of the nonhuman primate model, thus providing the means to study many aspects of PCP previously unapproachable due to the limitations of other animal models. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: PNEUMOCYSTIS ACTIVATION
CARINII:
MACROPHAGE
&
EPITHELIAL
Principal Investigator & Institution: Limper, Andrew H. Professor; Mayo Clinic Rochester 200 1St St Sw Rochester, MN 55905 Timing: Fiscal Year 2003; Project Start 10-JUL-1993; Project End 30-JUN-2008 Summary: (provided by applicant): Pneumocystis carinii pneumonia remains a significant cause of mortality and morbidity in immune compromised patients, particularly those with AIDS, malignancy, and organ transplantation. Our investigations demonstrate that respiratory impairment during PC pneumonia is more closely related to exuberant pulmonary inflammation than to toxic effects of the organism. Adjunctive anti-inflammatory corticosteroid therapy (given in addition to antibiotics) improves outcome in this infection. Our studies demonstrate that cell wall beta-glucans of Pneumocystis (PCBG) specifically interact with alveolar macrophages to trigger inflammatory activation through NF-kappaB translocation, stimulating release of TNFalpha and chemokines that promote neutrophil recruitment in the lungs. Additional investigations demonstrate that alveolar epithelial cells also interact with PC betaglucans and are potently activated to release chemokines including MIP-2, which further promote lung inflammation. Epithelial responses are robust and of magnitude comparable or greater than those elicited by macrophages. The mechanisms of activation of alveolar macrophages and epithelial cells by PCBG involve multiple distinct receptor systems. In the current proposal, we hypothesize that alveolar macrophages and epithelial cells are activated by PCBG through distinct receptor systems involving CD11b/CD18 in macrophages and lactosylceramide in epithelial cells
Studies 115
resulting in NF-kappaB-based activation. These concepts will be addressed through four independent but interrelated specific aims. In Aim 1, we will assess the roles of CD11b/CD18 integrins and TLR-2 (toll like) co-receptors in initiating NF-kappaB mediated inflammatory responses in macrophages. In Aim 2, the mechanisms through which lactosylceramide initiates inflammatory activation of epithelial cells will be determined. Aim 3 will evaluate the mechanisms of PCBG internalization in macrophage and epithelial cell inflammatory activation. Finally, Aim 4 will utilize mice deficient in CD11b or TLR2, and inhibitors of lactosylceramide, to study the roles of these lung responses during development of PC pneumonia in the intact host. Organisms burden and associated measures of lung inflammation will be studied during the course of PC pneumonia in these animals. Better understanding of the interactions of PC beta-glucans with host alveolar macrophages and epithelial cells will assist in the development of novel adjuvant anti-inflammatory. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: POST BMT LUNG INJURY PATHOPHYSIOLOGY Principal Investigator & Institution: Blazar, Bruce R. Director; Pediatrics; University of Minnesota Twin Cities 200 Oak Street Se Minneapolis, MN 554552070 Timing: Fiscal Year 2001; Project Start 15-SEP-1995; Project End 30-NOV-2004 Summary: (Applicant's abstract) Idiopathic pneumonia syndrome (IPS), formerly known as interstitial pneumonitis, accounts for up to 40% of non-GVHD deaths in allogeneic BMT patients. The pathophysiological mechanism(s) responsible for generating IPS are unknown. The applicants' laboratory has established a new murine IPS model which closely simulates the human condition. The severest form of IPS injury in humans occurs with the infusion of allogeneic T cells into recipients of cyclophosphamide (Cy) and total body irradiation (TBI). Therefore, they have constructed a murine model in which Cy/TBI conditioning and allogeneic T cells are used to generate IPS injury and mortality. Their central hypothesis is that these early peri-BMT inflammatory events establish an ideal environment for IPS injury as host MHC class II positive monocytes first are recruited into the lung (day 3), following which donor CD4+ and CD8+ T cells encounter these activated monocytes (Day 7). They will focus upon the early events that initiate lung injury. With respect to the T cell destructive component of IPS, they will determine whether donor T cells cause IPS injury via perforin or cause apoptotic injury via Fas ligand. The induction of endogenous IL-13 is associated with decreased IPS injury will be investigated. The role of IL-13 in downregulating IPS injury by donor T cells. They will explore two roles for these monocytes as: 1. facilitators of cytolytic T lymphocyte generation; 2. effector cells mediating tissue injury. B7 ligand expression is upregulated on host monocytes during IPS injury. Thus, they will use B7 ligand knockout (ko) mice to explore the requirement for B7 ligand expression in the lung for facilitating IPS injury. Their collaborator has shown that monocytes/macrophage secrete macrophage mealloelastase (MME) resulting in the destruction of essential matrix proteins leading to alveolar airspace destruction. They will determine whether MME is upregulated during IPS injury and if so, they will use MME ko recipients to determine whether MME is essential for IPS injury. Chemokines regulate cellular recruitment into damaged tissues. They will explore the critical role of chemokines known to regulate monocyte (MCP-1) and CD8+ T cell (MIP-1 alpha) recruitment in vivo; we will assess the role of proinflammatory Thelper type 1 (CCR5) and anti-inflammatory T-helper type 2 (CCR4) cell recruitment on IPS injury by infusing CC chemokine receptor (CCR) ko donor cells. Because adhesion molecules such as ICAM-1 are known to be critical in recruiting cells in the lung during
116 Pneumonia
TBI injury, they will determine whether ICAM-1 is responsible for residual cellular infiltration in the lung when chemokine/receptor interactions described above do not occur. This proposal will provide important new data as to the pathophysiology of IPS injury and may be useful in designing future clinical studies to prevent IPS injury. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: PPARGAMMA IN SEPSIS-INDUCED IMMUNOSUPPRESSION Principal Investigator & Institution: Reddy, Raju C. Internal Medicine; University of Michigan at Ann Arbor 3003 South State, Room 1040 Ann Arbor, MI 481091274 Timing: Fiscal Year 2002; Project Start 30-SEP-2002; Project End 31-AUG-2007 Summary: (provided by applicant): Patients with sepsis are highly susceptible to the development of nosocomial infection, particularly bacterial infection of the lung. While the exact mechanism(s) that contribute to sepsis-mediated immunosuppression remains unclear, dysregulation of monocyte/macrophage function is believed to play an important role in these phenomena. Recently, peroxisome proliferator-activated receptor-gamma (PPARy), a member of the nuclear receptor superfamily of liganddependent transcription factors, has been shown to inhibit the expression of inflammatory mediators from monocytes/macrophages and other leukocyte populations. The hypothesis of this proposal is that sepsis induced immunosuppression is mediated, in part, by PPARy. Furthermore, we postulate that inhibition of this ligand dependent transcription factor will reverse sepsis-induced changes in alveolar macrophage function, resulting in augmented lung antibacterial host defense. A murine model of cecal ligation and puncture (resulting in an abdominal sepsis syndrome) will be utilized to assess the following Specific Aims: I) to determine the time course and magnitude of PPARy expression in lung during the evolution of murine abdominal sepsis; II) to determine the functional significance of PPARy activation on effector cell functions of primary murine alveolar macrophages or murine alveolar macrophage cell lines; III) to identify the endogenous signals that regulate PPARy expression during the evolution of murine abdominal sepsis; and IV) to determine the effect of inhibition of PPARy on sepsis- induced alterations in alveolar macrophage function ex-vivo and susceptibility to Pseudomonas pneumonia in-vivo. Performance of the studies outlined will help define the role of PPARy as a mediator of sepsis-induced alveolar macrophage dysfunction, and may lead to the development of novel therapies to be employed in the treatment of patients with sepsis. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: PRECLINICAL DEVELOP. OF A NEW DRUG FOR PCP AND MALARIA Principal Investigator & Institution: Elsohly, Mahmoud A. President; Elsohly Laboratories, Inc. 5 Industrial Park Dr Oxford, MS 38655 Timing: Fiscal Year 2001; Project Start 15-SEP-2000; Project End 31-DEC-2002 Summary: (Adapted from the application): The overall objective of this Phase II STTR application is to complete the preclinical studies for NPC 1161B, a promising new drug candidate for the treatment and prophylaxis of malaria. The drug is also very effective in animal models for the treatment or prevention of Pneumonocysis carinii (PCP) and leshmaniasis. This project is the continuation of the STTR Phase I project and a continuing collaborative effort between Elsohly Laboratories Inc., Oxford MS and The National Center for Natural Products Research of the University of MS (UM). In this Phase II application, these studies will be extended to complete the package of
Studies 117
information necessary for the filing of the Investigational New Drug application. The objective will be accomplished through a plan of work to achieve the following specific aims: 1) Determine the physiochemical characteristics purity and stability of the GMP drug substance NPC1161B, assess compatibility of the drug with commonly used capsule formation excipients; 2) Evaluate the stereoisomers of NPC1161 (NCP1161A and NCP1161B) in primate models for relative antimalarial efficacy, toxicity, and metabolism/kinetics; 3) Develop analytical methods and a formulation of NCP1161B for clinical studies (drug product) and conduct accelerated stability studies; 4) Prepare and submit IND application. PROPOSED COMMERCIAL APPLICATION: NOT AVAILABLE Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: PREDICTING HOSPITALIZATION
PEDIATRIC
RISK
OF
DEATH
AFTER
Principal Investigator & Institution: Feudtner, John C.; Children's Hospital of Philadelphia 34Th St and Civic Ctr Blvd Philadelphia, PA 19104 Timing: Fiscal Year 2003; Project Start 01-AUG-2003; Project End 31-JUL-2006 Summary: (provided by applicant): The prospective identification of dying children is an essential task that must be accomplished in order to improve the beneficial impact of palliative, end-of-life, and bereavement (P-EOL-B) services on dying children and their families, since this prospective identification is essential if effective individual-level interventions are to be employed in a timely manner. We hypothesize that using administrative health service utilization data, one can prospectively identify with reasonable accuracy a substantial proportion of children who die from complex chronic conditions, and that proactive identification can improve the delivery of P-EOL-B care to these children and their families. We therefore aim to: 1. Develop a method of prognostication that would use administrative health utilization data to triage patients into low, medium-low, medium-high, and high risk groups for subsequent 1-year mortality. 2. Develop collaborative relationships and plan a larger replication study using data from other contexts, in order to validate techniques that would enable the recreation of this prognostication algorithm in the context of local and evolving systems of pediatric health care services. The algorithm will be developed using logistic regression and recursive partitioning, which will model the probability of dying 365 days after hospitalization among children age. We will utilize administrative hospital discharge data contained in the Pennsylvania Health Care Cost Commission database, linked to vital statistics records. With this innovative mortality risk prediction system in hand, we postulate that P-EOL-B and pastoral care teams in hospitals and health care programs would be able to identify individual patients or classes of patients (eg, those with cerebral palsy and the first or second hospitalization for an aspiration pneumonia) suitable for quality of care assessment and improvement, with targeted intensive care coordination to introduce P-EOL-B care earlier into these patients' and families' comprehensive package of care. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: PREDICTORS AND OUTCOMES OF PNEUMONIA AFTER STROKE Principal Investigator & Institution: Katzan, Irene L. Epidemiology and Biostatistics; Case Western Reserve University 10900 Euclid Ave Cleveland, OH 44106 Timing: Fiscal Year 2003; Project Start 01-FEB-2003; Project End 31-JAN-2008
118 Pneumonia
Summary: (provided by applicant): The candidate's long-term goals are to become an independent clinical researcher and make significant contributions to the study of stroke management and outcomes. To fulfill these goals, the candidate proposes a 5-year plan to learn research methodologies related to assessing and analyzing stroke management in the community setting. This will involve formal training as well as comprehensive research on pneumonia as a complication of acute stroke. Pneumonia is a frequent and serious complication occurring after stroke, yet the predictors and preventability of pneumonia, and its effect on outcomes after stroke, are poorly known. The Aims of the proposed study are to use a large community-based cohort of Medicare patients hospitalized for acute stroke to: 1) Evaluate the effect of pneumonia on length of stay, rate of discharge to home, and 30-day readmissions. 2) Determine the effect of pneumonia on hospital costs. 3) Evaluate the effect of process of care measures on occurrence of pneumonia. 4) Develop a clinically useful prediction rule to identify patients most likely to benefit from preventive interventions. A retrospective cohort will be used to evaluate Primary Aims 1 and 2 and nested case-control studies will be performed to evaluate Primary Aims 3 and 4. For the first two Aims, the independent effect of pneumonia on outcomes and costs will be determined using data on 11, 286 stroke patients hospitalized in the Cleveland region from 1991-1997. Regression analyses will be performed with adjustments for both susceptibility and selection bias. To evaluate Primary Aims 3 and 4, a supplemental chart review will be performed for each case and control in the 2 nested case-control studies. Patients with pneumonia (n = 400) in a subset of 19 hospitals will serve as cases for both. For Aim 3, to isolate the effect of process of care measures, controls for Aim 3 will be selected using multivariate matching to cases on patient characteristics correlated with their propensity for pneumonia. For Aim 4, a random sample of patients will serve as controls. Products of this investigation will fill important gaps in knowledge about a serious compilation of stroke and guide further research and patient care to prevent stroke-related pneumonia. Combined with rigorous coursework in research methods, this body of work will establish a solid foundation for the candidate's long-term goals. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: PREDICTORS OF POSTOPERATIVE ATELECTASIS PNEUMONIA Principal Investigator & Institution: Brooks-Brunn, Jo A. Assoc Scientist, Sch of Nursing; Medicine; Indiana Univ-Purdue Univ at Indianapolis 620 Union Drive, Room 618 Indianapolis, IN 462025167 Timing: Fiscal Year 2001; Project Start 15-JAN-1997; Project End 31-DEC-2001 Summary: (Adapted from investigator's abstract) Postoperative pulmonary complications (PPCs) are frequent and associated with increased morbidity, mortality, hospital length of stay and resource utilization. Atelectasis and pneumonia account for >80% of reported PPCs. The objective of this study is to develop predictive models for stratifying the risk of clinically significant atelectasis and/or pneumonia using readily accessible or existing clinical data in an adult abdominal and cardiothoracic surgical population. The long term goal is to develop predictive model(s) for use in the clinical setting to guide preoperative and postoperative pulmonary care. The primary aim of this study is to develop, compare and validate models to predict the risk of clinically significant atelectasis and/or pneumonia following abdominal or cardiothoracic procedures by assessing combinations of risk factors available at differing time periods during the surgical episode of care. Secondary aims are to compare the incidence of clinically significant atelectasis and/or pneumonia following abdominal and cardiothoracic procedures and postoperative length of stay between patients who
Studies 119
develop these complications and those who do not. Four institutions will be utilized for data collection and the target population is adults who are undergoing elective abdominal or cardiothoracic procedures with general anesthesia. The target sample size is 1500 subjects over a three year period. Multi-criteria definitions will be used to measure the outcomes of clinically significant atelectasis and pneumonia as not to overestimate the incidence. The risk factors of interest are: increased age, impaired preoperative level of cognitive function, history of chronic lung disease, preexisting comorbid diseases, low or high body mass index (BMI), increased preoperative length of stay, smoking history, absence of preoperative respiratory education, high anesthesia physical risk status (ASA), increased duration of anesthesia, type and location of surgical procedure, incision direction and length, duration of intubation/mechanical ventilation in the postanesthesia period, pain management, postoperative mobility, administration of H2 blockers/antacids and presence of a nasogastric tube. Data will be collected on each subject prior to surgery and on a daily basis until hospital discharge. Logistic regression analysis will be used to examine the risk factors for univariate effects on clinically significant atelectasis and pneumonia and to develop and compare the multivariate models. Models will be evaluated for utility and goodness-of-fit. A splitsample technique will be used for model validation. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: PNEUMONIA
PROGNOSTICATION
IN
IDIOPATHIC
INTERSTITIAL
Principal Investigator & Institution: Flaherty, Kevin R. Internal Medicine; University of Michigan at Ann Arbor 3003 South State, Room 1040 Ann Arbor, MI 481091274 Timing: Fiscal Year 2002; Project Start 19-DEC-2001; Project End 30-NOV-2006 Summary: (provided by applicant): It has been proposed that idiopathic interstitial pneumonia (IIP) be divided into histopathologic categories. The overall prognosis differs between histopathologic categories; however, individual patients within categories can have an unpredictable response to therapy and survival. The potential for disease progression despite therapy often leads to the early listing of patients for lung transplantation as the mean time on the waiting list is 2-3 years. There is a shortage of donor lungs and this approach can lead to overpopulation of the waiting list and has the potential of preventing allocation of organs to the patients with the greatest need. This project will examine prognostic factors in patients with IIP and use these factors to develop a model that predicts survival. This model will help patients and physicians decide on optimal timing for lung transplantation. The histologic type of IIP is the most important, although not exclusive, factor influencing survival. Determination of histologic type requires a surgical biopsy which is not possible in all patients. Semiquantitative high resolution CT (HRCT) scoring for the amount of fibrosis also gives prognostic information. A drawback of this technique is observer variability, which could limit widespread utilization. We will collaborate with the University of Iowa to utilize a computerized quantitative scoring system which quantifies HRCT patterns (ground glass, fibrosis) present in the lungs of patients with IIP. We hypothesize that a computerized technique to determine the baseline and serial change in the amount of fibrosis will provide key prognostic information for patients with IIP. It has been suggested that radiologists can accurately diagnose categories of IIP. We will utilize survival analyses to compare the impact of a histologic diagnosis compared to a HRCT diagnosis for patients with IIP. We hypothesize that radiologists will have moderate accuracy in the diagnosis of IIP and that a HRCT diagnosis will provide more prognostic information when compared to a surgically obtained histopathologic
120 Pneumonia
diagnosis. The change in a clinical, radiographic, and physiologic (CRP) scoring system after three months of treatment also influences prognosis. A drawback is the requirement of a cardiopulmonary exercise test. We hypothesize that a scoring system utilizing the change in oxygen saturation during a six-minute hall walk will provide equal information without the need for a cardiopulmonary exercise test. During the past 10 years patients undergoing CRP testing have also performed a six-minute walk test. This information will be utilized to develop a new exercise component for a modified CRP scoring system. We will utilize survival analysis to define the patient population most likely to have improved survival through lung transplantation. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: PROPHYLAXIS FOR MAC, PNEUMONIA, AND HIV INFECTION Principal Investigator & Institution: Muschatt, David M.; Tulane University of Louisiana New Orleans, LA 70118 Timing: Fiscal Year 2001 Summary: Recent short-term studies have reported significant decreases in viral load and increases in CD4+ cell counts in people with HIV infection treated with combinations of antiretroviral agents. These changes in immunologic and virologic parameters have been shown to correlate with a decreased risk for development of AIDS-associated opportunistic infections (OIs). The question of whether there is a need to continue MAC prophylaxis in people who have had such responses to antiretroviral therapy is important in view of the toxicities, drug interactions, and complexity of drug regimens used to treat HIV infection and its complications. Deferred prophylaxis for MAC may be a reasonable option, provided this can be done without an unacceptably increased risk. The strategy of deferred prophylaxis may allow patients to avoid adverse side effects, the development of resistant organisms, and the extra pills and costs that are required to maintain a MAC prophylaxis regimen. Finally, the disadvantages associated with continued prophylaxis may outweigh the advantages in the context of a diminished risk of DMAC. This study will assess the impact of a strategy of prophylaxis versus deferred prophylaxis for MAC. It will evaluate the effect of azithromycin versus deferred azithromycin on the combined endpoint of DMAC and bacterial pneumonia. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: PROTECTIVE IMMUNITY TO VARICELLA ZOSTER VIRUS AFTER BONE MARROW TRANSPLANTATION Principal Investigator & Institution: Arvin, Ann M. Professor of Microbiology and Immunology; Stanford University Stanford, CA 94305 Timing: Fiscal Year 2002; Project Start 11-JUL-2002; Project End 28-FEB-2007 Summary: Reactivation of varicella-zoster virus (VZV) causes herpes zoster, which is common after bone marrow transplantation and is associated with considerable morbidity and even with life-threatening infection in some patients. The goals are to investigate the immunologic correlates of protection against VZV reactivation after hematopoietic cell transplantation (HCT), the role of viral tropism for human T cells in the pathogenesis of recurrent VZV infections, and the contributions of two novel VZV glycoproteins, gM and gN, to infectivity for T cells and skin. We propose to continue our studies of the reconstitution of VZV immunity by administration of inactivated varicella vaccine in a placebo controlled trial that incorporates a focus on refined analysis of the possible mechanisms and immunologic correlates of protection. The vaccine preparation to be tested will also be of higher initial virus content. The evidence from our current
Studies 121
studies is that the inactivated vaccine accelerates reconstitution of VZV specific CD4 T cells in autologous HCT recipients who are vaccinated before as well as after transplant. We will continue to evaluate VZV immune reconstitution using novel assays to quantitate the CD8 as well as CD4 T cell responses in vaccine recipients. Immunologic correlates of protection will be defined by prospective monitoring for VZV-specific memory T cell recovery, and for the occurrence of herpes zoster as well as subclinical VZV reactivations documented by real time polymerase chain reaction (PCR). VZV infects human CD4 and CD8 T cells, which allows transport of the virus to visceral organs; this lymphotropism is an important event in the pathogenesis of VZV infections after HCT since it is responsible for the most serious complications of herpes zoster, such as pneumonia and encephalitis. In viral pathogenesis experiments, we plan to continue our focus on the contributions of VZV glycoproteins. The objective is to use our cosmid approach to generate recombinant VZV strains with modifications or deletions of the newly identified VZV glycoprotein genes, gM and gN. These genes are likely to be dispensable in vitro, but may be manipulated to reduce VZV virulence in vivo, providing a new approach for VZV attenuation. VZV recombinants that have deletions or selected mutations in gM and gN will be evaluated for changes in skin and T cell tropism in vivo in the SCID-hu model. A comprehensive assessment of immunologic correlates of protection from herpes zoster after immunization with inactivated varicella vaccine should suggest ways to enhance the control of VZV reactivation after HCT through targeting restoration of particular host responses; this work should have direct relevance to strategies for optimal reconstitution of host responses to other viral pathogens in high risk patients who have impaired immune function. Better understanding of VZV tropism for T cells and skin, and the contributions of the viral glycoprotein genes to virulence will provide basic information that may allow the design of live attenuated VZV vaccines which are safe and immunogenic in immunocompromised patients. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: PROTOCOL TO DEVELOP MODEL OF PNEUMOCYSTIS CARINII PNEUMONIA IN RHESUS MONKEY Principal Investigator & Institution: Rudolf P Bohm, Jr; Tulane University of Louisiana New Orleans, LA 70118 Timing: Fiscal Year 2001 Summary: This study is a continuation of previously reported work to develop a rhesus monkey model of Pneumocystis carinii pneumonia (PCP). This model will be important to study the pathogenesis and novel drug compounds that may be used to treat PCP. Four rhesus monkeys were chosen for this pilot study. Three animals received alternate day dosing of prednisone and cyclophosphamide to induce immunosuppression. The fourth animal was used as a non-immunosuppressed control. Bronchoalveolar lavage (BAL) was performed one week prior to immunosuppression and weekly thereafter. All four animals were inoculated via a bronchoscope with a homogenate from P. carinii frozen lung tissue derived from three SIV infected animals. Viability was assessed prior to the time of inoculation. Five ml of homogenate (2.8 x 106 organisms/ml) was inoculated in the right caudal lung lobe of each animal. Followup included BAL, silver stain, PCR, bacterial culture, complete blood counts, serum chemistries, chest radiographs, and physical examinations performed at weekly intervals. Total lymphocyte counts in peripheral blood as well as CD4+ And CD8+ subsets decreased to a nadir by day 21. The lung homogenate was positive by DNA PCR for SIV at the time of inoculation. All four animals became positive by DNA PCR for SIV by 14 days post
122 Pneumonia
inoculation. BAL samples were negtive for P. carinii by PCR and by Giemsa stain evaluation at all time points. Silver stains of cytospin samples from BAL were also negative. Thoracic radiographs were normal throughout the study period. Future experiments will involve timing of inoculation at the nadir of the CD4+ lymphocyte count and inoculation of SIV-negative lung homogenate. FUNDING Base Grant PUBLICATIONS None Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: PSEUDOMONAS AERUGINOSA LPS CORE AND PATHOGENESIS Principal Investigator & Institution: Goldberg, Joanna B. Professor; Microbiology; University of Virginia Charlottesville Box 400195 Charlottesville, VA 22904 Timing: Fiscal Year 2001; Project Start 30-SEP-1997; Project End 31-AUG-2003 Summary: (Adapted from the applicant's abstract): Chronic lung infections with the opportunistic pathogen Pseudomonas aeruginosa remain the major cause of morbidity and mortality in patients with cystic fibrosis (CF). Initially P. aeruginosa strains that infect CF patients have a nonmucoid and smooth lipopolysaccharide (LPS) phenotype, typical of those found in the environment. As the clinical course of CF progresses, typical P. aeruginosa strains that are mucoid and have a rough LPS phenotype become predominant. The long-term objective of this proposal is to determine the bacterial and host factors responsible for the hypersusceptibility of CF patients to this infection. In vitro studies from the investigators' laboratory have shown that P. aeruginosa is internalized by human airway epithelial cells expressing wild-type CF transconductance membrane regulator (CFTR) significantly better than by epithelial cells that express the F508 mutant CFTR. Using structurally defined P. aeruginosa LPS mutants, we have identified the outer portion of the LPS core as an important ligand for this interaction. This ligand inhibited uptake of P. aeruginosa by the human airway epithelial cells and inhibited clearance of P. aeruginosa in vivo using a neonatal mouse model of pneumonia. The investigators suggest that the internalization of P. aeruginosa into normal airway epithelial cells represents an under-appreciated host defense mechanism that promotes desquamation and subsequent clearance. Further, this defense mechanism is ineffective in CF patient; thus, P. aeruginosa remains in the mucus layer and can cause a chronic infection. P. aeruginosa exacerbates this situation and evades the residual uptake mechanism of the CF cells by converting to an LPS-rough form that is even more poorly internalized. The specific aims of this proposal attempt to further define the P. aeruginosa LPS core structures involved in the interaction with human airway epithelial cells. The investigators will test structurally defined LPS core mutants for uptake by human airway epithelial cells. They will clone and sequence the P. aeruginosa LPS core genes encoding the proteins responsible for the synthesis of this ligand. This analysis will allow them to construct and characterize genetically defined LPS core mutants of P. aeruginosa and verify that the ligand is required for internalization. They will also determine the structure of the LPS core of three different P. aeruginosa CF isolates, since poor internalization of these strains suggests a defect in LPS core. The information derived from these studies may allow the investigators to devise a strategy to increase P. aeruginosa elimination by CF airway epithelial cells, and thereby inhibit the infection caused by this opportunistic pathogen. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
Studies 123
•
Project Title: PSEUDOMONAS PRODUCTS, OXYGEN RADICALS, AND LUNG INJURY Principal Investigator & Institution: Britigan, Bradley E. Professor; Internal Medicine; University of Iowa Iowa City, IA 52242 Timing: Fiscal Year 2001; Project Start 01-DEC-1993; Project End 30-NOV-2003 Summary: Pseudomonas aeruginosa causes acute nosocomial pneumonia as well as chronic lung infections in cystic fibrosis patients. The mechanisms responsible for the resulting lung injury remain unclear. Formation of oxidant species such as superoxide and hydrogen peroxide are associated with many forms of lung injury. During the initial funding period of this program, we obtained evidence that three compounds actively secreted by P. aeruginosa damage pulmonary epithelial and endothelial cells via oxidant production. In the next funding period we will define the cellular mechanisms of action of redox cycling. This results in superoxide and hydrogen peroxide generation. Pyocyanin causes a host of deleterious effects on cellular functions both in vitro and in vivo. In spite of this, there is only limited data on the cellular events by cells. Furthermore, the site(s), mechanism(s), and nature of the oxidants produced by pyocyanin, as well as the cellular targets are also poorly understood. We hypothesize that the complex series of effects mediated by pyocyanin occur through its ability to induce site specific oxidant production which leads to the disruption of cellular energy generation and activation of oxidant sensitive signaling pathways. To test this hypothesis three specific aims will be accomplished. Aim 1 is to identify the mechanism(s) of epithelial cell acquisition, cellular trafficking, and metabolism of pyocyanin under in vitro conditions. Aim 2 is to determine how pyocyanin deplete epithelial cells of ATP and cAMP by defining the effects of pyocyanin on oxidative phosphorylation and glycolysis. This aim will also address if pyocyanin acts on oxidantregulated signaling pathways, IL-8 expression will serve as a model system. The first two aims will use an in vitro system of polarized epithelial cell monolayers using normal and CF cells. Aim 3 will examine the extent to which the in vitro effects of pyocyanin are observed occur under in vivo conditions. This work will focus on IL-8 release and utilize xenografts of human respiratory epithelial cells in SCID mice. These studies will use state of the art technique of cell biology and oxidant chemistry to define novel and previously unexplored mechanisms whereby P. aeruginosa may contribute to acute and/or chronic lung injury. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: PULMONARY DIAGNOSIS BY MULTICHANNEL LUNG SOUND ANALYZER Principal Investigator & Institution: Murphy, Raymond L.; Stethographics, Inc. 38 Cypress Rd Wellesley Hills, MA 02481 Timing: Fiscal Year 2002; Project Start 01-MAY-2002; Project End 31-OCT-2002 Summary: (Applicant's abstract): Medical personnel routinely use the acoustic stethoscope to listen to lung sounds because the sounds provide important clinical information. These sounds are complex signals that reflect the underlying pulmonary pathophysiology. Unfortunately, studies of auscultation of the chest consistently show significant observer variability casting doubt on its clinical reliability. We developed user friendly, practical computerized technologies to obtain the important information provided by the sounds. Our results have been validated, patented, presented at scientific meetings and published in prominent journals. Our method provides objective, reliable information not previously possible to obtain with the human ear. It
124 Pneumonia
can be used even in severely ill patients. We are confident that automated lung sound analysis will replace the acoustic stethoscope in many of its current applications and become the new standard. In Phase I, we plan to determine whether our preliminary observations are correct that the acoustic patterns found in patients with heart failure are significantly different than those found in pneumonia. As a treatment of these very common disorders are different, more accurate diagnosis can have significant clinical and monetary benefit. In Phase II we will optimize our methods and demonstrate the value of automated lung sound analysis in broader clinical trials. PROPOSED COMMERCIAL APPLICATION: NOT AVAILABLE Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: PULMONARY IMMUNE DEFENCES AGAINST M. BOVIS-BCG INFECTION Principal Investigator & Institution: Fulton, Scott A. Medicine; Case Western Reserve University 10900 Euclid Ave Cleveland, OH 44106 Timing: Fiscal Year 2001; Project Start 01-SEP-2000; Project End 31-JUL-2005 Summary: Dr. Fulton is an Instructor at Case Western Reserve University School of Medicine in the Division of Infectious Diseases. As a fellow, Dr. Fulton was supported by an institutional training grant supported by the NIAID and a training grant from the American Lung Association. He has been responsible for setting up a new animal model to study the immune response to tuberculosis and chosen to continue studying tuberculosis at CWRU because of its long and productive interest in in immunity to tuberculosis. The scholarly environment was initiated by Dr. J. Ellner who is the current PI for a multi-center collaborative Tuberculosis Research Unit. Dr. Fulton's mentors, Drs. W. H. Boom and F. P. Heinzel are interested in cellular immune responses to complex intracellular pathogens and have had significant success in training physician scientists. Other members include Dr. Z. Toossi, Dr. R. Wallis, Dr. C. Hirsch and Dr. R. Silver who contribute to the intellectual environment. Additional formal and informal interactions with scientists in Geographic Medicine (Dr. J. Kazura, Dr. C. King, Dr. E. Pearlman) will foster Dr. Fulton's training environment. Dr. Fulton now proposes addditional specialized training with the goal of becoming an independent physician scientist. He has set up a mouse model of aerogenic M. bovis-BCG infection as a model of human disease since M. bovis-BCG grows in the lung and elicits protective T cell responses that eradicate 99 percent of the bacteria. 1 percent of bacteria persist in a steady state infection characterized by granuloma formation and immune surveillance. In contrast, viulent M. tuberculosis leads to progressive infection. Since human pulmonary immune responses can be only partially and indirectly studied, animal models have provided a means for studying the unique susceptibilty of the lung. To analyze immune responses that characterize the susceptibility of the lung to mycobacteria, three aims are proposed: Aim 1. To characterize the expression of chemokines and cytokines within the bronchoalveolar and lung microenvironments during early, maximal, and late immune activation phases of aerogenic M. bovis-BCG and M. tuberculosis infection. Aim 2. To characterize mycobacterial antigen presentation and T cell activation within the bronchoalveolar and lung microenvironments during early, maximal and late immune activation phases of aerogenic M. bovis-BCG and M. tuberculosis infection. Aim 3. To characterize the early pulmonary immune responses to aerogenic M. bovis-BCG and M. tuberculosis during local and systemic immunomodulation of cytokine and chemokine expression. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
Studies 125
•
Project Title: PULMONARY PATHOGEN DEFENSE MECHANISMS Principal Investigator & Institution: Boom, W Henry. Professor of Medicine; Pediatrics; Case Western Reserve University 10900 Euclid Ave Cleveland, OH 44106 Timing: Fiscal Year 2003; Project Start 01-JUL-1998; Project End 30-JUN-2008 Summary: (provided by applicant): This competitive renewal application for a postdoctoral training program in pulmonary host defenses to microbial pathogens (HL07889) at Case Western Reserve University (CWRU) seeks renewal funding for a research training program for M.D.,M.D.-Ph.D. and Ph.D. scientists. Funding for this novel training program was awarded in7/1998 on the strength of there search programs at CWRU in programmatic are as of tuberculosis, HIV and complications of cystic fibrosis. Research in pulmonary host defenses at CWRU has remained an institutional strength, with internationally recognized faculty with research programs on major pulmonary pathogens such as M. tuberculosis, HIV-1, Streptococcus pneumonia and Pseudomonas aeruginosa. Interdisciplinary approaches to study of host defenses to these bacterial and viral pulmonary pathogens involve faculty across basic and clinical departments and include immunology, molecular biology, biochemistry, genetics and cell biology. The interdisciplinary collaborations at CWRU in the area of pulmonary host defenses against microbial pathogens are greatly facilitated by the infrastructures of the Tuberculosis Research Unit (TBRU), the Center for AIDS Research (CFAR), the AIDS Clinical Trails Unit (ACTU), the Cystic Fibrosis Center and the NIH-funded Clinical Research Center (GCRC). In addition, strong basic research programs in the Departments of Pediatrics and Medicine in close proximity to and collaboration with clinical scientists has created a rich environment allowing trainees to learn how basic research translates into clinical investigation. The goals of the research training program are: 1. To provide rigorous training for promising M.D., M.D.-Ph.D. and Ph.D. postdoctoral fellows in the application of the tools of immunology, molecular biology or biochemistry to pulmonary host defenses to pathogens such as M. tuberculosis and HIV-I. 2. To assume an active role in career development by training and assisting trainees in securing funding either for additional postdoctoral training or for faculty development depending on their level of training at entree into the program and development in the training program. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: RECEPTOR-MEDIATED PNEUMOPHILA
ENDOCYTOSIS
OF
LEGIONELLA
Principal Investigator & Institution: Abu Kwaik, Yousef; Associate Professor; Microbiology Immunology, and Molecular Genetics; University of Kentucky 109 Kinkead Hall Lexington, KY 40506 Timing: Fiscal Year 2001; Project Start 15-JUL-2000; Project End 30-JUN-2005 Summary: Description (Adapted from applicant's abstract): The ability of Legionella pneumophila (Lpn) to cause pneumonia is dependent on intracellular replication within pulmonary phagocytic and epithelial cells. In the environment, the bacteria are ubiquitous where they multiply intracellularly with amoebae. Invasion and intracellular replication within protozoa play major factors in the amplification and dissemination of Lpn in the environment and in transmission and infectivity to humans. We have recently shown that uptake of Lpn by the protozoan Hartmannella vermiformis is mediated by bacterial attachment to a b2 integrin-like Galactose/N-acetyl-galactosamine lectin on the protozoan surface. Bacterial attachment to the lectin is associated with induction of protozoan gene expression and with tyrosine dephosphorylation of the
126 Pneumonia
lectin and several cytoskeletal proteins including actin, focal adhesion kinase, paxillin, and vinculin. Our data suggested a cytoskeletal disruption in the protozoan host upon bacterial attachment. Transmission electron microscopy showed that these bacterialinduced manipulations of cell processes in the protozoan host are associated with entry of the majority of the bacteria through a cup shape-like invagination that resemble receptor-mediated endocytosis, but some bacteria are internalized by coiling phagocytosis. Our preliminary data suggest that the mechanism of entry of Lpn is novel, which may contribute to its subsequent intracellular fate. Our hypothesis is that the lectin is a protozoan receptor involved in uptake of Lpn, and is dissociated from the cytoskeleton upon bacterial attachment and invasion. Our specific aims are, 1) to clone the lectin encoding gene and examine its regulation of expression; 2) to clone and characterize the bacterial ligand that binds the lectin receptor and the mode of ligandreceptor interaction; 3) to determine cellular distribution of the lectin receptor and its subsequent fate after internalization; and 4) to evaluate the interaction of the receptor with the cytoskeleton. The results derived for the proposed studies will uncover new paradigms of uptake of intracellular pathogens and will contribute to our understanding of targeting of molecules into a "protected vacuole" inside eukaryotic cells. Our proposed studies may also facilitate the design of future preventive strategies to control the amplification and spread of Lpn in the aquatic environment, which is the only source of bacterial transmission to humans. Our studies may uncover potential pathogenic evolution of Lpn to invade the more evolved mammalian cells, and may contribute to the understanding of invasion of protozoa by Mycobacterium and Chlamydia. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: RE-EXPLORING RACIAL DISPARITIES IN HOSPITAL CARE Principal Investigator & Institution: Shen, Jay J. Health Services Administration; Governors State University University Park, IL 60466 Timing: Fiscal Year 2002; Project Start 30-SEP-2002; Project End 29-SEP-2003 Summary: Eliminating racial disparities in health care is a national priority. Although many studies have examined racial differences in aspects of hospital care such as severity of illness, care-seeking patterns, use of clinical procedures, use of resources, and outcome, no published research has integrated and examined these aspects simultaneously. Moreover, while many studies have reported racial disparities in hospital care only a few of them have examined the interactive effects between race and other factors on hospital care. Finally, while most of race-related studies on hospital care have focused on comparisons between one minority and non-Hispanic Caucasians, very few studies have examined health outcomes among the three largest racial groups (nonHispanic Caucasians, African-Americans, and Hispanic-Americans) simultaneously, let alone other ethnic groups. The proposed study forms an integrated conceptual framework, based on the concept of episode of care, the behavioral framework of health care use, and the structure-process-outcome triad, to examine the relationships between race and hospital care, in a systemic and comprehensive manner. The episode of hospital care, from the patient?s perspective, can be described by five dimensions: severity of illness, care-seeking patterns, process or receiving treatment, economic outcome, and clinical outcome. The study, with the inclusion of patients from all ethnic groups, focuses on four major diseases (heart attack, congestive heart failure, pneumonia, and stroke), extracts data from the 1995, 1997, 1999 National Inpatient Sample (NIS) datasets collected by the Hospital Cost and Utilization Project (HCUP), adopts validated administrative data based, risk adjustment methods, conducts
Studies 127
multivariate analysis to control for potential confounding factors. This allows systemic exploration of the relationships between race and the five episode of hospital care dimensions and, in particular, to examines the interactive effects between race and other factors on outcome that are measured by the in-hospital mortality risk. Findings from this research will furnish information to help public and private sectors decision-makers better understand the racial gaps in hospital care in a more systemic way. It will also elucidate key factors that result in gaps in service to vulnerable populations. This will aid public policy development of effective interventions to improve health care deliverywith regard to eliminating racial disparities. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: COLLECTINS
REGULATION
OF
INFLAMMATION
BY
PULMONARY
Principal Investigator & Institution: Greene, Kelly E.; National Jewish Medical & Res Ctr and Research Center Denver, CO 80206 Timing: Fiscal Year 2002; Project Start 30-SEP-2002; Project End 30-JUN-2003 Summary: (provided by applicant): Every day we breathe more than 7,000 liters of air, loaded with inorganic and organic particles and array of microbes. We all aspirate grampositive and gram-negative microorganisms and their products every night during sleep yet, most normal humans rarely develop pneumonia. This is due to highly effective host defenses that have evolved to protect the lung. Understanding the mechanisms that keep the pulmonary immune system and the associated inflammatory response in check and yet prepared to respond quickly to potentially deadly or disease-causing materials is crucial in developing approaches to intervene in many pulmonary diseases. Pulmonary surfactant, a complex mixture of lipids and proteins within the alveolar compartment, is the first biological interface encountered by airborne microorganisms and inflammatory mediators and is uniquely situated to play a role in host defense and modulation of inflammation. Surfactant-associated proteins A and D (SP-A and SP-D) are both members of the C-type lectin superfamily and have been shown in recent in vivo studies to recognize a significant number of microorganisms and play a role in their clearance. On the other hand, they also appear to be important in regulating the degree of lung inflammation. In this proposal we will address the mechanisms that allow the pulmonary collectins to serve this dual discriminatory role in the lung. We hypothesize that in the resting alveolus SP-A and SP-D provide an anti-inflammatory screen to prevent casual activation of macrophages and other inflammatory cells. We will 1) determine the characteristics and mechanisms of the anti-inflammatory effect in vivo as well as 2) examine the effect of pulmonary collectins on inflammatory mediator production from macrophages and neutrophils. Next we will 3) examine the mechanisms by which lung collectins inhibit proinflammatory signal pathways, focusing on CD45 as a potential cell surface ligand that delivers anti-inflammatory signals to the cell via inhibition of the src family kinases (specifically Lyn) and preventing activation of P38MAPKinase. Finally we will determine the mechanisms involved in the role of SP-A and -D as "defense collagens," which is in complete contrast to their anti-inflammatory role. We will 4) show that attachment and aggregation of pulmonary collectins to particles or organisms such that they are presented to macrophages via their collagenous tails, leads to proinflammatory effects. We propose that caireticulin is important for this effect. The challenge remaining in acute lung injury is to unravel at the cellular and molecular level the complexities of the inflammatory response in order to target therapeutic interventions so that they will lessen the injurious consequences of inflammation while leaving the beneficial effects intact.
128 Pneumonia
Gaining an understanding of the mechanisms by which pulmonary collectins inhibit or stimulate lung inflammation will be critical to this process. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: RESEARCH PROGRAM TO IMPROVE QUALITY CARE FOR PNEUMONIA Principal Investigator & Institution: Fine, Michael J. Professor of Medicine; Medicine; University of Pittsburgh at Pittsburgh 350 Thackeray Hall Pittsburgh, PA 15260 Timing: Fiscal Year 2001; Project Start 30-SEP-2000; Project End 31-AUG-2005 Summary: (adapted from application abstract): This is a K24 application from Michael Fine, M.D., M.Sc. Dr. Fine is an Associate Professor in the Division of General Medicine at the University of Pittsburgh. His intermediate career objectives are (1) to further establish himself as a leading national authority on the quality and cost-efficiency of medical care for patients with community-acquired pneumonia (CAP), and (2) to serve as a mentor for medical trainees and junior faculty member pursuing patient- oriented research careers. His long-term objectives are (1) to apply the expertise in quality improvement developed throughout his systematic study of CAP to other clinical research areas of high priority to NIAID, and (2) to actively participate in the institutional commitment to promote patient- oriented research at the University of Pittsburgh. The candidate's patient- oriented research will be conducted in two phases. In phase I (years 1-3), he will direct a randomized clinical trial to assess the effectiveness of two medical practice guideline implementation strategies in improving the quality of medical care for patients with CAP. This trial will be supported by an RO1. In phase II (years 4 and 5), he will expand his research to the quality improvement of other clinical domains of high priority to NIAID. In both phases, medical trainees and junior faculty mentored by the candidate will be integral participants in his research activities. Over the course of the award, the candidate will mentor 5 medical students and residents, 6 clinical research fellows, and 4 junior faculty members in patient-oriented research. The candidate has already identified 2 of the clinical fellows and 1 junior faculty that he will mentor. Research training and education experiences, tailored to the level of the menthe, will include a mentored patient-oriented research project, participation in a weekly journal club, weekly research seminars, and year-round graduate-level coursework. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: RESPIRATORY FAILURE IN A MODEL OF P. CARINII PNEUMONIA Principal Investigator & Institution: Paine, Robert; Internal Medicine; University of Michigan at Ann Arbor 3003 South State, Room 1040 Ann Arbor, MI 481091274 Timing: Fiscal Year 2001; Project Start 01-JUL-2000; Project End 30-JUN-2005 Summary: (from applicant's abstract): It is hypothesized that infection with P. carinii renders the alveolar epithelium more susceptible to secondary insults, particularly hyperoxia, leading to respiratory failure in patients with PCP. To evaluate this hypothesis, the investigators will utilize a well-established CD4 depleted mouse model of P. carinii pneumonia, which is subsequently exposed to hyperoxia as a prototypical stress for alveolar wall injury. They propose that P. carinii infected mice will develop more severe lung injury following exposure to hyperoxia. They also postulate that GMCSF, a potent cytokine generated by alveolar epithelial cells and macrophages, is critical in ameliorating this response. GM-CSF expression induced in response to P. carinii infection exerts a protective effect to limit lung injury. They postulate that inhibition of lung GM-CSF expression as a result of hyperoxia is a critical event promoting lung
Studies 129
injury and respiratory failure. Four specific aims will be undertaken. Initially they will characterize the response of P. carinii infected mice to hyperoxia. Next, they will determine the expression of GM-CSF in this animal infection model and in mice that genetically lack GM-CSF following exposure to PCP and hyperoxic conditions. They will further determine whether direct interaction of P. carinii and alveolar epithelial cells through integrins induces GM-CSF expression. Finally, they will evaluate the protective effect of GM-CSF in P. carinii pneumonia and in subsequent progression of lung injury following hyperoxia. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: RESPIRATORY IMMUNIZATION
SYNCYTIAL
VIRUS
ESCAPE
FROM
Principal Investigator & Institution: Sullender, Wayne M. Associate Professor; Pediatrics; University of Alabama at Birmingham Uab Station Birmingham, AL 35294 Timing: Fiscal Year 2001; Project Start 01-FEB-2001; Project End 31-JAN-2005 Summary: (Adapted from Applicant's Abstract) Respiratory syncytial virus (RSV) is the most common viral agent of lower respiratory tract infections of infants and causes repeat infections throughout life. RSV antigenic variability may contribute to the ability of RSV to cause repeated infections. RSV is also a cause of significant morbidity and mortality in bone marrow transplant (BTM) patients. Neutralizing antibodies to RSV may be pre-existing in and/or may be passively administered to BMT patients. It is hypothesized that due to selective pressure by antibody RSV will accumulate changes in the F and G proteins during prolonged replication in immunocompromised patients. Sequential RSV isolates from BMT patients will be monitored for the development of F and/or G protein genetic changes that are associated with resistance to antibody may result in impaired fitness for replication. Therefore the antibody resistant viruses will be characterized as to their fitness for replication in cell culture and in animals (Aim 2). The ability of the mutant viruses to evade passive immunity in animals will also be determined (Aim 3). In a clinical trial BMT patients with RSV pneumonia will receive therapy with a humanized F monoclonal antibody (palivizumab). This will result in the replication of RSV in the presence of an antibody that is known to select for escape mutants. Thus, palivizumab escape mutants will be selected in cell culture (Aim 4) and characterized as to fitness and capacity to evade passive immunity in the manner described for the human derived viruses. These experiments will define the extent to which RSV becomes resistant to antibodies during prolonged replication in immunocompromised host. In addition, the likelihood that resistant viruses derived in cell culture will maintain normal fitness for replication and escape passive immunity in animals will be determined. These studies will provide evidence from humans and from animals as to the clinical challenges that antibody resistant viruses may pose to the current passive immunization approaches against RSV. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: RESPIRATORY VIRUS NEUTRALIZATION BY INTRACELLULAR AB Principal Investigator & Institution: Crowe, James E. Associate Professor of Pediatrics; Pediatrics; Vanderbilt University 3319 West End Ave. Nashville, TN 372036917 Timing: Fiscal Year 2001; Project Start 01-SEP-2000; Project End 31-AUG-2003 Summary: (Adapted from applicant's abstract): Respiratory Syncytial virus (RSV) is the leading cause of pneumonia and bronchiolitis in infants and children. The immune mediators of resistance to infection with RSV are still under investigation. In previous
130 Pneumonia
work the Principal Investigator generated large panels of live attenuated RSV viruses and performed the preclinical testing of these viruses in rodents and chimpanzees. New data from the applicant s clinical trials with these vaccines suggest that an IgA response correlates with protection against reinfection even in the absence of an IgG or neutralizing antibody response in the nasopharyngeal secretions or serum. The investigator's observations led to the hypothesis that IgA is indeed the principal mediator of protection against RSV reinfection in neonates. The question is: how do IgA antibodies that do not exhibit neutralizing activity protect against RSV? The hypothesis to be tested is that polymeric IgA (pIgAs) antibodies mediate intracellular neutralization of RSV. IgA transcytosis mediated by the polymeric immunoglobulin receptor (pIgR) was thought to be simply a mechanism for delivering high concentrations of antibodies to repertory secretions. Recent studies with several viruses, including Sendai virus, influenza virus, murine rotavirus, and HIV-1 suggest that IgA antibodies may neutralize viruses inside infected cells as the antibodies traverse the cell. The Principal Investigator will test this hypothesis using polarized epithelial cell cultures that express human or mouse pIgR. The Principal Investigator has developed panels of murine hybridoma lines secreting anti-RSV antibodies to either surface or internal proteins. The panels contain matched pairs of hybridoma lines that are identical except they are of the IgG or IgA isotype. The Principal Investigator will determine if murine PIgA binds to RSV inside polarized epithelial cells expressing the mouse pIgR and neutralizes RSV inside the cell. The applicants also will demonstrate this mechanism of virus inhibition in a cell line expressing human pIgR using pIgA purified from secretions of RSV vaccinees. Next, they will test the hypothesis that the compartment in which IgA complexes with RSV surface proteins is the apical recycling endosome, a site in which 80% of the intracellular IgA normally resides. Finally, the investigators will develop novel recombinant bi- specific antibodies that bind to both RSV and human pIgR. The Principal Investigator proposes that such novel antibody fragments will mimic the ability of IgA to enter cells and neutralize RSV, but will be vastly more potent in vivo due to their smaller size and hence better ability to exit the intravascular space following parenteral administration. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: RISK FACTORS FOR DRUG RESISTANT PNEUMOCOCCAL PNEUMONIA Principal Investigator & Institution: Metlay, Joshua P. Medicine; University of Pennsylvania 3451 Walnut Street Philadelphia, PA 19104 Timing: Fiscal Year 2001; Project Start 01-APR-2000; Project End 31-MAR-2004 Summary: Adapted from the Applicant's Abstract): The emergence of antimicrobial drug resistance among isolates of S. pneumoniae threatens to have a major impact on the management of patients with community-acquired pneumonia (CAP). S. pneumoniae is the most common cause of CAP and adequate pneumococcal coverage is at the center of empirical guidelines for the management of this disease. Yet, risk factors for infection with drug-resistant vs. drug-susceptible S. pneumoniae are controversial and the clinical impact of in vitro levels of resistance is poorly understood. This study will focus on resistance to penicillin because penicillin and related ,8-lactam antimicrobials are a major component of current empirical treatment options for patients with CAP. Thus, understanding the risk factors for penicillin resistance can make a major contribution to the empirical management of these patients. The primary aim of this study is to identify risk factors for penicillin drug resistance in patients with bacteremic pneumococcal pneumonia. The primary study hypothesis is that both
Studies 131
individual and community risk factors independently predict infection with penicillin resistant S. pneumoniae in patients with bacteremic pneumococcal pneumonia. A secondary hypothesis is that the duration of prior antibiotic use is a strong independent predictor of penicillin resistance in these patients. The secondary aims of this study are (1) to develop a prediction rule for penicillin resistance in patients with bacteremic pneumococcal pneumonia and (2) to measure the impact of different levels of penicillin resistance on medical outcomes in these patients. The hypotheses for these secondary aims are that (1) a prediction rule can be developed which accurately categorizes patients into high and low risk groups in order to improve the empirical selection of antimicrobial therapy for patients with CAP and (2) the in vitro level of penicillin resistance, alone, is a poor predictor of medical outcomes, but categorization of the adequacy of antimicrobial drug coverage, based on drug susceptibility profiles and pharmacodynamic drug considerations, will be a strong predictor of medical outcomes. This study is a population-based, case-control study, enrolling all hospitalized patients diagnosed with bacteremic pneumococcal pneumonia within the Pennsylvania Delaware Valley. Risk factors will be identified through patient interview and outpatient and inpatient medical record review. Pneumococcal drug resistance will be categorized at our microbiology laboratory with standardized susceptibility testing of all pneumococcal blood isolates. Finally, a cohort study will be completed within the study design, by examining outcomes for all patients, stratifying by pneumococcal drug susceptibility and adequacy of antimicrobial drug coverage. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: ROLE OF B CELLS IN RESOLUTION OF P CARINII PNEUMONIA Principal Investigator & Institution: Garvy, Beth A. Assistant Professor; Medicine; University of Kentucky 109 Kinkead Hall Lexington, KY 40506 Timing: Fiscal Year 2001; Project Start 30-SEP-1999; Project End 31-AUG-2004 Summary: Pneumocystis carinii (PC) pneumonia is a significant problem in immunocompromised patients, particularly those with HIV. It has been well documented that the presence of CD4+ T cells is required for resolution PC infections. In addition, it has recently been reported that mice that are deficient in B cells are susceptible to PC (4,9). This is important because AIDS patients have been shown to have B cell defects that may also render them susceptible to PC. Until recently, there have not been good animal models for studying the role of B cells in host defense to infectious diseases. Although B cell deficient mice have proven to be useful, it is not possible to determine whether susceptibility to PC in these mice is due to a lack of natural antibody, PC-specific antibody, or B cell effector functions such as antigen presentation, costimulation of T cells, or cytokine production. The goal of this proposal is to test the hypothesis that B cells play multiple roles in the resolution of PC including activating CD4+ cells through antigen presentation, producing protective antibody, and producing cytokines that lead to resolution of PC pneumonia (PCP). We will utilize existing mice that are transgenic for the B cell receptor as well as generate new murine models including 1) making mixed chimeric mice whose B cells are defective in expression of cytokines or costimulatory molecules and 2) generating new transgenic mice whose B cells express the Herpes Simplex Virus thymidine kinase gene. These new mice will have B cells that are susceptible to killing by ganciclovir. With these murine models we will address the following specific aims: 1) to determine whether B cell-T cell interactions are required for resolution of PCP; 2) to determine whether B cell-produced cytokines are required for the resolution of PC; 3) to determine whether protection against PCP is dependent on specific recognition of PC antigens by the B cells; 4) to
132 Pneumonia
determine whether natural antibody is required for resolution of PCP; and 5) To determine the kinetic requirements for B cell function in PC infection. Understanding host defense to PC is critical for developing vaccines or efficient therapies for preventing this potentially fatal infection. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: ROLE INFLAMMATION
OF
ENDOTHELIAL
DUFFY
ANTIGEN
IN
LUNG
Principal Investigator & Institution: Lee, Janet S. Medicine; University of Washington Seattle, WA 98195 Timing: Fiscal Year 2002; Project Start 01-JUL-2002; Project End 30-JUN-2007 Summary: (provided by applicant): The major goal of this proposal is to determine the role of Duffy Antigen/ Receptor for Chemokines (DARC) in endothelial cells during lung inflammation. DARC binds multiple CXC and CC chemokines and is expressed on post-capillary venular endothelial cells, the site where leukocytes traverse the endothelium in response to inflammatory signals released from a site of tissue injury. Although endothelial DARC is upregulated during inflammation, its biological function remains unknown. It's focal location at the site of leukocyte emigration, its upregulation during inflammation, and preservation of expression on endothelial cells in all individuals suggest that it may participate in the regulation of inflammatory cell recruitment at the bloodtissue interface. The specific aims will explore the following : (1)endothelial DARC's role in chemokine transport, (2) its ability to modify neutrophil transendothelial migration, (3) its in vivo expression in the lung during suppurative pneumonia, (4) and DARC's contribution to neutrophil recruitment in a mouse model of pneumonia. A human endothelial cell line stably expressing DARC cDNA has been developed to study its ability to modify the biological activity of chemokines in vitro. Immunohistochemical analysis of human lungs will define the expression pattern of endothelial DARC during suppurative pneumonia. Finally, DARC's role will be examined in an animal model of bacterial pneumonia using DARC knockout mice. These studies are important, as they will determine endothelial DARC's contribution to the pulmonary recruitment of neutrophils during lung inflammation. Understanding endothelial DARC's function may provide novel strategies in modifying the inflammatory component of specific diseases such as bacterial pneumonia. These studies will further the candidate's research training in cell and molecular biology and provide the foundation for a career as a physicianscientist. The proposed studies will be conducted at the Pulmonary VA Research laboratories under the guidance of the sponsor and co-sponsor. Interactions with consultants throughout the University of Washington research community will enrich the candidate's training and ensure the success of the proposal. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: ROLE OF LYSOZYME IN AIRWAYS HOST DEFENSE Principal Investigator & Institution: Akinbi, Henry T.; Children's Hospital Med Ctr (Cincinnati) 3333 Burnet Ave Cincinnati, OH 45229 Timing: Fiscal Year 2002; Project Start 15-FEB-2002; Project End 31-JAN-2007 Summary: Lysozyme is a cationic protein of 146 amino acid residues (Mr approximately 14k) that is bactericidal against multiple gram-positive bacteria in vitro. Although lysozyme is the most abundant antimicrobial protein in airway surface fluid (ASL), its role in protecting the airways against infection, chronic colonization, and inflammation
Studies 133
in vivo remains unproven. The results of preliminary studies reported in this application demonstrate a dose-dependent relationship between the level of lysozyme activity in bronchoalveolar lavage fluid and the rate of bacterial killing, of both gram positive and negative organisms, in acutely infected transgenic mice that overexpress lysozyme. Studies proposed in this application will test the central hypothesis that lysozyme is a critical component of airway host defense in vivo. Pathogen killing will be assessed in lysozyme (-/-) mice and lysozyme overexpressing mice following acute and chronic lung infection. The antimicrobial spectrum and potency of exogenouslyadministered recombinant lysozyme protein will also be assessed. These studies will provide insight into the role of lysozyme in airway host defense and provide a preliminary assessment of the therapeutic potential of exogenously administered lysozyme. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: ROLE OF SP-A IN INFLAMMATION AFTER ALLOGENEIC BMT Principal Investigator & Institution: Haddad, Imad Y. Associate Professor of Pediatrics; Pediatrics; University of Minnesota Twin Cities 200 Oak Street Se Minneapolis, MN 554552070 Timing: Fiscal Year 2001; Project Start 01-MAY-2001; Project End 30-APR-2005 Summary: (Applicant's Abstract): In addition to innate host-defense functions, surfactant protein A (SP-A) suppresses T cell-immune responses in vitro, and may be responsible for the hyporesponsive state of lung lymphocytes in vivo. Recent evidence indicate that donor T cells play a major role in the pathogenesis of non-infectious lung dysfunction after allogeneic bone marrow transplantation (BMT), also referred to as idiopathic pneumonia syndrome (IPS). IPS accounts for up to 40 percent of non-GVHD deaths in allogeneic BMT patients. In a murine IPS model that simulates the human condition, lung dysfunction is dependent on infusion of allogeneic T cells. The most severe lung injury is observed during the generation of severe oxidative/nitrative stress in BMT mice given both allogeneic T cells and cyclophosphamide, a commonly used conditioning drug known to deplete antioxidant defenses. Oxidative/nitrative stress inhibits SP-A production, and can damage SP-A structure and function. Keratinocyte growth factor (KGF), a mediator of epithelial cell-proliferation, enhances SP-A expression and prevents experimental lung injury, but the protective mechanisms are incompletely understood. The role of SP-A and KGF-derived SP-A and the effects of reactive oxygen/nitrogen species on T cell-dependent inflammation and IPS injury in vivo have not been thoroughly investigated. We hypothesize that SP-A protects the lung in vivo from IPS injury by inhibiting allogeneic donor T cell-immune responses. We further hypothesize that injection of cyclophosphamide into T cell-recipient mice injures SP-A-producing cells and prevents upregulation of SP-A expression by the generation of peroxynitrite (ONOO), a potent oxidant and nitrating species. Our hypothesis has been formulated based on strong preliminary data showing that exogenous SP-A downregulates alveolar inflammation in vivo. The rationale for the proposed research is that, once the role of SP-A in T cell-dependent inflammation and repair is established, new and innovative anti-inflammatory and antioxidant approaches to limit IPS injury can be developed. Using our BMT model in normal and gene targeted irradiated mice infused with donor T cells from normal and knockout mice, our hypothesis will be tested by completing the following specific aims: 1. Establish the role and mechanism of SP-A in regulation of alveolar inflammation and IPS injury; 2. Determine the mechanism by which allogeneic T cells and cyclophosphamide increase oxidative/nitrative stress; 3. Define the role of SP-A and oxidative/nitrative stress in the immuno-modulatory effects
134 Pneumonia
of keratinocyte growth factor after allogeneic marrow transplantation. Completion of aims will establish whether exogenous SP-A and upregulation of endogenous SP-A may be utilized as therapeutic options for the treatment of IPS and, potentially, other lifethreatening inflammatory lung diseases. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: SCCOR IN TRANSLATIONAL RESEARCH IN ACUTE LUNG INJURY Principal Investigator & Institution: Matthay, Michael A. Professor; Cardiovascular Research Institute; University of California San Francisco 500 Parnassus Ave San Francisco, CA 94122 Timing: Fiscal Year 2003; Project Start 30-SEP-2003; Project End 30-JUN-2008 Summary: (provided by applicant): This is an Acute Lung Injury SCCOR application designed to study the pathogenesis and treatment of early acute lung injury. Although considerable progress has been made in selected areas of research and treatment of clinical acute lung injury, the pathogenesis of clinical lung injury is incompletely understood and mortality remains too high. Clinical and basic research is needed to provide new knowledge regarding fundamental mechanisms of lung injury as well as to test new therapies for acute lung injury (ALl), an important cause of acute respiratory failure in critically ill patients. Project 1 proposes a randomized, double-blind, phase II clinical trial to evaluate the potential efficacy of activated protein C (APC) for the treatment of acute lung injury. This project will also explore mechanistically the contribution of coagulation and inflammation dependent mechanisms to clinical lung injury. Project 2 is a clinical project to investigate the interactions among human genetics, bacterial genetics, and host events in the development of acute lung injury from bacterial pneumonia. This project will test the potential contribution of Mannose Binding Lectin genetic abnormalities as a cause of severe pneumonia and acute lung injury. This project will also test the hypothesis that P.aeruginosa colonization transforms to lung infection (ventilator-associated pneumonia) when the P.aeruginosa strains express type III virulence genes. Project 3 will examine the contribution of coagulation dependent mechanisms in experimental lung injury in mice by studying genetically modified mice as well as testing the impact of recombinant mouse AP C as therapy for experimental lung injury. Project 4 will examine the role of transforming growth factor-beta1 as a pathogenetic mechanism for early experimental acute lung injury, evaluating the mechanisms for TGF-beta1 activation, and also will identify the mechanisms for responsible for the TGF-beta1 induced alterations in alveolar epithelial fluid transport. The administrative and clinical cores (Cores A & B) will support the scientific objective of the projects. The proteomics core (Core C) will provide innovative methods for identifying novel proteins in the bronchoalveolar lavage fluid from patients and animals with acute lung injury, both before and after several treatment strategies. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: SEVERE ASTHMA FROM RESPIRATORY INFECTIONS Principal Investigator & Institution: Busse, William W. Professor of Medicine; Medicine; University of Wisconsin Madison 750 University Ave Madison, WI 53706 Timing: Fiscal Year 2001; Project Start 20-SEP-2001; Project End 30-JUN-2006 Summary: (provided by applicant): Chronic severe asthma affects only a subsegment of patients with asthma and is characterized, in part, by persistent airflow obstruction and symptoms despite ongoing treatment. Because of the severity of their disease, this population of asthmatic patients has the greatest morbidity and health care costs. At
Studies 135
present, the mechanisms that cause severe asthma are not fully established. The overall goal of this research project is to define the features of severe asthma, identify the mechanisms that lead to this phenotype and discover possible inroads for new and more effective therapies. Based upon existing evidence and preliminary data, it is the hypothesis of this research project that severe asthma is caused, in some patients, by a persistent respiratory infection by viruses (i.e. rhinovirus, respiratory syncytial virus, or adenovirus), Mycoplasma pneumonia, or Chlamydia pneumonia. It is further proposed that these agents infect lower airway epithelium and macrophages to enhance the production of inflammatory cytokines/chemokines (i.e. IL-8) and recruitment of inflammatory cells, particularly neutrophils, to further airway injury and airflow obstruction. To accomplish these goals, subjects with severe asthma (i.e. FEV1 <75% predicted, and ongoing symptoms despite high doses of inhaled corticosteroids) will be recruited along with three groups for comparison: Mild asthma, asthma with airflow obstruction, i.e. FEV, <75% predicted, but reversible to beta agonists, and normals. Measurements of preliminary physiology will be made in these four groups to test the hypothesis that severe asthma is characterized by airway-parenchymal uncoupling. In addition, imaging techniques will be used to correlate determinants of pulmonary physiology with airway structure, by high resolution computerized tomography, and ventilation abnormalities, by magnetic resonance imaging with inhaled hyperpolarized helium. To determine the characteristics of inflammation in peripheral blood, sputum, and lavage fluid, mucosal biopsies will be obtained to assess the hypothesis that neutrophilic inflammation and IL-8 are characteristic features of fixed airway obstruction in severe asthma whereas eosinophilic injury and IL-5 are associated more with reversible airway obstruction. Finally, PCR and immunohistochemistry of lavage fluid and mucosal biopsies will be used to test the hypothesis that severe asthma and fixed airway obstruction with IL-8 and neutrophils are associated with a persistent respiratory infection by respiratory viruses (i.e. adenovirus, influenza, respiratory syncytial virus or rhinovirus), Mycoplasma pneumonia, or Chlamydia pneumonia. It is proposed that these studies will provide new insights into mechanisms of asthma, and particularly severe persistent disease, and potential new approaches to treatment. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: SMOKING AND ETHANOL-INDUCED DEFECTS IN PNEUMONIA DEFENSE Principal Investigator & Institution: Gentry-Nielsen, Martha J. Medicine; Creighton University 2500 California St Omaha, NE 68178 Timing: Fiscal Year 2002; Project Start 01-DEC-2001; Project End 30-NOV-2004 Summary: (provided by applicant): The goal of this application is to use a novel rat model to study the compounding effects of cigarette smoke and alcohol abuse on susceptibility to severe pneumococcal pneumonia. Pneumonia is a major cause of morbidity and mortality in alcoholics, and the pneumococcus is the most common bacterial cause. Alcoholics have a higher incidence of pneumococcal pneumonia and they have a greater likelihood of developing bacteremia, which increases their mortality rate. Although scientists have studied the deleterious effects of ethanol ingestion on resistance to infectious diseases for years, the concurrent effects of smoking have been ignored. Because 80-90% of alcoholics smoke and >50% of multi-pack/day smokers are alcohol dependent, it is imperative to consider the additional effects of smoking when studying alcohol-induced defects in host defense against respiratory infections. Our hypothesis is that smoking exacerbates the detrimental effects of ethanol ingestion on host defense mechanisms critical for protection against lethal pneumococcal
136 Pneumonia
pneumonia. To test this hypothesis, rats will be exposed twice daily to cigarette smoke or room air in whole body chambers. Half of the rats also will be fed ethanol in a liquid diet. In Specific Aim 1, the rats will be infected intranasally, and the numbers of pneumococci reaching their lungs will be quantified by plate-counts. Movement of the organisms into the lungs will be correlated with alterations in the ciliary beat frequency of the rats' tracheal epithelial cells. In Specific Aim 2, novel in vitro assays will be used to determine the effects of ethanol ingestion, with and without smoke exposure, on the ability of the rats' pulmonary neutrophils to phagocytose and kill pneumococci. In Specific Aim 3, quantitative blood cultures will be used to determine the separate and combined effects of smoke exposure and ethanol ingestion on bacteremia development after establishment of pneumonia. Bacteremia will be correlated with mortality for 10days post-infection with the use of a hypothermia model to predict death and determine the appropriate time for euthanasia. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: SP-A MOUSE MODELS OF PNEUMOCYSTIS INFECTION Principal Investigator & Institution: Walzer, Peter D. Professor of Medicine; Internal Medicine; University of Cincinnati 2624 Clifton Ave Cincinnati, OH 45221 Timing: Fiscal Year 2001; Project Start 01-APR-2000; Project End 31-MAR-2005 Summary: Pneumocystis carinii (Pc) is a fungus of low virulence that is major cause of pneumonia (P) in HIV patients. Surfactant protein (SP-A), a member of the collectins, plays an important role in the host's innate immunity against pulmonary pathogens. Studies of the interaction of SP-A with Pc have mainly been conducted in vitro and have produced conflicting results. Gene targeted mice deficient in SP-A appear more susceptible to PcP than wild type mice administered the same immunosuppression. The application proposes the following hypotheses: SP-A facilitates the clearance of Pc in the immunocompetent host; this activity can be localized to specific domains of SP-A and is mediated at least in part by alveolar macrophages; SP-A delays the development and reduces the severity of PcP in the immunocompromised host; SP-A down regulates the host immune/inflammatory response to Pc. The specific aims are: 1) To analyze the effects of SP-A on Pc infection in the immunocompetent host. These studies will: 1.1) investigate the effects of SP-A on the clearance of Pc from the lungs; 1.2) determine if the administration of SP-A can reverse the changes in SP-A deficient mice and to localize the specific domains involved; 1.3) study the effects of SP-A on the interaction of Pc with alveolar macrophages; and 1.4) analyze the effects of SP-A on the host immune/inflammatory response to Pc infection. 2) To analyze the effects of SP-A on PcP in the immunocompromised host. These studies will: 2.1) analyze the effects of SP-A on the development of PcP induced by different forms of immunosuppression; 2.2) examine the influence of SP-A on the changes in alveolar cells, sufactant constituents, and lung function that occur with PcP; and 2.3) analyze the influence of SP-A on the host immune/inflammatory response that occurs during the recovery from PcP. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: SPINAL GLYCOPROTEIN
CORD
INJURY,
METHYLPREDNISOLONE
&
P
Principal Investigator & Institution: Bernards, Christopher M. Anesthesiology; University of Washington Seattle, WA 98195 Timing: Fiscal Year 2001; Project Start 10-MAY-1999; Project End 30-APR-2003
Studies 137
Summary: Spinal cord injuries causing permanent neurologic damage affect approximately 280,000 Americans. The only currently available therapy shown to reduce the severity of neurologic damage is massive intravenous doses of a glucocorticoid (methylprednisolone) administered during the first 3-48 hrs after injury. Unfortunately, the benefit of methylprednisolone therapy in terms of neurologic recovery is relatively small and the deleterious side effects of huge, immunesuppressive glucocorticoid doses are significant (e.g., sepsis, pneumonia). In fact, there is reason to believe that the deleterious systemic side-effects of high dose methylprednisolone therapy may actually ameliorate some of the potential neurologic benefit. Thus, developing drug delivery strategies that increase the bioavailability of methylprednisolone in the spinal cord and therefore allow a parallel reduction in the required systemic dose may significantly improve outcome. To achieve this goal of improved therapeutic index requires a thorough understanding of methylprednisolone's pharmacokinetics. Unfortunately this information is not currently available. In addition, it is essential to understand why the bioavailability of methylprednisolone in the spinal cord is so poor after intravenous methylprednisolone administration. To achieve these goals we propose the following aims: 1. To thoroughly define methylprednisolone's compartmental pharmacokinetics (spinal cord, plasma, cerebrospinal fluid) following intrathecal and intravenous administration. 2. To identify the role of p-glycoprotein in limiting methylprednisolone penetration of the blood-spinal cord barrier. 3. To identify p-glycoprotein inhibitors that increase the spinal cord bioavailability of intravenously and intrathecally administered methylprednisolone. 4. To determine whether increased spinal cord bioavailability of methylprednisolone decreases secondary damage following spinal cord injury. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: STRUCTURAL STUDIES OF AIDS RESPONSIVE DRUGS Principal Investigator & Institution: Cody, Vivian; Senior Research Scientist Ii; Hauptman-Woodward Medical Research Inst 73 High St Buffalo, NY 14203 Timing: Fiscal Year 2001; Project Start 01-APR-1995; Project End 31-MAR-2005 Summary: (provided by applicant): Pneumocystis carinii (pc) and toxoplasma gondii (tg) are major causes of opportunistic infection and mortality in immuno-suppressed patients, particularly those with AIDS. Antifolate drugs, usually consisting of a sulfonamide in combination with trimethoprim, an inhibitor of the enzyme dihydrofolate reductase (DHFR), have been the most effective drugs in clinical use to date. However, their use has been limited by problems of toxicity and resistance. The major goal of this project is determination of the three-dimensional crystal structures of dihydrofolate reductase (DHFR) from fungal (Pneuntocystis carinii, pc), protozoal (toxoplasma gondii, tg), and mammalian (rat liver, mouse and human) sources as complexes with antifolates that show selectivity and specificity for the pc or tg enzyme. The aim is to compare structural details of antifolate-enzyme interactions in order to design more selective and potent agents as effective treatment for opportunistic infections that cause pneumonia, a major cause of mortality among AIDS patients. As part of this protocol we plan to exploit these structural data for the design and synthesis of new selective antifolates. Six specific aims are proposed to test the hypothesis that efficacy of antifolate use in combating opportunistic infections from Pneumocystis carinii or toxoplasma gondii organisms is a result of specific enzyme-inhibitor interactions. We will analyze: (1) the first human-derived pcDHFR inhibitor complexes to examine the effects on ligand binding that result from the significant sequence changes between species, (2) the first rat liver DHFR complexes to validate correlations
138 Pneumonia
of inhibition with human DHFR, (3) the first tgDHFR complexes, (4) mouse DHFR for comparison to human DHFR, (5) DHFR complexes with novel antifolates, and (6) homology modeling data to understand features that control antifolate selectivity. The knowledge gained by these studies will be utilized in the design and synthesis of new antifolates. Appropriate targets have been selected for study with various DHFR enzymes. Analysis of these data will provide molecular level details of inhibitor-enzyme geometry, hydrogen bonding, conformation and the role of specific active site residues, especially the contribution by the substitution at positions 31 and 64 between human and pcDHFR in modulating pc selectivity. Since selectivity apparently requires only small changes in enzyme-inhibitor geometry, we propose to look for subtle differences in a series of carefully determined crystal structures of DHFR complexes with antifolates that show selectivity to a particular species of DHFR. Thus knowledge of the three dimensional structure of enzyme-inhibitor complexes are required to define the mechanism of DHFR selectivity and action. Dr. Sherry Queener, Indiana University, will measure inhibitory activity of selected antifolates. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: STRUCTURE/FUNCTION OF BACTERIAL ADHESION PILI Principal Investigator & Institution: Bullitt, Esther S. Assistant Professor; Biophysics; Boston University Medical Campus 715 Albany St, 560 Boston, MA 02118 Timing: Fiscal Year 2001; Project Start 01-MAY-1998; Project End 30-APR-2003 Summary: The aim of this research is to understand the structure and assembly of adhesion pili found on pathogenic bacteria, thereby providing insight into how the architecture of these pili supports their role as a virulence factor. Bacterial survival and colonization require attachment of the bacteria to hosts. In many stains, this process is initiated and maintained by pili; in Escherichia coli that cause pyelonephritis, adhesion and virulence depend on P-pili. Hib-pili expressed on the surface of Haemophilus influenzae mediate H. flu's colonization of the upper respiratory tract, and thus its ability to cause diseases such as childhood meningitis, otitis media, and pneumonia of the elderly. As bacteria become more resistant to traditional antibiotics, it is important to develop new therapies against bacterial infections. Structural information about adhesion pili will provide a basis for future rational design of new therapies to prevent bacterial binding or to remove pathogenic bacteria bound to the human host. The proposed research addresses this long-term goal through structural studies of bacterial adhesion pili. These studies focus on: 1) electron microscopy and three-dimensional (3D) helical reconstruction of P-pili preserved in vitreous ice and of Hib-pili negative stain, 2) controlled damage/recovery of pili to investigate the possibility of re-formation of intact helical filaments, 3) investigation of the 3-D structure of P-pili with mutant structural proteins (pilins), to examine regions of the PapA pilin essential for their assembly into tightly coiled helical filaments, 4) bacterial attachment assays, to assess the effect of mutations and the effect of damage on bacterial binding, and 5) in vitro reconstitution of hetero-pilin polymers from chaperone-pilin complexes, to improve our understanding of the bioassembly process of a prototypical macromolecule. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: STRUCTURES, MECHANISMS AND BIOGENESIS OF AMINE OXIDASES Principal Investigator & Institution: Dooley, David M. Provost and Vice President; Chemistry and Biochemistry; Montana State University (Bozeman) Bozeman, MT 59717
Studies 139
Timing: Fiscal Year 2001; Project Start 01-JUL-1980; Project End 30-JUN-2005 Summary: Copper-containing amine oxidases are widely distributed in nature and are involved in the metabolism of biogenic primary amines. Amine oxidases may have a variety of functions in the cardiovascular, gastrointestinal, and nervous systems of mammals. Amine oxidases are also responsible for the cross-linking of connective tissue structural proteins (elastin and collagen). It appears that numerous compounds with antifungal, antiprotozoal, or anticancer activities may target amine oxidases. For example pentamidine, a leading drug for the treatment of Pneumocystis carinii pneumonia (PCP) in AIDS patients belongs to class of compounds that inhibit amine oxidases. A major goal are to determine the 3-D structures of multiple amine oxidases, including human kidney diamine oxidase, which has been over-expressed and purified to homogeneity. Other major goals are to define the molecular bases for substrate specificity and selective inhibition among amine oxidases, and to elucidate the mechanisms of amine oxidation and cofactor (TPQ) biogenesis. In addition, the structure and biogenesis of a related enzyme, galactose oxidase, will be examined. Site-directed mutagenesis, spectroscopy, kinetics measurements, and crystallography are employed. Combining structural and mechanistic data will permit a detailed understanding of the structure and function of these important enzymes to be developed. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: STUDY OF S PNEUMONIAE VIRULENCE GENE REGULATION Principal Investigator & Institution: Camilli, Andrew; Associate Professor; Molecular Biol & Microbiology; Tufts University Boston Boston, MA 02111 Timing: Fiscal Year 2002; Project Start 15-SEP-2002; Project End 14-SEP-2004 Summary: (provided by applicant): The overall goal of our research is to understand the pathogenicity of Streptococcus pneumoniae, the most common cause of bacteremia, bacterial meningitis, otitis media and community-acquired pneumonia in the U.S.A. Current capsule-based vaccines, which only contain a subset of the capsular types in circulation, do not provide adequate protection from pneumonia and otitis media, which account for the majority of S. pneumoniae morbidity. Despite more than a century of research, understanding of S. pneumoniae virulence factors is limited. Furthermore, almost nothing is known concerning the regulation of S. pneumoniae virulence factors during infection. These limitations, plus an increasing incidence of antibiotic-resistance mandate increased study of the pathogenicity of this organism. We have completed a large-scale screen that resulted in the identification of 233 genes that are essential in a murine model of pneumonia. Additionally, we tested the importance of each of these genes in murine models of bacteremia and nasopharygeal carriage. Included among these novel virulence factors are 21 surface proteins, and 20 putative regulators that we hypothesize coordinate tissue-specific virulence gene expression. The first goal of the proposed work is to gain an understanding of both the regulation and mechanisms of action of two factors hypothesized to localize to the bacterial surface and interact with host components. Mutational analyses and virulence assays will be combined to define their interacting domains. The second goal is to identify major virulence gene regulons and their modes of coordination during infection. Five putative transcription factors identified in our screen will be placed under inducible expression, and the subset of genes regulated by each will be determined by transcriptional profiling on microarrays. For selected genes, the level of expression during nasopharyngeal carriage in mice and humans will be determined using quantitative RTPCR. The requirement for each cognate regulator for expression of these virulence genes during infection of mice will be confirmed. These studies will enhance our knowledge
140 Pneumonia
and understanding of S. pneumoniae-host interactions and virulence mechanisms, and will constitute the first broad study of S. pneumoniae virulence gene regulation. These studies will aid in the development of novel vaccines, and will suggest new targets for antimicrobial drug development. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: SURFACTANT METABOLISM IN PNEUMOCYSTIS CARINII PNEUMONIA Principal Investigator & Institution: Beers, Michael F. Associate Professor; University of Pennsylvania 3451 Walnut Street Philadelphia, PA 19104 Timing: Fiscal Year 2001; Project Start 15-MAY-2001; Project End 14-MAY-2002 Summary: Despite recent advances in its diagnosis, therapy, and prophylaxis, Pneumocystis carinii pneumonia (PCP) remains a leading cause of morbidity and mortality in patients with the Acquired Immunodeficiency Syndrome (AIDS). This lifethreatening opportunistic infection is associated with impaired gas exchange leading to clinically significant hypoxemia. The disease is caused by an enigmatic pathogen whose basic biology is poorly understood because of difficulty culturing the organism in vitro and cumbersome animal models of the infection. Surfactant abnormalities and pulmonary inflammation appear to have an important role in the pathogenesis of PCP and its associated hypoxemia; however the initiating and effector mechanisms for these events are not known. Because the hypoxic lung injury produced by PCP is associated with abnormalities in surfactant biophysics and lipid content, we hypothesize that: (i) severe disruption of normal pulmonary surfactant homeostasis is induced directly by P. carinii. The interaction of P. carinii with the distal alveolar epithelium is mediated by an abundant, immunogenic, cell-surface protein, glycoprotein A (gpA) found on the outer cell wall of the organism. These events include alteration in surfactant lipid metabolism and changes in the expression and cellular metabolism of surfactant specific proteins. (ii) Additional indirect mechanisms mediated via TNF-alpha produced by the host inflammatory response further disrupt surfactant homeostasis. We propose to characterize the role of gpA in the specific interaction of this organism with host epithelial cells and study mechanisms by which Pneumocystis mediates the severe lung injury seen with PCP using a murine model of infection. The specific aims are: (1) Define the cellular effects of Pneumocystis gp-A on lung surfactant metabolism in vitro; (2) Characterize changes in surfactant metabolism in an immunocompromised mouse model of PCP. To accomplish these aims, we will utilize in vivo animal systems to grow P. carinii as a source of purified gp-A and a well- controlled model of PCP infection. The project will combine elements derived from several thematic research programs to yield a comprehensive investigative proposal including: 1) A Principal Investigator with expertise in the major areas of surfactant biology; 2) a co-investigator experiences with P. carinii biology, gpA purification and animal models of PCP; 3) A consultant recognized as an authority on the scid mouse model of PCP. Results from these studies will further our understanding of the pathogenesis of P. carinii lung infection. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: SURFACTANT PROTEIN A IN PULMONARY HOST DEFENSE Principal Investigator & Institution: Mccormack, Francis X. Internal Medicine; University of Cincinnati 2624 Clifton Ave Cincinnati, OH 45221 Timing: Fiscal Year 2001; Project Start 01-DEC-1998; Project End 30-NOV-2002
Studies 141
Summary: Bacterial pneumonia is a leading cause of morbidity and mortality in the United States. Infection is initiated by inhaled microorganisms that are deposited in the aqueous lining film which coats the alveolar epithelium. This compartment contains pulmonary surfactant, a mixture of phospholipids and proteins that maintains alveolar patency by reducing surface tension forces at the dir-liquid interface. Recent data suggests that surfactant protein A (SP-A), an abundant oligomeric glycoprotein in the distal airspaces, is also an acute phase reactant that functions as a major preimmune opsonin and lipopolysaccharide (LPs)-binding protein in the lung. The response of the alveolar macrophage (AM), the predominant inflammatory cell in the alveolar lumen, to microbes and microbial products must be tightly regulated to promote effective clearance while avoiding inappropriate inflammatory responses that may compromise gas exchange. Preliminary data presented herein suggests that SP-A enhances the clearance of pulmonary bacterial infections in mice and regulates the interaction of LPS with macrophages. Using recombinant SP-As with targeted mutations in critical structural domains and transgenic mice that overexpress rat and mutant of SP-A, we will test the hypothesis that SP-A modulates the inflammatory response of the lung to LPS and pathogenic microorganisms in the lung, and in the clearance of LPS and microbial infection from the airspace. Specific aim #2 will examine the structural domains of SP- A that mediate binding to LPS and bacterial microorganisms, the production of proinflammatory mediators and nitric oxide, and the clearance of LPS and microorganisms from the airspace. These studies will elucidate the role of SP-A in the innate immune defense of the lung, and may assist in the design of optimal antimicrobial strategies. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: THE NEUROPATHY
ROLE
OF
NUTRITION
IN
VIRUS-INDUCED
OPTIC
Principal Investigator & Institution: Beck, Melinda A. Associate Professor; Pediatrics; University of North Carolina Chapel Hill Office of Sponsored Research Chapel Hill, NC 27599 Timing: Fiscal Year 2003; Project Start 15-APR-1999; Project End 31-MAR-2007 Summary: (provided by applicant): Coxsackievirus A9 (CA9) and a variant, impaired in replication but persistently present in CSF over several months, were isolated from patients' CSF specimens during an epidemic of optic and peripheral neuropathy in Cuba in the early 1990's. The epidemic was clearly related to dietary deficiencies in several nutrients, including the antioxidants selenium, vitamin E, and lycopene. We are studying these isolates in the context of our previous work in mice, which demonstrated that deficiency of selenium or vitamin E can lead to increased severity of both Coxsackievirus B3 myocarditis and influenza pneumonia, with concomitant mutations in the viral genome. These mutations are reproducible, and the mutant strains have increased virulence for mice with normal nutriture. We hypothesize that host nutritional deficiencies induced mutations in CA9, leading to a new viral variant with altered pathogenic potential. We have completed genomic sequence analysis of three Cuban CA9 isolates from neuropathy patients and of five meningitis isolates from before the epidemic. Phylogenetic analysis shows the neuropathy isolates to be different, with a unique mutation near the active site of 2a protease that may contribute to the altered capsid proteins previously demonstrated in the variant virus. Using homologous regions among the CA9 already sequenced, we designed improved primers for sequencing the variant, which required special methods for RNA isolation because of apparent instability and/or very limited quantity. We have produced full-length cDNA
142 Pneumonia
from the variant, and sequences in the 5' non-translated region are consistent with a CA9 not identical to the other isolates. Using electron microscopy, we have demonstrated typical picornavirus virions in thin sections of CA9, but not of the variant, although the latter produces abundant viral antigen as demonstrated by immunofluorescence with homologous antiserum. We have produced mutations in CB3 by in vitro exposure to hydrogen peroxide in cell culture, and we will now apply the methods developed to CA9. In this continuation proposal, our objectives are 1) to characterize the quasispecies populations of the CA9 and variant isolates from Cuban patients; 2) to determine the role of the 2a protease and other mutations in altering the capsid proteins and replication patterns of the variant; 3) to determine the effects of repeated passage of CA9 and variant viruses in cells exposed to, or protected from, oxidative stress; and 4) to study the capsid morphology of the variant by comparing it to normal CA9 using cryo-electron microscopy. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: THE TREATMENT OF PNEUMONIA WITH ANTISERUM 1892-1942 Principal Investigator & Institution: Podolsky, Scott H.; Massachusetts General Hospital 55 Fruit St Boston, MA 02114 Timing: Fiscal Year 2002; Project Start 30-SEP-2001; Project End 28-FEB-2003 Summary: (provided by applicant): The era between the Golden Age of Microbiology in the 1880 and the onset of the Antibiotic Revolution in the 1940's has been characterized, historically, as a barren time for therapeutic attacks upon infectious diseases (especially in view of the emerging findings of basic science), as though scientists and practitioners "awaited" such an inevitable Revolution. The proposed manuscript, relating the history of the treatment of pneumonia with antiserum between 1892 and 1942, would be an attempt to challenge such a characterization, with several consequences: 1) Through relating the rise of antipneumococcal serotherapy atop the support of applied immunology and controlled clinical trials in the first four decades of this century, it would demonstrate the tensions that accompanied the reformulation of the treatment of infectious diseases, as "specific" attacks on specific organisms accompanied and then replaced the physiological support of patients themselves. Demonstrating such a reformulation which antedated the onset of the Antibiotic Revolution itself would permit the modem approach to the pneumonia patient (as type for all infectious diseases) to be placed in historical context, identifying the origins of such an approach s eventual narrowing. 2) While utilizing pneumonia to demonstrate such broad therapeutic themes, the manuscript would likewise dissect the historical disease category of pneumonia itself from anatomical to microbiological entity, from private disease to public health issue to demonstrate further the plasticity of such categories and the medical profession s approach to them. 3) Finally, through an analysis of the transition from antiserum to chemotherapy and antibiotics for the treatment of pneumonia in the late 1930s and early 1940s, the manuscript would expose the heterogeneous nature of this "revolution" itself (and perhaps, to some degree, most therapeutic "revolutions"), as well as the implications of the rhetorical aspects of such a revolution in the first place for the subsequent approach by the medical profession to pneumonia and to its own history. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
Studies 143
•
Project Title: TLRS IN INNATE IMMUNITY TO VIRAL INFECTION Principal Investigator & Institution: Finberg, Robert W. Professor of Medicine & Microbiology; Medicine; Univ of Massachusetts Med Sch Worcester Office of Research Funding Worcester, MA 01655 Timing: Fiscal Year 2002; Project Start 01-APR-2002; Project End 31-MAR-2007 Summary: (provided by applicant): Respiratory Syncytial Virus (RSV) is a major cause of pneumonia in young children. Our experiments indicate that this organism interacts with monocytes to produce inflammatory cytokines which are important in the host response to infection. Monocytes are key components of the innate immune system in humans. These cells express an array of pattern recognition receptors and co-factors on their surface, including CD14 and Toll-like receptors (TLRs). The role of monocyte cell surface CD14 in the innate immune response to bacteria has been well documented. Recent studies suggest that TLR2 and TLR4 are important co-receptors for monocyte responses to lipopolysaccharide, lipopeptides and other microbial antigens. Our data indicate that TLR2, TLR4 and CD14 are important in the response to RSV. Using chimeric proteins and knock-out mice we will define the pathophysiology of the innate immune response to RSV and other viral pathogens, including Newcastle disease virus and polyoma virus. These studies should enable us to better understand the pathophysiology of viral infections. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: TRANSCRIPTIONAL BIOSYNTHESIS
REGULATION
OF
GBS
CAPSULE
Principal Investigator & Institution: Cieslewicz, Michael J. Medicine; Harvard University (Medical School) Medical School Campus Boston, MA 02115 Timing: Fiscal Year 2001; Project Start 01-FEB-2001 Summary: (provided by applicant): Streptococcus agalactiae (Group B Streptococcus or GBS) is a common cause of neonatal pneumonia, sepsis and meningitis. Acapsular GBS mutants exhibit decreased virulence in mice suggesting that the capsular polysaccharide is a major virulence factor. Strains of GBS are found to express nine different capsule serotypes, Ia, Ib and II-VIII. We have focused our study on one of the most important in GBS capsule serotypes in human infection, type Ia. The GBS operon that directs synthesis of the type Ia capsule consists of 16 genes and is predicted to contain two promoters. The first promoter is upstream of the first gene, cpsIaA. A second, downstream promoter is predicted to lie upstream of cpsIaE. A non-polar cpsIaA deletion mutant exhibits decreased capsule expression at the surface of the cell, yet individual capsule chains in the cpsIaA deletion mutant and its parent wild-type strain are the same molecular size. Additionally, transcription of genes downstream of cpsIaA is down-regulated in a cpsIaA deletion mutant. These results are suggestive of CpsIaA acting as a transcriptional activator. In this proposal we will determine the transcriptional organization and relative promoter strength of the type Ia GBS capsule operon. In addition, we will determine if CpsIaA directly modulates transcription of the type Ia capsule genes. Experiments outlined in this proposal will lead to a better understanding of transcriptional regulation of GBS capsule biosynthesis. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: TRANSMISSION OF PNEUMOCYSTIS INFECTION Principal Investigator & Institution: Cushion, Melanie T. Associate Professor; Internal Medicine; University of Cincinnati 2624 Clifton Ave Cincinnati, OH 45221
144 Pneumonia
Timing: Fiscal Year 2001; Project Start 01-MAR-1991; Project End 31-MAR-2003 Summary: (Adapted from the Investigator's Abstract): Pneumocystis carinii (Pc) organisms are eukaryotic opportunistic pathogens that cause an oftentimes fatal pneumonia (PcP) in immunocompromised hosts, especially those with AIDS. Despite the progress made towards understanding the genetic structure of Pc, knowledge of its basic biology, including life cycle, transmission and epidemiology remains limited, resulting in reduced ability to clinically manage or prevent PcP. During the previous grant period, 2 genetically distinct Pc populations in a rat model PcP, "prototype" and "variant" and several sub-populations were defined. A cryopreserved catalogue of these different Pc populations has been established in the PIs laboratory and is a primary resource for the proposed studies. Recent studies of the epidemiology of human PcP have shown that patients with AIDS can also be infected with 2 different types of Pc, as well as a single type. Recurrent human Pc infections were caused by a previous Pc type or another type presumably acquired through the environment. Understanding of the reservoir for PC and the ability of hosts to transmit infection is of critical importance. Studies planned in the present proposal will exploit the rat model of PcP as a paradigm of human PcP using the characterized Pc population to: 1. Characterize the progression of infection and pathology of mixed and single Pc infections. Co-infections of prototype and variant Pc populations within a single rat lung are common, while co-infections of prototype-populations are rare. It is the PI's hypothesis that prototype-variant and single prototype infections are advantageous to organism survival while most prototype coinfections inhibit the progression of infection and aid the host response. In this Aim, the virulence of single and mixed infections will be assessed by growth rates; organism burden; mortality; and histopathology. Effects of the Pc infections on the host will be measured by humoral and cell-mediated functional assays. 2. Assess latency and transmission of mixed and single infections in immune competent and immunosuppressed hosts. The reservoir (s) of PC infection is not known, which is a critical issue in control of PcP. Some Pc populations have been observed to be more dominant among the rat colonies surveyed. A series of studies are planned to investigate the transmission of mixed and single Pc populations. The times of exposure needed to induce infection will be assessed; the latency period of Pc and ability to transmit the infection in immunocompetent hosts will be determined; and the role of host immune responses in latency and transmission will be evaluated. These studies will result in a clearer understanding of the biology leading to infection with Pc and will provide a rational basis for clinical management and therapeutic intervention. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: TREATMENT FOR GBS COLONIZATION IN PREGNANT WOMEN Principal Investigator & Institution: Bhatt, Bakul M.; Biomedical Development Corporation 500 Sandau, Ste 200 San Antonio, TX 78216 Timing: Fiscal Year 2001; Project Start 20-SEP-1997; Project End 31-MAY-2004 Summary: (Adapted from Applicant's Abstract): The goal of this project is to further develop Iocide, a novel iodine-based antimicrobial technology, for use as a topical bacteriocide for group B streptococci (GBS) in the vaginal tract of pregnant women during the intrapartum period. GBS is the leading cause of neonatal bacterial disease and death, and most frequently occurs in neonates as sepsis, meningitis, and pneumonia. Despite clinical advances to date, GBS continues to be a major cause of illness and death among newborns. Due to the limitations of current clinical strategies, a need exists for alternate approaches to prevent GBS-related neonatal disease. The following specific aims have been designed to achieve this goal: 1) to optimize the
Studies 145
formulation of the Iocide vaginal gel, 2) to determine the effective range of Iocide in vitro, 3) to demonstrate safety and efficacy to the Iocide in animals, and 4) to determine safety and efficacy of Iocide in human clinical trials. PROPOSED COMMERCIAL APPLICATION: NOT AVAILABLE Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: TREATMENT GOALS AT THE END OF LIFE Principal Investigator & Institution: Fried, Terri R. Associate Professor; Internal Medicine; Yale University 47 College Street, Suite 203 New Haven, CT 065208047 Timing: Fiscal Year 2002; Project Start 15-FEB-2002; Project End 31-JAN-2007 Summary: (provided by applicant): A geriatrician with both quantitative and qualitative research skills, Dr. Fried is poised to consolidate her career as an independent investigator. The K02, described as a time-off clinical duties award, would permit her to avoid the additional clinical responsibilities she would otherwise be expected to assume as her early career development awards end. Her research program is focused on the elicitation of older persons preferences for different intensities and sites of in care and on the outcomes of these alternative care strategies. It began with projects examining attitudes toward life-sustaining treatment and advance directives, and outcomes of pneumonia in nursing home residents treated with and without hospital transfer. Additional studies have examined the use of and older persons attitudes toward home as a treatment site in acute and terminal illness. Recent work has focused on older persons treatment preferences in serious and terminal illness. Results of this work include reliable and valid new patient-centered measures of treatment preference and the development of a unique cohort of seriously ill older outpatients. Building upon this earlier work, the overall objective of the proposed study is to examine changes in the preferences of both patients and their families across a spectrum of diseases. The primary aim is to determine the effect of primary diagnosis, health status, and healthcare utilization on the preferences of patients and their families. The study will involve 226 terminally ill older persons and a family member. They will be interviewed in their homes every four months if medically stable, and as frequently as every month if the illness is progressing. The relationship of disease diagnosis, health status (functional status, symptoms, self-rated health), healthcare utilization, and understanding of the illness prognosis to preferences will be examined using longitudinal repeated measures analysis. Dr. Fried s research program also consists of additional cohort studies examining communication, symptoms, and function in this study group and intervention studies to enhance physician-patient communication. With colleagues skilled in patient-centered research, extensive data management and analysis support, and senior faculty and administration committed to Dr. Fried s continued success, Yale offers the resources necessary to ensure Dr. Fried s continued development as an independent investigator. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: TROPOELASTIN REQUIREMENT FOR EXTRACELLULAR REPAIR OF LUNG ELASTIN FIBERS Principal Investigator & Institution: Stone, Phillip J.; Boston University Medical Campus 715 Albany St, 560 Boston, MA 02118 Timing: Fiscal Year 2001 Summary: Oligosaccharides that block the adherence of bacteria to epithelial cells in vitro-lacto-N-neotetraose (LNnT) and its alpha 2-1,3- and alpha 2-6-sialylated
146 Pneumonia
derivatives were tested for their abilities to attenuate the course of pneumococcal pneumonia and to prevent colonization of thenasopharynx in animal models. Intratracheal administration of these agents concurrently with bacteria dramatically decreased pneumococcal load in the lungs of rabbits and conferred protection from bacteremia. Several oligosaccharides were prepared by a combination of chemical andenzymatic synthesis. The samples ameliorated pneumonia and bacteremia when given therapeutically 24 h after infection was established. When administered intranasally, neoglycoconjugates of the active oligosaccharides prevented colonization of the nasopharynx of infant rats. In addition to in-vitro anti-adherence properties, LNnT acted directly on cultured lung epithelial cell lines to induce changes such that pneumococcal adherence was prevented for prolonged periods. These activities have encourage continued development of oligosaccharides as a class of potentially preventive and therapeutic agents for infectious diseases. The work with the MS Resource is to carefully check the products synthesized for sequence and linkage. Additional concern for the compounds prepared is that we have some assessment for purity. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: UNIVERSITY OF P.R., PEDIATRIC AIDS CLINICAL TRIALS UNIT Principal Investigator & Institution: Febo, Irma L. Pediatrics; University of Puerto Rico Med Sciences Medical Sciences Campus San Juan, PR 00936 Timing: Fiscal Year 2001; Project Start 01-MAR-1992; Project End 28-FEB-2002 Summary: -This is a new proposal for the Pediatric AIDS Clinical Trials Unit at the University of Puerto Rico, School of Medicine. Our main objective is to comply and collaborate with the Pediatric AIDS Clinical Trials Group Research Agenda. Through the ACTG Clinical Trials Protocols we enroll pediatric HIV infected patients and HIVinfected pregnant women to perinatal studies, contributing to the research protocols. Our unit follows the design and methods specified by each of the ACTG protocols to comply with each study requirements. In the last 4 years we have enrolled 164 patients to PACTG Protocols with an excellent retention rate. Our unit has been able to maintain a performance in the excellent range through 1995-96. Our Pediatric AIDS Program/PACTU located at the University Pediatric Hospital (UPH) has a multidisciplinary staff to serve the patient population, that consists of physicians, (pediatrics and pediatric infectious diseases), nurses, pharmacists, nutritionist and administrative and data management personnel. We are participants of the Women and Infants Transmission Study since 1989; enrolling over 50 HIV infected pregnant women per year. Our unit receives referrals of HIV infected children throughout public and private agencies and community based organizations to enter clinical trials. We evaluate an average of 58 new pediatric patients per year. We have the capability to enroll over 10 new parents per year to PACTG protocols and over 12 pregnant women to ACTG perinatal protocols. Our unit has the ability to comply with all the goals of the Pediatric AIDS Clinical Trials Group. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: USING PLASMA TGFB1 LEVELS TO ESCALATE RADIOTHERAPY DOSES Principal Investigator & Institution: Anscher, Mitchell S. Professor and Vice Chairman; Radiation Oncology; Duke University Durham, NC 27706 Timing: Fiscal Year 2001; Project Start 15-FEB-2000; Project End 31-JAN-2003
Studies 147
Summary: This abstract is not available. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: VANDERBILT ADULT AIDS CLINICAL TRIALS UNIT Principal Investigator & Institution: Haas, David W. Associate Professor of Medicine; Medicine; Vanderbilt University 3319 West End Ave. Nashville, TN 372036917 Timing: Fiscal Year 2001; Project Start 01-JAN-2000; Project End 31-DEC-2004 Summary: (adapted from applicant's abstract): An estimated 700,000 people in the United States are infected with HIV. Effective treatment of HIV infection requires prolonged administration of multiple antiretroviral agents. Incorporating clinical pharmacology expertise into the design, performance, and analysis of HIV clinical trials is therefore essential. Establishment of a main AIDS Clinic Trial Unit (ACTU) at Vanderbilt University would bring extensive expertise in clinical pharmacology to the AIDS Clinic Trials Group (ACTG). Vanderbilt ACTU investigators will participate in several studies including: inter-individual variability in response to antiretroviral therapy; drug disposition and metabolism; drug-drug interactions; tissue delivery of protease inhibitors and other drugs by membrane transporters (including Pglycoprotein); and the application of ultra-intensive CSF sampling approaches to study HIV treatment and pathogenesis in the CNS. The investigators also may apply advanced mass spectroscopy techniques to HIV clinical trials. The use of state-of-the-art clinical pharmacology strategies to HIV clinical trials may ultimately improve treatment of HIV infection and its complications, and allow therapy to be appropriately individualized. Vanderbilt University investigators also will contribute expertise to other innovative HIV-related laboratory efforts. These include: developing novel antiretroviral therapeutics; studying HIV-1 virion assembly and HIV-1 accessory proteins; developing novel HIV-related assays; understanding viral pathogenesis of AIDS-related malignancies; characterizing host-pathogen interactions in the gastrointestinal tract during AIDS; and developing strategies to optimize the design of antiretroviral agents and AIDS vaccines. The Principal Investigator leads an established HIV clinical trials program at Vanderbilt University, and the proposed ACTU incorporates a large Vanderbilt- affiliated HIV primary care clinic. Technically demanding studies will be facilitated by the Vanderbilt University General Clinical Research Center (GCRC). The proposed ACTU will not only enroll patients into ACTG clinical trials, but will provide the ACTG the ability to address important questions concerning AIDS treatment and pathogenesis. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: VITAMIN A/ZINC--PREVENTION OF PNEUMONIA (VAZPOP) STUDY Principal Investigator & Institution: Griffiths, Jeffrey K. Associate Professor; Family Medicine & Cmty Health; Tufts University Boston Boston, MA 02111 Timing: Fiscal Year 2001; Project Start 18-JAN-2000; Project End 31-DEC-2004 Summary: (Adapted from applicant's description): The Vitamin A and Zinc - Prevention of Pneumonia (VAZPOP) Study. Linking Vitamin A and Zinc Deficiencies, Immunity, Growth, and the Prevention of the Leading Cause of Childhood Death. The objective is to delineate how vitamin A and zinc supplementation interact in improving immunity, fostering growth, and preventing infection, in populations at risk for malnutrition and vitamin A and zinc deficiency. Malnutrition is involved in half of the global deaths in children less than 5. Acute respiratory infection (ARI), especially acute lower respiratory
148 Pneumonia
infection (ALRI) or pneumonia, is the leading cause of death in children. The investigators propose to conduct a randomized, placebo controlled, double blind, nutritionally stratified study of low dose vitamin A, 10 mg/day elemental zinc, both, or placebo in 2,400 children in Quito Ecuador. They will test the hypotheses that: a) lowdose vitamin A has paradoxically positive and negative effects on ALRI in underweight and well nourished children; b) zinc will protect against ALRI and diarrhea while boosting cell mediated immunity; c) growth will be fostered by zinc (and potentially by vitamin A) in deficient children; and d) misclassification of ALRI cases can mask the benefits or risks of vitamin A. The investigators will use state-of- the-art field techniques to assess body composition and growth, and utilize sophisticated techniques to assess vitamin A and zinc deficiency. In addition, they will use rigorous definitions of ALRI/pneumoma to avoid misclassification and ascertainment bias, which may have affected prior studies. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
E-Journals: PubMed Central3 PubMed Central (PMC) is a digital archive of life sciences journal literature developed and managed by the National Center for Biotechnology Information (NCBI) at the U.S. National Library of Medicine (NLM).4 Access to this growing archive of e-journals is free and unrestricted.5 To search, go to http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=Pmc, and type “pneumonia” (or synonyms) into the search box. This search gives you access to full-text articles. The following is a sample of items found for pneumonia in the PubMed Central database: •
"Flexispira rappini" Bacteremia in a Child with Pneumonia. by Tee W, Leder K, Karroum E, Dyall-Smith M. 1998 Jun; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=104899
•
(1-->3) beta-D-glucan as a quantitative serological marker for Pneumocystis carinii pneumonia. by Yasuoka A, Tachikawa N, Shimada K, Kimura S, Oka S. 1996 Mar; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=170276
•
[Cu,Zn]-Superoxide Dismutase Mutants of the Swine Pathogen Actinobacillus pleuropneumoniae Are Unattenuated in Infections of the Natural Host. by Sheehan BJ, Langford PR, Rycroft AN, Kroll JS. 2000 Aug; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=98436
3 4
Adapted from the National Library of Medicine: http://www.pubmedcentral.nih.gov/about/intro.html.
With PubMed Central, NCBI is taking the lead in preservation and maintenance of open access to electronic literature, just as NLM has done for decades with printed biomedical literature. PubMed Central aims to become a world-class library of the digital age. 5 The value of PubMed Central, in addition to its role as an archive, lies in the availability of data from diverse sources stored in a common format in a single repository. Many journals already have online publishing operations, and there is a growing tendency to publish material online only, to the exclusion of print.
Studies 149
•
A Histologically Distinctive Interstitial Pneumonia Induced by Overexpression of the Interleukin 6, Transforming Growth Factor [beta]1, or Platelet-Derived Growth Factor B Gene. by Yoshida M, Sakuma J, Hayashi S, Abe K, Saito I, Harada S, Sakatani M, Yamamoto S, Matsumoto N, Kaneda Y, Kishmoto T. 1995 Oct 10; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=40843
•
A Mouse Model for Investigating the Molecular Pathogenesis of Adenovirus Pneumonia. by Ginsberg HS, Moldawer LL, Sehgal PB, Redington M, Kilian PL, Chanock RM, Prince GA. 1991 Mar 1; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=51082
•
A multicenter, randomized study comparing the efficacy and safety of intravenous and/or oral levofloxacin versus ceftriaxone and/or cefuroxime axetil in treatment of adults with community-acquired pneumonia. by File TM Jr, Segreti J, Dunbar L, Player R, Kohler R, Williams RR, Kojak C, Rubin A. 1997 Sep; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=164046
•
A Novel Enzyme-Linked Immunosorbent Assay Using the Recombinant Actinobacillus pleuropneumoniae ApxII Antigen for Diagnosis of Pleuropneumonia in Pig Herds. by Leiner G, Franz B, Strutzberg K, Gerlach GF. 1999 Jul; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=95743
•
A Novel Type of AmpC [beta]-Lactamase, ACC-1, Produced by a Klebsiella pneumoniae Strain Causing Nosocomial Pneumonia. by Bauernfeind A, Schneider I, Jungwirth R, Sahly H, Ullmann U. 1999 Aug; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=89392
•
Acquired Immunity to Chlamydia pneumoniae Is Dependent on Gamma Interferon in Two Mouse Strains That Initially Differ in This Respect after Primary Challenge. by Vuola JM, Puurula V, Anttila M, Makela PH, Rautonen N. 2000 Feb; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=97231
•
Acquisition of Expression of the Pseudomonas aeruginosa ExoU Cytotoxin Leads to Increased Bacterial Virulence in a Murine Model of Acute Pneumonia and Systemic Spread. by Allewelt M, Coleman FT, Grout M, Priebe GP, Pier GB. 2000 Jul; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=101680
•
Activities of Tigecycline (GAR-936) against Legionella pneumophila In Vitro and in Guinea Pigs with L. pneumophila Pneumonia. by Edelstein PH, Weiss WJ, Edelstein MA. 2003 Feb; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=151731
•
Activity of the new fluoroquinolone trovafloxacin (CP-99,219) against DNA gyrase and topoisomerase IV mutants of Streptococcus pneumoniae selected in vitro. by Gootz TD, Zaniewski R, Haskell S, Schmieder B, Tankovic J, Girard D, Courvalin P, Polzer RJ. 1996 Dec; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=163605
150 Pneumonia
•
Acute Mycoplasma pneumoniae Infection Presenting as Cholestatic Hepatitis. by Grullich C, Baumert TF, Blum HE. 2003 Jan; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=149592
•
Alpha-Toxin Damages the Air-Blood Barrier of the Lung in a Rat Model of Staphylococcus aureus-Induced Pneumonia. by McElroy MC, Harty HR, Hosford GE, Boylan GM, Pittet JF, Foster TJ. 1999 Oct; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=96922
•
Alveolar macrophages are required for protective pulmonary defenses in murine Klebsiella pneumonia: elimination of alveolar macrophages increases neutrophil recruitment but decreases bacterial clearance and survival. by Broug-Holub E, Toews GB, van Iwaarden JF, Strieter RM, Kunkel SL, Paine R 3rd, Standiford TJ. 1997 Apr; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=175109
•
Amikacin levels in bronchial secretions of 10 pneumonia patients with respiratory support treated once daily versus twice daily. by Santre C, Georges H, Jacquier JM, Leroy O, Beuscart C, Buguin D, Beaucaire G. 1995 Jan; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=162523
•
Amoxicillin dose-effect relationship with Streptococcus pneumoniae in a mouse pneumonia model and roles of in vitro penicillin susceptibilities, autolysis, and tolerance properties of the strains. by Azoulay-Dupuis E, Moine P, Bedos JP, Rieux V, Vallee E. 1996 Apr; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=163235
•
Amplified-Fragment Length Polymorphism Analysis versus Macro-Restriction Fragment Analysis for Molecular Typing of Streptococcus pneumoniae Isolates. by van Eldere J, Janssen P, Hoefnagels-Schuermans A, van Lierde S, Peetermans WE. 1999 Jun; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=85030
•
Analysis of Complement Fixation and Commercial Enzyme Immunoassays for Detection of Antibodies to Mycoplasma pneumoniae in Human Serum. by Thacker WL, Talkington DF. 2000 Sep; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=95955
•
Animal Model of Mycoplasma pneumoniae Infection Using Germfree Mice. by Hayakawa M, Taguchi H, Kamiya S, Fujioka Y, Watanabe H, Kawai S, Kobayashi H. 2002 May; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=119980
•
Antibody response to Prevotella spp. in patients with ventilator-associated pneumonia. by Grollier G, Dore P, Robert R, Ingrand P, Grejon C, Fauchere JL. 1996 Jan; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=170248
Studies 151
•
Antibody to Pneumocystis carinii Protects Rats and Mice from Developing Pneumonia. by Bartlett MS, Angus WC, Shaw MM, Durant PJ, Lee CH, Pascale JM, Smith JW. 1998 Jan; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=121395
•
Antibody-mediated shift in the profile of glycoprotein A phenotypes observed in a mouse model of Pneumocystis carinii pneumonia. by Gigliotti F, Garvy BA, Harmsen AG. 1996 Jun; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=174013
•
Antimicrobial Resistance and Serotype Distribution of Streptococcus pneumoniae Strains Causing Childhood Infections in Bangladesh, 1993 to 1997. by Saha SK, Rikitomi N, Ruhulamin M, Masaki H, Hanif M, Islam M, Watanabe K, Ahmed K, Matsumoto K, Sack RB, Nagatake T. 1999 Mar; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=84560
•
Assessing the Quality of Clinical Data in a Computer-based Record for Calculating the Pneumonia Severity Index. by Aronsky D, Haug PJ. 2000 Jan; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=61455
•
Assessment of two penicillins plus beta-lactamase inhibitors versus cefotaxime in treatment of murine Klebsiella pneumoniae infections. by Fournier JL, Ramisse F, Jacolot AC, Szatanik M, Petitjean OJ, Alonso JM, Scavizzi MR. 1996 Feb; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=163110
•
Asthma after childhood pneumonia: six year follow up study. by Clark CE, Coote JM, Silver DA, Halpin DM. 2000 Jun 3; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=27396
•
Bacteremic Pneumonia Caused by a Single Clone of Streptococcus pneumoniae with Different Optochin Susceptibilities. by Tsai HY, Hsueh PR, Teng LJ, Lee PI, Huang LM, Lee CY, Luh KT. 2000 Jan; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=88751
•
Bactericidal Effect and Pharmacodynamics of Cethromycin (ABT-773) in a Murine Pneumococcal Pneumonia Model. by Kim MK, Zhou W, Tessier PR, Xuan D, Ye M, Nightingale CH, Nicolau DP. 2002 Oct; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=128791
•
Beneficial Effect of Adjunctive Azithromycin in Treatment of Mucoid Pseudomonas aeruginosa Pneumonia in the Murine Model. by Nicolau DP, Banevicius MA, Nightingale CH, Quintiliani R. 1999 Dec; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=89611
•
Binding to and Opsonophagocytic Activity of O-Antigen-Specific Monoclonal Antibodies against Encapsulated and Nonencapsulated Klebsiella pneumoniae Serotype O1 Strains. by Held TK, Jendrike NR, Rukavina T, Podschun R, Trautmann M. 2000 May; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=97438
152 Pneumonia
•
Bleeding and pneumonia in intensive care patients given ranitidine and sucralfate for prevention of stress ulcer: meta-analysis of randomised controlled trials. by Messori A, Trippoli S, Vaiani M, Gorini M, Corrado A. 2000 Nov 4; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=27516
•
Breast Milk Transmission of a Panton-Valentine Leukocidin-Producing Staphylococcus aureus Strain Causing Infantile Pneumonia. by Le Thomas I, MarianiKurkdjian P, Collignon A, Gravet A, Clermont O, Brahimi N, Gaudelus J, Aujard Y, Navarro J, Beaufils F, Bingen E. 2001 Feb; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=87805
•
Capsular Serotype and Antibiotic Resistance of Streptococcus pneumoniae Isolates in Two Chilean Cities. by Inostroza J, Trucco O, Prado V, Vinet AM, Retamal G, Ossa G, Facklam RR, Sorensen RU. 1998 Mar; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=121354
•
Cavitary Pneumonia in an AIDS Patient Caused by an Unusual Bordetella bronchiseptica Variant Producing Reduced Amounts of Pertactin and Other Major Antigens. by Lorenzo-Pajuelo B, Villanueva JL, Rodriguez-Cuesta J, Vergara-Irigaray N, Bernabeu-Wittel M, Garcia-Curiel A, Martinez de Tejada G. 2002 Sep; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=130797
•
Cefepime versus Ceftriaxone for Empiric Treatment of Hospitalized Patients with Community-Acquired Pneumonia. by Zervos M, Nelson M. 1998 Apr; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=105532
•
Cefepime versus Ceftriaxone for Empiric Treatment of Hospitalized Patients with Community-Acquired Pneumonia. by Borja J, Jane F. 1999 Feb; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=89101
•
Cefuroxime efficacy in treatment of bacteremic pneumonia due to penicillin-resistant and cefuroxime-resistant Streptococcus pneumoniae. by Caballero-Granado FJ, Palomino-Nicas J, Pachon J, Garcia-Curiel A. 1996 May; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=163322
•
Characterization of a Murine Model of Ureaplasma urealyticum Pneumonia. by Viscardi RM, Kaplan J, Lovchik JC, He JR, Hester L, Rao S, Hasday JD. 2002 Oct; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=128302
•
Chemokine-Dependent Neutrophil Recruitment in a Murine Model of Legionella Pneumonia: Potential Role of Neutrophils as Immunoregulatory Cells. by Tateda K, Moore TA, Newstead MW, Tsai WC, Zeng X, Deng JC, Chen G, Reddy R, Yamaguchi K, Standiford TJ. 2001 Apr; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=98125
Studies 153
•
Chlamydia pneumoniae and Atherosclerosis: Critical Assessment of Diagnostic Methods and Relevance to Treatment Studies. by Boman J, Hammerschlag MR. 2002 Jan; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=118057
•
Chlamydia pneumoniae Exacerbates Aortic Inflammatory Foci Caused by Murine Cytomegalovirus Infection in Normocholesterolemic Mice. by Burian K, Berencsi K, Endresz V, Gyulai Z, Valyi-Nagy T, Valyi-Nagy I, Bakay M, Geng Y, Virok D, Kari L, Hajnal-Papp R, Trinchieri G, Gonczol E. 2001 Nov; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=96259
•
Chlamydia pneumoniae infection induces inflammatory changes in the aortas of rabbits. by Laitinen K, Laurila A, Pyhala L, Leinonen M, Saikku P. 1997 Nov; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=175693
•
Chlamydia pneumoniae Infects and Multiplies in Lymphocytes In Vitro. by Haranaga S, Yamaguchi H, Friedman H, Izumi SI, Yamamoto Y. 2001 Dec; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=98871
•
Clinical Efficacy of Intravenous followed by Oral Azithromycin Monotherapy in Hospitalized Patients with Community-Acquired Pneumonia. by Plouffe J, Schwartz DB, Kolokathis A, Sherman BW, Arnow PM, Gezon JA, Suh B, Anzuetto A, Greenberg RN, Niederman M, Paladino JA, Ramirez JA, Inverso J, Knirsch CA. 2000 Jul; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=89964
•
Clinical features of culture-proven Mycoplasma pneumoniae infections at King Abdulaziz University Hospital, Jeddah, Saudi Arabia. by Madani TA, Al-Ghamdi AA. 2001; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=35282
•
Clinical review: Non-antibiotic strategies for preventing ventilator-associated pneumonia. by Ferrer R, Artigas A. 2002; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=137396
•
Clinical Use of Capillary PCR To Diagnose Mycoplasma Pneumonia. by Honda J, Yano T, Kusaba M, Yonemitsu J, Kitajima H, Masuoka M, Hamada K, Oizumi K. 2000 Apr; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=86449
•
Clinically achievable plasma deferoxamine concentrations are therapeutic in a rat model of Pneumocystis carinii pneumonia. by Merali S, Chin K, Del Angel L, Grady RW, Armstrong M, Clarkson AB Jr. 1995 Sep; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=162875
•
Close Association between Pulmonary Disease Manifestation in Mycoplasma pneumoniae Infection and Enhanced Local Production of Interleukin-18 in the Lung, Independent of Gamma Interferon. by Narita M, Tanaka H, Abe S, Yamada S, Kubota M, Togashi T. 2000 Nov; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=95984
154 Pneumonia
•
Community-Acquired Bacteremic Acinetobacter Pneumonia in Tropical Australia Is Caused by Diverse Strains of Acinetobacter baumannii, with Carriage in the Throat in At-Risk Groups. by Anstey NM, Currie BJ, Hassell M, Palmer D, Dwyer B, Seifert H. 2002 Feb; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=153418
•
Comparing Pharmacokinetics of Amoxicillin Given Twice or Three Times per Day to Children Older than 3 Months with Pneumonia. by Fonseca W, Hoppu K, Rey LC, Amaral J, Qazi S. 2003 Mar; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=149282
•
Comparison of cefdinir and cefaclor in treatment of community-acquired pneumonia. by Drehobl M, Bianchi P, Keyserling CH, Tack KJ, Griffin TJ. 1997 Jul; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=163963
•
Comparison of Corticosteroids for Treatment of Respiratory Syncytial Virus Bronchiolitis and Pneumonia in Cotton Rats. by Ottolini MG, Curtis SJ, Porter DD, Mathews A, Richardson JY, Hemming VG, Prince GA. 2002 Jul; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=127305
•
Comparison of Nucleic Acid Amplification, Serology, and Microbiologic Culture for Diagnosis of Rhodococcus equi Pneumonia in Foals. by Sellon DC, Besser TE, Vivrette SL, McConnico RS. 2001 Apr; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=87926
•
Comparison of PCR, Culture, and Serological Tests for Diagnosis of Mycoplasma pneumoniae Respiratory Tract Infection in Children. by Dorigo-Zetsma JW, Zaat SA, Wertheim-van Dillen PM, Spanjaard L, Rijntjes J, van Waveren G, Jensen JS, Angulo AF, Dankert J. 1999 Jan; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=84154
•
Comparison of Strategies Using Cefpirome and Ceftazidime for Empiric Treatment of Pneumonia in Intensive Care Patients. by Wolff M. 1998 Jan; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=105451
•
Continuous infusion of DL-alpha-difluoromethylornithine and improved efficacy against a rat model of Pneumocystis carinii pneumonia. by Chin K, Merali S, Saric M, Clarkson AB Jr. 1996 Oct; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=163527
•
Contribution of specific Pseudomonas aeruginosa virulence factors to pathogenesis of pneumonia in a neonatal mouse model of infection. by Tang HB, DiMango E, Bryan R, Gambello M, Iglewski BH, Goldberg JB, Prince A. 1996 Jan; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=173724
Studies 155
•
Coronavirus and Pasteurella Infections in Bovine Shipping Fever Pneumonia and Evans' Criteria for Causation. by Storz J, Lin X, Purdy CW, Chouljenko VN, Kousoulas KG, Enright FM, Gilmore WC, Briggs RE, Loan RW. 2000 Sep; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=87376
•
Cost effectiveness in treating ventilator-associated pneumonia. by Niederman MS. 2001; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=137281
•
CXC Chemokine Receptor CXCR2 Is Essential for Protective Innate Host Response in Murine Pseudomonas aeruginosa Pneumonia. by Tsai WC, Strieter RM, Mehrad B, Newstead MW, Zeng X, Standiford TJ. 2000 Jul; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=101748
•
Cytokine modulation alters pulmonary clearance of Rhodococcus equi and development of granulomatous pneumonia. by Kanaly ST, Hines SA, Palmer GH. 1995 Aug; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=173413
•
Decreased Virulence of a Pneumolysin-Deficient Strain of Streptococcus pneumoniae in Murine Meningitis. by Wellmer A, Zysk G, Gerber J, Kunst T, von Mering M, Bunkowski S, Eiffert H, Nau R. 2002 Nov; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=130334
•
Detection and Identification of Actinobacillus pleuropneumoniae Serotype 5 by Multiplex PCR. by Lo TM, Ward CK, Inzana TJ. 1998 Jun; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=104904
•
Detection of Mycoplasma hyopneumoniae in Bronchoalveolar Lavage Fluids of Pigs by PCR. by Baumeister AK, Runge M, Ganter M, Feenstra AA, Delbeck F, Kirchhoff H. 1998 Jul; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=104965
•
Detection of Mycoplasma pneumoniae in Spiked Clinical Samples by Nucleic Acid Sequence-Based Amplification. by Loens K, Ursi D, Ieven M, van Aarle P, Sillekens P, Oudshoorn P, Goossens H. 2002 Apr; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=140351
•
Detection of Pneumocystis DNA in samples from patients suspected of bacterial pneumonia- a case-control study. by Helweg-Larsen J, Jensen JS, Dohn B, Benfield TL, Lundgren B. 2002; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=139972
•
Determinants for hospitalization in " low-risk" community acquired pneumonia. by Aliyu ZY, Aliyu MH, McCormick K. 2003; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=165606
156 Pneumonia
•
Determination of Penicillin Resistance in Streptococcus pneumoniae and Use of CoTrimoxazole in Treatment of Pneumococcal Pneumonia. by Lalitha MK, Manoharan A, Pai R. 1999 Aug; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=85338
•
Development and Evaluation of a Quantitative, Touch-Down, Real-Time PCR Assay for Diagnosing Pneumocystis carinii Pneumonia. by Larsen HH, Masur H, Kovacs JA, Gill VJ, Silcott VA, Kogulan P, Maenza J, Smith M, Lucey DR, Fischer SH. 2002 Feb; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=153364
•
Development of a Genomics-Based PCR Assay for Detection of Mycoplasma pneumoniae in a Large Outbreak in New York State. by Waring AL, Halse TA, Csiza CK, Carlyn CJ, Musser KA, Limberger RJ. 2001 Apr; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=87943
•
Development of a New Experimental Model of Penicillin-Resistant Streptococcus pneumoniae Pneumonia and Amoxicillin Treatment by Reproducing Human Pharmacokinetics. by Piroth L, Martin L, Coulon A, Lequeu C, Duong M, Buisson M, Portier H, Chavanet P. 1999 Oct; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=89505
•
Development of experimental pneumonia by infection with penicillin-insensitive Streptococcus pneumoniae in guinea pigs and their treatment with amoxicillin, cefotaxime, and meropenem. by Ponte C, Parra A, Nieto E, Soriano F. 1996 Dec; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=163606
•
Diagnosis and Differentiation of Mycoplasma hyopneumoniae and Mycoplasma hyorhinis Infections in Pigs by PCR Amplification of the p36 and p46 Genes. by Caron J, Ouardani M, Dea S. 2000 Apr; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=86451
•
Diagnosis of Mycoplasma pneumoniae Infection in Autopsy and Open-Lung Biopsy Tissues by Nested PCR. by Talkington DF, Thacker WL, Keller DW, Jensen JS. 1998 Apr; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=104711
•
Diagnosis of Mycoplasma pneumoniae Pneumonia in Children. by Waris ME, Toikka P, Saarinen T, Nikkari S, Meurman O, Vainionpaa R, Mertsola J, Ruuskanen O. 1998 Nov; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=105292
•
Differential Selection of Multidrug Efflux Mutants by Trovafloxacin and Ciprofloxacin in an Experimental Model of Pseudomonas aeruginosa Acute Pneumonia in Rats. by Join-Lambert OF, Michea-Hamzehpour M, Kohler T, Chau F, Faurisson F, Dautrey S, Vissuzaine C, Carbon C, Pechere JC. 2001 Feb; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=90328
Studies 157
•
Discovery of virulence genes of Legionella pneumophila by using signature tagged mutagenesis in a guinea pig pneumonia model. by Edelstein PH, Edelstein MA, Higa F, Falkow S. 1999 Jul 6; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=22210
•
Divergent Role of Gamma Interferon in a Murine Model of Pulmonary versus Systemic Klebsiella pneumoniae Infection. by Moore TA, Perry ML, Getsoian AG, Newstead MW, Standiford TJ. 2002 Nov; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=130357
•
DNA fingerprinting by pulsed-field gel electrophoresis to investigate a nosocomial pneumonia caused by Legionella bozemanii serogroup 1. by Luck PC, Helbig JH, Hagedorn HJ, Ehret W. 1995 Jul; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=167548
•
Dosing of Aminoglycosides To Rapidly Attain Pharmacodynamic Goals and Hasten Therapeutic Response by Using Individualized Pharmacokinetic Monitoring of Patients with Pneumonia Caused by Gram-Negative Organisms. by Kashuba AD, Bertino JS Jr, Nafziger AN. 1998 Jul; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=105693
•
Effect of atovaquone and atovaquone drug combinations on prophylaxis of Pneumocystis carinii pneumonia in SCID mice. by Comley JC, Sterling AM. 1995 Apr; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=162633
•
Effect of Azithromycin plus Rifampin versus Amoxicillin Alone on Eradication and Inflammation in the Chronic Course of Chlamydia pneumoniae Pneumonitis in Mice. by Bin XX, Wolf K, Schaffner T, Malinverni R. 2000 Jun; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=89955
•
Effect of Azithromycin plus Rifampin versus That of Azithromycin Alone on the Eradication of Chlamydia pneumoniae from Lung Tissue in Experimental Pneumonitis. by Wolf K, Malinverni R. 1999 Jun; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=89304
•
Effect of routine zinc supplementation on pneumonia in children aged 6 months to 3 years: randomised controlled trial in an urban slum. by Bhandari N, Bahl R, Taneja S, Strand T, Molbak K, Ulvik RJ, Sommerfelt H, Bhan MK. 2002 Jun 8; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=115208
•
Effective Combination Therapy for Invasive Pneumococcal Pneumonia with Ampicillin and Intravenous Immunoglobulins in a Mouse Model. by De Hennezel L, Ramisse F, Binder P, Marchal G, Alonso JM. 2001 Jan; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=90282
158 Pneumonia
•
Effects of Ginseng Treatment on Neutrophil Chemiluminescence and Immunoglobulin G Subclasses in a Rat Model of Chronic Pseudomonas aeruginosa Pneumonia. by Song Z, Kharazmi A, Wu H, Faber V, Moser C, Krogh Johansen H, Rygaard J, Hoiby N. 1998 Nov; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=96218
•
Effects of Respiratory Mycoplasma pneumoniae Infection on Allergen-Induced Bronchial Hyperresponsiveness and Lung Inflammation in Mice. by Chu HW, Honour JM, Rawlinson CA, Harbeck RJ, Martin RJ. 2003 Mar; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=148884
•
Effects of two antibiotic regimens on course and persistence of experimental Chlamydia pneumoniae TWAR pneumonitis. by Malinverni R, Kuo CC, Campbell LA, Lee A, Grayston JT. 1995 Jan; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=162482
•
Efficacies of Cefepime, Ceftazidime, and Imipenem Alone or in Combination with Amikacin in Rats with Experimental Pneumonia Due to Ceftazidime-Susceptible or Resistant Enterobacter cloacae Strains. by Mimoz O, Jacolot A, Leotard S, Hidri N, Samii K, Nordmann P, Petitjean O. 1998 Dec; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=106042
•
Efficacies of cefotaxime and ceftriaxone in a mouse model of pneumonia induced by two penicillin- and cephalosporin-resistant strains of Streptococcus pneumoniae. by Sauve C, Azoulay-Dupuis E, Moine P, Darras-Joly C, Rieux V, Carbon C, Bedos JP. 1996 Dec; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=163631
•
Efficacies of Imipenem, Meropenem, Cefepime, and Ceftazidime in Rats with Experimental Pneumonia Due to a Carbapenem-Hydrolyzing [beta]-LactamaseProducing Strain of Enterobacter cloacae. by Mimoz O, Leotard S, Jacolot A, Padoin C, Louchahi K, Petitjean O, Nordmann P. 2000 Apr; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=89787
•
Efficacy of [beta]-Lactams for Treating Experimentally Induced Pneumonia Due to a Carbapenem-Hydrolyzing Metallo-[beta]-Lactamase-Producing Strain of Pseudomonas aeruginosa. by Bellais S, Mimoz O, Leotard S, Jacolot A, Petitjean O, Nordmann P. 2002 Jun; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=127240
•
Efficacy of Colistin versus [beta]-Lactams, Aminoglycosides, and Rifampin as Monotherapy in a Mouse Model of Pneumonia Caused by Multiresistant Acinetobacter baumannii. by Montero A, Ariza J, Corbella X, Domenech A, Cabellos C, Ayats J, Tubau F, Ardanuy C, Gudiol F. 2002 Jun; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=127272
•
Efficacy of CS-834 against Experimental Pneumonia Caused by Penicillin-Susceptible and -Resistant Streptococcus pneumoniae in Mice. by Fukuoka T, Kawada H,
Studies 159
Kitayama A, Koga T, Kubota M, Harasaki T, Kamai Y, Ohya S, Yasuda H, Iwata M, Kuwahara S. 1998 Jan; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=105450 •
Efficacy of Sulfamethoxypyridazine in a Murine Model of Pneumocystis carinii Pneumonia. by Bartlett MS, Shaw MM, Smith JW, Meshnick SR. 1998 Apr; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=105571
•
Efficacy of Trovafloxacin against Penicillin-Susceptible and Multiresistant Strains of Streptococcus pneumoniae in a Mouse Pneumonia Model. by Bedos JP, Rieux V, Bauchet J, Muffat-Joly M, Carbon C, Azoulay-Dupuis E. 1998 Apr; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=105556
•
Elevated Cytokine and Chemokine Levels and Prolonged Pulmonary Airflow Resistance in a Murine Mycoplasma pneumoniae Pneumonia Model: a Microbiologic, Histologic, Immunologic, and Respiratory Plethysmographic Profile. by Hardy RD, Jafri HS, Olsen K, Wordemann M, Hatfield J, Rogers BB, Patel P, Duffy L, Cassell G, McCracken GH, Ramilo O. 2001 Jun; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=98411
•
Endobronchial inoculation with Apx toxins of Actinobacillus pleuropneumoniae leads to pleuropneumonia in pigs. by Kamp EM, Stockhofe-Zurwieden N, van Leengoed LA, Smits MA. 1997 Oct; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=175624
•
Epidemiological and Environmental Investigations of Legionella pneumophila Infection in Cattle and Case Report of Fatal Pneumonia in a Calf. by Fabbi M, Pastoris MC, Scanziani E, Magnino S, Di Matteo L. 1998 Jul; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=104957
•
Erythromycin Inhibits Tumor Necrosis Factor Alpha and Interleukin 6 Production Induced by Heat-Killed Streptococcus pneumoniae in Whole Blood. by Schultz MJ, Speelman P, Zaat S, van Deventer SJ, van der Poll T. 1998 Jul; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=105654
•
Evaluation of a PCR Assay for Detection of Streptococcus pneumoniae in Respiratory and Nonrespiratory Samples from Adults with Community-Acquired Pneumonia. by Murdoch DR, Anderson TP, Beynon KA, Chua A, Fleming AM, Laing RT, Town GI, Mills GD, Chambers ST, Jennings LC. 2003 Jan; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=149569
•
Evaluation of a Rapid Immunochromatographic Test for Detection of Streptococcus pneumoniae Antigen in Urine Samples from Adults with Community-Acquired Pneumonia. by Murdoch DR, Laing RT, Mills GD, Karalus NC, Town GI, Mirrett S, Reller LB. 2001 Oct; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=88378
160 Pneumonia
•
Evaluation of Chlamydia pneumoniae 43- and 53-Kilodalton Recombinant Proteins for Serodiagnosis by Western Blot. by Campbell LA, Roberts S, Inoue S, Kong L, Kuo CC. 2001 Nov; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=96254
•
Evaluation of Chlamydia pneumoniae and Mycoplasma pneumoniae as Etiologic Agents of Persistent Cough in Adolescents and Adults. by Wadowsky RM, Castilla EA, Laus S, Kozy A, Atchison RW, Kingsley LA, Ward JI, Greenberg DP. 2002 Feb; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=153367
•
Evaluation of Four Commercial Immunoglobulin G (IgG)- and IgM-Specific Enzyme Immunoassays for Diagnosis of Mycoplasma pneumoniae Infections. by Petitjean J, Vabret A, Gouarin S, Freymuth F. 2002 Jan; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=120121
•
Evaluation of PCR, Culture, and Serology for Diagnosis of Chlamydia pneumoniae Respiratory Infections. by Verkooyen RP, Willemse D, Hiep-van Casteren SC, Mousavi Joulandan SA, Snijder RJ, van den Bosch JM, van Helden HP, Peeters MF, Verbrugh HA. 1998 Aug; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=105036
•
Extracellular neuraminidase production by a Pasteurella multocida A:3 strain associated with bovine pneumonia. by White DJ, Jolley WL, Purdy CW, Straus DC. 1995 May; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=173213
•
Extracorporeal membrane oxygenation for overwhelming Blastomyces dermatitidis pneumonia. by Dalton HJ, Hertzog JH, Hannan RL, Vezza P, Hauser GJ. 1999; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=29020
•
Fatal Case of Pneumonia Caused by a Nonhemolytic Strain of Streptococcus pyogenes. by Taylor MB, Barkham T. 2002 Jun; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=130749
•
Genetic Diversity of Pseudomonas aeruginosa Strains Isolated from Ventilated Patients with Nosocomial Pneumonia, Cancer Patients with Bacteremia, and Environmental Water. by Ruimy R, Genauzeau E, Barnabe C, Beaulieu A, Tibayrenc M, Andremont A. 2001 Jan; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=97924
•
Genotypes at the Internal Transcribed Spacers of the Nuclear rRNA Operon of Pneumocystis jiroveci in Nonimmunosuppressed Infants without Severe Pneumonia. by Totet A, Pautard JC, Raccurt C, Roux P, Nevez G. 2003 Mar; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=150306
•
Genotyping of Mycoplasma pneumoniae Clinical Isolates Reveals Eight P1 Subtypes within Two Genomic Groups. by Dorigo-Zetsma JW, Dankert J, Zaat SA. 2000 Mar; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=86314
Studies 161
•
Ginseng treatment reduces bacterial load and lung pathology in chronic Pseudomonas aeruginosa pneumonia in rats. by Song Z, Johansen HK, Faber V, Moser C, Kharazmi A, Rygaard J, Hoiby N. 1997 May; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=163833
•
Identification of a New Variable Sequence in the P1 Cytadhesin Gene of Mycoplasma pneumoniae: Evidence for the Generation of Antigenic Variation by DNA Recombination between Repetitive Sequences. by Kenri T, Taniguchi R, Sasaki Y, Okazaki N, Narita M, Izumikawa K, Umetsu M, Sasaki T. 1999 Sep; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=96778
•
Immunization with Pneumocystis carinii gpA Is Immunogenic but Not Protective in a Mouse Model of P. carinii Pneumonia. by Gigliotti F, Wiley JA, Harmsen AG. 1998 Jul; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=108330
•
Immunomodulating Effects of HMR 3004 on Pulmonary Inflammation Caused by Heat-Killed Streptococcus pneumoniae in Mice. by Duong M, Simard M, Bergeron Y, Ouellet N, Cote-Richer M, Bergeron MG. 1998 Dec; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=106043
•
Immunomodulatory and Protective Effects of Moxifloxacin against Candida albicansInduced Bronchopneumonia in Mice Injected with Cyclophosphamide. by Shalit I, Horev-Azaria L, Fabian I, Blau H, Kariv N, Shechtman I, Alteraz H, Kletter Y. 2002 Aug; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=127325
•
Impact of breast feeding on admission for pneumonia during postneonatal period in Brazil: nested case-control study. by Cesar JA, Victora CG, Barros FC, Santos IS, Flores JA. 1999 May 15; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=27869
•
Impact of nosocomial pneumonia on the outcome of mechanically-ventilated patients. by Violan JS, Sanchez-Ramirez C, Mujica AP, Cendrero JA, Fernandez JA, de Castro FR. 1998; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=28997
•
Improved Efficacy of Ciprofloxacin Administered in Polyethylene Glycol-Coated Liposomes for Treatment of Klebsiella pneumoniae Pneumonia in Rats. by BakkerWoudenberg IA, ten Kate MT, Guo L, Working P, Mouton JW. 2001 May; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=90493
•
In Vitro Activity of a New 8-Methoxyquinolone, BAY 12-8039, against Chlamydia pneumoniae. by Roblin PM, Hammerschlag MR. 1998 Apr; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=105577
•
In Vitro Activity of ABT-773 against Legionella pneumophila, Its Pharmacokinetics in Guinea Pigs, and Its Use to Treat Guinea Pigs with L. pneumophila Pneumonia. by Edelstein PH, Higa F, Edelstein MA. 2001 Oct; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=90717
162 Pneumonia
•
In Vitro Activity of Gemifloxacin (SB-265805, LB20304a) against Legionella pneumophila and Its Pharmacokinetics in Guinea Pigs with L. pneumophila Pneumonia. by Edelstein PH, Shinzato T, Doyle E, Edelstein MA. 2001 Aug; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=90632
•
In Vitro Activity of Telithromycin (HMR3647), a New Ketolide, against Clinical Isolates of Mycoplasma pneumoniae in Japan. by Yamaguchi T, Hirakata Y, Izumikawa K, Miyazaki Y, Maesaki S, Tomono K, Yamada Y, Kamihira S, Kohno S. 2000 May; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=89878
•
In Vitro Activity of the Ketolide HMR 3647 (RU 6647) for Legionella spp., Its Pharmacokinetics in Guinea Pigs, and Use of the Drug To Treat Guinea Pigs with Legionella pneumophila Pneumonia. by Edelstein PH, Edelstein MA. 1999 Jan; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=89026
•
In Vitro and In Vivo Efficacies of T-3811ME (BMS-284756) against Mycoplasma pneumoniae. by Takahata M, Shimakura M, Hori R, Kizawa K, Todo Y, Minami S, Watanabe Y, Narita H. 2001 Jan; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=90281
•
In Vivo Activity and Pharmacokinetics of Ziracin (SCH27899), a New Long-Acting Everninomicin Antibiotic, in a Murine Model of Penicillin-Susceptible or PenicillinResistant Pneumococcal Pneumonia. by Wang E, Simard M, Bergeron Y, Beauchamp D, Bergeron MG. 2000 Apr; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=89806
•
In Vivo Efficacies of Combinations of [beta]-Lactams, [beta]-Lactamase Inhibitors, and Rifampin against Acinetobacter baumannii in a Mouse Pneumonia Model. by Wolff M, Joly-Guillou ML, Farinotti R, Carbon C. 1999 Jun; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=89287
•
In Vivo Penicillin MIC Drift to Extremely High Resistance in Serotype 14 Streptococcus pneumoniae Persistently Colonizing the Nasopharynx of an Infant with Chronic Suppurative Lung Disease: a Case Study. by Leach AJ, Morris PS, SmithVaughan H, Mathews JD. 2002 Nov; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=128758
•
Incidence of Upper Respiratory Tract Mycoplasma pneumoniae Infections among Outpatients in Rhone-Alpes, France, during Five Successive Winter Periods. by Layani-Milon MP, Gras I, Valette M, Luciani J, Stagnara J, Aymard M, Lina B. 1999 Jun; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=84933
•
Increased Anionic Peptide Distribution and Intensity during Progression and Resolution of Bacterial Pneumonia. by Fales-Williams AJ, Gallup JM, Ramirez-Romero R, Brogden KA, Ackermann MR. 2002 Jan; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=119892
Studies 163
•
Increased Host Resistance against Pneumocystis carinii Pneumonia in [gamma][delta] T-Cell-Deficient Mice: Protective Role of Gamma Interferon and CD8 + T Cells. by Steele C, Zheng M, Young E, Marrero L, Shellito JE, Kolls JK. 2002 Sep; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=128275
•
Increased Virulence of a Fibronectin-Binding Protein Mutant of Staphylococcus aureus in a Rat Model of Pneumonia. by McElroy MC, Cain DJ, Tyrrell C, Foster TJ, Haslett C. 2002 Jul; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=128079
•
Indirect Enzyme-Linked Immunosorbent Assay for Detection of Immunoglobulin G Reactive with a Recombinant Protein Expressed from the Gene Encoding the 116Kilodalton Protein of Mycoplasma pneumoniae. by Duffy MF, Whithear KG, Noormohammadi AH, Markham PF, Catton M, Leydon J, Browning GF. 1999 Apr; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=88644
•
Induction of Fibrinogen Expression in the Lung Epithelium during Pneumocystis carinii Pneumonia. by Simpson-Haidaris PJ, Courtney MA, Wright TW, Goss R, Harmsen A, Gigliotti F. 1998 Sep; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=108536
•
Infectivity-Neutralizing and Hemagglutinin-Inhibiting Antibody Responses to Respiratory Coronavirus Infections of Cattle in Pathogenesis of Shipping Fever Pneumonia. by Lin X, O'Reilly KL, Burrell ML, Storz J. 2001 Mar; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=96063
•
Inflammatory myopathy, bronchiolitis obliterans/organizing pneumonia, and anti-Jo1 antibodies--an interesting association. by Kalenian M, Zweiman B. 1997 Mar; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=170510
•
Influence of Cefodizime on Pulmonary Inflammatory Response to Heat-Killed Klebsiella pneumoniae in Mice. by Bergeron Y, Deslauriers AM, Ouellet N, Gauthier MC, Bergeron MG. 1999 Sep; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=89463
•
Interaction between Mycoplasma hyopneumoniae and Swine Influenza Virus. by Thacker EL, Thacker BJ, Janke BH. 2001 Jul; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=88180
•
Interleukin-10 Gene Therapy-Mediated Amelioration of Bacterial Pneumonia. by Morrison DF, Foss DL, Murtaugh MP. 2000 Aug; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=98427
•
Intracellular Trafficking and Killing of Streptococcus pneumoniae by Human Alveolar Macrophages Are Influenced by Opsonins. by Gordon SB, Irving GR, Lawson RA, Lee ME, Read RC. 2000 Apr; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=97415
164 Pneumonia
•
Intransal or intragastric immunization with proteosome-Shigella lipopolysaccharide vaccines protects against lethal pneumonia in a murine model of Shigella infection. by Mallett CP, Hale TL, Kaminski RW, Larsen T, Orr N, Cohen D, Lowell GH. 1995 Jun; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=173317
•
Intrapulmonary Delivery of Tumor Necrosis Factor Agonist Peptide Augments Host Defense in Murine Gram-Negative Bacterial Pneumonia. by Laichalk LL, Bucknell KA, Huffnagle GB, Wilkowski JM, Moore TA, Romanelli RJ, Standiford TJ. 1998 Jun; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=108277
•
Intrapulmonary Expression of Macrophage Inflammatory Protein 1[alpha] (CCL3) Induces Neutrophil and NK Cell Accumulation and Stimulates Innate Immunity in Murine Bacterial Pneumonia. by Zeng X, Moore TA, Newstead MW, HernandezAlcoceba R, Tsai WC, Standiford TJ. 2003 Mar; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=148850
•
Isolation and Characterization of H4N6 Avian Influenza Viruses from Pigs with Pneumonia in Canada. by Karasin AI, Brown IH, Carman S, Olsen CW. 2000 Oct 1; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=102133
•
Ketolide Treatment of Haemophilus influenzae Experimental Pneumonia. by Piper KE, Rouse MS, Steckelberg JM, Wilson WR, Patel R. 1999 Mar; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=89190
•
Kinetic Study of the Inflammatory Response in Streptococcus pneumoniae Experimental Pneumonia Treated with the Ketolide HMR 3004. by Duong M, Simard M, Bergeron Y, Bergeron MG. 2001 Jan; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=90269
•
Lack of Protection in Mice and Necrotizing Bronchointerstitial Pneumonia with Bronchiolitis in Guinea Pigs Immunized with Vaccines Directed against the hsp60 Molecule of Mycobacterium tuberculosis. by Turner OC, Roberts AD, Frank AA, Phalen SW, McMurray DM, Content J, Denis O, D'Souza S, Tanghe A, Huygen K, Orme IM. 2000 Jun; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=97658
•
Large-Scale Identification of Virulence Genes from Streptococcus pneumoniae. by Polissi A, Pontiggia A, Feger G, Altieri M, Mottl H, Ferrari L, Simon D. 1998 Dec; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=108710
•
Leukotriene B4 Augments Neutrophil Phagocytosis of Klebsiella pneumoniae. by Mancuso P, Nana-Sinkam P, Peters-Golden M. 2001 Apr; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=98124
•
Levels of azithromycin and alpha-1 acid glycoprotein in serum in patients with community-acquired pneumonia. by Bohte R, Mattie H, van den Broek PJ. 1995 Dec; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=163034
Studies 165
•
Lumbar Vertebral Osteomyelitis with Mycotic Abdominal Aortic Aneurysm Caused by Highly Penicillin-Resistant Streptococcus pneumoniae. by Naktin J, DeSimone J. 1999 Dec; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=85926
•
Macrophage Inflammatory Protein 1[alpha]/CCL3 Is Required for Clearance of an Acute Klebsiella pneumoniae Pulmonary Infection. by Lindell DM, Standiford TJ, Mancuso P, Leshen ZJ, Huffnagle GB. 2001 Oct; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=98771
•
Management of Infections Due to Antibiotic-Resistant Streptococcus pneumoniae. by Kaplan SL, Mason EO Jr. 1998 Oct; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=88901
•
Measurement of sputum antibodies in the diagnosis of acute and chronic respiratory infections associated with Chlamydia pneumoniae. by von Hertzen L, Leinonen M, Surcel HM, Karjalainen J, Saikku P. 1995 Jul; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=170178
•
Microbiologic Efficacy of Azithromycin and Susceptibilities to Azithromycin of Isolates of Chlamydia pneumoniae from Adults and Children with CommunityAcquired Pneumonia. by Roblin PM, Hammerschlag MR. 1998 Jan; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=105482
•
Microbiological Efficacy of Levofloxacin for Treatment of Community-Acquired Pneumonia Due to Chlamydia pneumoniae. by Hammerschlag MR, Roblin PM. 2000 May; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=89886
•
Modeling the response of pneumonia to antimicrobial therapy. by Hyatt JM, Luzier AB, Forrest A, Ballow CH, Schentag JJ. 1997 Jun; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=163898
•
Molecular Analysis of the Contribution of the Capsular Polysaccharide and the Lipopolysaccharide O Side Chain to the Virulence of Klebsiella pneumoniae in a Murine Model of Pneumonia. by Cortes G, Borrell N, de Astorza B, Gomez C, Sauleda J, Alberti S. 2002 May; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=127904
•
Molecular Approaches to Diagnosis of Pulmonary Diseases Due to Mycoplasma pneumoniae. by Abele-Horn M, Busch U, Nitschko H, Jacobs E, Bax R, Pfaff F, Schaffer B, Heesemann J. 1998 Feb; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=104575
166 Pneumonia
•
Molecular characterization of a ribonucleotide reductase (nrdF) gene fragment of Mycoplasma hyopneumoniae and assessment of the recombinant product as an experimental vaccine for enzootic pneumonia. by Fagan PK, Djordjevic SP, Eamens GJ, Chin J, Walker MJ. 1996 Mar; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=173882
•
Molecular Characterization of Equine Isolates of Streptococcus pneumoniae: Natural Disruption of Genes Encoding the Virulence Factors Pneumolysin and Autolysin. by Whatmore AM, King SJ, Doherty NC, Sturgeon D, Chanter N, Dowson CG. 1999 Jun; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=96581
•
Molecular Detection of Mycoplasma pneumoniae in Adults with CommunityAcquired Pneumonia Requiring Hospitalization. by Dorigo-Zetsma JW, Verkooyen RP, van Helden HP, van der Nat H, van den Bosch JM. 2001 Mar; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=87901
•
Molecular Epidemiology of Penicillin-Resistant Streptococcus pneumoniae Isolates Recovered in Italy from 1993 to 1996. by Marchese A, Ramirez M, Schito GC, Tomasz A. 1998 Oct; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=105092
•
Molecular Evolution of Mycoplasma capricolum subsp. capripneumoniae Strains, Based on Polymorphisms in the 16S rRNA Genes. by Pettersson B, Bolske G, Thiaucourt F, Uhlen M, Johansson KE. 1998 May 1; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=107175
•
Monitoring of co-trimoxazole concentrations in serum during treatment of pneumocystis carinii pneumonia. by Joos B, Blaser J, Opravil M, Chave JP, Luthy R. 1995 Dec; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=163008
•
Monodrug efficacies of sulfonamides in prophylaxis for Pneumocystis carinii pneumonia. by Hughes WT, Killmar J. 1996 Apr; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=163239
•
Moxifloxacin for Community-Acquired Pneumonia. by Rijnders BJ. 2003 Jan; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=149037
•
Murine Model of Interstitial Cytomegalovirus Pneumonia in Syngeneic Bone Marrow Transplantation: Persistence of Protective Pulmonary CD8-T-Cell Infiltrates after Clearance of Acute Infection. by Podlech J, Holtappels R, Pahl-Seibert MF, Steffens HP, Reddehase MJ. 2000 Aug 15; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=112270
Studies 167
•
Mycoplasma hyopneumoniae Potentiation of Porcine Reproductive and Respiratory Syndrome Virus-Induced Pneumonia. by Thacker EL, Halbur PG, Ross RF, Thanawongnuwech R, Thacker BJ. 1999 Mar; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=84495
•
Mycoplasma pneumoniae Induces Chronic Respiratory Infection, Airway Hyperreactivity, and Pulmonary Inflammation: a Murine Model of InfectionAssociated Chronic Reactive Airway Disease. by Hardy RD, Jafri HS, Olsen K, Hatfield J, Iglehart J, Rogers BB, Patel P, Cassell G, McCracken GH, Ramilo O. 2002 Feb; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=127700
•
Mycoplasma pneumoniae P1 Type 1- and Type 2-Specific Sequences within the P1 Cytadhesin Gene of Individual Strains. by Dorigo-Zetsma JW, Wilbrink B, Dankert J, Zaat SA. 2001 Sep; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=98676
•
Naturally acquired Pneumocystis carinii pneumonia in gene disruption mutant mice: roles of distinct T-cell populations in infection. by Hanano R, Reifenberg K, Kaufmann SH. 1996 Aug; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=174208
•
Nitric oxide is required for effective innate immunity against Klebsiella pneumoniae. by Tsai WC, Strieter RM, Zisman DA, Wilkowski JM, Bucknell KA, Chen GH, Standiford TJ. 1997 May; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=175233
•
Noncompromised penicillin-resistant pneumococcal pneumonia CBA/J mouse model and comparative efficacies of antibiotics in this model. by Tateda K, Takashima K, Miyazaki H, Matsumoto T, Hatori T, Yamaguchi K. 1996 Jun; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=163360
•
Nosocomial Pneumonia Caused by Three Genetically Different Strains of Legionella pneumophila and Detection of These Strains in the Hospital Water Supply. by Luck PC, Wenchel HM, Helbig JH. 1998 Apr; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=104714
•
Novel Genes Affecting Urease Activity in Actinobacillus pleuropneumoniae. by Bosse JT, Gilmour HD, MacInnes JI. 2001 Feb 15; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=94997
•
Number of specific antibody-secreting cells in the peripheral blood among children with mycoplasma pneumonia. by Iseki M, Takahashi T, Kimura K, Yamashita R, Sasaki T. 1996 Jul; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=174142
168 Pneumonia
•
Ofloxacin versus standard therapy in treatment of community-acquired pneumonia requiring hospitalization. Pneumonia Study Group. by Plouffe JF, Herbert MT, File TM Jr, Baird I, Parsons JN, Kahn JB, Rielly-Gauvin KT. 1996 May; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=163286
•
Optimizing Aminoglycoside Therapy for Nosocomial Pneumonia Caused by GramNegative Bacteria. by Kashuba AD, Nafziger AN, Drusano GL, Bertino JS Jr. 1999 Mar; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=89170
•
Oral immunization of pigs with viable or inactivated Actinobacillus pleuropneumoniae serotype 9 induces pulmonary and systemic antibodies and protects against homologous aerosol challenge. by Hensel A, Stockhofe-Zurwieden N, Petzoldt K, Lubitz W. 1995 Aug; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=173415
•
Passive Intranasal Monoclonal Antibody Prophylaxis against Murine Pneumocystis carinii Pneumonia. by Gigliotti F, Haidaris CG, Wright TW, Harmsen AG. 2002 Mar; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=127758
•
Pathogenesis of Influenza Virus-Induced Pneumonia: Involvement of Both Nitric Oxide and Oxygen Radicals. by Akaike T, Noguchi Y, Ijiri S, Setoguchi K, Suga M, Zheng YM, Dietzschold B, Maeda H. 1996 Mar 19; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=39817
•
Pathogenesis of Pneumococcal Pneumonia in Cyclophosphamide-Induced Leukopenia in Mice. by Wang E, Simard M, Ouellet N, Bergeron Y, Beauchamp D, Bergeron MG. 2002 Aug; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=128150
•
Patterns of Macrolide Resistance Determinants among Community-Acquired Streptococcus pneumoniae Isolates over a 5-Year Period of Decreased Macrolide Susceptibility Rates. by Oster P, Zanchi A, Cresti S, Lattanzi M, Montagnani F, Cellesi C, Rossolini GM. 1999 Oct; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=89509
•
Performance of Five Serological Assays for Diagnosis of Rhodococcus equi Pneumonia in Foals. by Giguere S, Hernandez J, Gaskin J, Prescott JF, Takai S, Miller C. 2003 Mar; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=150531
•
Pharmacodynamic Activity and Efficacy of Linezolid in a Rat Model of Pneumococcal Pneumonia. by Gentry-Nielsen MJ, Olsen KM, Preheim LC. 2002 May; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=127197
Studies 169
•
Pharmacodynamic Assessment of Clarithromycin in a Murine Model of Pneumococcal Pneumonia. by Tessier PR, Kim MK, Zhou W, Xuan D, Li C, Ye M, Nightingale CH, Nicolau DP. 2002 May; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=127127
•
Pharmacodynamics of Trovafloxacin, Ofloxacin, and Ciprofloxacin against Streptococcus pneumoniae in an In Vitro Pharmacokinetic Model. by Lister PD, Sanders CC. 1999 May; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=89120
•
Phase I study of intravenous ribavirin treatment of respiratory syncytial virus pneumonia after marrow transplantation. by Lewinsohn DM, Bowden RA, Mattson D, Crawford SW. 1996 Nov; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=163574
•
Pneumococcal Behavior and Host Responses during Bronchopneumonia Are Affected Differently by the Cytolytic and Complement-Activating Activities of Pneumolysin. by Jounblat R, Kadioglu A, Mitchell TJ, Andrew PW. 2003 Apr; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=152068
•
Pneumocystis carinii f. sp. hominis DNA in Immunocompetent Health Care Workers in Contact with Patients with P. carinii Pneumonia. by Miller RF, Ambrose HE, Wakefield AE. 2001 Nov; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=88458
•
Pneumocystis carinii pneumonia in scid mice induced by viable organisms propagated in vitro. by Beck JM, Newbury RL, Palmer BE. 1996 Nov; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=174425
•
Pneumonia Due to Bordetella bronchiseptica in a Cystic Fibrosis Patient: 16S rRNA Sequencing for Diagnosis Confirmation. by Wallet F, Perez T, Armand S, Wallaert B, Courcol RJ. 2002 Jun; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=130795
•
Prevalence of Chlamydia pneumoniae and Mycoplasma pneumoniae Immunoglobulin G and A Antibodies in a Healthy Finnish Population as Analyzed by Quantitative Enzyme Immunoassays. by Tuuminen T, Varjo S, Ingman H, Weber T, Oksi J, Viljanen M. 2000 Sep; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=95947
•
Prevalence of Specific Antibodies to Chlamydia pneumoniae in Korea. by Choi TY, Kim DA, Kim SK, Kang JO, Park SS, Jung SR. 1998 Nov; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=105350
•
Prevention of influenza and pneumococcal pneumonia in Canadian long-term care facilities: How are we doing? by Stevenson CG, McArthur MA, Naus M, Abraham E, McGeer AJ. 2001 May 15; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=81067
170 Pneumonia
•
Prospective Randomized Comparison of Imipenem-Cilastatin and PiperacillinTazobactam in Nosocomial Pneumonia or Peritonitis. by Jaccard C, Troillet N, Harbarth S, Zanetti G, Aymon D, Schneider R, Chiolero R, Ricou B, Romand J, Huber O, Ambrosetti P, Praz G, Lew D, Bille J, Glauser MP, Cometta A. 1998 Nov; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=105974
•
Protection against Fatal Pseudomonas aeruginosa Pneumonia in Mice after Nasal Immunization with a Live, Attenuated aroA Deletion Mutant. by Priebe GP, Meluleni GJ, Coleman FT, Goldberg JB, Pier GB. 2003 Mar; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=148856
•
Protection against Pneumocystis carinii pneumonia by antibodies generated from either T helper 1 or T helper 2 responses. by Garvy BA, Wiley JA, Gigliotti F, Harmsen AG. 1997 Dec; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=175728
•
Pulmonary and Systemic Host Response to Streptococcus pneumoniae and Klebsiella pneumoniae Bacteremia in Normal and Immunosuppressed Mice. by Wang E, Ouellet N, Simard M, Fillion I, Bergeron Y, Beauchamp D, Bergeron MG. 2001 Sep; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=98638
•
Pulmonary Inflammation Disrupts Surfactant Function during Pneumocystis carinii Pneumonia. by Wright TW, Notter RH, Wang Z, Harmsen AG, Gigliotti F. 2001 Feb; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=97949
•
Quantitative Detection of Respiratory Chlamydia pneumoniae Infection by RealTime PCR. by Kuoppa Y, Boman J, Scott L, Kumlin U, Eriksson I, Allard A. 2002 Jun; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=130697
•
Quantitative Detection of Streptococcus pneumoniae in Nasopharyngeal Secretions by Real-Time PCR. by Greiner O, Day PJ, Bosshard PP, Imeri F, Altwegg M, Nadal D. 2001 Sep; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=88308
•
Randomized Controlled Trial of Sequential Intravenous (i.v.) and Oral Moxifloxacin Compared with Sequential i.v. and Oral Co-Amoxiclav with or without Clarithromycin in Patients with Community-Acquired Pneumonia Requiring Initial Parenteral Treatment. by Finch R, Schurmann D, Collins O, Kubin R, McGivern J, Bobbaers H, Izquierdo JL, Nikolaides P, Ogundare F, Raz R, Zuck P, Hoeffken G. 2002 Jun; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=127227
•
Rapid-Cycle PCR for Detection and Typing of Mycoplasma pneumoniae in Clinical Specimens. by Kong F, Gordon S, Gilbert GL. 2000 Nov; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=87576
Studies 171
•
Recurrent pneumonia with mild hypogammaglobulinemia diagnosed as X-linked agammaglobulinemia in adults. by Usui K, Sasahara Y, Tazawa R, Hagiwara K, Tsukada S, Miyawaki T, Tsuchiya S, Nukiwa T. 2001; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=56209
•
Reduction by Cefodizime of the Pulmonary Inflammatory Response Induced by Heat-Killed Streptococcus pneumoniae in Mice. by Bergeron Y, Ouellet N, Deslauriers AM, Simard M, Olivier M, Bergeron MG. 1998 Oct; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=105879
•
Relationship between Capsular Type, Penicillin Susceptibility, and Virulence of Human Streptococcus pneumoniae Isolates in Mice. by Azoulay-Dupuis E, Rieux V, Muffat-Joly M, Bedos JP, Vallee E, Rivier C, Isturiz R, Carbon C, Moine P. 2000 Jun; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=89915
•
Relevance of Chlamydia pneumoniae murine pneumonitis model to evaluation of antimicrobial agents. by Masson ND, Toseland CD, Beale AS. 1995 Sep; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=162863
•
Response of rat model of Pneumocystis carinii pneumonia to continuous infusion of deferoxamine. by Merali S, Chin K, Grady RW, Weissberger L, Clarkson AB Jr. 1995 Jul; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=162759
•
Role of Alveolar Macrophages in Initiation and Regulation of Inflammation in Pseudomonas aeruginosa Pneumonia. by Kooguchi K, Hashimoto S, Kobayashi A, Kitamura Y, Kudoh I, Wiener-Kronish J, Sawa T. 1998 Jul; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=108328
•
Role of Early Genes in Pathogenesis of Adenovirus Pneumonia. by Ginsberg HS, Horswood RL, Chanock RM, Prince GA. 1990 Aug 15; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=54498
•
Role of gamma interferon in the pathogenesis of bacteremic pneumococcal pneumonia. by Rubins JB, Pomeroy C. 1997 Jul; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=175417
•
Role of Lung Epithelial Cells in Defense against Klebsiella pneumoniae Pneumonia. by Cortes G, Alvarez D, Saus C, Alberti S. 2002 Mar; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=127765
•
Role of Pneumococcal Surface Protein C in Nasopharyngeal Carriage and Pneumonia and Its Ability To Elicit Protection against Carriage of Streptococcus pneumoniae. by Balachandran P, Brooks-Walter A, Virolainen-Julkunen A, Hollingshead SK, Briles DE. 2002 May; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=127914
172 Pneumonia
•
Role of putative virulence factors of Streptococcus pyogenes in mouse models of long-term throat colonization and pneumonia. by Husmann LK, Yung DL, Hollingshead SK, Scott JR. 1997 Apr; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=175149
•
Role of tumor necrosis factor alpha in pathogenesis of pneumococcal pneumonia in mice. by Takashima K, Tateda K, Matsumoto T, Iizawa Y, Nakao M, Yamaguchi K. 1997 Jan; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=174584
•
Safety and toxicity of amphotericin B in glucose 5% or intralipid 20% in neutropenic patients with pneumonia or fever of unknown origin: randomised study. by Schoffski P, Freund M, Wunder R, Petersen D, Kohne CH, Hecker H, Schubert U, Ganser A. 1998 Aug 8; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=28631
•
Sensitive and Specific Method for Rapid Identification of Streptococcus pneumoniae Using Real-Time Fluorescence PCR. by McAvin JC, Reilly PA, Roudabush RM, Barnes WJ, Salmen A, Jackson GW, Beninga KK, Astorga A, McCleskey FK, Huff WB, Niemeyer D, Lohman KL. 2001 Oct; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=88370
•
Serum Cytokines in Patients with Legionella Pneumonia: Relative Predominance of Th1-Type Cytokines. by Tateda K, Matsumoto T, Ishii Y, Furuya N, Ohno A, Miyazaki S, Yamaguchi K. 1998 May; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=104531
•
Should Pseudomonas aeruginosa isolates resistant to one of the fluorinated quinolones be tested for the others? Studies with an experimental model of pneumonia. by Chidiac C, Roussel-Delvallez M, Guery B, Beaucaire G. 1995 Mar; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=162604
•
Significant Role of Interleukin-8 in Pathogenesis of Pulmonary Disease Due to Mycoplasma pneumoniae Infection. by Narita M, Tanaka H, Yamada S, Abe S, Ariga T, Sakiyama Y. 2001 Sep; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=96192
•
Species-Specific Monoclonal Antibodies to Escherichia coli-Expressed p36 Cytosolic Protein of Mycoplasma hyopneumoniae. by Caron J, Sawyer N, Moumen BB, Bouh KC, Dea S. 2000 Jul; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=95908
•
Successful treatment of Pneumocystis carinii Pneumonia in mice with benanomicin A (ME1451). by Yasuoka A, Oka S, Komuro K, Shimizu H, Kitada K, Nakamura Y, Shibahara S, Takeuchi T, Kondo S, Shimada K. 1995 Mar; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=162611
•
Synergy between amoxicillin and gentamicin in combination against a highly penicillin-resistant and -tolerant strain of Streptococcus pneumoniae in a mouse
Studies 173
pneumonia model. by Darras-Joly C, Bedos JP, Sauve C, Moine P, Vallee E, Carbon C, Azoulay-Dupuis E. 1996 Sep; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=163489 •
T- and B-lymphocyte-independent formation of alveolar macrophage-derived multinucleated giant cells in murine Pneumocystis carinii pneumonia. by Hanano R, Reifenberg K, Kaufmann SH. 1996 Jul; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=174147
•
Therapeutic Effect of Anti-Macrophage Inflammatory Protein 2 Antibody on Influenza Virus-Induced Pneumonia in Mice. by Sakai S, Kawamata H, Mantani N, Kogure T, Shimada Y, Terasawa K, Sakai T, Imanishi N, Ochiai H. 2000 Mar 1; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=111734
•
Therapeutic Effects of Water-Soluble Echinocandin Compounds on Pneumocystis Pneumonia in Mice. by Furuta T, Muramatsu H, Fujie A, Fujihira S, Rain Abudullah N, Kojima S. 1998 Jan; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=105452
•
Therapeutic Efficacy of Liposome-Encapsulated Gentamicin in Rat Klebsiella pneumoniae Pneumonia in Relation to Impaired Host Defense and Low Bacterial Susceptibility to Gentamicin. by Schiffelers RM, Storm G, ten Kate MT, BakkerWoudenberg IA. 2001 Feb; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=90314
•
Toll-Like Receptor 4-Positive Macrophages Protect Mice from Pasteurella pneumotropica-Induced Pneumonia. by Hart ML, Mosier DA, Chapes SK. 2003 Feb; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=145384
•
Transmission of Pneumocystis carinii DNA from a Patient with P. carinii Pneumonia to Immunocompetent Contact Health Care Workers. by Vargas SL, A. Ponce C, Gigliotti F, Ulloa AV, Prieto S, Munoz MP, Hughes WT. 2000 Apr; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=86483
•
Treatment of experimental pneumonia due to penicillin-resistant Streptococcus pneumoniae in immunocompetent rats. by Gavalda J, Capdevila JA, Almirante B, Otero J, Ruiz I, Laguarda M, Allende H, Crespo E, Pigrau C, Pahissa A. 1997 Apr; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=163797
•
Treatment of Pneumocystis carinii Pneumonia with 1,3-[beta]-Glucan Synthesis Inhibitors. by Schmatz DM, Romancheck MA, Pittarelli LA, Schwartz RE, Fromtling RA, Nollstadt KH, Vanmiddlesworth FL, Wilson KE, Turner MJ. 1990 Aug 1; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=54447
174 Pneumonia
•
Trophozoite elimination in a rat model of Pneumocystis carinii pneumonia by clinically achievable plasma deferoxamine concentrations. by Merali S, Chin K, Grady RW, Clarkson AB Jr. 1996 May; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=163314
•
Trovafloxacin Concentrations in Airway Fluids of Patients with Severe CommunityAcquired Pneumonia. by Peleman RA, Van De Velde V, Germonpre PR, Fleurinck C, Rosseel MT, Pauwels RA. 2000 Jan; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=89648
•
Tumor necrosis factor mediates lung antibacterial host defense in murine Klebsiella pneumonia. by Laichalk LL, Kunkel SL, Strieter RM, Danforth JM, Bailie MB, Standiford TJ. 1996 Dec; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=174510
•
Two Actinobacillus pleuropneumoniae Serotype 8 Reference Strains in Circulation. by Gram T, Ahrens P, Angen O. 2000 Jan; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=88757
•
Two Pharmacodynamic Models for Assessing the Efficacy of Amoxicillin-Clavulanate against Experimental Respiratory Tract Infections Caused by Strains of Streptococcus pneumoniae. by Woodnutt G, Berry V. 1999 Jan; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=89016
•
Use of a critical pathway for the management of community-acquired pneumonia: the CAPITAL study. by Farquhar D. 2000 Sep 19; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=80189
•
Use of a new mouse model of Acinetobacter baumannii pneumonia to evaluate the postantibiotic effect of imipenem. by Joly-Guillou ML, Wolff M, Pocidalo JJ, Walker F, Carbon C. 1997 Feb; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=163712
•
Use of Terbinafine in Mouse and Rat Models of Pneumocystis carinii Pneumonia. by Walzer PD, Ashbaugh A. 2002 Feb; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=127063
•
Usefulness of PCR and Antigen Latex Agglutination Test with Samples Obtained by Transthoracic Needle Aspiration for Diagnosis of Pneumococcal Pneumonia. by Garcia A, Roson B, Perez JL, Verdaguer R, Dorca J, Carratala J, Casanova A, Manresa F, Gudiol F. 1999 Mar; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=84531
•
Vaccination and Protection of Pigs against Pleuropneumonia with a Vaccine Strain of Actinobacillus pleuropneumoniae Produced by Site-Specific Mutagenesis of the ApxII Operon. by Prideaux CT, Lenghaus C, Krywult J, Hodgson AL. 1999 Apr; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=96553
Studies 175
•
Validation of Immune-Complex Enzyme Immunoassays for Diagnosis of Pneumococcal Pneumonia among Adults in Kenya. by Scott JA, Hall AJ, Leinonen M. 2000 Jan; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=95824
•
Ventilator-associated pneumonia in a surgical intensive care unit: epidemiology, etiology and comparison of three bronchoscopic methods for microbiological specimen sampling. by Woske HJ, Roding T, Schulz I, Lode H. 2001; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=31581
•
Western blot analysis of antibody response to pneumococcal protein antigens in a murine model of pneumonia. by Mouneimne H, Juvin M, Beretti JL, Azoulay-Dupuis E, Vallee E, Geslin P, Petitpretz P, Berche P, Gaillard JL. 1997 Nov; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=exter nal&artid=170658
The National Library of Medicine: PubMed One of the quickest and most comprehensive ways to find academic studies in both English and other languages is to use PubMed, maintained by the National Library of Medicine.6 The advantage of PubMed over previously mentioned sources is that it covers a greater number of domestic and foreign references. It is also free to use. If the publisher has a Web site that offers full text of its journals, PubMed will provide links to that site, as well as to sites offering other related data. User registration, a subscription fee, or some other type of fee may be required to access the full text of articles in some journals. To generate your own bibliography of studies dealing with pneumonia, simply go to the PubMed Web site at http://www.ncbi.nlm.nih.gov/pubmed. Type “pneumonia” (or synonyms) into the search box, and click “Go.” The following is the type of output you can expect from PubMed for pneumonia (hyperlinks lead to article summaries): •
A 12-year-old girl with asthma, pneumonia, and pneumatoceles. Author(s): Tahzib MN, Schuval SJ. Source: Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology. 2003 May; 90(5): 480-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12775128&dopt=Abstract
•
A 22-year-old woman with fulminant Chlamydia pneumoniae pneumonia. Author(s): Ikeda K, Mita M, Yamaki T, Maehara K, Maruyama Y. Source: Fukushima J Med Sci. 2002 June; 48(1): 57-62. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12365599&dopt=Abstract
6
PubMed was developed by the National Center for Biotechnology Information (NCBI) at the National Library of Medicine (NLM) at the National Institutes of Health (NIH). The PubMed database was developed in conjunction with publishers of biomedical literature as a search tool for accessing literature citations and linking to full-text journal articles at Web sites of participating publishers. Publishers that participate in PubMed supply NLM with their citations electronically prior to or at the time of publication.
176 Pneumonia
•
A case of Pneumocystis pneumonia in an HIV-negative patient. Author(s): Kim AC, Gonzalez C, Holzman RS. Source: The Journal of Infection. 2003 August; 47(2): 176-80. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12860156&dopt=Abstract
•
A case of primary tularemic pneumonia presenting with necrotizing mediastinal and hilar lymph nodes. Author(s): Valipour A, Koller H, Kreuzer A, Kossler W, Csokay A, Burghuber OC. Source: Wiener Klinische Wochenschrift. 2003 March 31; 115(5-6): 196-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12741082&dopt=Abstract
•
A child with severe pneumonia, pleural effusion and acute hypoalbuminemia. Author(s): Porat S, Bhatia N, Barnett DW. Source: Clinical Pediatrics. 2002 April; 41(3): 199-200. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11999686&dopt=Abstract
•
A comparison of cefditoren pivoxil and amoxicillin/ clavulanate in the treatment of community-acquired pneumonia: a multicenter, prospective, randomized, investigator-blinded, parallel-group study. Author(s): Fogarty CM, Cyganowski M, Palo WA, Hom RC, Craig WA. Source: Clinical Therapeutics. 2002 November; 24(11): 1854-70. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12501879&dopt=Abstract
•
A comparison of 'cough and cold' and pneumonia: risk factors for pneumonia in children under 5 years revisited. Author(s): Fatmi Z, White F. Source: International Journal of Infectious Diseases : Ijid : Official Publication of the International Society for Infectious Diseases. 2002 December; 6(4): 294-301. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12718824&dopt=Abstract
•
A controlled, double-blind, multicenter study comparing clarithromycin extendedrelease tablets and levofloxacin tablets in the treatment of community-acquired pneumonia. Author(s): Gotfried MH, Dattani D, Riffer E, Devcich KJ, Busman TA, Notario GF, Palmer RN. Source: Clinical Therapeutics. 2002 May; 24(5): 736-51. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12075942&dopt=Abstract
•
A formula for prediction of posttraumatic pneumonia based on early anatomic and physiologic parameters. Author(s): Croce MA, Tolley EA, Fabian TC. Source: The Journal of Trauma. 2003 April; 54(4): 724-9; Discussion 729-30. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12707535&dopt=Abstract
Studies 177
•
A multicenter, open-label, randomized comparison of levofloxacin and azithromycin plus ceftriaxone in hospitalized adults with moderate to severe community-acquired pneumonia. Author(s): Frank E, Liu J, Kinasewitz G, Moran GJ, Oross MP, Olson WH, Reichl V, Freitag S, Bahal N, Wiesinger BA, Tennenberg A, Kahn JB. Source: Clinical Therapeutics. 2002 August; 24(8): 1292-308. Erratum In: Clin Ther. 2003 March; 25(3): 1039. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12240780&dopt=Abstract
•
A plasminogen activator inhibitor-1 promoter polymorphism and idiopathic interstitial pneumonia. Author(s): Kim KK, Flaherty KR, Long Q, Hattori N, Sisson TH, Colby TV, Travis WD, Martinez FJ, Murray S, Simon RH. Source: Molecular Medicine (Cambridge, Mass.). 2003 January-February; 9(1-2): 52-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12765340&dopt=Abstract
•
A position paper on the treatment of hospital acquired pneumonia (HAP): do we need guidelines? Author(s): Ramphal R. Source: Acta Clin Belg. 2002 July-August; 57(4): 202-6. Review. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12462796&dopt=Abstract
•
A prediction rule to identify allocation of inpatient care in community-acquired pneumonia. Author(s): Espana PP, Capelastegui A, Quintana JM, Soto A, Gorordo I, Garcia-Urbaneja M, Bilbao A. Source: The European Respiratory Journal : Official Journal of the European Society for Clinical Respiratory Physiology. 2003 April; 21(4): 695-701. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12762359&dopt=Abstract
•
A predictive model for the management of community-acquired pneumonia. Author(s): Raz R, Dyachenko P, Levy Y, Flatau E, Reichman N. Source: Infection. 2003 January; 31(1): 3-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12590325&dopt=Abstract
•
A prospective, double-blind, multicenter study comparing clarithromycin extendedrelease with trovafloxacin in patients with community-acquired pneumonia. Author(s): Sokol WN Jr, Sullivan JG, Acampora MD, Busman TA, Notario GF. Source: Clinical Therapeutics. 2002 April; 24(4): 605-15. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12017405&dopt=Abstract
178 Pneumonia
•
A prospective, randomized study of ventilator-associated pneumonia in patients using a closed vs. open suction system. Author(s): Zeitoun SS, de Barros AL, Diccini S. Source: Journal of Clinical Nursing. 2003 July; 12(4): 484-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12790861&dopt=Abstract
•
A prospective, randomized, double-blind multicenter comparison of parenteral ertapenem and ceftriaxone for the treatment of hospitalized adults with communityacquired pneumonia. Author(s): Vetter N, Cambronero-Hernandez E, Rohlf J, Simon S, Carides A, Oliveria T, Isaacs R; Protocol 020 Study Group. Source: Clinical Therapeutics. 2002 November; 24(11): 1770-85. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12501873&dopt=Abstract
•
A rapid staging system for predicting mortality from HIV-associated communityacquired pneumonia. Author(s): Arozullah AM, Parada J, Bennett CL, Deloria-Knoll M, Chmiel JS, Phan L, Yarnold PR. Source: Chest. 2003 April; 123(4): 1151-60. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12684306&dopt=Abstract
•
A standardized protocol for the treatment of severe pneumonia in kidney transplant recipients. Author(s): Sileri P, Pursell KJ, Coady NT, Giacomoni A, Berliti S, Tzoracoleftherakis E, Testa G, Benedetti E. Source: Clinical Transplantation. 2002 December; 16(6): 450-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12437626&dopt=Abstract
•
A study evaluating the efficacy, safety, and tolerability of ertapenem versus ceftriaxone for the treatment of community-acquired pneumonia in adults. Author(s): Ortiz-Ruiz G, Caballero-Lopez J, Friedland IR, Woods GL, Carides A; Protocol 018 Ertapenem Community-Acquired Pneumonia Study Group. Source: Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America. 2002 April 15; 34(8): 1076-83. Epub 2002 March 18. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11914996&dopt=Abstract
•
Acute community-acquired pneumonia in adults: guidelines for initial antimicrobial therapy based on local evidence from a South American working group (ConsenSur). Author(s): Bantar C, Bavestrello L, Curcio D, Jasovich A, Absi R, Bagnulo H, Famiglietti A, Garcia P, Labarca J, Mera J, Pedreira W, Sader H, Thompson L, Wey S; ConsenSur Group. Source: Journal of Chemotherapy (Florence, Italy). 2002 December; 14(6): 635-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12583558&dopt=Abstract
Studies 179
•
Acute community-acquired pneumonia in adults: guidelines for initial antimicrobial therapy based on local evidence from a South American Working Group (ConsenSur). Author(s): Bantar C, Bavestrello L, Curcio D, Jasovich A, Absi R, Bagnulo H, Famiglietti A, Garcia P, Labarca J, Mera J, Pedreira W, Sader H, Thompson L, Wey S; South American Working Group ConsenSur Group. Source: Journal of Chemotherapy (Florence, Italy). 2002 December; 14 Suppl 4: 1-22. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12680511&dopt=Abstract
•
Acute eosinophilic pneumonia associated with amitriptyline in a hemodialysis patient. Author(s): Noh H, Lee YK, Kan SW, Choi KH, Ha DS, Lee HY. Source: Yonsei Medical Journal. 2001 June; 42(3): 357-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11456405&dopt=Abstract
•
Acute eosinophilic pneumonia following cigarette smoking: a case report including cigarette-smoking challenge test. Author(s): Watanabe K, Fujimura M, Kasahara K, Yasui M, Myou S, Kita T, Watanabe A, Nakao S. Source: Intern Med. 2002 November; 41(11): 1016-20. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12487181&dopt=Abstract
•
Acute eosinophilic pneumonia in a New York City firefighter exposed to World Trade Center dust. Author(s): Rom WN, Weiden M, Garcia R, Yie TA, Vathesatogkit P, Tse DB, McGuinness G, Roggli V, Prezant D. Source: American Journal of Respiratory and Critical Care Medicine. 2002 September 15; 166(6): 797-800. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12231487&dopt=Abstract
•
Acute eosinophilic pneumonia with fine nodular shadows. Author(s): Abe K, Yanagi S, Imadsu Y, Sano A, Iiboshi H, Mukae H, Matsukura S. Source: Intern Med. 2003 January; 42(1): 88-91. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12583626&dopt=Abstract
•
Acute eosinophilic pneumonia: possible role of hyperreactivity of airway epithelial cells. Author(s): Takizawa H. Source: Intern Med. 2002 November; 41(11): 917. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12487158&dopt=Abstract
180 Pneumonia
•
Acute fibrinous and organizing pneumonia: a histological pattern of lung injury and possible variant of diffuse alveolar damage. Author(s): Beasley MB, Franks TJ, Galvin JR, Gochuico B, Travis WD. Source: Archives of Pathology & Laboratory Medicine. 2002 September; 126(9): 1064-70. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12204055&dopt=Abstract
•
Acute interstitial pneumonia: clues from the white stuff. Author(s): Hansell DM. Source: American Journal of Respiratory and Critical Care Medicine. 2002 June 1; 165(11): 1465-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12045115&dopt=Abstract
•
Acute interstitial pneumonia: report of a series. Author(s): Bonaccorsi A, Cancellieri A, Chilosi M, Trisolini R, Boaron M, Crimi N, Poletti V. Source: The European Respiratory Journal : Official Journal of the European Society for Clinical Respiratory Physiology. 2003 January; 21(1): 187-91. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12570127&dopt=Abstract
•
Acute stroke predisposes to oral gram-negative bacilli -- a cause of aspiration pneumonia? Author(s): Millns B, Gosney M, Jack CI, Martin MV, Wright AE. Source: Gerontology. 2003 May-June; 49(3): 173-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12679608&dopt=Abstract
•
Addition of a macrolide to a beta-lactam-based empirical antibiotic regimen is associated with lower in-hospital mortality for patients with bacteremic pneumococcal pneumonia. Author(s): Martinez JA, Horcajada JP, Almela M, Marco F, Soriano A, Garcia E, Marco MA, Torres A, Mensa J. Source: Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America. 2003 February 15; 36(4): 389-95. Epub 2003 January 31. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12567294&dopt=Abstract
•
Adult bacteremic pneumococcal pneumonia acquired in the community. A prospective study on 101 patients. Author(s): Gentile JH, Sparo MD, Mercapide ME, Luna CM. Source: Medicina (B Aires). 2003; 63(1): 9-14. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12673954&dopt=Abstract
Studies 181
•
Aerosolized ceftazidime for prevention of ventilator-associated pneumonia and drug effects on the proinflammatory response in critically ill trauma patients. Author(s): Wood GC, Boucher BA, Croce MA, Hanes SD, Herring VL, Fabian TC. Source: Pharmacotherapy. 2002 August; 22(8): 972-82. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12173800&dopt=Abstract
•
Aerosolized pentamidine prophylaxis for Pneumocystis carinii pneumonia after allogeneic marrow transplantation. Author(s): Marras TK, Sanders K, Lipton JH, Messner HA, Conly J, Chan CK. Source: Transplant Infectious Disease : an Official Journal of the Transplantation Society. 2002 June; 4(2): 66-74. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12220242&dopt=Abstract
•
Aetiology and outcome of severe community-acquired pneumonia in children admitted to a paediatric intensive care unit. Author(s): Delport SD, Brisley T. Source: South African Medical Journal. Suid-Afrikaanse Tydskrif Vir Geneeskunde. 2002 November; 92(11): 907-11. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12506595&dopt=Abstract
•
AIDS-related Pneumocystis carinii pneumonia with disappearance of cystic lesions after treatment. Author(s): Konishi M, Amimoto M, Yoshimoto E, Takahashi K, Mori K, Mikasa K, Narita N. Source: Intern Med. 2002 October; 41(10): 896-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12413019&dopt=Abstract
•
Alveolar and serum oxidative stress in ventilator-associated pneumonia. Author(s): Duflo F, Debon R, Goudable J, Chassard D, Allaouchiche B. Source: British Journal of Anaesthesia. 2002 August; 89(2): 231-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12378658&dopt=Abstract
•
Amoeba-resisting bacteria and ventilator-associated pneumonia. Author(s): La Scola B, Boyadjiev I, Greub G, Khamis A, Martin C, Raoult D. Source: Emerging Infectious Diseases. 2003 July; 9(7): 815-21. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12890321&dopt=Abstract
182 Pneumonia
•
An economic evaluation of sequential i.v./po moxifloxacin therapy compared to i.v./po co-amoxiclav with or without clarithromycin in the treatment of communityacquired pneumonia. Author(s): Drummond MF, Becker DL, Hux M, Chancellor JV, Duprat-Lomon I, Kubin R, Sagnier PP. Source: Chest. 2003 August; 124(2): 526-35. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12907538&dopt=Abstract
•
An elderly patient with hemophagocytic syndrome due to severe mycoplasma pneumonia with marked hypercytokinemia. Author(s): Mizukane R, Kadota Ji J, Yamaguchi T, Kiya T, Fukushima H, Nakatomi M, Kohno S. Source: Respiration; International Review of Thoracic Diseases. 2002; 69(1): 87-91. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11844970&dopt=Abstract
•
An empirical approach to the treatment of multidrug-resistant ventilator-associated pneumonia. Author(s): Kollef MH. Source: Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America. 2003 May 1; 36(9): 1119-21. Epub 2003 April 14. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12715305&dopt=Abstract
•
An intervention to improve antibiotic delivery and sputum procurement in patients hospitalized with community-acquired pneumonia. Author(s): Lawrence SJ, Shadel BN, Leet TL, Hall JB, Mundy LM. Source: Chest. 2002 September; 122(3): 913-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12226032&dopt=Abstract
•
An outbreak of pneumococcal pneumonia among military personnel at high risk: control by low-dose azithromycin postexposure chemoprophylaxis. Author(s): Sanchez JL, Craig SC, Kolavic S, Hastings D, Alsip BJ, Gray GC, Hudspeth MK, Ryan MA. Source: Military Medicine. 2003 January; 168(1): 1-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12546236&dopt=Abstract
•
An unusual case of nonspecific interstitial pneumonia treated initially with surgical resection. Author(s): Kor AC, Chan CC, Kaw G, Yap WM. Source: Singapore Med J. 2002 June; 43(6): 314-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12380731&dopt=Abstract
Studies 183
•
An unusual case of pneumonia. Author(s): Mangoni AA, Desai SR, Shaikh H, Barker RD, Mufti GJ, Jackson SH. Source: Int J Clin Pract. 2003 March; 57(2): 153-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12661804&dopt=Abstract
•
An unusual nosocomial pneumonia. Author(s): Baddi L, Ray D. Source: Chest. 2002 September; 122(3): 1077-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12226057&dopt=Abstract
•
Analysis of underlying diseases and prognosis factors associated with Pneumocystis carinii pneumonia in immunocompromised HIV-negative patients. Author(s): Roblot F, Godet C, Le Moal G, Garo B, Faouzi Souala M, Dary M, De Gentile L, Gandji JA, Guimard Y, Lacroix C, Roblot P, Becq-Giraudon B. Source: European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology. 2002 July; 21(7): 523-31. Epub 2002 July 13. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12172743&dopt=Abstract
•
Antibiotic guidelines for pneumonia in chronic-care facilities. Author(s): Marras TK, Chan CK. Source: Clinical and Investigative Medicine. Medecine Clinique Et Experimentale. 2002 June; 25(3): 63-4; Author Reply 64. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12137250&dopt=Abstract
•
Antibiotic resistance and virulence properties of Pseudomonas aeruginosa strains from mechanically ventilated patients with pneumonia in intensive care units: comparison with imipenem-resistant extra-respiratory tract isolates from uninfected patients. Author(s): Di Martino P, Gagniere H, Berry H, Bret L. Source: Microbes and Infection / Institut Pasteur. 2002 May; 4(6): 613-20. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12048030&dopt=Abstract
•
Antibiotic therapy for ambulatory patients with community-acquired pneumonia in an emergency department setting. Author(s): Malcolm C, Marrie TJ. Source: Archives of Internal Medicine. 2003 April 14; 163(7): 797-802. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12695270&dopt=Abstract
•
Antibiotic therapy of ventilator-associated pneumonia: in search of the magic bullet. Author(s): Brun-Buisson C. Source: Chest. 2003 March; 123(3): 670-3. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12628858&dopt=Abstract
184 Pneumonia
•
Anticoagulant therapy for acute lung injury or pneumonia. Author(s): Schultz MJ, Levi M, van der Poll T. Source: Current Drug Targets. 2003 May; 4(4): 315-21. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12699352&dopt=Abstract
•
Antimicrobial susceptibility and serotypes of nasopharyngeal Streptococcus pneumoniae in children with pneumonia and in children attending day-care centres in Fortaleza, Brazil. Author(s): Rey LC, Wolf B, Moreira JL, Milatovic D, Verhoef J, Farhat CK. Source: International Journal of Antimicrobial Agents. 2002 August; 20(2): 86-92. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12297356&dopt=Abstract
•
Antimicrobial susceptibility in community-acquired bacterial pneumonia in adults. Author(s): Kariuki S, Muyodi J, Mirza B, Mwatu W, Daniels JJ. Source: East Afr Med J. 2003 April; 80(4): 213-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12918806&dopt=Abstract
•
Antimicrobial therapy for community-acquired pneumonia in adults. Author(s): da Cunha CA, Sader HS, Nicodemo AC; Brazilian Society for Infectious Diseases Practice Guidelines Committee. Source: The Brazilian Journal of Infectious Diseases : an Official Publication of the Brazilian Society of Infectious Diseases. 2002 April; 6(2): 82-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11980608&dopt=Abstract
•
Antimicrobial treatment of community-acquired pneumonia in Hong Kong. Author(s): You JH, Lee VW, Au PS, Lee KK. Source: American Journal of Health-System Pharmacy : Ajhp : Official Journal of the American Society of Health-System Pharmacists. 2002 September 15; 59(18): 1785-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12298121&dopt=Abstract
•
Applying sputum as a diagnostic tool in pneumonia: limited yield, minimal impact on treatment decisions. Author(s): Ewig S, Schlochtermeier M, Goke N, Niederman MS. Source: Chest. 2002 May; 121(5): 1486-92. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12006433&dopt=Abstract
•
Appropriate antibiotic therapy for ventilator-associated pneumonia and sepsis: a necessity, not an issue for debate. Author(s): Kolleff MH. Source: Intensive Care Medicine. 2003 February; 29(2): 147-9. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12675039&dopt=Abstract
Studies 185
•
Are follow up chest x ray examinations helpful in the management of children recovering from pneumonia? Author(s): Wacogne I, Negrine RJ. Source: Archives of Disease in Childhood. 2003 May; 88(5): 457-8. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12716727&dopt=Abstract
•
Aspergillosis: The most common community-acquired pneumonia with gramnegative Bacilli as copathogens in stem cell transplant recipients with graft-versushost disease. Author(s): Alangaden GJ, Wahiduzzaman M, Chandrasekar PH; Bone Marrow Transplant Group. Source: Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America. 2002 September 15; 35(6): 659-64. Epub 2002 August 23. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12203161&dopt=Abstract
•
Aspiration pneumonia and altered dental status. Author(s): Finucane TE. Source: Journal of the American Geriatrics Society. 2002 March; 50(3): 589; Author Reply 589-90. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11943064&dopt=Abstract
•
Aspiration pneumonia and dysphagia in the elderly. Author(s): Marik PE, Kaplan D. Source: Chest. 2003 July; 124(1): 328-36. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12853541&dopt=Abstract
•
Aspiration pneumonia as a complication of severe mania. Author(s): Jain S, Gibson RH, Guedet PJ, Lehrmann JA, Tsao CI. Source: General Hospital Psychiatry. 2003 March-April; 25(2): 136-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12676428&dopt=Abstract
•
Aspiration pneumonia following severe self-poisoning. Author(s): Liisanantti J, Kaukoranta P, Martikainen M, Ala-Kokko T. Source: Resuscitation. 2003 January; 56(1): 49-53. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12505738&dopt=Abstract
•
Aspiration pneumonia in association with oral vitamin K. Author(s): Bhandari V, Tin NO, Ahmed SR. Source: Archives of Disease in Childhood. Fetal and Neonatal Edition. 2002 November; 87(3): F232. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12391003&dopt=Abstract
186 Pneumonia
•
Aspiration pneumonia. Recognizing and managing a potentially growing disorder. Author(s): Johnson JL, Hirsch CS. Source: Postgraduate Medicine. 2003 March; 113(3): 99-102, 105-6, 111-2. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12647477&dopt=Abstract
•
Aspiration pneumonia: incidence, mortality, and at-risk populations. Author(s): DeLegge MH. Source: Jpen. Journal of Parenteral and Enteral Nutrition. 2002 November-December; 26(6 Suppl): S19-24; Discussion S24-5. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12405619&dopt=Abstract
•
Assessment of illness severity in community acquired pneumonia: a useful new prediction tool? Author(s): Woodhead M. Source: Thorax. 2003 May; 58(5): 371-2. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12728152&dopt=Abstract
•
Association between Staphylococcus aureus strains carrying gene for PantonValentine leukocidin and highly lethal necrotising pneumonia in young immunocompetent patients. Author(s): Gillet Y, Issartel B, Vanhems P, Fournet JC, Lina G, Bes M, Vandenesch F, Piemont Y, Brousse N, Floret D, Etienne J. Source: Lancet. 2002 March 2; 359(9308): 753-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11888586&dopt=Abstract
•
Association of crackles and/or wheezing with tachypnea or chest indrawing in children with pneumonia. Author(s): Nascimento-Carvalho CM, Rocha H, Benguigui Y. Source: Indian Pediatrics. 2002 February; 39(2): 205-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11867857&dopt=Abstract
•
Association of IL-10 polymorphism with severity of illness in community acquired pneumonia. Author(s): Gallagher PM, Lowe G, Fitzgerald T, Bella A, Greene CM, McElvaney NG, O'Neill SJ. Source: Thorax. 2003 February; 58(2): 154-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12554901&dopt=Abstract
•
Associations between empirical antimicrobial therapy at the hospital and mortality in patients with severe community-acquired pneumonia. Author(s): Rello J, Catalan M, Diaz E, Bodi M, Alvarez B. Source: Intensive Care Medicine. 2002 August; 28(8): 1030-5. Epub 2002 April 25. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12185421&dopt=Abstract
Studies 187
•
Atypical pathogens in adult patients admitted with community-acquired pneumonia in Korea. Author(s): Lee SJ, Lee MG, Jeon MJ, Jung KS, Lee HK, Kishimoto T. Source: Japanese Journal of Infectious Diseases. 2002 October; 55(5): 157-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12501255&dopt=Abstract
•
Atypical pneumonia in children. Author(s): Salaria M, Singh M. Source: Indian Pediatrics. 2002 March; 39(3): 259-66. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11910135&dopt=Abstract
•
Azathioprine and low-dose corticosteroids for the treatment of cryptogenic organizing pneumonia in an older patient. Author(s): Laszlo A, Espolio Y, Auckenthaler A, Michel JP, Janssens JP. Source: Journal of the American Geriatrics Society. 2003 March; 51(3): 433-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12588596&dopt=Abstract
•
Azithromycin monotherapy for patients hospitalized with community-acquired pneumonia: a 31/2-year experience from a veterans affairs hospital. Author(s): Feldman RB, Rhew DC, Wong JY, Charles RA, Goetz MB; American Thoracic Society. Source: Archives of Internal Medicine. 2003 July 28; 163(14): 1718-26. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12885688&dopt=Abstract
•
Azithromycin treatment failure in community-acquired pneumonia caused by Streptococcus pneumoniae resistant to macrolides by a 23S rRNA mutation. Author(s): Kays MB, Wack MF, Smith DW, Denys GA. Source: Diagnostic Microbiology and Infectious Disease. 2002 June; 43(2): 163-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12088625&dopt=Abstract
•
Bacteremic and leukopenic pneumococcal pneumonia: successful treatment with antibiotics, pulse steroid, and continuous hemodiafiltration. Author(s): Yokoyama T, Sakamoto T, Shida N, Shimada T, Kaku N, Aizawa H, Oizumi K. Source: Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy. 2002 September; 8(3): 247-51. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12373489&dopt=Abstract
•
Bacterial community-acquired pneumonia in children: changes in causative agents. Author(s): Korppi M, Heiskanen-Kosma T. Source: Monaldi Arch Chest Dis. 2001 April; 56(2): 132-6. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11499302&dopt=Abstract
188 Pneumonia
•
Bacterial pneumonia can increase serum concentration of clozapine. Author(s): Raaska K, Raitasuo V, Arstila M, Neuvonen PJ. Source: European Journal of Clinical Pharmacology. 2002 August; 58(5): 321-2. Epub 2002 June 25. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12185555&dopt=Abstract
•
Bacterial pneumonia. Managing a deadly complication of influenza in older adults with comorbid disease. Author(s): Sethi S. Source: Geriatrics. 2002 March; 57(3): 56-61. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11899549&dopt=Abstract
•
Bacterial pneumonia: commoner than perceived. Author(s): Shann F. Source: Lancet. 2001 June 30; 357(9274): 2070-2. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11445094&dopt=Abstract
•
Bacterial pneumonia: comparison between diabetics and non-diabetics. Author(s): Akbar DH. Source: Acta Diabetologica. 2001; 38(2): 77-82. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11757805&dopt=Abstract
•
Bactericidal effect and pharmacodynamics of cethromycin (ABT-773) in a murine pneumococcal pneumonia model. Author(s): Kim MK, Zhou W, Tessier PR, Xuan D, Ye M, Nightingale CH, Nicolau DP. Source: Antimicrobial Agents and Chemotherapy. 2002 October; 46(10): 3185-92. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12234843&dopt=Abstract
•
BAL induces an increase in peripheral blood neutrophils and cytokine levels in healthy volunteers and patients with pneumonia. Author(s): Terashima T, Amakawa K, Matsumaru A, van Eeden S, Hogg JC, Yamaguchi K. Source: Chest. 2001 June; 119(6): 1724-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11399697&dopt=Abstract
•
Balantidium coli pneumonia in an immunocompromised patient. Author(s): Vasilakopoulou A, Dimarongona K, Samakovli A, Papadimitris K, Avlami A. Source: Scandinavian Journal of Infectious Diseases. 2003; 35(2): 144-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12693570&dopt=Abstract
Studies 189
•
Bilateral pneumothorax, pneumonia, and pneumomediastinum after injection of a hard drug into the neck. Author(s): Filosso PL, Arslanian A, Ruffini E, Mancuso M. Source: The Journal of Thoracic and Cardiovascular Surgery. 2002 December; 124(6): 1233-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12447193&dopt=Abstract
•
Biofilm formation in endotracheal tubes. Association between pneumonia and the persistence of pathogens. Author(s): Bauer TT, Torres A, Ferrer R, Heyer CM, Schultze-Werninghaus G, Rasche K. Source: Monaldi Arch Chest Dis. 2002 February; 57(1): 84-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12174708&dopt=Abstract
•
Blood cultures and pneumonia. Author(s): Tracy GE. Source: S D J Med. 2001 November; 54(11): 446. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11725409&dopt=Abstract
•
Blood cultures from Brazilian pediatric outpatients with community-acquired pneumonia (CAP). Author(s): Nascimento-Carvalho CM, Gomes MD, Magalhaes MP, Oliveira JR, VilasBoas AL, Ferracuti R, Alves NN, Athayde LA, Caldas RM, Barberino MG, Duarte J, Brandao MA, Brandileone MC, Guerra ML, Rocha H, Benguigui Y, Di Fabio JL. Source: Journal of Tropical Pediatrics. 2002 February; 48(1): 58-60. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11871370&dopt=Abstract
•
Blood cultures in community-acquired pneumonia: are we ready to quit? Author(s): Luna CM. Source: Chest. 2003 April; 123(4): 977-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12684278&dopt=Abstract
•
Brainstem and striatal encephalitis complicating Mycoplasma pneumoniae pneumonia: possible benefit of intravenous immunoglobulin. Author(s): Sakoulas G. Source: The Pediatric Infectious Disease Journal. 2001 May; 20(5): 543-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11368117&dopt=Abstract
•
Breast milk transmission of a Panton-Valentine leukocidin-producing Staphylococcus aureus strain causing infantile pneumonia. Author(s): Le Thomas I, Mariani-Kurkdjian P, Collignon A, Gravet A, Clermont O, Brahimi N, Gaudelus J, Aujard Y, Navarro J, Beaufils F, Bingen E. Source: Journal of Clinical Microbiology. 2001 February; 39(2): 728-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11158136&dopt=Abstract
190 Pneumonia
•
British Thoracic Society Guidelines for the Management of Community Acquired Pneumonia in Childhood. Author(s): British Thoracic Society Standards of Care Committee. Source: Thorax. 2002 May; 57 Suppl 1: I1-24. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11994552&dopt=Abstract
•
Bronchial adenoma presenting with chronic asthma and obstructive pneumonia: a case report. Author(s): Reechaipichitkul W, Saengsaard S, Puapairoj A, Boonsawat W. Source: Southeast Asian J Trop Med Public Health. 2002 March; 33(1): 164-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12118446&dopt=Abstract
•
Bronchiolitis obliterans and organising pneumonia caused by carbamazepine and mimicking community acquired pneumonia. Author(s): Banka R, Ward MJ. Source: Postgraduate Medical Journal. 2002 October; 78(924): 621-2. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12415089&dopt=Abstract
•
Bronchiolitis obliterans organising pneumonia in pregnancy. Author(s): Futagami M, Sakamoto T, Sakamoto A, Shigetou T, Taniguchi R, Fukuhara R. Source: Journal of Obstetrics and Gynaecology : the Journal of the Institute of Obstetrics and Gynaecology. 2003 May; 23(3): 309. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12918462&dopt=Abstract
•
Bronchiolitis obliterans organizing pneumonia (BOOP) in a child with mild-tomoderate asthma: evidence of mast cell and eosinophil recruitment in lung specimens. Author(s): Barbato A, Panizzolo C, D'Amore ES, La Rosa M, Saetta M. Source: Pediatric Pulmonology. 2001 May; 31(5): 394-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11340687&dopt=Abstract
•
Bronchiolitis obliterans organizing pneumonia (BOOP) with suspected liver graftversus-host disease after allogeneic bone marrow transplantation. Author(s): Kanamori H, Mishima A, Tanaka M, Yamaji S, Fujisawa S, Koharazawa H, Nishikawa M, Matsuzaki M, Mohri H, Ishigatsubo Y. Source: Transplant International : Official Journal of the European Society for Organ Transplantation. 2001 August; 14(4): 266-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11512061&dopt=Abstract
Studies 191
•
Bronchiolitis obliterans organizing pneumonia after tangential beam irradiation to the breast: discrimination from radiation pneumonitis. Author(s): Nambu A, Araki T, Ozawa K, Kanazawa M, Ohki Z, Miyata K. Source: Radiat Med. 2002 May-June; 20(3): 151-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12126090&dopt=Abstract
•
Bronchiolitis obliterans organizing pneumonia associated with Evans syndrome. Author(s): Maiz L, Munoz A, Maldonado S, Pacheco A, Lamas A, Fogue L. Source: Respiration; International Review of Thoracic Diseases. 2001; 68(6): 631-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11786723&dopt=Abstract
•
Bronchiolitis obliterans organizing pneumonia associated with lower respiratory tract infection by respiratory syncytial virus in an immunocompetent adult. Author(s): Trisolini R, Dallari R, Cancellieri A, Poletti V. Source: Sarcoidosis Vasc Diffuse Lung Dis. 2002 October; 19(3): 234-5. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12405494&dopt=Abstract
•
Bronchiolitis obliterans organizing pneumonia in a patient with chronic myelogenous leukemia developing after initiation of interferon and cytosine arabinoside. Author(s): Patel M, Ezzat W, Pauw KL, Lowsky R. Source: European Journal of Haematology. 2001 November-December; 67(5-6): 318-21. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11872080&dopt=Abstract
•
Bronchiolitis obliterans organizing pneumonia in an orthotopic liver transplant patient. Author(s): DeAngelo AJ, Ouellette D. Source: Transplantation. 2002 February 27; 73(4): 544-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11889426&dopt=Abstract
•
Bronchiolitis obliterans organizing pneumonia in cancer: a case series. Author(s): Mokhtari M, Bach PB, Tietjen PA, Stover DE. Source: Respiratory Medicine. 2002 April; 96(4): 280-6. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12000009&dopt=Abstract
•
Bronchiolitis obliterans organizing pneumonia. Author(s): Epler GR. Source: Archives of Internal Medicine. 2001 January 22; 161(2): 158-64. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11176728&dopt=Abstract
192 Pneumonia
•
Bronchiolitis obliterans organizing pneumonia: clinicopathologic review of a series of 45 Korean patients including rapidly progressive form. Author(s): Chang J, Han J, Kim DW, Lee I, Lee KY, Jung S, Han HS, Chun BK, Cho SJ, Lee K, Lim BJ, Shin DH. Source: Journal of Korean Medical Science. 2002 April; 17(2): 179-86. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11961300&dopt=Abstract
•
Bronchiolitis obliterans with organizing pneumonia associated with acute Coxiella burnetii infection. Author(s): Perez de Llano LA, Racamonde AV, Bande MJ, Piquer MO, Nieves FB, Feijoo AR. Source: Respiration; International Review of Thoracic Diseases. 2001; 68(4): 425-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11464095&dopt=Abstract
•
Bronchiolitis obliterans with organizing pneumonia versus chronic eosinophilic pneumonia: high-resolution CT findings in 81 patients. Author(s): Arakawa H, Kurihara Y, Niimi H, Nakajima Y, Johkoh T, Nakamura H. Source: Ajr. American Journal of Roentgenology. 2001 April; 176(4): 1053-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11264110&dopt=Abstract
•
Bronchiolitis obliterans with organizing pneumonia: possible association with human herpesvirus-7 infection after lung transplantation. Author(s): Ross DJ, Chan RC, Kubak B, Laks H, Nichols WS. Source: Transplantation Proceedings. 2001 June; 33(4): 2603-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11406259&dopt=Abstract
•
Bronchiolitis obliterans. Organizing pneumonia. Author(s): Popper HH. Source: Verh Dtsch Ges Pathol. 2002; 86: 101-6. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12647357&dopt=Abstract
•
Bronchioloalveolar carcinoma: sonographic pattern of 'pneumonia'. Author(s): Gorg C, Seifart U, Holzinger I, Wolf M, Zugmaier G. Source: European Journal of Ultrasound : Official Journal of the European Federation of Societies for Ultrasound in Medicine and Biology. 2002 October; 15(3): 109-17. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12423736&dopt=Abstract
•
Bronchoalveolar coagulation and fibrinolysis in endotoxemia and pneumonia. Author(s): Levi M, Schultz MJ, Rijneveld AW, van der Poll T. Source: Critical Care Medicine. 2003 April; 31(4 Suppl): S238-42. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12682446&dopt=Abstract
Studies 193
•
Bronchoalveolar interleukin-1 beta: a marker of bacterial burden in mechanically ventilated patients with community-acquired pneumonia. Author(s): Wu CL, Lee YL, Chang KM, Chang GC, King SL, Chiang CD, Niederman MS. Source: Critical Care Medicine. 2003 March; 31(3): 812-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12626989&dopt=Abstract
•
Bronchoalveolar lavage fluid cytology in patients with Pneumocystis carinii pneumonia. Author(s): Jacobs JA, Dieleman MM, Cornelissen EI, Groen EA, Wagenaar SS, Drent M. Source: Acta Cytol. 2001 May-June; 45(3): 317-26. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11393061&dopt=Abstract
•
Bronchoalveolar lavage suggesting diffuse alveolar damage in a patient with acute eosinophilic pneumonia. Author(s): Trisolini R, Cancellieri A, Bonaccorsi A, Poletti V. Source: Sarcoidosis Vasc Diffuse Lung Dis. 2001 October; 18(3): 311-2. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11587106&dopt=Abstract
•
BTS Guidelines for the Management of Community Acquired Pneumonia in Adults. Author(s): British Thoracic Society Standards of Care Committee. Source: Thorax. 2001 December; 56 Suppl 4: Iv1-64. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11713364&dopt=Abstract
•
BTS guidelines on CAP. Community acquired pneumonia. Author(s): Gould IM. Source: Thorax. 2002 July; 57(7): 657. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12096214&dopt=Abstract
•
Can optimal management prevent mortality in ventilator-associated pneumonia? Author(s): Niederman MS. Source: Critical Care Medicine. 2002 August; 30(8): 1916-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12163822&dopt=Abstract
•
Caring for people with pneumonia. Author(s): Mehr DR. Source: Provider. 2003 April; 29(4): 33-6. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12708247&dopt=Abstract
194 Pneumonia
•
Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 14-2003. A 73-year-old woman with pneumonia and progressive respiratory failure. Author(s): Waxman AB, Shepard JA, Mark EJ. Source: The New England Journal of Medicine. 2003 May 8; 348(19): 1902-12. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12736284&dopt=Abstract
•
Cavitary pneumonia due to Rhodococcus equi in a heart transplant recipient. Author(s): Kwak EJ, Strollo DC, Kulich SM, Kusne S. Source: Transplant Infectious Disease : an Official Journal of the Transplantation Society. 2003 March; 5(1): 43-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12791074&dopt=Abstract
•
Cavitary Rhodococcus equi pneumonia with endobronchial granulomas: report of an unusual case. Author(s): Fidvi SA, Brudnicki AR, Chowdhury MI, Beneck D. Source: Pediatric Radiology. 2003 February; 33(2): 140-2. Epub 2002 December 10. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12557073&dopt=Abstract
•
Cervical cord syndrome complicating pneumococcal pneumonia. Author(s): Ben-Dov N, Hallevy C, Almog Y. Source: Journal of Neurology. 2002 September; 249(9): 1309-10. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12242560&dopt=Abstract
•
Characterization of a murine model of Ureaplasma urealyticum pneumonia. Author(s): Viscardi RM, Kaplan J, Lovchik JC, He JR, Hester L, Rao S, Hasday JD. Source: Infection and Immunity. 2002 October; 70(10): 5721-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12228302&dopt=Abstract
•
Characterizing and developing strategies for the treatment of community-acquired pneumonia at a community hospital. Author(s): Fok MC, Kanji Z, Mainra R, Boldt M. Source: Can Respir J. 2002 July-August; 9(4): 247-52. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12195270&dopt=Abstract
•
Chest X-ray quiz. Right middle lobe consolidation/atelectasis from pneumonia. Author(s): Reading M. Source: Intensive & Critical Care Nursing : the Official Journal of the British Association of Critical Care Nurses. 2003 February; 19(1): 41, 42. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12680426&dopt=Abstract
Studies 195
•
China joins global effort over pneumonia virus. Author(s): Parry J. Source: Bmj (Clinical Research Ed.). 2003 April 12; 326(7393): 781. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12689957&dopt=Abstract
•
China joins investigation of mystery pneumonia. Author(s): Cyranoski D. Source: Nature. 2003 April 3; 422(6931): 459. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12673214&dopt=Abstract
•
Chlamydia pneumonia seropositivity correlates with serum fibrinogen and lipoprotein a levels: any role in atherosclerosis? Author(s): Tutuncu NB, Guvener N, Tutuncu T, Yilmaz M, Guvener M, Boke E, Pasaoglu I, Erbas T. Source: Endocr J. 2001 April; 48(2): 269-74. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11456278&dopt=Abstract
•
Chlamydia pneumoniae in community-acquired pneumonia: seven years of experience. Author(s): Monno R, De Vito D, Losito G, Sibilio G, Costi A, Fumarola L, D'Aprile A, Marcuccio P. Source: The Journal of Infection. 2002 October; 45(3): 135-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12387767&dopt=Abstract
•
Chlamydia pneumoniae infection among healthy children and children hospitalised with pneumonia in Greece. Author(s): Triga MG, Anthracopoulos MB, Saikku P, Syrogiannopoulos GA. Source: European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology. 2002 April; 21(4): 300-3. Epub 2002 April 10. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12072942&dopt=Abstract
•
Chlamydia species as a cause of community-acquired pneumonia in Canada. Author(s): Marrie TJ, Peeling RW, Reid T, De Carolis E; Canadian Community-Acquired Pneumonia Investigators. Source: The European Respiratory Journal : Official Journal of the European Society for Clinical Respiratory Physiology. 2003 May; 21(5): 779-84. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12765420&dopt=Abstract
196 Pneumonia
•
Chlamydophila (Chlamydia) pneumoniae as a cause of community-acquired pneumonia in Thailand. Author(s): Suttithawil W, Wangroongsarb P, Naigowit P, Nunthapisud P, Chantadisai N, Ploysongsang Y. Source: J Med Assoc Thai. 2001 March; 84(3): 430-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11460948&dopt=Abstract
•
Chronic eosinophilic pneumonia due to visceral larva migrans. Author(s): Inoue K, Inoue Y, Arai T, Nawa Y, Kashiwa Y, Yamamoto S, Sakatani M. Source: Intern Med. 2002 June; 41(6): 478-82. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12135183&dopt=Abstract
•
Chronic eosinophilic pneumonia presenting with pericarditis and ventricular wall hypertrophy. Author(s): Blanco P, Viallard JF, Roudaut R, Mercie P, Pellegrin JL. Source: International Journal of Cardiology. 2003 February; 87(2-3): 279-82. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12559551&dopt=Abstract
•
Chronic eosinophilic pneumonia: a case report and national survey. Author(s): Wubbel C, Fulmer D, Sherman J. Source: Chest. 2003 May; 123(5): 1763-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12740299&dopt=Abstract
•
Chronic Klebsiella pneumonia in an immunocompetent host. Author(s): Sinha R, Panjabi C, Varma M, Vijayan VK, Shah A. Source: J Assoc Physicians India. 2003 March; 51: 306-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12839360&dopt=Abstract
•
Chronic Pneumocystis carinii pneumonia associated with extensive pneumatocele formation in a child with human immunodeficiency virus infection. Author(s): Holland ET, Saulsbury FT. Source: Pediatric Pulmonology. 2003 February; 35(2): 144-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12526077&dopt=Abstract
•
Citrobacter koseri pneumonia and meningitis in an infant. Author(s): Aller SC, Chusid MJ. Source: The Journal of Infection. 2002 July; 45(1): 65-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12217738&dopt=Abstract
Studies 197
•
Classical and latent class analysis evaluation of sputum polymerase chain reaction and urine antigen testing for diagnosis of pneumococcal pneumonia in adults. Author(s): Butler JC, Bosshardt SC, Phelan M, Moroney SM, Tondella ML, Farley MM, Schuchat A, Fields BS. Source: The Journal of Infectious Diseases. 2003 May 1; 187(9): 1416-23. Epub 2003 April 09. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12717623&dopt=Abstract
•
Clinical analysis of patients requiring long-term mechanical ventilation of over three months: ventilator-associated pneumonia as a primary complication. Author(s): Kobashi Y, Matsushima T. Source: Intern Med. 2003 January; 42(1): 25-32. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12583614&dopt=Abstract
•
Clinical and economic outcomes of pneumonia in children: a longitudinal observational study in an Italian paediatric hospital. Author(s): Di Ciommo V, Russo P, Attanasio E, Di Liso G, Graziani C, Caprino L. Source: Journal of Evaluation in Clinical Practice. 2002 August; 8(3): 341-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12164981&dopt=Abstract
•
Clinical and epidemiologic features of group a streptococcal pneumonia in Ontario, Canada. Author(s): Muller MP, Low DE, Green KA, Simor AE, Loeb M, Gregson D, McGeer A; Ontario Group A Streptococcal Study. Source: Archives of Internal Medicine. 2003 February 24; 163(4): 467-72. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12588207&dopt=Abstract
•
Clinical aspects and prognostic factors in elderly patients hospitalised for community-acquired pneumonia. Author(s): Garcia-Ordonez MA, Garcia-Jimenez JM, Paez F, Alvarez F, Poyato B, Franquelo M, Colmenero JD, Juarez C. Source: European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology. 2001 January; 20(1): 14-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11245317&dopt=Abstract
•
Clinical aspects of pneumonia. Author(s): Puli V, Clarke SC. Source: British Journal of Biomedical Science. 2002; 59(3): 170-2. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12371063&dopt=Abstract
198 Pneumonia
•
Clinical characteristics of children with complicated pneumonia caused by Streptococcus pneumoniae. Author(s): Tan TQ, Mason EO Jr, Wald ER, Barson WJ, Schutze GE, Bradley JS, Givner LB, Yogev R, Kim KS, Kaplan SL. Source: Pediatrics. 2002 July; 110(1 Pt 1): 1-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12093940&dopt=Abstract
•
Clinical diagnosis of Legionella pneumonia revisited: evaluation of the CommunityBased Pneumonia Incidence Study Group scoring system. Author(s): Fernandez-Sabe N, Roson B, Carratala J, Dorca J, Manresa F, Gudiol F. Source: Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America. 2003 August 15; 37(4): 483-9. Epub 2003 July 28. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12905131&dopt=Abstract
•
Clinical efficacy of 3 days versus 5 days of oral amoxicillin for treatment of childhood pneumonia: a multicentre double-blind trial. Author(s): Pakistan Multicentre Amoxycillin Short Course Therapy (MASCOT) pneumonia study group. Source: Lancet. 2002 September 14; 360(9336): 835-41. Erratum In: Lancet. 2003 March 1; 361(9359): 788. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12243918&dopt=Abstract
•
Clinical evaluation of the management of community-acquired pneumonia by general practitioners in France. Author(s): Fantin B, Aubert JP, Unger P, Lecoeur H, Carbon C. Source: Chest. 2001 July; 120(1): 185-92. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11451836&dopt=Abstract
•
Clinical features of community-acquired pneumonia treated at Srinagarind Hospital, Khon Kaen, Thailand. Author(s): Reechaipichitkul W, Tantiwong P. Source: Southeast Asian J Trop Med Public Health. 2002 June; 33(2): 355-61. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12236437&dopt=Abstract
•
Clinical picture: bronchiolitis obliterans with organising pneumonia during interferon beta-1a treatment. Author(s): Ferriby D, Stojkovic T. Source: Lancet. 2001 March 10; 357(9258): 751. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11253968&dopt=Abstract
Studies 199
•
Clinical progression and viral load in a community outbreak of coronavirusassociated SARS pneumonia: a prospective study. Author(s): Peiris JS, Chu CM, Cheng VC, Chan KS, Hung IF, Poon LL, Law KI, Tang BS, Hon TY, Chan CS, Chan KH, Ng JS, Zheng BJ, Ng WL, Lai RW, Guan Y, Yuen KY; HKU/UCH SARS Study Group. Source: Lancet. 2003 May 24; 361(9371): 1767-72. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12781535&dopt=Abstract
•
Clinical review: non-antibiotic strategies for preventing ventilator-associated pneumonia. Author(s): Ferrer R, Artigas A. Source: Critical Care (London, England). 2002 February; 6(1): 45-51. Epub 2001 January 11. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11940265&dopt=Abstract
•
Clinical signs and scores for the diagnosis of ventilator-associated pneumonia. Author(s): Pugin J. Source: Minerva Anestesiol. 2002 April; 68(4): 261-5. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12024096&dopt=Abstract
•
CMS releases new standards for community-acquired pneumonia. Author(s): Golden WE, Brown P, Godsey N. Source: J Ark Med Soc. 2003 March; 99(9): 288-9. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12674913&dopt=Abstract
•
Combination antibiotic therapy with macrolides in community-acquired pneumonia: more smoke but is there any fire? Author(s): Waterer GW. Source: Chest. 2003 May; 123(5): 1328-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12740239&dopt=Abstract
•
Community acquired pneumonia. Author(s): Loeb M. Source: Clin Evid. 2002 June; (7): 1358-68. Review. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12230751&dopt=Abstract
•
Community acquired pneumonia--how does Tennessee measure up? Author(s): Jain M, Weddle J. Source: Tenn Med. 2003 June; 96(6): 271-4. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12814067&dopt=Abstract
200 Pneumonia
•
Community-acquired MRSA bacteraemia: four additional cases including one associated with severe pneumonia. Author(s): Nimmo GR, Playford EG. Source: The Medical Journal of Australia. 2003 March 3; 178(5): 245. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12603193&dopt=Abstract
•
Community-acquired pneumonia and do not resuscitate orders. Author(s): Marrie TJ, Fine MJ, Kapoor WN, Coley CM, Singer DE, Obrosky DS. Source: Journal of the American Geriatrics Society. 2002 February; 50(2): 290-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12028211&dopt=Abstract
•
Community-acquired pneumonia caused by Enterobacter asburiae. Author(s): Stewart JM, Quirk JR. Source: The American Journal of Medicine. 2001 July; 111(1): 82-3. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11460856&dopt=Abstract
•
Community-acquired pneumonia due to gram-negative bacteria and pseudomonas aeruginosa: incidence, risk, and prognosis. Author(s): Arancibia F, Bauer TT, Ewig S, Mensa J, Gonzalez J, Niederman MS, Torres A. Source: Archives of Internal Medicine. 2002 September 9; 162(16): 1849-58. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12196083&dopt=Abstract
•
Community-acquired pneumonia guidelines: much guidance, but not much evidence. Author(s): Woodhead M. Source: The European Respiratory Journal : Official Journal of the European Society for Clinical Respiratory Physiology. 2002 July; 20(1): 1-3. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12166553&dopt=Abstract
•
Community-acquired pneumonia in adults. Author(s): Ramirez JA. Source: Primary Care. 2003 March; 30(1): 155-71. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12825254&dopt=Abstract
•
Community-acquired pneumonia in children aged 2 months to 5 years: application of the WHO guidelines in a developed country setting (Switzerland). Author(s): Dirlewanger M, Krahenbuhl JD, Fanconi S, Vaudaux B, Gehri M. Source: European Journal of Pediatrics. 2002 August; 161(8): 460-1. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12269258&dopt=Abstract
Studies 201
•
Community-acquired pneumonia in elderly patients. Author(s): Niederman MS, Ahmed QA. Source: Clinics in Geriatric Medicine. 2003 February; 19(1): 101-20. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12735117&dopt=Abstract
•
Community-acquired pneumonia in immunocompromised patients. Opportunistic infections to consider in differential diagnosis. Author(s): Cebular S, Lee S, Tolaney P, Lutwick L. Source: Postgraduate Medicine. 2003 January; 113(1): 65-6, 69-70, 73-4 Passim. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12545593&dopt=Abstract
•
Community-acquired pneumonia in older people: the need for a broader perspective. Author(s): Loeb MB. Source: Journal of the American Geriatrics Society. 2003 April; 51(4): 539-43. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12657076&dopt=Abstract
•
Community-acquired pneumonia in older veterans: does the pneumonia prognosis index help? Author(s): Mody L, Sun R, Bradley S. Source: Journal of the American Geriatrics Society. 2002 March; 50(3): 434-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11943037&dopt=Abstract
•
Community-acquired pneumonia in southeast Asia: the microbial differences between ambulatory and hospitalized patients. Author(s): Wattanathum A, Chaoprasong C, Nunthapisud P, Chantaratchada S, Limpairojn N, Jatakanon A, Chanthadisai N. Source: Chest. 2003 May; 123(5): 1512-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12740268&dopt=Abstract
•
Community-acquired pneumonia in the elderly: Spanish multicentre study. Author(s): Zalacain R, Torres A, Celis R, Blanquer J, Aspa J, Esteban L, Menendez R, Blanquer R, Borderias L; Pneumonia in the elderly working group, Area de Tuberculosis e Infecciones Respiratorias. Source: The European Respiratory Journal : Official Journal of the European Society for Clinical Respiratory Physiology. 2003 February; 21(2): 294-302. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12608444&dopt=Abstract
•
Community-acquired pneumonia in the emergency department: a practical approach to diagnosis and management. Author(s): Pimentel L, McPherson SJ. Source: Emergency Medicine Clinics of North America. 2003 May; 21(2): 395-420. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12793621&dopt=Abstract
202 Pneumonia
•
Community-acquired pneumonia in Ugandan adults: short-term parenteral ampicillin therapy for bacterial pneumonia. Author(s): Yoshimine H, Oishi K, Mubiru F, Nalwoga H, Takahashi H, Amano H, Ombasi P, Watanabe K, Joloba M, Aisu T, Ahmed K, Shimada M, Mugerwa R, Nagatake T. Source: Am J Trop Med Hyg. 2001 March-April; 64(3-4): 172-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11442214&dopt=Abstract
•
Community-acquired pneumonia in very elderly patients: causative organisms, clinical characteristics, and outcomes. Author(s): Fernandez-Sabe N, Carratala J, Roson B, Dorca J, Verdaguer R, Manresa F, Gudiol F. Source: Medicine; Analytical Reviews of General Medicine, Neurology, Psychiatry, Dermatology, and Pediatrics. 2003 May; 82(3): 159-69. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12792302&dopt=Abstract
•
Community-acquired pneumonia. Author(s): Niederman MS. Source: Isr Med Assoc J. 2003 February; 5(2): 133-8. Review. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12674669&dopt=Abstract
•
Community-acquired pneumonia. Author(s): Andrews J, Nadjm B, Gant V, Shetty N. Source: Current Opinion in Pulmonary Medicine. 2003 May; 9(3): 175-80. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12682561&dopt=Abstract
•
Community-acquired pneumonia. Author(s): Luh JY, Karnath BM. Source: The New England Journal of Medicine. 2003 April 3; 348(14): 1408-9; Author Reply 1408-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12672875&dopt=Abstract
•
Community-acquired pneumonia. Author(s): Spoto S, De Galasso L, Costantino S. Source: Clin Ter. 2002 May-June; 153(3): 225-7. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12161986&dopt=Abstract
•
Community-acquired pneumonia. Author(s): Loeb M. Source: American Family Physician. 2002 July 1; 66(1): 135-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12126028&dopt=Abstract
Studies 203
•
Community-acquired Pseudomonas aeruginosa pneumonia complicated with loculated empyema in an infant with selective IgA deficiency. Author(s): Chen SM, Sheu JN, Chen JP, Yang MH. Source: Acta Paediatr Taiwan. 2002 May-June; 43(3): 157-61. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12148967&dopt=Abstract
•
Comparative randomized trial of azithromycin versus erythromycin and amoxicillin for treatment of community-acquired pneumonia in children. Author(s): Kogan R, Martinez MA, Rubilar L, Paya E, Quevedo I, Puppo H, Girardi G, Castro-Rodriguez JA. Source: Pediatric Pulmonology. 2003 February; 35(2): 91-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12526069&dopt=Abstract
•
Compared protective effect of nasal immunoprophylaxis using a new human monoclonal IgM antibody, human polyclonal antibodies, F(ab')2, amantadine, and zanamivir for prophylaxis of influenza A virus pneumonia in mice. Author(s): Hernandez E, Ramisse F, Lhonneux A, Noury J, Bazin H, Cavallo JD. Source: Military Medicine. 2003 March; 168(3): 246-51. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12685693&dopt=Abstract
•
Comparing pharmacokinetics of amoxicillin given twice or three times per day to children older than 3 months with pneumonia. Author(s): Fonseca W, Hoppu K, Rey LC, Amaral J, Qazi S. Source: Antimicrobial Agents and Chemotherapy. 2003 March; 47(3): 997-1001. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12604533&dopt=Abstract
•
Comparison of clinical characteristics of adenovirus and non-adenovirus pneumonia in children. Author(s): Farng KT, Wu KG, Lee YS, Lin YH, Hwang BT. Source: J Microbiol Immunol Infect. 2002 March; 35(1): 37-41. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11950118&dopt=Abstract
•
Comparison of processes and outcomes of pneumonia care between hospitalists and community-based primary care physicians. Author(s): Rifkin WD, Conner D, Silver A, Eichorn A. Source: Mayo Clinic Proceedings. 2002 October; 77(10): 1053-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12374249&dopt=Abstract
•
Connective tissue responses in acute community-acquired pneumonia. Author(s): Nordenbaek C, Teisner B, Junker P. Source: Respiratory Medicine. 2003 June; 97(6): 660-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12814151&dopt=Abstract
204 Pneumonia
•
Continuation of a randomized, double-blind, multicenter study of linezolid versus vancomycin in the treatment of patients with nosocomial pneumonia. Author(s): Wunderink RG, Cammarata SK, Oliphant TH, Kollef MH; Linezolid Nosocomial Pneumonia Study Group. Source: Clinical Therapeutics. 2003 March; 25(3): 980-92. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12852712&dopt=Abstract
•
Contributions of symptoms, signs, erythrocyte sedimentation rate, and C-reactive protein to a diagnosis of pneumonia in acute lower respiratory tract infection. Author(s): Hopstaken RM, Muris JW, Knottnerus JA, Kester AD, Rinkens PE, Dinant GJ. Source: The British Journal of General Practice : the Journal of the Royal College of General Practitioners. 2003 May; 53(490): 358-64. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12830562&dopt=Abstract
•
Cost-effectiveness of IV-to-oral switch therapy: azithromycin vs cefuroxime with or without erythromycin for the treatment of community-acquired pneumonia. Author(s): Paladino JA, Gudgel LD, Forrest A, Niederman MS. Source: Chest. 2002 October; 122(4): 1271-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12377852&dopt=Abstract
•
Costs of broad-spectrum antibiotic use for acute sinusitis, chronic bronchitis, and pneumonia in a managed care population. Author(s): Coughlin CM, Nelson M, Merchant S, Gondek K. Source: Manag Care Interface. 2003 June; 16(6): 34-40, 55. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12841074&dopt=Abstract
•
C-reactive protein levels in community-acquired pneumonia. Author(s): Garcia Vazquez E, Martinez JA, Mensa J, Sanchez F, Marcos MA, de Roux A, Torres A. Source: The European Respiratory Journal : Official Journal of the European Society for Clinical Respiratory Physiology. 2003 April; 21(4): 702-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12762360&dopt=Abstract
•
Cryptococcal pneumonia in an immunocompetent host: radiographic findings. Author(s): Himmel JE, Stark P. Source: Seminars in Respiratory Infections. 2003 June; 18(2): 129-31. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12840794&dopt=Abstract
Studies 205
•
CT differentiation of pneumonic-type bronchioloalveolar cell carcinoma and infectious pneumonia. Author(s): Jung JI, Kim H, Park SH, Kim HH, Ahn MI, Kim HS, Kim KJ, Chung MH, Choi BG. Source: The British Journal of Radiology. 2001 June; 74(882): 490-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11459727&dopt=Abstract
•
Culture proven Legionella pneumophila pneumonia in a HIV-infected patient: case report and review. Author(s): Franzin L, Dal Conte I, Cabodi D, Sinicco A. Source: The Journal of Infection. 2002 October; 45(3): 199-201. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12387779&dopt=Abstract
•
Cytomegalovirus pneumonia mimicking lung cancer in an immunocompetent host. Author(s): Karakelides H, Aubry MC, Ryu JH. Source: Mayo Clinic Proceedings. 2003 April; 78(4): 488-90. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12683701&dopt=Abstract
•
Daily oral care and risk factors for pneumonia among elderly nursing home patients. Author(s): Yoshino A, Ebihara T, Ebihara S, Fuji H, Sasaki H. Source: Jama : the Journal of the American Medical Association. 2001 November 14; 286(18): 2235-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11710887&dopt=Abstract
•
Death from pneumonia in patients with progressive dementia. Author(s): Neurauter G, Fuchs D, Wirleitner B. Source: Journal of the American Geriatrics Society. 2003 May; 51(5): 721. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12752853&dopt=Abstract
•
Deaths from pneumonia after welding. Author(s): Wergeland E, Iversen BG. Source: Scand J Work Environ Health. 2001 October; 27(5): 353. Review. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11712617&dopt=Abstract
•
Decisions to treat or not to treat pneumonia in demented psychogeriatric nursing home patients: evaluation of a guideline. Author(s): van der Steen JT, Ooms ME, Ribbe MW, van der Wal G. Source: Alzheimer Disease and Associated Disorders. 2001 July-September; 15(3): 11928. Erratum In: Alzheimer Dis Assoc Disord 2002 January-March; 16(1): 48. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11522929&dopt=Abstract
206 Pneumonia
•
Decreased mortality after implementation of a treatment guideline for communityacquired pneumonia. Author(s): Dean NC, Silver MP, Bateman KA, James B, Hadlock CJ, Hale D. Source: The American Journal of Medicine. 2001 April 15; 110(6): 451-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11331056&dopt=Abstract
•
Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Author(s): Lim WS, van der Eerden MM, Laing R, Boersma WG, Karalus N, Town GI, Lewis SA, Macfarlane JT. Source: Thorax. 2003 May; 58(5): 377-82. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12728155&dopt=Abstract
•
Defining prognostic factors in the elderly with community acquired pneumonia: a case controlled study of patients aged > or = 75 yrs. Author(s): Lim WS, Macfarlane JT. Source: The European Respiratory Journal : Official Journal of the European Society for Clinical Respiratory Physiology. 2001 February; 17(2): 200-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11334120&dopt=Abstract
•
Defining severe community-acquired pneumonia. Author(s): Neuhaus T, Ewig S. Source: The Medical Clinics of North America. 2001 November; 85(6): 1413-25. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11680110&dopt=Abstract
•
Defining the potential impact of conjugate bacterial polysaccharide-protein vaccines in reducing the burden of pneumonia in human immunodeficiency virus type 1infected and -uninfected children. Author(s): Madhi SA, Cumin E, Klugman KP. Source: The Pediatric Infectious Disease Journal. 2002 May; 21(5): 393-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12150175&dopt=Abstract
•
Deletion allele of the angiotensin-converting enzyme gene as a risk factor for pneumonia in elderly patients. Author(s): Morimoto S, Okaishi K, Onishi M, Katsuya T, Yang J, Okuro M, Sakurai S, Onishi T, Ogihara T. Source: The American Journal of Medicine. 2002 February 1; 112(2): 89-94. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11835945&dopt=Abstract
•
Demystifying idiopathic interstitial pneumonia. Author(s): Collard HR, King TE Jr. Source: Archives of Internal Medicine. 2003 January 13; 163(1): 17-29. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12523913&dopt=Abstract
Studies 207
•
Detection and quantification of human herpesvirus 6 genomes using bronchoalveolar lavage fluid in immunocompromised patients with interstitial pneumonia. Author(s): Nagate A, Ohyashiki JH, Kasuga I, Minemura K, Abe K, Yamamoto K, Ohyashiki K. Source: International Journal of Molecular Medicine. 2001 October; 8(4): 379-83. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11562775&dopt=Abstract
•
Detection of antivimentin antibody in sera of patients with idiopathic pulmonary fibrosis and non-specific interstitial pneumonia. Author(s): Yang Y, Fujita J, Bandoh S, Ohtsuki Y, Yamadori I, Yoshinouchi T, Ishida T. Source: Clinical and Experimental Immunology. 2002 April; 128(1): 169-74. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11982605&dopt=Abstract
•
Detection of bronchial breathing caused by pneumonia. Author(s): Gross V, Fachinger P, Penzel T, Koehler U, von Wichert P, Vogelmeier C. Source: Biomed Tech (Berl). 2002 June; 47(6): 146-50. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12149800&dopt=Abstract
•
Detection of Pneumocystis DNA in samples from patients suspected of bacterial pneumonia--a case-control study. Author(s): Helweg-Larsen J, Jensen JS, Dohn B, Benfield TL, Lundgren B. Source: Bmc Infectious Diseases [electronic Resource]. 2002 November 25; 2(1): 28. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12445330&dopt=Abstract
•
Determinants of adult influenza and pneumonia immunization rates. Author(s): Kamal KM, Madhavan SS, Amonkar MM. Source: J Am Pharm Assoc (Wash Dc). 2003 May-June; 43(3): 403-11. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12836791&dopt=Abstract
•
Development and evaluation of a quantitative, touch-down, real-time PCR assay for diagnosing Pneumocystis carinii pneumonia. Author(s): Larsen HH, Masur H, Kovacs JA, Gill VJ, Silcott VA, Kogulan P, Maenza J, Smith M, Lucey DR, Fischer SH. Source: Journal of Clinical Microbiology. 2002 February; 40(2): 490-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11825961&dopt=Abstract
•
Development and validation of a multifactorial risk index for predicting postoperative pneumonia after major noncardiac surgery. Author(s): Arozullah AM, Khuri SF, Henderson WG, Daley J; Participants in the National Veterans Affairs Surgical Quality Improvement Program. Source: Annals of Internal Medicine. 2001 November 20; 135(10): 847-57. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11712875&dopt=Abstract
208 Pneumonia
•
Diabetes and rapidly advancing pneumonia. Author(s): Bhansali A, Suresh V, Chaudhry D, Vaiphei K, Dash RJ, Kotwal N. Source: Postgraduate Medical Journal. 2001 November; 77(913): 734-5, 740-1. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11677289&dopt=Abstract
•
Diagnosing and treating atypical pneumonia. Author(s): Smith G, Hosker H. Source: Practitioner. 2001 September; 245(1626): 736-40, 742, 746. Review. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11584587&dopt=Abstract
•
Diagnosing pneumonia during mechanical ventilation: the clinical pulmonary infection score revisited. Author(s): Fartoukh M, Maitre B, Honore S, Cerf C, Zahar JR, Brun-Buisson C. Source: American Journal of Respiratory and Critical Care Medicine. 2003 July 15; 168(2): 173-9. Epub 2003 May 08. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12738607&dopt=Abstract
•
Diagnosis and management of pneumonia in the intensive care unit. Author(s): Cardenas VJ Jr. Source: Chest Surg Clin N Am. 2002 May; 12(2): 379-95. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12122830&dopt=Abstract
•
Diagnosis of ambulatory community-acquired pneumonia. Comparison of clinical assessment versus chest X-ray. Author(s): Lieberman D, Shvartzman P, Korsonsky I, Lieberman D. Source: Scandinavian Journal of Primary Health Care. 2003 March; 21(1): 57-60. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12718463&dopt=Abstract
•
Diagnosis of gram negative, ventilator associated pneumonia by assaying endotoxin in bronchial lavage fluid. Author(s): Flanagan PG, Jackson SK, Findlay G. Source: Journal of Clinical Pathology. 2001 February; 54(2): 107-10. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11215277&dopt=Abstract
•
Diagnosis of legionellaceae as a cause of community-acquired pneumonia- “. continue to treat first and not bother to ask questions later”--not a good idea. Author(s): Marrie TJ. Source: The American Journal of Medicine. 2001 January; 110(1): 73-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11152873&dopt=Abstract
Studies 209
•
Diagnosis of nosocomial pneumonia in medical ward: repeatability of the protected specimen brush. Author(s): Herer B, Fuhrman C, Demontrond D, Gazevic Z, Housset B, Chouaid C. Source: The European Respiratory Journal : Official Journal of the European Society for Clinical Respiratory Physiology. 2001 July; 18(1): 157-63. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11510788&dopt=Abstract
•
Diagnosis of pneumococcal pneumonia by psaA PCR analysis of lung aspirates from adult patients in Kenya. Author(s): Scott JA, Marston EL, Hall AJ, Marsh K. Source: Journal of Clinical Microbiology. 2003 June; 41(6): 2554-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12791880&dopt=Abstract
•
Diagnosis of pneumococcal pneumonia. Author(s): Leinonen M, Makela PH. Source: Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America. 2001 October 15; 33(8): 1440-1. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11565089&dopt=Abstract
•
Diagnosis of pneumonia by community health volunteers: experience of BRAC, Bangladesh. Author(s): Hadi A. Source: Trop Doct. 2001 April; 31(2): 75-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11321276&dopt=Abstract
•
Diagnostic and therapeutic management of nosocomial pneumonia in surgical patients: results of the Eole study. Author(s): Montravers P, Veber B, Auboyer C, Dupont H, Gauzit R, Korinek AM, Malledant Y, Martin C, Moine P, Pourriat JL. Source: Critical Care Medicine. 2002 February; 30(2): 368-75. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11889312&dopt=Abstract
•
Diagnostic investigation of ventilator-associated pneumonia using bronchoalveolar lavage: comparative study with a postmortem lung biopsy. Author(s): Balthazar AB, Von Nowakonski A, De Capitani EM, Bottini PV, Terzi RG, Araujo S. Source: Brazilian Journal of Medical and Biological Research = Revista Brasileira De Pesquisas Medicas E Biologicas / Sociedade Brasileira De Biofisica. [et Al.]. 2001 August; 34(8): 993-1001. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11471037&dopt=Abstract
210 Pneumonia
•
Diagnostic value of D dimer in pulmonary embolism and pneumonia. Author(s): Castro DJ, Perez-Rodriguez E, Montaner L, Flores J, Nuevo GD. Source: Respiration; International Review of Thoracic Diseases. 2001; 68(4): 371-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11464083&dopt=Abstract
•
Differences in mortality among patients with community-acquired pneumonia in California by ethnicity and hospital characteristics. Author(s): Haas JS, Dean ML, Hung Y, Rennie DJ. Source: The American Journal of Medicine. 2003 June 1; 114(8): 660-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12798454&dopt=Abstract
•
Differential role for T cells in the development of fibrotic lesions associated with reovirus 1/L-induced bronchiolitis obliterans organizing pneumonia versus Acute Respiratory Distress Syndrome. Author(s): Majeski EI, Harley RA, Bellum SC, London SD, London L. Source: American Journal of Respiratory Cell and Molecular Biology. 2003 February; 28(2): 208-17. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12540488&dopt=Abstract
•
Differentiation of bacterial and viral pneumonia in children. Author(s): Virkki R, Juven T, Rikalainen H, Svedstrom E, Mertsola J, Ruuskanen O. Source: Thorax. 2002 May; 57(5): 438-41. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11978922&dopt=Abstract
•
Discontinuation of primary prophylaxis in HIV-infected patients at high risk of Pneumocystis carinii pneumonia: prospective multicentre study. Author(s): Furrer H, Opravil M, Rossi M, Bernasconi E, Telenti A, Bucher H, Schiffer V, Boggian K, Rickenbach M, Flepp M, Egger M; Swiss HIV Cohort Study. Source: Aids (London, England). 2001 March 9; 15(4): 501-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11242147&dopt=Abstract
•
Discontinuation of secondary prophylaxis against Pneumocystis carinii pneumonia in patients with HIV infection who have a response to antiretroviral therapy. Eight European Study Groups. Author(s): Ledergerber B, Mocroft A, Reiss P, Furrer H, Kirk O, Bickel M, Uberti-Foppa C, Pradier C, D'Arminio Monforte A, Schneider MM, Lundgren JD; Eight European Study Groups. Source: The New England Journal of Medicine. 2001 January 18; 344(3): 168-74. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11188837&dopt=Abstract
Studies 211
•
Discontinuation of secondary prophylaxis and the risk of Pneumocystis carinii pneumonia. Author(s): Miguez-Burbano MJ, Archer H, Rodriguez M, Shor-Posner G. Source: Aids (London, England). 2003 January 3; 17(1): 140-1. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12478087&dopt=Abstract
•
Discontinuation of secondary prophylaxis for Pneumocystis carinii pneumonia in human immunodeficiency virus-infected patients: a randomized trial by the CIOP Study Group. Author(s): Mussini C, Pezzotti P, Antinori A, Borghi V, Monforte A, Govoni A, De Luca A, Ammassari A, Mongiardo N, Cerri MC, Bedini A, Beltrami C, Ursitti MA, Bini T, Cossarizza A, Esposito R; Changes in Opportunistic Prophylaxis (CIOP) Study Group. Source: Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America. 2003 March 1; 36(5): 645-51. Epub 2003 February 12. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12594647&dopt=Abstract
•
Discontinuing prophylaxis against Pneumocystis carinii pneumonia. Author(s): Le Moal G, Breux JP, Roblot F. Source: The New England Journal of Medicine. 2001 May 24; 344(21): 1639-41. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11374363&dopt=Abstract
•
Discontinuing prophylaxis against Pneumocystis carinii pneumonia. Author(s): Bender MA, Sax PE. Source: The New England Journal of Medicine. 2001 May 24; 344(21): 1639; Author Reply 1640-1. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11374364&dopt=Abstract
•
Disseminated Pseudomonas aeruginosa and necrotizing pneumonia with complete recovery. Author(s): Kumar PD, Ravakhah K, West BC. Source: Southern Medical Journal. 2001 February; 94(2): 229-32. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11235039&dopt=Abstract
•
Distribution of Pneumocystis carinii f. sp. hominis types in the lung of a child dying of Pneumocystis pneumonia. Author(s): Ambrose HE, Ponce CA, Wakefield AE, Miller RF, Vargas SL. Source: Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America. 2001 November 1; 33(9): E100-2. Epub 2001 September 24. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11568852&dopt=Abstract
212 Pneumonia
•
Disturbed surface properties in preterm infants with pneumonia. Author(s): Rudiger M, Friedrich W, Rustow B, Schmalisch G, Wauer R. Source: Biology of the Neonate. 2001 February; 79(2): 73-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11223646&dopt=Abstract
•
Do guidelines for community-acquired pneumonia improve the cost-effectiveness of hospital care? Author(s): Nathwani D, Rubinstein E, Barlow G, Davey P. Source: Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America. 2001 March 1; 32(5): 728-41. Epub 2001 February 28. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11229840&dopt=Abstract
•
Do published guidelines predict pneumonia in children presenting to an urban ED? Author(s): Rothrock SG, Green SM, Fanelli JM, Cruzen E, Costanzo KA, Pagane J. Source: Pediatric Emergency Care. 2001 August; 17(4): 240-3. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11493820&dopt=Abstract
•
Do viridans streptococci cause pneumonia in children? Author(s): Nascimento-Carvalho CM, Brandileone MC, Guerra ML, Di Fabio JL. Source: The Pediatric Infectious Disease Journal. 2001 July; 20(7): 726-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11465856&dopt=Abstract
•
Does bronchoalveolar lavage enhance our ability to treat ventilator-associated pneumonia in a trauma-burn intensive care unit? Author(s): Wahl WL, Franklin GA, Brandt MM, Sturm L, Ahrns KS, Hemmila MR, Arbabi S. Source: The Journal of Trauma. 2003 April; 54(4): 633-8; Discussion 638-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12707523&dopt=Abstract
•
Does smoking contribute to community acquired pneumonia? Author(s): Peach H, Barnett N. Source: Aust Fam Physician. 2001 January; 30(1): 10. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11211703&dopt=Abstract
•
Does the use of fluoroquinolones for the empiric treatment of pneumonia delay initiation of treatment of tuberculosis? Author(s): Abiad H. Source: Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America. 2002 December 15; 35(12): 1572; Author Reply 1572-3. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12471582&dopt=Abstract
Studies 213
•
Dollars and sense in the intensive care unit: the costs of ventilator-associated pneumonia. Author(s): Shorr AF, Wunderink RG. Source: Critical Care Medicine. 2003 May; 31(5): 1582-3. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12771639&dopt=Abstract
•
Doppler echocardiographic evaluation of pulmonary artery pressure in children with acute pneumonia. Author(s): Uner A, Caksen H, Arslan S, Abuhandan M, Oner AF, Odabas D. Source: Acta Paediatr Taiwan. 2002 January-February; 43(1): 10-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11890220&dopt=Abstract
•
Doxycycline for treatment of community-acquired pneumonia. Author(s): Johnson JR. Source: Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America. 2002 September 1; 35(5): 632; Author Reply 632-3. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12173142&dopt=Abstract
•
Duration of antimicrobial therapy for nosocomial pneumonia: possible strategies for minimizing antimicrobial use in intensive care units. Author(s): Dugan HA, MacLaren R, Jung R. Source: Journal of Clinical Pharmacy and Therapeutics. 2003 April; 28(2): 123-9. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12713609&dopt=Abstract
•
Dying from or with a nosocomial pneumonia in the intensive care unit? Author(s): Carlet J. Source: Critical Care Medicine. 2001 December; 29(12): 2392-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11801851&dopt=Abstract
•
Dynamics of cytokines and role of immunocorrection in nosocomial pneumonia. Author(s): Kuznetsov VP, Markelova EV, Silich EV, Belyaev DL, Babayants AA, Kuznetsova SY. Source: Russ J Immunol. 2002 July; 7(2): 151-60. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12687258&dopt=Abstract
•
Early IL-6 plasma concentrations correlate with severity of brain injury and pneumonia in brain-injured patients. Author(s): Woiciechowsky C, Schoning B, Cobanov J, Lanksch WR, Volk HD, Docke WD. Source: The Journal of Trauma. 2002 February; 52(2): 339-45. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11834998&dopt=Abstract
214 Pneumonia
•
Early switch and early discharge strategies in patients with community-acquired pneumonia: a meta-analysis. Author(s): Rhew DC, Tu GS, Ofman J, Henning JM, Richards MS, Weingarten SR. Source: Archives of Internal Medicine. 2001 March 12; 161(5): 722-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11231705&dopt=Abstract
•
Early switch from intravenous to oral antibiotics in hospitalized patients with bacteremic community-acquired Streptococcus pneumoniae pneumonia. Author(s): Ramirez JA, Bordon J. Source: Archives of Internal Medicine. 2001 March 26; 161(6): 848-50. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11268227&dopt=Abstract
•
Early trauma polymorphonuclear neutrophil responses to chemokines are associated with development of sepsis, pneumonia, and organ failure. Author(s): Adams JM, Hauser CJ, Livingston DH, Lavery RF, Fekete Z, Deitch EA. Source: The Journal of Trauma. 2001 September; 51(3): 452-6; Discussion 456-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11535890&dopt=Abstract
•
Early-onset Pneumocystis carinii pneumonia complicating Norwood II operation in a 3-month-old patient. Author(s): Dittrich S, Grollmuss O, Kruger M, Hentschel R, Mehwald P, Schlensak C, Kececioglu D. Source: Intensive Care Medicine. 2002 November; 28(11): 1685-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12583383&dopt=Abstract
•
Eccentric mitral regurgitation can imitate a diagnosis of pneumonia. Author(s): Orgus T, Altinmakus S, Bilgen F. Source: International Journal of Cardiology. 2001 February; 77(2-3): 307-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11393134&dopt=Abstract
•
Effect of an education program aimed at reducing the occurrence of ventilatorassociated pneumonia. Author(s): Zack JE, Garrison T, Trovillion E, Clinkscale D, Coopersmith CM, Fraser VJ, Kollef MH. Source: Critical Care Medicine. 2002 November; 30(11): 2407-12. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12441746&dopt=Abstract
•
Effect of continuous lateral rotational therapy on the prevalence of ventilatorassociated pneumonia in patients requiring long-term ventilatory care. Author(s): Kirschenbaum L, Azzi E, Sfeir T, Tietjen P, Astiz M. Source: Critical Care Medicine. 2002 September; 30(9): 1983-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12352030&dopt=Abstract
Studies 215
•
Effect of design-related bias in studies of diagnostic tests for ventilator-associated pneumonia. Author(s): Michaud S, Suzuki S, Harbarth S. Source: American Journal of Respiratory and Critical Care Medicine. 2002 November 15; 166(10): 1320-5. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12421741&dopt=Abstract
•
Effect of enriched thioglycolate on direct examination of respiratory specimens and guiding initial empirical therapy in intubated patients with pneumonia: a prospective, randomized study. Author(s): Rello J, Mariscal D, Gallego M, Valles J. Source: Critical Care Medicine. 2002 February; 30(2): 311-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11889300&dopt=Abstract
•
Effect of maclorides on duration and resolution of symptoms and complication of pneumonia in children with influenza. Author(s): Ninomiya K, Fukui T, Imai T, Matsui M, Matsuoka K. Source: Journal of Nippon Medical School = Nihon Ika Daigaku Zasshi. 2002 February; 69(1): 53-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11847511&dopt=Abstract
•
Effect of pneumonia case management on mortality in neonates, infants, and preschool children: a meta-analysis of community-based trials. Author(s): Sazawal S, Black RE; Pneumonia Case Management Trials Group. Source: The Lancet Infectious Diseases. 2003 September; 3(9): 547-56. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12954560&dopt=Abstract
•
Effect of step-down therapy of ceftriaxone plus loracarbef versus parenteral therapy of ceftriaxone on the intestinal microflora in patients with community-acquired pneumonia. Author(s): Vogel F, Ochs HR, Wettich K, Kalich S, Nilsson-Ehle I, Odenholt I, Nord CE. Source: Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases. 2001 July; 7(7): 376-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11531985&dopt=Abstract
•
Effectiveness of 0.12% chlorhexidine gluconate oral rinse in reducing prevalence of nosocomial pneumonia in patients undergoing heart surgery. Author(s): Houston S, Hougland P, Anderson JJ, LaRocco M, Kennedy V, Gentry LO. Source: American Journal of Critical Care : an Official Publication, American Association of Critical-Care Nurses. 2002 November; 11(6): 567-70. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12425407&dopt=Abstract
216 Pneumonia
•
Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than five years of age for prevention of pneumonia. Author(s): Black SB, Shinefield HR, Ling S, Hansen J, Fireman B, Spring D, Noyes J, Lewis E, Ray P, Lee J, Hackell J. Source: The Pediatric Infectious Disease Journal. 2002 September; 21(9): 810-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12352800&dopt=Abstract
•
Effectiveness of oral moxifloxacin in standard first-line therapy in communityacquired pneumonia. Author(s): Torres A, Muir JF, Corris P, Kubin R, Duprat-Lomon I, Sagnier PP, Hoffken G. Source: The European Respiratory Journal : Official Journal of the European Society for Clinical Respiratory Physiology. 2003 January; 21(1): 135-43. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12570122&dopt=Abstract
•
Effectiveness of twice-weekly pyrimethamine-sulfadoxine as primary prophylaxis of Pneumocystis carinii pneumonia and toxoplasmic encephalitis in patients with advanced HIV infection. Author(s): Schurmann D, Bergmann F, Albrecht H, Padberg J, Wunsche T, Grunewald T, Schurmann M, Grobusch M, Vallee M, Ruf B, Suttorp N. Source: European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology. 2002 May; 21(5): 353-61. Epub 2002 May 18. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12072919&dopt=Abstract
•
Effectiveness, safety and tolerability of gatifloxacin, a new 8methoxyfluoroquinolone, in the treatment of outpatients with community-acquired pneumonia: a Brazilian study. Author(s): Franca SA, Carvalho CR. Source: The Brazilian Journal of Infectious Diseases : an Official Publication of the Brazilian Society of Infectious Diseases. 2002 August; 6(4): 157-63. Epub 2003 April 01. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12204182&dopt=Abstract
•
Effects of a practice guideline for community-acquired pneumonia in an outpatient setting. Author(s): Suchyta MR, Dean NC, Narus S, Hadlock CJ. Source: The American Journal of Medicine. 2001 March; 110(4): 306-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11239849&dopt=Abstract
Studies 217
•
Effects of antibiotics on protected specimen brush sampling in ventilator-associated pneumonia. Author(s): Prats E, Dorca J, Pujol M, Garcia L, Barreiro B, Verdaguer R, Gudiol F, Manresa F. Source: The European Respiratory Journal : Official Journal of the European Society for Clinical Respiratory Physiology. 2002 May; 19(5): 944-51. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12030737&dopt=Abstract
•
Efficacy and pharmacodynamics of simulated human-like treatment with levofloxacin on experimental pneumonia induced with penicillin-resistant pneumococci with various susceptibilities to fluoroquinolones. Author(s): Croisier D, Chavanet P, Lequeu C, Ahanou A, Nierlich A, Neuwirth C, Piroth L, Duong M, Buisson M, Portier H. Source: The Journal of Antimicrobial Chemotherapy. 2002 September; 50(3): 349-60. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12205059&dopt=Abstract
•
Efficacy and safety of gatifloxacin in elderly outpatients with community-acquired pneumonia. Author(s): Nicholson SC, Wilson WR, Naughton BJ, Gothelf S, Webb CD. Source: Diagnostic Microbiology and Infectious Disease. 2002 September; 44(1): 117-25. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12376041&dopt=Abstract
•
Efficacy and safety of gemifloxacin in the treatment of community-acquired pneumonia: a randomized, double-blind comparison with trovafloxacin. Author(s): File TM Jr, Schlemmer B, Garau J, Cupo M, Young C; 049 Clinical Study Group. Source: The Journal of Antimicrobial Chemotherapy. 2001 July; 48(1): 67-74. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11474633&dopt=Abstract
•
Efficacy and safety of telithromycin in community-acquired pneumonia. Author(s): Van Rensburg DJ, Matthews PA, Leroy B. Source: Current Medical Research and Opinion. 2002; 18(7): 397-400. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12487505&dopt=Abstract
•
Efficacy and tolerability of once-daily oral therapy with telithromycin compared with trovafloxacin for the treatment of community-acquired pneumonia in adults. Author(s): Pullman J, Champlin J, Vrooman PS Jr. Source: Int J Clin Pract. 2003 June; 57(5): 377-84. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12846341&dopt=Abstract
218 Pneumonia
•
Efficacy and tolerability of once-daily telithromycin compared with high-dose amoxicillin for treatment of community-acquired pneumonia. Author(s): Hagberg L, Torres A, van Rensburg D, Leroy B, Rangaraju M, Ruuth E. Source: Infection. 2002 December; 30(6): 378-86. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12478329&dopt=Abstract
•
Efficacy of amoxicillin-sulbactam, given twice-a-day, for the treatment of communityacquired pneumonia: a clinical trial based on a pharmacodynamic model. Author(s): Jasovich A, Soutric J, Morera G, Mastruzzo M, Vesco E, Izaguirre M, Mobilia L, Prieto S, Franco D, Curcio D, Absi R, Larrateguy L, Bustos JL, Oliva ME, Arenoso H, Bantar C. Source: Journal of Chemotherapy (Florence, Italy). 2002 December; 14(6): 591-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12583551&dopt=Abstract
•
Efficacy of cefepime versus ceftazidime in the treatment of adult pneumonia. Author(s): Lin JC, Yeh KM, Peng MY, Chang FY. Source: J Microbiol Immunol Infect. 2001 June; 34(2): 131-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11456359&dopt=Abstract
•
Efficacy of intravenous immunoglobulin in the prevention of pneumonia in patients with common variable immunodeficiency. Author(s): Busse PJ, Razvi S, Cunningham-Rundles C. Source: The Journal of Allergy and Clinical Immunology. 2002 June; 109(6): 1001-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12063531&dopt=Abstract
•
Efficacy of recombinant human granulocyte colony-stimulating factor in a murine model of pneumococcal pneumonia: effects of lung inflammation and timing of treatment. Author(s): Dallaire F, Ouellet N, Simard M, Bergeron Y, Bergeron MG. Source: The Journal of Infectious Diseases. 2001 January 1; 183(1): 70-7. Epub 2000 November 15. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11087202&dopt=Abstract
•
Elderly trauma patients with rib fractures are at greater risk of death and pneumonia. Author(s): Bergeron E, Lavoie A, Clas D, Moore L, Ratte S, Tetreault S, Lemaire J, Martin M. Source: The Journal of Trauma. 2003 March; 54(3): 478-85. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12634526&dopt=Abstract
Studies 219
•
Electrocardiogram in Pneumocystis carinii pneumonia: can it be used as a prognostic variable? Author(s): Caldera AE, Crespo GJ, Maraj S, Kotler M, Braitman LE, Eiger G. Source: Critical Care Medicine. 2002 July; 30(7): 1425-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12130956&dopt=Abstract
•
Elevated KL-6 levels in fatal measles pneumonia. Author(s): Narita M, Nakayama M, Yamada S, Togashi T. Source: European Journal of Pediatrics. 2001 July; 160(7): 454-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11475589&dopt=Abstract
•
Elevated levels of thymus- and activation-regulated chemokine in bronchoalveolar lavage fluid from patients with eosinophilic pneumonia. Author(s): Miyazaki E, Nureki S, Fukami T, Shigenaga T, Ando M, Ito K, Ando H, Sugisaki K, Kumamoto T, Tsuda T. Source: American Journal of Respiratory and Critical Care Medicine. 2002 April 15; 165(8): 1125-31. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11956056&dopt=Abstract
•
Elevation of serum KL-6 levels in patients with hematological malignancies associated with cytomegalovirus or Pneumocystis carinii pneumonia. Author(s): Tanaka M, Tanaka K, Fukahori S, Fujimatsu Y, Jojima H, Shiraishi K, Honda J, Oizumi K. Source: Hematology (Amsterdam, Netherlands). 2002 April; 7(2): 105-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12186700&dopt=Abstract
•
Elevations in procalcitonin but not C-reactive protein are associated with pneumonia after cardiopulmonary resuscitation. Author(s): Oppert M, Reinicke A, Muller C, Barckow D, Frei U, Eckardt KU. Source: Resuscitation. 2002 May; 53(2): 167-70. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12009220&dopt=Abstract
•
Email recruitment to use web decision support tools for pneumonia. Author(s): Flanagan JR, Peterson M, Dayton C, Strommer Pace L, Plank A, Walker K, Carlson WS. Source: Proceedings / Amia. Annual Symposium. Amia Symposium. 2002; : 255-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12463826&dopt=Abstract
220 Pneumonia
•
Emergence of levofloxacin-resistant pneumococci in immunocompromised adults after therapy for community-acquired pneumonia. Author(s): Anderson KB, Tan JS, File TM Jr, DiPersio JR, Willey BM, Low DE. Source: Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America. 2003 August 1; 37(3): 376-81. Epub 2003 July 14. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12884162&dopt=Abstract
•
Emergence of macrolide resistance during treatment of pneumococcal pneumonia. Author(s): Musher DM, Dowell ME, Shortridge VD, Flamm RK, Jorgensen JH, Le Magueres P, Krause KL. Source: The New England Journal of Medicine. 2002 February 21; 346(8): 630-1. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11856810&dopt=Abstract
•
Emerging resistance to antibiotics against respiratory bacteria: impact on therapy of community-acquired pneumonia in children. Author(s): Esposito S, Principi N. Source: Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy. 2002 April; 5(2): 73-87. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12135583&dopt=Abstract
•
Empiric treatment of community-acquired pneumonia with fluoroquinolones, and delays in the treatment of tuberculosis. Author(s): Dooley KE, Golub J, Goes FS, Merz WG, Sterling TR. Source: Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America. 2002 June 15; 34(12): 1607-12. Epub 2002 May 23. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12032896&dopt=Abstract
•
Endogenous endophthalmitis and necrotising pneumonia caused by Klebsiella pneumoniae in a child with beta-thalassaemia major. Author(s): Yao TC, Hung IJ, Su LH, Chiu CH. Source: European Journal of Pediatrics. 2001 July; 160(7): 449. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11475586&dopt=Abstract
•
Enhanced expression of Duffy antigen in the lungs during suppurative pneumonia. Author(s): Lee JS, Frevert CW, Thorning DR, Segerer S, Alpers CE, Cartron JP, Colin Y, Wong VA, Martin TR, Goodman RB. Source: The Journal of Histochemistry and Cytochemistry : Official Journal of the Histochemistry Society. 2003 February; 51(2): 159-66. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12533524&dopt=Abstract
Studies 221
•
Enhanced resistancy of thioredoxin-transgenic mice against influenza virus-induced pneumonia. Author(s): Nakamura H, Tamura S, Watanabe I, Iwasaki T, Yodoi J. Source: Immunology Letters. 2002 June 3; 82(1-2): 165-70. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12008049&dopt=Abstract
•
Enteral naloxone reduces gastric tube reflux and frequency of pneumonia in critical care patients during opioid analgesia. Author(s): Meissner W, Dohrn B, Reinhart K. Source: Critical Care Medicine. 2003 March; 31(3): 776-80. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12626983&dopt=Abstract
•
Eosinophilic pneumonia after administration of fludarabine for the treatment of nonHodgkin's lymphoma. Author(s): Trojan A, Meier R, Licht A, Taverna C. Source: Annals of Hematology. 2002 September; 81(9): 535-7. Epub 2002 August 01. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12373357&dopt=Abstract
•
Eosinophilic pneumonia in an infant. Author(s): Makimoto A, Pearson MG, Jaffe N, Colasurdo GN. Source: Medical and Pediatric Oncology. 2002 January; 38(1): 75-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11835248&dopt=Abstract
•
Eotaxin and monocyte chemoattractant protein-1 in chronic eosinophilic pneumonia. Author(s): Tateno H, Nakamura H, Minematsu N, Amakawa K, Terashima T, Fujishima S, Luster AD, Lilly CM, Yamaguchi K. Source: The European Respiratory Journal : Official Journal of the European Society for Clinical Respiratory Physiology. 2001 May; 17(5): 962-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11488333&dopt=Abstract
•
Epidemiologic trends in the hospitalization of elderly Medicare patients for pneumonia, 1991-1998. Author(s): Baine WB, Yu W, Summe JP. Source: American Journal of Public Health. 2001 July; 91(7): 1121-3. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11441742&dopt=Abstract
•
Epidemiology and impact of aspiration pneumonia in patients undergoing surgery in Maryland, 1999-2000. Author(s): Kozlow JH, Berenholtz SM, Garrett E, Dorman T, Pronovost PJ. Source: Critical Care Medicine. 2003 July; 31(7): 1930-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12847385&dopt=Abstract
222 Pneumonia
•
Epidemiology and outcomes of ventilator-associated pneumonia in a large US database. Author(s): Rello J, Ollendorf DA, Oster G, Vera-Llonch M, Bellm L, Redman R, Kollef MH; VAP Outcomes Scientific Advisory Group. Source: Chest. 2002 December; 122(6): 2115-21. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12475855&dopt=Abstract
•
Epidemiology of pneumonia hospitalizations in Spain, 1995-1998. Author(s): Gil A, San-Martin M, Carrasco P, Gonzalez A. Source: The Journal of Infection. 2002 February; 44(2): 84-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12076066&dopt=Abstract
•
Estimated frequency of nursing facility-acquired pneumonia? Author(s): Metersky M, Angus DC, Linde-Zwirble WT. Source: American Journal of Respiratory and Critical Care Medicine. 2003 May 1; 167(9): 1287-8; Author Reply 1288. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12714345&dopt=Abstract
•
Etanercept (Enbrel) administration for idiopathic pneumonia syndrome after allogeneic hematopoietic stem cell transplantation. Author(s): Yanik G, Hellerstedt B, Custer J, Hutchinson R, Kwon D, Ferrara JL, Uberti J, Cooke KR. Source: Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation. 2002; 8(7): 395-400. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12171486&dopt=Abstract
•
Etiological diagnosis of childhood pneumonia by use of transthoracic needle aspiration and modern microbiological methods. Author(s): Vuori-Holopainen E, Salo E, Saxen H, Hedman K, Hyypia T, Lahdenpera R, Leinonen M, Tarkka E, Vaara M, Peltola H. Source: Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America. 2002 March 1; 34(5): 583-90. Epub 2002 January 16. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11803504&dopt=Abstract
•
Etiology and management of community-acquired pneumonia in Asia. Author(s): Matsushima T, Miyashita N, File TM Jr. Source: Current Opinion in Infectious Diseases. 2002 April; 15(2): 157-62. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11964917&dopt=Abstract
Studies 223
•
Etiology of childhood community acquired pneumonia and its implications for vaccination. Author(s): Nascimento-Carvalho CM. Source: The Brazilian Journal of Infectious Diseases : an Official Publication of the Brazilian Society of Infectious Diseases. 2001 April; 5(2): 87-97. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11493414&dopt=Abstract
•
Etiology of severe pneumonia in the very elderly. Author(s): El-Solh AA, Sikka P, Ramadan F, Davies J. Source: American Journal of Respiratory and Critical Care Medicine. 2001 March; 163(3 Pt 1): 645-51. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11254518&dopt=Abstract
•
Etiology, reasons for hospitalization, risk classes, and outcomes of communityacquired pneumonia in patients hospitalized on the basis of conventional admission criteria. Author(s): Roson B, Carratala J, Dorca J, Casanova A, Manresa F, Gudiol F. Source: Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America. 2001 July 15; 33(2): 158-65. Epub 2001 June 15. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11418874&dopt=Abstract
•
European best practice guidelines for renal transplantation. Section IV: Long-term management of the transplant recipient. IV.7.1 Late infections. Pneumocystis carinii pneumonia. Author(s): EBPG Expert Group on Renal Transplantation. Source: Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association. 2002; 17 Suppl 4: 369. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12091642&dopt=Abstract
•
Evaluation of a PCR assay for detection of Streptococcus pneumoniae in respiratory and nonrespiratory samples from adults with community-acquired pneumonia. Author(s): Murdoch DR, Anderson TP, Beynon KA, Chua A, Fleming AM, Laing RT, Town GI, Mills GD, Chambers ST, Jennings LC. Source: Journal of Clinical Microbiology. 2003 January; 41(1): 63-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12517826&dopt=Abstract
•
Evaluation of children with recurrent pneumonia diagnosed by World Health Organization criteria. Author(s): Heffelfinger JD, Davis TE, Gebrian B, Bordeau R, Schwartz B, Dowell SF. Source: The Pediatric Infectious Disease Journal. 2002 February; 21(2): 108-12. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11840076&dopt=Abstract
224 Pneumonia
•
Evaluation of endotoxin release and cytokine production induced by antibiotics in patients with Gram-negative nosocomial pneumonia. Author(s): Maskin B, Fontan PA, Spinedi EG, Gammella D, Badolati A. Source: Critical Care Medicine. 2002 February; 30(2): 349-54. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11889308&dopt=Abstract
•
Evaluation of nonresolving and progressive pneumonia. Author(s): Menendez R, Perpina M, Torres A. Source: Seminars in Respiratory Infections. 2003 June; 18(2): 103-11. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12840791&dopt=Abstract
•
Evaluation of outcomes in community-acquired pneumonia: a guide for patients, physicians, and policy-makers. Author(s): Barlow GD, Lamping DL, Davey PG, Nathwani D. Source: The Lancet Infectious Diseases. 2003 August; 3(8): 476-88. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12901890&dopt=Abstract
•
Evaluation of panipenem/betamipron (PAPM/BP) in pneumonia in elderly patients. Author(s): Shibuya Y, Kitamura S, Tani G, Fukushima Y, Yatagai S, Nakamoto T, Motojima S. Source: Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy. 2002 June; 8(2): 151-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12111568&dopt=Abstract
•
Evaluation of the immunochromatographic Binax NOW assay for detection of Streptococcus pneumoniae urinary antigen in a prospective study of communityacquired pneumonia in Spain. Author(s): Gutierrez F, Masia M, Rodriguez JC, Ayelo A, Soldan B, Cebrian L, Mirete C, Royo G, Hidalgo AM. Source: Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America. 2003 February 1; 36(3): 286-92. Epub 2003 January 15. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12539069&dopt=Abstract
•
Evidence based medicine: review of BTS guidelines for the management of community acquired pneumonia in adults. Author(s): Mckean MC. Source: The Journal of Infection. 2002 November; 45(4): 213-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12423607&dopt=Abstract
Studies 225
•
Evidence of type II pneumocyte apoptosis in the pathogenesis of idiopathic pulmonary fibrosis (IFP)/usual interstitial pneumonia (UIP). Author(s): Barbas-Filho JV, Ferreira MA, Sesso A, Kairalla RA, Carvalho CR, Capelozzi VL. Source: Journal of Clinical Pathology. 2001 February; 54(2): 132-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11215282&dopt=Abstract
•
Evidence-based guidelines for management of nursing home-acquired pneumonia. Author(s): Hutt E, Kramer AM. Source: The Journal of Family Practice. 2002 August; 51(8): 709-16. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12184969&dopt=Abstract
•
Exhaled breath condensate and serum levels of hepatocyte growth factor in pneumonia. Author(s): Nayeri F, Millinger E, Nilsson I, Zetterstrom, Brudin L, Forsberg P. Source: Respiratory Medicine. 2002 February; 96(2): 115-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11860168&dopt=Abstract
•
Exogenous lipoid pneumonia following ingestion of liquid paraffin. Author(s): Ohwada A, Yoshioka Y, Shimanuki Y, Mitani K, Kumasaka T, Dambara T, Fukuchi Y. Source: Intern Med. 2002 June; 41(6): 483-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12135184&dopt=Abstract
•
Exogenous lipoid pneumonia with unusual CT pattern and FDG positron emission tomography scan findings. Author(s): Tahon F, Berthezene Y, Hominal S, Blineau N, Guerin JC, Cinotti L, Marchand B. Source: European Radiology. 2002 December; 12 Suppl 3: S171-3. Epub 2002 October 01. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12522633&dopt=Abstract
•
Experience with a clinical guideline for the treatment of ventilator-associated pneumonia. Author(s): Ibrahim EH, Ward S, Sherman G, Schaiff R, Fraser VJ, Kollef MH. Source: Critical Care Medicine. 2001 June; 29(6): 1109-15. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11395584&dopt=Abstract
•
Exposure to allogeneic plasma and risk of postoperative pneumonia and/or wound infection in coronary artery bypass graft surgery. Author(s): Vamvakas EC, Carven JH. Source: Transfusion. 2002 January; 42(1): 107-13. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11896321&dopt=Abstract
226 Pneumonia
•
Exposure to metal fume and infectious pneumonia. Author(s): Palmer KT, Poole J, Ayres JG, Mann J, Burge PS, Coggon D. Source: American Journal of Epidemiology. 2003 February 1; 157(3): 227-33. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12543622&dopt=Abstract
•
Factors associated with death among adults <55 years of age hospitalized for community-acquired pneumonia. Author(s): Marrie TJ, Carriere KC, Jin Y, Johnson DH. Source: Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America. 2003 February 15; 36(4): 413-21. Epub 2003 January 22. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12567298&dopt=Abstract
•
Factors associated with hospitalization costs for patients with community-acquired pneumonia. Author(s): Merchant S, Mullins CD, Shih YC. Source: Clinical Therapeutics. 2003 February; 25(2): 593-610. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12749516&dopt=Abstract
•
Factors associated with unknown aetiology in patients with community-acquired pneumonia. Author(s): Ewig S, Torres A, Angeles Marcos M, Angrill J, Rano A, de Roux A, Mensa J, Martinez JA, de la Bellacasa JP, Bauer T. Source: The European Respiratory Journal : Official Journal of the European Society for Clinical Respiratory Physiology. 2002 November; 20(5): 1254-62. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12449182&dopt=Abstract
•
Factors contributing to high mortality due to pneumonia among under-fives in Kalabo District, Zambia. Author(s): Stekelenburg J, Kashumba E, Wolffers I. Source: Tropical Medicine & International Health : Tm & Ih. 2002 October; 7(10): 886-93. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12358625&dopt=Abstract
•
Factors predicting ventilator-associated pneumonia recurrence. Author(s): Combes A, Figliolini C, Trouillet JL, Kassis N, Dombret MC, Wolff M, Gibert C, Chastre J. Source: Critical Care Medicine. 2003 April; 31(4): 1102-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12682479&dopt=Abstract
•
Failure of trimethoprim/sulfamethoxazole prophylaxis for Pneumocystis carinii pneumonia with concurrent leucovorin use. Author(s): Razavi B, Lund B, Allen BL, Schlesinger L. Source: Infection. 2002 January; 30(1): 41-2. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11876516&dopt=Abstract
Studies 227
•
Failure to thrive and history of pneumocystis carinii pneumonia in a six-year-old Hispanic boy. Author(s): Abarbanell G, Janner D. Source: The Pediatric Infectious Disease Journal. 2002 March; 21(3): 259, 268-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12005094&dopt=Abstract
•
Fatal aspiration pneumonia during transition from donepezil to rivastigmine. Author(s): Taylor AM, Hoehns JD, Anderson DM, Tobert DG. Source: The Annals of Pharmacotherapy. 2002 October; 36(10): 1550-3. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12243604&dopt=Abstract
•
Fatal case of influenza B virus pneumonia in a preterm neonate. Author(s): van den Dungen FA, van Furth AM, Fetter WP, Zaaijer HL, van Elburg RM. Source: The Pediatric Infectious Disease Journal. 2001 January; 20(1): 82-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11176576&dopt=Abstract
•
Fatal case of pneumonia caused by a nonhemolytic strain of Streptococcus pyogenes. Author(s): Taylor MB, Barkham T. Source: Journal of Clinical Microbiology. 2002 June; 40(6): 2311-2. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12037120&dopt=Abstract
•
Fatal idiopathic acute eosinophilic pneumonia with acute lung injury. Author(s): Kawayama T, Fujiki R, Morimitsu Y, Rikimaru T, Aizawa H. Source: Respirology (Carlton, Vic.). 2002 December; 7(4): 373-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12421248&dopt=Abstract
•
Fatal legionella pneumonia after fludarabine treatment in chronic lymphocytic leukaemia. Author(s): Hendrick A. Source: Journal of Clinical Pathology. 2001 May; 54(5): 412-3. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11328847&dopt=Abstract
•
Fatal Pneumocystis carinii pneumonia in HIV-seropositive infants in Harare, Zimbabwe. Author(s): Nathoo KJ, Gondo M, Gwanzura L, Mhlanga BR, Mavetera T, Mason PR. Source: Trans R Soc Trop Med Hyg. 2001 January-February; 95(1): 37-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11280062&dopt=Abstract
228 Pneumonia
•
Fatal sepsis in an AIDS patient during therapy for Pneumocystis carinii pneumonia. Author(s): Piso RJ, Rossi M, Oehler T, Nguyen XM, Tauber MG. Source: Infection. 2002 October; 30(5): 314-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12382094&dopt=Abstract
•
Fever, abdominal pain, and interstitial pneumonia in a 13-year-old female. Author(s): Tangsinmankong N, Khan HA, Jones OY, Good RA. Source: Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology. 2003 May; 90(5): 485-90. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12775129&dopt=Abstract
•
Fever, cough, and bilateral lung infiltrates. Achalasia associated with aspiration pneumonia. Author(s): Akritidis N, Gousis C, Dimos G, Paparounas K. Source: Chest. 2003 February; 123(2): 608-12. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12576387&dopt=Abstract
•
Fibroblastic foci in usual interstitial pneumonia: idiopathic versus collagen vascular disease. Author(s): Flaherty KR, Colby TV, Travis WD, Toews GB, Mumford J, Murray S, Thannickal VJ, Kazerooni EA, Gross BH, Lynch JP 3rd, Martinez FJ. Source: American Journal of Respiratory and Critical Care Medicine. 2003 May 15; 167(10): 1410-5. Epub 2003 February 20. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12615630&dopt=Abstract
•
Filgrastim in patients with pneumonia and severe sepsis or septic shock. Author(s): Wunderink R, Leeper K Jr, Schein R, Nelson S, DeBoisblanc B, Fotheringham N, Logan E. Source: Chest. 2001 February; 119(2): 523-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11171733&dopt=Abstract
•
Filgrastim treatment of acute myelogenous leukemia (M7) relapse after allogeneic peripheral stem cell transplantation resulting in both graft-versus-leukemia effect with cytogenetic remission and chronic graft-versus-host disease manifesting as polyserositis and subsequent bronchiolitis obliterans with organizing pneumonia. Author(s): Law L, Tuscano J, Wun T, Ahlberg K, Richman C. Source: International Journal of Hematology. 2002 November; 76(4): 360-4. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12463601&dopt=Abstract
•
Fire breathing pneumonia. Author(s): Moore M, Fitzgerald E, Bennett M. Source: Ir Med J. 2002 October; 95(9): 276-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12470000&dopt=Abstract
Studies 229
•
Fire eater's risk: lipoid pneumonia following aspiration of a liquid hydrocarbon mixture. Author(s): Junge B, Popp W, Ruehm S, Rettenmeier AW, Duhrsen U, Runzi M. Source: Pneumologie (Stuttgart, Germany). 2002 September; 56(9): 547-9. English, German. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12215913&dopt=Abstract
•
Flexible bronchoscopy in nosocomial pneumonia. Author(s): Ewig S, Torres A. Source: Clinics in Chest Medicine. 2001 June; 22(2): 263-79, Viii. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11444111&dopt=Abstract
•
Fluoroquinolones for the treatment of outpatient community-acquired pneumonia. Author(s): Jones RN, Mandell LA. Source: Diagnostic Microbiology and Infectious Disease. 2002 September; 44(1): 69-76. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12376035&dopt=Abstract
•
Focal organizing pneumonia: CT and pathologic findings. Author(s): Yang PS, Lee KS, Han J, Kim EA, Kim TS, Choo IW. Source: Journal of Korean Medical Science. 2001 October; 16(5): 573-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11641525&dopt=Abstract
•
Frequency and determinants of vitamin A deficiency in children under 5 years of age with pneumonia. Author(s): Reyes H, Villalpando S, Perez-Cuevas R, Rodriguez L, Perez-Cuevas M, Montalvo I, Guiscafre H. Source: Archives of Medical Research. 2002 March-April; 33(2): 180-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11886719&dopt=Abstract
•
Frequency of isolation of pathogens from bloodstream, nosocomial pneumonia, skin and soft tissue, and urinary tract infections occurring in European patients. Author(s): Fluit AC, Schmitz FJ, Verhoef J; European SENTRY Participant Group. Source: European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology. 2001 March; 20(3): 188-91. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11347669&dopt=Abstract
•
Frequency of Mycoplasma pneumoniae among atypical pneumonia of childhood. Author(s): Oguz F, Unuvar E, Aydin D, Yilmaz K, Sidal M. Source: Turk J Pediatr. 2002 October-December; 44(4): 283-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12458801&dopt=Abstract
230 Pneumonia
•
Frequency of sinusitis in the patients with pneumonia. Author(s): Ozbay B, Arslan H. Source: Clinical Imaging. 2002 March-April; 26(2): 92-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11852214&dopt=Abstract
•
Fulminant Mycoplasma pneumoniae pneumonia. Author(s): Takiguchi Y, Shikama N, Aotsuka N, Koseki H, Terano T, Hirai A. Source: Intern Med. 2001 April; 40(4): 345-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11334397&dopt=Abstract
•
Fulminant pneumonia due to Aeromonas hydrophila in a man with chronic renal failure and liver cirrhosis. Author(s): Murata H, Yoshimoto H, Masuo M, Tokuda H, Kitamura S, Otsuka Y, Miura Y. Source: Intern Med. 2001 February; 40(2): 118-23. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11300143&dopt=Abstract
•
Future considerations in aspiration pneumonia in the critically ill patient: what is not known, areas for future research, and experimental methods. Author(s): DiSario JA. Source: Jpen. Journal of Parenteral and Enteral Nutrition. 2002 November-December; 26(6 Suppl): S75-8; Discussion S79. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12405627&dopt=Abstract
•
Gatifloxacin used for therapy of outpatient community-acquired pneumonia caused by Streptococcus pneumoniae. Author(s): Jones RN, Andes DR, Mandell LA, Gothelf S, Ehrhardt AF, Nicholson SC. Source: Diagnostic Microbiology and Infectious Disease. 2002 September; 44(1): 93-100. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12376038&dopt=Abstract
•
G-CSF application in patients with severe bacterial pneumonia increases IL-10 expression in neutrophils. Author(s): Spuck S, Schaaf B, Wiedorn KH, Hansen F, Vollmer E, Dalhoff K, Braun J. Source: Respiratory Medicine. 2003 January; 97(1): 51-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12556011&dopt=Abstract
•
Genetic diversity of Pseudomonas aeruginosa strains isolated from ventilated patients with nosocomial pneumonia, cancer patients with bacteremia, and environmental water. Author(s): Ruimy R, Genauzeau E, Barnabe C, Beaulieu A, Tibayrenc M, Andremont A. Source: Infection and Immunity. 2001 January; 69(1): 584-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11119558&dopt=Abstract
Studies 231
•
Genotypes at the internal transcribed spacers of the nuclear rRNA operon of Pneumocystis jiroveci in nonimmunosuppressed infants without severe pneumonia. Author(s): Totet A, Pautard JC, Raccurt C, Roux P, Nevez G. Source: Journal of Clinical Microbiology. 2003 March; 41(3): 1173-80. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12624048&dopt=Abstract
•
Genotypes of clustered cases of Pneumocystis carinii pneumonia. Author(s): Olsson M, Eriksson BM, Elvin K, Strandberg M, Wahlgren M. Source: Scandinavian Journal of Infectious Diseases. 2001; 33(4): 285-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11345221&dopt=Abstract
•
Giant cell interstitial pneumonia in a 15-year-old boy. Author(s): Kakugawa T, Mukae H, Nagata T, Ishii H, Kaida H, Hayashi T, Suematsu T, Kadota J, Kohno S. Source: Intern Med. 2002 November; 41(11): 1007-12. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12487179&dopt=Abstract
•
Giant cell pneumonia in a leukemic child in remission: a case report. Author(s): Kanra G, Cetin I, Akcoren Z, Caglar M, Cengiz AB, Baykan A, Kara A. Source: Turk J Pediatr. 2001 October-December; 43(4): 338-41. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11765166&dopt=Abstract
•
Giant cells and pneumonia in a transplant patient. What is the link? Author(s): Kleshinski JF, Rao PS, Duggan J, Zaher A. Source: Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association. 2002 November; 17(11): 2030-2. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12401869&dopt=Abstract
•
Glycyrrhizin: an alternate drug for Pneumocystis carinii pneumonia in AIDS patients. Author(s): Badam L. Source: J Assoc Physicians India. 2002 February; 50: 287-8. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12038674&dopt=Abstract
•
Granulocyte colony-stimulating factor for severe pneumonia: what do we do when the best laid plans for men (and mice and rats.) fail? Author(s): Niederman MS. Source: Critical Care Medicine. 2003 February; 31(2): 635-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12576978&dopt=Abstract
232 Pneumonia
•
Granulomatous Pneumocystis carinii pneumonia complicating hematopoietic cell transplantation. Author(s): Gal AA, Plummer AL, Langston AA, Mansour KA. Source: Pathology, Research and Practice. 2002; 198(8): 553-8; Discussion 559-61. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12389999&dopt=Abstract
•
Granulomatous Pneumocystis carinii pneumonia in patients with malignancy. Author(s): Bondoc AY, White DA. Source: Thorax. 2002 May; 57(5): 435-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11978921&dopt=Abstract
•
Guidelines and critical pathways for severe hospital-acquired pneumonia. Author(s): Fiel S. Source: Chest. 2001 February; 119(2 Suppl): 412S-418S. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11171778&dopt=Abstract
•
Guidelines for community-acquired pneumonia in the US and Canada: a practical approach to antibiotic selection. Author(s): Ramirez JA. Source: Compr Ther. 2002 Fall; 28(3): 201-7. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12360632&dopt=Abstract
•
Guidelines for managing community acquired pneumonia in adults. Author(s): Keeley D. Source: Bmj (Clinical Research Ed.). 2002 February 23; 324(7335): 436-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11859031&dopt=Abstract
•
Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. Author(s): Niederman MS, Mandell LA, Anzueto A, Bass JB, Broughton WA, Campbell GD, Dean N, File T, Fine MJ, Gross PA, Martinez F, Marrie TJ, Plouffe JF, Ramirez J, Sarosi GA, Torres A, Wilson R, Yu VL; American Thoracic Society. Source: American Journal of Respiratory and Critical Care Medicine. 2001 June; 163(7): 1730-54. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11401897&dopt=Abstract
•
Guidelines for the management of community-acquired pneumonia in Saudi Arabia: a model for the Middle East region. Author(s): Memish ZA, Shibl AM, Ahmed QA; Saudi Arabian Community-Acquired Pneumonia Working Group (SACAPWG). Source: International Journal of Antimicrobial Agents. 2002; 20 Suppl 1: S1-12. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12445763&dopt=Abstract
Studies 233
•
Guidelines for the management of community-acquired pneumonia. Current recommendations and antibiotic selection issues. Author(s): Niederman MS. Source: The Medical Clinics of North America. 2001 November; 85(6): 1493-509. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11680113&dopt=Abstract
•
Guidelines for treatment of community-acquired pneumonia. Author(s): Kim MK, Nightingale C, Quintiliani R. Source: Conn Med. 2001 August; 65(8): 473-5. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11550446&dopt=Abstract
•
Have guidelines for the management of community-acquired pneumonia influenced outcomes? Author(s): Cazzola M, Centanni S, Blasi F. Source: Respiratory Medicine. 2003 March; 97(3): 205-11. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12645826&dopt=Abstract
•
Health labs focus on mystery pneumonia. Author(s): Cyranoski D. Source: Nature. 2003 March 20; 422(6929): 247. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12646882&dopt=Abstract
•
Heart failure and community-acquired pneumonia: cases for home hospital? Author(s): Santos-Eggimann B, Chavaz N, Larequi T, Lamy O, Yersin B. Source: International Journal for Quality in Health Care : Journal of the International Society for Quality in Health Care / Isqua. 2001 August; 13(4): 301-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11560349&dopt=Abstract
•
Heat shock protein 70-2+1267 AA homozygotes have an increased risk of septic shock in adults with community-acquired pneumonia. Author(s): Waterer GW, ElBahlawan L, Quasney MW, Zhang Q, Kessler LA, Wunderink RG. Source: Critical Care Medicine. 2003 May; 31(5): 1367-72. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12771604&dopt=Abstract
•
Hepatocyte growth factor may act as an early therapeutic predictor in pneumonia. Author(s): Nayeri F, Brudin L, Darelid J, Nilsson I, Fryden A, Soderstrom C, Forsberg P. Source: Scandinavian Journal of Infectious Diseases. 2002; 34(7): 500-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12195875&dopt=Abstract
234 Pneumonia
•
Herpes simplex type 2 pneumonia. Author(s): Calore EE. Source: The Brazilian Journal of Infectious Diseases : an Official Publication of the Brazilian Society of Infectious Diseases. 2002 December; 6(6): 305-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12585974&dopt=Abstract
•
Herpes simplex viral pneumonia after coronary artery bypass grafting. Author(s): Arata K, Sakata R, Iguro Y, Toda R, Watanabe S, Eitsuru Y. Source: Jpn J Thorac Cardiovasc Surg. 2003 April; 51(4): 158-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12723587&dopt=Abstract
•
Herpes simplex virus 1 pneumonia: conventional chest radiograph pattern. Author(s): Umans U, Golding RP, Duraku S, Manoliu RA. Source: European Radiology. 2001; 11(6): 990-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11419176&dopt=Abstract
•
Herpes simplex virus pneumonia after cardiac surgery: report of a case. Author(s): Shimokawa S, Watanabe S, Taira A, Eizuru Y. Source: Surgery Today. 2001; 31(9): 814-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11686562&dopt=Abstract
•
Herpes simplex virus pneumonia presenting as failure to wean from a ventilator. Author(s): Eisenstein LE, Cunha BA. Source: Heart & Lung : the Journal of Critical Care. 2003 January-February; 32(1): 65-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12571550&dopt=Abstract
•
Herpesvirus type 1-8 in BAL fluid from HIV-1-infected patients with suspected pneumonia and from healthy individuals. Author(s): Tarp B, Jensen-Fangel S, Dahl R, Obel N. Source: The European Respiratory Journal : Official Journal of the European Society for Clinical Respiratory Physiology. 2001 July; 18(1): 146-50. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11510785&dopt=Abstract
•
High concentration of (1-->3)-beta-D-glucan in BAL fluid in patients with acute eosinophilic pneumonia. Author(s): Kawayama T, Fujiki R, Honda J, Rikimaru T, Aizawa H. Source: Chest. 2003 April; 123(4): 1302-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12684329&dopt=Abstract
Studies 235
•
High levels of sulfated mucins in bronchoalveolar lavage fluid of ICU patients with ventilator-associated pneumonia. Author(s): Dennesen P, Veerman E, van Nieuw Amerongen A, Jacobs J, Kessels A, van der Keybus P, Ramsay G, van der Ven A. Source: Intensive Care Medicine. 2003 May; 29(5): 715-9. Epub 2003 March 25. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12655393&dopt=Abstract
•
High serum concentrations of surfactant protein A in usual interstitial pneumonia compared with non-specific interstitial pneumonia. Author(s): Ishii H, Mukae H, Kadota J, Kaida H, Nagata T, Abe K, Matsukura S, Kohno S. Source: Thorax. 2003 January; 58(1): 52-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12511721&dopt=Abstract
•
High short-term mortality following lung biopsy for usual interstitial pneumonia. Author(s): Utz JP, Ryu JH, Douglas WW, Hartman TE, Tazelaar HD, Myers JL, Allen MS, Schroeder DR. Source: The European Respiratory Journal : Official Journal of the European Society for Clinical Respiratory Physiology. 2001 February; 17(2): 175-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11334116&dopt=Abstract
•
Histopathological approach to patterns of interstitial pneumonia in patient with connective tissue disorders. Author(s): Nicholson AG, Colby TV, Wells AU. Source: Sarcoidosis Vasc Diffuse Lung Dis. 2002 March; 19(1): 10-7. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12002379&dopt=Abstract
•
Histopathology and prediction of survival in usual interstitial pneumonia. Author(s): Khoshnevis MR. Source: American Journal of Respiratory and Critical Care Medicine. 2002 May 15; 165(10): 1451; Author Reply 1451. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12016111&dopt=Abstract
•
HIV infection and chronic chest disease as risk factors for bacterial pneumonia: a case-control study. Author(s): Charalambous S, Day JH, Fielding K, De Cock KM, Churchyard GJ, Corbett EL. Source: Aids (London, England). 2003 July 4; 17(10): 1531-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12824791&dopt=Abstract
236 Pneumonia
•
HIV, Pneumocystis carinii pneumonia, and pneumothoraces. Author(s): Hoyt TL, Tarver RD. Source: Seminars in Respiratory Infections. 2002 December; 17(4): 315-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12497549&dopt=Abstract
•
HIV-associated community-acquired pneumonia in the highly active antiretroviral therapy era. Author(s): Viale P, Scudeller L, Signorini L, Cadeo B, Petrosillo N, Pagani L, Carosi G; POP-HIV Study Group. Pneumonia Outcome Predictors in HIV-infected Patients. Source: Aids (London, England). 2002 November 22; 16(17): 2361-2. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12441819&dopt=Abstract
•
HIV-related Pneumocystis carinii pneumonia in older patients hospitalized in the early HAART era. Author(s): Kim B, Lyons TM, Parada JP, Uphold CR, Yarnold PR, Hounshell JB, Sipler AM, Goetz MB, DeHovitz JA, Weinstein RA, Campo RE, Bennett CL. Source: Journal of General Internal Medicine : Official Journal of the Society for Research and Education in Primary Care Internal Medicine. 2001 September; 16(9): 583-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11556938&dopt=Abstract
•
HMR 3647 human-like treatment of experimental pneumonia due to penicillinresistant and erythromycin-resistant Streptococcus pneumoniae. Author(s): Piroth L, Desbiolles N, Mateo-Ponce V, Martin L, Lequeu C, Charles PE, Portier H, Chavanet P. Source: The Journal of Antimicrobial Chemotherapy. 2001 January; 47(1): 33-42. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11152429&dopt=Abstract
•
Hospital acquired pneumonia. Author(s): Lim WS, Macfarlane JT. Source: Clinical Medicine (London, England). 2001 May-June; 1(3): 180-4. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11446609&dopt=Abstract
•
Hospital admissions for pneumonia in Spain. Author(s): Monge V, Gonzalez A. Source: Infection. 2001 January-February; 29(1): 3-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11261755&dopt=Abstract
•
Hospital-acquired pneumonia and de-escalation of antimicrobial treatment. Author(s): Kollef MH. Source: Critical Care Medicine. 2001 July; 29(7): 1473-5. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11445712&dopt=Abstract
Studies 237
•
Hospital-acquired pneumonia: challenges and options for diagnosis and treatment. Author(s): Harmanci A, Harmanci O, Akova M. Source: The Journal of Hospital Infection. 2002 July; 51(3): 160-7. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12144794&dopt=Abstract
•
Hospital-acquired pneumonia: microbiological data and potential adequacy of antimicrobial regimens. Author(s): Leroy O, Giradie P, Yazdanpanah Y, Georges H, Alfandari S, Sanders V, Devos P, Beaucaire G. Source: The European Respiratory Journal : Official Journal of the European Society for Clinical Respiratory Physiology. 2002 August; 20(2): 432-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12212978&dopt=Abstract
•
Hospital-acquired pneumonia: risk factors for antimicrobial-resistant causative pathogens in critically ill patients. Author(s): Leroy O, Jaffre S, D'Escrivan T, Devos P, Georges H, Alfandari S, Beaucaire G. Source: Chest. 2003 June; 123(6): 2034-42. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12796186&dopt=Abstract
•
Hospital-acquired pneumonia: risk factors, microbiology, and treatment. Author(s): Lynch JP 3rd. Source: Chest. 2001 February; 119(2 Suppl): 373S-384S. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11171773&dopt=Abstract
•
Hospitalization decision for ambulatory patients with community-acquired pneumonia: a prospective study with general practitioners in France. Author(s): Laurichesse H, Gerbaud L, Baud O, Gourdon F, Beytout J; Study Group of General Practitioners. Source: Infection. 2001 December; 29(6): 320-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11787832&dopt=Abstract
•
Hospitalization for community-acquired pneumonia: the pneumonia severity index vs clinical judgment. Author(s): Arnold FW, Ramirez JA, McDonald LC, Xia EL. Source: Chest. 2003 July; 124(1): 121-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12853513&dopt=Abstract
238 Pneumonia
•
Hospitalizations for bacterial pneumonia after renal transplantation in the United States. Author(s): Tveit DJ, Hypolite IO, Poropatich RK, Hshieh P, Cruess D, Hawkes CA, Agodoa LY, Abbott KC. Source: Journal of Nephrology. 2002 May-June; 15(3): 255-62. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12113596&dopt=Abstract
•
Hospitalized community-acquired pneumonia in the elderly: age- and sex-related patterns of care and outcome in the United States. Author(s): Kaplan V, Angus DC, Griffin MF, Clermont G, Scott Watson R, LindeZwirble WT. Source: American Journal of Respiratory and Critical Care Medicine. 2002 March 15; 165(6): 766-72. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11897642&dopt=Abstract
•
Hot tub-associated necrotizing pneumonia due to Pseudomonas aeruginosa. Author(s): Crnich CJ, Gordon B, Andes D. Source: Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America. 2003 February 1; 36(3): E55-7. Epub 2003 January 20. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12539092&dopt=Abstract
•
How accurate is the clinical diagnosis of pneumonia? Author(s): Kelsberg G, Safranek S. Source: The Journal of Family Practice. 2003 January; 52(1): 63-4; Discussion 64. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12540315&dopt=Abstract
•
How do we optimize outcomes for patients with severe community-acquired pneumonia? Author(s): Niederman MS. Source: Intensive Care Medicine. 2002 August; 28(8): 1003-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12398086&dopt=Abstract
•
How should we make the admission decision in community-acquired pneumonia? Author(s): Aronsky D, Dean NC. Source: The Medical Clinics of North America. 2001 November; 85(6): 1397-411. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11680109&dopt=Abstract
•
Human parainfluenza virus giant cell pneumonia following cord blood transplant associated with pulmonary alveolar proteinosis. Author(s): Butnor KJ, Sporn TA. Source: Archives of Pathology & Laboratory Medicine. 2003 February; 127(2): 235-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12562244&dopt=Abstract
Studies 239
•
Human surfactant protein a suppresses T cell-dependent inflammation and attenuates the manifestations of idiopathic pneumonia syndrome in mice. Author(s): Yang S, Milla C, Panoskaltsis-Mortari A, Ingbar DH, Blazar BR, Haddad IY. Source: American Journal of Respiratory Cell and Molecular Biology. 2001 May; 24(5): 527-36. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11350821&dopt=Abstract
•
Hypercalcemia in a renal transplant recipient suffering with Pneumocystis carinii pneumonia. Author(s): Chen WC, Chang SC, Wu TH, Yang WC, Tarng DC. Source: American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation. 2002 February; 39(2): E8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11840399&dopt=Abstract
•
Hyper-IgM syndrome complicated with interstitial pneumonia and peritonitis. Author(s): Huang CF, Wang CL, Huang YF, Hsieh KS, Yang KD. Source: Chang Gung Med J. 2003 January; 26(1): 53-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12656310&dopt=Abstract
•
Hypersensitivity pneumonia: UIP/IPF histopathologic presentation. Author(s): Jacobs RL. Source: The Journal of Allergy and Clinical Immunology. 2002 September; 110(3): 532-3. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12209109&dopt=Abstract
•
Hypersensitivity pneumonia-nonspecific interstitial pneumonia/fibrosis histopathologic presentation: a study in diagnosis and long-term management. Author(s): Jacobs RL, Andrews CP. Source: Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology. 2003 February; 90(2): 265-70. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12602678&dopt=Abstract
•
Hypoxaemia in children with severe pneumonia in Papua New Guinea. Author(s): Duke T, Mgone J, Frank D. Source: The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union against Tuberculosis and Lung Disease. 2001 June; 5(6): 511-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11409576&dopt=Abstract
240 Pneumonia
•
I am a 64-year-old man, and I've always been proud of my perfect health record. I've also been proud of my full head of hair, even after the gray started creeping in. Four months ago I caught pneumonia and spent eight days in the hospital (three in intensive care). It took a while, but I'm finally back to normal - except that my hair is falling out. It comes out in clumps when I shampoo or even comb it, and it's gotten noticeably thin all over. I remember reading about Propecia in your newsletter but I don't have the old issue. Should I try the medication? Author(s): Simon HB. Source: Harvard Men's Health Watch. 2002 June; 6(11): 8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12079806&dopt=Abstract
•
Identification of early predictors for post-traumatic pneumonia. Author(s): Croce MA, Fabian TC, Waddle-Smith L, Maxwell RA. Source: The American Surgeon. 2001 February; 67(2): 105-10. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11243529&dopt=Abstract
•
Idiopathic acute eosinophilic pneumonia: a study of 22 patients. Author(s): Philit F, Etienne-Mastroianni B, Parrot A, Guerin C, Robert D, Cordier JF. Source: American Journal of Respiratory and Critical Care Medicine. 2002 November 1; 166(9): 1235-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12403693&dopt=Abstract
•
Idiopathic bronchiolocentric interstitial pneumonia. Author(s): Yousem SA, Dacic S. Source: Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc. 2002 November; 15(11): 1148-53. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12429793&dopt=Abstract
•
Idiopathic interstitial pneumonia: are we missing hypersensitivity pneumonitis? Author(s): Zacharisen MC. Source: Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology. 2002 January; 88(1): 4-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11814276&dopt=Abstract
•
Idiopathic pneumonia syndrome after bone marrow transplantation: the role of pretransplant radiation conditioning and local cytokine dysregulation in promoting lung inflammation and fibrosis. Author(s): Shankar G, Cohen DA. Source: International Journal of Experimental Pathology. 2001 April; 82(2): 101-13. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11454101&dopt=Abstract
Studies 241
•
Idiopathic pneumonia syndrome following myeloablative chemotherapy and autologous transplantation. Author(s): Bilgrami SF, Metersky ML, McNally D, Naqvi BH, Kapur D, Raible D, Bona RD, Edwards RL, Feingold JM, Clive JM, Tutschka PJ. Source: The Annals of Pharmacotherapy. 2001 February; 35(2): 196-201. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11215840&dopt=Abstract
•
Imaging of cavitary necrosis in complicated childhood pneumonia. Author(s): Hodina M, Hanquinet S, Cotting J, Schnyder P, Gudinchet F. Source: European Radiology. 2002 February; 12(2): 391-6. Epub 2001 August 28. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11870440&dopt=Abstract
•
Imaging of pneumonia: trends and algorithms. Author(s): Franquet T. Source: The European Respiratory Journal : Official Journal of the European Society for Clinical Respiratory Physiology. 2001 July; 18(1): 196-208. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11510793&dopt=Abstract
•
Immune reconstitution pneumonitis following Pneumocystis carinii pneumonia in HIV-infected subjects. Author(s): Barry SM, Lipman MC, Deery AR, Johnson MA, Janossy G. Source: Hiv Medicine. 2002 July; 3(3): 207-11. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12139660&dopt=Abstract
•
Immune reconstitution syndrome after successful treatment of Pneumocystis carinii pneumonia in a man with human immunodeficiency virus type 1 infection. Author(s): Koval CE, Gigliotti F, Nevins D, Demeter LM. Source: Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America. 2002 August 15; 35(4): 491-3. Epub 2002 July 24. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12145736&dopt=Abstract
•
Immunohistochemical characterisation of pulmonary hyaline membrane in various types of interstitial pneumonia. Author(s): Sun AP, Ohtsuki Y, Fujita J, Ishida T, Yoshinouchi T, Kohno N. Source: Pathology. 2003 April; 35(2): 120-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12745458&dopt=Abstract
•
Impact of appropriateness of initial antibiotic therapy on the outcome of ventilatorassociated pneumonia. Author(s): Dupont H, Mentec H, Sollet JP, Bleichner G. Source: Intensive Care Medicine. 2001 February; 27(2): 355-62. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11396279&dopt=Abstract
242 Pneumonia
•
Impact of BAL on the diagnosis and treatment of nosocomial pneumonia in ICU patients. Author(s): Ferrer R, Ioanas M, Agusti C, Torres A. Source: Monaldi Arch Chest Dis. 2001 December; 56(6): 521-6. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11980284&dopt=Abstract
•
Impact of Gram-positive resistance on outcome of nosocomial pneumonia. Author(s): Bodi M, Ardanuy C, Rello J. Source: Critical Care Medicine. 2001 April; 29(4 Suppl): N82-6. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11292880&dopt=Abstract
•
Impact of initial antibiotic choice on clinical outcomes in community-acquired pneumonia: analysis of a hospital claims-made database. Author(s): Brown RB, Iannini P, Gross P, Kunkel M. Source: Chest. 2003 May; 123(5): 1503-11. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12740267&dopt=Abstract
•
Impact of invasive strategy on management of antimicrobial treatment failure in institutionalized older people with severe pneumonia. Author(s): El-Solh AA, Aquilina AT, Dhillon RS, Ramadan F, Nowak P, Davies J. Source: American Journal of Respiratory and Critical Care Medicine. 2002 October 15; 166(8): 1038-43. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12379545&dopt=Abstract
•
Impact of unplanned extubation and reintubation after weaning on nosocomial pneumonia risk in the intensive care unit: a prospective multicenter study. Author(s): de Lassence A, Alberti C, Azoulay E, Le Miere E, Cheval C, Vincent F, Cohen Y, Garrouste-Orgeas M, Adrie C, Troche G, Timsit JF; OUTCOMEREA Study Group. Source: Anesthesiology. 2002 July; 97(1): 148-56. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12131116&dopt=Abstract
•
Impaired cough reflex in patients with recurrent pneumonia. Author(s): Niimi A, Matsumoto H, Ueda T, Takemura M, Suzuki K, Tanaka E, Chin K, Mishima M, Amitani R. Source: Thorax. 2003 February; 58(2): 152-3. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12554900&dopt=Abstract
•
Impaired cough reflex in patients with recurrent pneumonia. Author(s): Barber CM, Curran AD, Fishwick D. Source: Thorax. 2003 July; 58(7): 645-6; Author Reply 646. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12832690&dopt=Abstract
Studies 243
•
Implications of TeqCES: efficacy and safety of gatifloxacin in community-acquired pneumonia. Author(s): Mandell LA, Jones RN. Source: Diagnostic Microbiology and Infectious Disease. 2002 September; 44(1): 127-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12376042&dopt=Abstract
•
Improved survival with highly active antiretroviral therapy in HIV-infected patients with severe Pneumocystis carinii pneumonia. Author(s): Morris A, Wachter RM, Luce J, Turner J, Huang L. Source: Aids (London, England). 2003 January 3; 17(1): 73-80. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12478071&dopt=Abstract
•
Improvement of symptomatic human immunodeficiency virus-related lymphoid interstitial pneumonia in patients receiving highly active antiretroviral therapy. Author(s): Dufour V, Wislez M, Bergot E, Mayaud C, Cadranel J. Source: Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America. 2003 May 15; 36(10): E127-30. Epub 2003 May 06. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12746792&dopt=Abstract
•
Improving the quality of care for patients with pneumonia in very small hospitals. Author(s): Chu LA, Bratzler DW, Lewis RJ, Murray C, Moore L, Shook C, Weingarten SR. Source: Archives of Internal Medicine. 2003 February 10; 163(3): 326-32. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12578513&dopt=Abstract
•
Improving the quality of pneumonia care that patients experience. Author(s): Horowitz CR, Chassin MR. Source: The American Journal of Medicine. 2002 October 1; 113(5): 379-83. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12401532&dopt=Abstract
•
Incidence and outcome of polymicrobial ventilator-associated pneumonia. Author(s): Combes A, Figliolini C, Trouillet JL, Kassis N, Wolff M, Gibert C, Chastre J. Source: Chest. 2002 May; 121(5): 1618-23. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12006452&dopt=Abstract
•
Incidence of adult immunization for influenza and pneumonia in a preadmission testing unit. Author(s): Laney M, Bayley EW. Source: Journal of Perianesthesia Nursing : Official Journal of the American Society of Perianesthesia Nurses / American Society of Perianesthesia Nurses. 2002 October; 17(5): 325-36. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12384900&dopt=Abstract
244 Pneumonia
•
Incidence of and risk factors for nosocomial pneumonia in patients with tetanus. Author(s): Cavalcante NJ, Sandeville ML, Medeiros EA. Source: Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America. 2001 December 1; 33(11): 1842-6. Epub 2001 October 19. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11668432&dopt=Abstract
•
Increased exhaled nitric oxide in bronchiolitis obliterans organizing pneumonia after allogeneic bone marrow transplantation. Author(s): Kanamori H, Fujisawa S, Tsuburai T, Yamaji S, Tomita N, Fujimaki K, Miyashita A, Suzuki S, Ishigatsubo Y. Source: Transplantation. 2002 November 15; 74(9): 1356-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12451281&dopt=Abstract
•
Increased IL-10 production and HLA-DR suppression in the lungs of injured patients precede the development of nosocomial pneumonia. Author(s): Muehlstedt SG, Lyte M, Rodriguez JL. Source: Shock (Augusta, Ga.). 2002 June; 17(6): 443-50. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12069178&dopt=Abstract
•
Increased interleukin-5 levels in bronchoalveolar lavage fluid is a major factor for eosinophil accumulation in acute eosinophilic pneumonia. Author(s): Nakahara Y, Hayashi S, Fukuno Y, Kawashima M, Yatsunami J. Source: Respiration; International Review of Thoracic Diseases. 2001; 68(4): 389-95. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11464086&dopt=Abstract
•
Increased vascular endothelial growth factor in acute eosinophilic pneumonia. Author(s): Nishigaki Y, Fujiuchi S, Yamazaki Y, Matsumoto H, Takeda A, Fujita Y, Okamoto K, Fujikane T, Shimizu T, Kikuchi K. Source: The European Respiratory Journal : Official Journal of the European Society for Clinical Respiratory Physiology. 2003 May; 21(5): 774-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12765419&dopt=Abstract
•
Independent risk of mechanical ventilation for AIDS-related Pneumocystis carinii pneumonia associated with bronchoalveolar lavage neutrophilia. Author(s): Bang D, Emborg J, Elkjaer J, Lundgren JD, Benfield TL. Source: Respiratory Medicine. 2001 August; 95(8): 661-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11530954&dopt=Abstract
•
Indomethacin induced bulky lymphadenopathy and eosinophilic pneumonia. Author(s): Oishi Y, Sando Y, Tajima S, Maeno T, Maeno Y, Sato M, Hosono T, Suga T, Kurabayashi M, Nagai R. Source: Respirology (Carlton, Vic.). 2001 March; 6(1): 57-60. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11264764&dopt=Abstract
Studies 245
•
Induced sputum as a diagnostic specimen for Pneumocystis carinii pneumonia in HIV positive patients. Author(s): Baliga S, Shenoy S, Kuruvilla T, Reddy AK. Source: J Assoc Physicians India. 2001 August; 49: 858, 860. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11837488&dopt=Abstract
•
Induced sputum for diagnosing Pneumocystis carinii pneumonia in HIV patients: new data, new issues. Author(s): Turner D, Schwarz Y, Yust I. Source: The European Respiratory Journal : Official Journal of the European Society for Clinical Respiratory Physiology. 2003 February; 21(2): 204-8. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12611375&dopt=Abstract
•
Ineffectiveness of trimethoprim-sulfamethoxazole prophylaxis and the importance of bacterial and viral coinfections in African children with Pneumocystis carinii pneumonia. Author(s): Madhi SA, Cutland C, Ismail K, O'Reilly C, Mancha A, Klugman KP. Source: Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America. 2002 November 1; 35(9): 1120-6. Epub 2002 October 07. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12384847&dopt=Abstract
•
Infectious disease. Update on treatment of pneumonia, influenza, and urinary tract infections. Author(s): Wallach FR. Source: Geriatrics. 2001 September; 56(9): 43-7; Quiz 48. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11582973&dopt=Abstract
•
Influence of deviation from guidelines on the outcome of community-acquired pneumonia. Author(s): Menendez R, Ferrando D, Valles JM, Vallterra J. Source: Chest. 2002 August; 122(2): 612-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12171840&dopt=Abstract
•
Influence on outcome of ventilator-associated pneumonia in multiple trauma patients with head trauma treated with selected digestive decontamination. Author(s): Leone M, Bourgoin A, Giuly E, Antonini F, Dubuc M, Viviand X, Albanese J, Martin C. Source: Critical Care Medicine. 2002 August; 30(8): 1741-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12163786&dopt=Abstract
246 Pneumonia
•
Influenza A pneumonia with rhabdomyolysis. Author(s): Morton SE, Mathai M, Byrd RP Jr, Fields CL, Roy TM. Source: Southern Medical Journal. 2001 January; 94(1): 67-9. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11213946&dopt=Abstract
•
Influenza A-associated bronchiolitis obliterans organizing pneumonia mimicking Wegener's granulomatosis. Author(s): Staud R, Ramos LG. Source: Rheumatology International. 2001 April; 20(3): 125-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11354560&dopt=Abstract
•
Influenza pneumonia in lung transplant recipients: clinical features and association with bronchiolitis obliterans syndrome. Author(s): Garantziotis S, Howell DN, McAdams HP, Davis RD, Henshaw NG, Palmer SM. Source: Chest. 2001 April; 119(4): 1277-80. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11296201&dopt=Abstract
•
Influenza pneumonia in thoracic organ transplant recipients : what can we do to avoid it? Author(s): Massad MG, Ramirez AM. Source: Chest. 2001 April; 119(4): 997-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11296159&dopt=Abstract
•
Influenza pneumonia: a descriptive study. Author(s): Oliveira EC, Marik PE, Colice G. Source: Chest. 2001 June; 119(6): 1717-23. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11399696&dopt=Abstract
•
Initial risk class and length of hospital stay in community-acquired pneumonia. Author(s): Menendez R, Ferrando D, Valles JM, Martinez E, Perpina M. Source: The European Respiratory Journal : Official Journal of the European Society for Clinical Respiratory Physiology. 2001 July; 18(1): 151-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11510787&dopt=Abstract
•
Instability on hospital discharge and the risk of adverse outcomes in patients with pneumonia. Author(s): Halm EA, Fine MJ, Kapoor WN, Singer DE, Marrie TJ, Siu AL. Source: Archives of Internal Medicine. 2002 June 10; 162(11): 1278-84. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12038946&dopt=Abstract
Studies 247
•
Instillation of normal saline before suctioning in patients with pneumonia. Author(s): Ji YR, Kim HS, Park JH. Source: Yonsei Medical Journal. 2002 October; 43(5): 607-12. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12402373&dopt=Abstract
•
Intercellular adhesion molecule-1 in patients with idiopathic interstitial pneumonia. Author(s): Takehara H, Tada S, Kataoka M, Matsuo K, Ueno Y, Ozaki S, Miyake T, Fujimori Y, Yamadori I, Harada M. Source: Acta Medica Okayama. 2001 August; 55(4): 205-11. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11512562&dopt=Abstract
•
International Conference for the Development of Consensus on the Diagnosis and Treatment of Ventilator-associated Pneumonia. Author(s): Rello J, Paiva JA, Baraibar J, Barcenilla F, Bodi M, Castander D, Correa H, Diaz E, Garnacho J, Llorio M, Rios M, Rodriguez A, Sole-Violan J. Source: Chest. 2001 September; 120(3): 955-70. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11555535&dopt=Abstract
•
International guidelines for the treatment of community-acquired pneumonia in adults: the role of macrolides. Author(s): File TM Jr, Tan JS. Source: Drugs. 2003; 63(2): 181-205. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12515565&dopt=Abstract
•
Interstitial pneumonia accompanying ulcerative colitis. Author(s): Chikano S, Sawada K, Ohnishi K, Fukunaga K, Tanaka J, Shimoyama T. Source: Intern Med. 2001 September; 40(9): 883-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11579949&dopt=Abstract
•
Interstitial pneumonia in progressive systemic sclerosis: serial high-resolution CT findings with functional correlation. Author(s): Kim EA, Johkoh T, Lee KS, Ichikado K, Koh EM, Kim TS, Kim EY. Source: Journal of Computer Assisted Tomography. 2001 September-October; 25(5): 75763. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11584237&dopt=Abstract
•
Interstitial pneumonia induced by ticlopidine. Author(s): Nakamura R, Imamura T, Onitsuka H, Mishima K, Ishikawa T, Nagoshi T, Fujiura Y, Date H, Maeno M, Matsuo T, Koiwaya Y, Eto T. Source: Circulation Journal : Official Journal of the Japanese Circulation Society. 2002 August; 66(8): 773-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12197605&dopt=Abstract
248 Pneumonia
•
Interstitial pneumonia possibly due to a novel anticancer drug, TS-1: first case report. Author(s): Kurakawa E, Kasuga I, Ishizuka S, Yoshida T, Kunisawa A, Minemura K, Utsumi K, Ohyashiki K. Source: Japanese Journal of Clinical Oncology. 2001 June; 31(6): 284-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11463808&dopt=Abstract
•
Interventions to prevent aspiration pneumonia in older adults: a systematic review. Author(s): Loeb MB, Becker M, Eady A, Walker-Dilks C. Source: Journal of the American Geriatrics Society. 2003 July; 51(7): 1018-22. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12834525&dopt=Abstract
•
Interventions to prevent pneumonia among older adults. Author(s): Yamaya M, Yanai M, Ohrui T, Arai H, Sasaki H. Source: Journal of the American Geriatrics Society. 2001 January; 49(1): 85-90. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11207848&dopt=Abstract
•
Intracellular adhesion molecule Gly241Arg polymorphism has no impact on ARDS or septic shock in community-acquired pneumonia. Author(s): Quasney MW, Waterer GW, Dahmer MK, Turner D, Zhang Q, Cantor RM, Wunderink RG. Source: Chest. 2002 March; 121(3 Suppl): 85S-86S. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11893710&dopt=Abstract
•
Intravenous immunoglobulin in adult varicella pneumonia complicated by acute respiratory distress syndrome. Author(s): Tokat O, Kelebek N, Turker G, Kahveci SF, Ozcan B. Source: J Int Med Res. 2001 May-June; 29(3): 252-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11471863&dopt=Abstract
•
Intravenous/oral sequential therapy in patients hospitalised with communityacquired pneumonia: which patients, when and what agents? Author(s): Vogel F. Source: Drugs. 2002; 62(2): 309-17. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11817975&dopt=Abstract
•
Intravenous-to-oral transition therapy in community-acquired pneumonia: the INOVA Health System experience. Author(s): Milkovich G. Source: Pharmacotherapy. 2001 July; 21(7 Pt 2): 83S-88S. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11446523&dopt=Abstract
Studies 249
•
Introduction of simple swallowing ability test for prevention of aspiration pneumonia in the elderly and investigation of factors of swallowing disorders. Author(s): Miyazaki Y, Arakawa M, Kizu J. Source: Yakugaku Zasshi. Journal of the Pharmaceutical Society of Japan. 2002 January; 122(1): 97-105. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11828754&dopt=Abstract
•
Introduction: Nosocomial pneumonia in intensive care units. Author(s): Williams JD. Source: Journal of Chemotherapy (Florence, Italy). 2001 November; 13 Spec No 1(1): 2024. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11936366&dopt=Abstract
•
Is “nonusual interstitial pneumonia” an acceptable diagnosis? Author(s): Behr J. Source: The European Respiratory Journal : Official Journal of the European Society for Clinical Respiratory Physiology. 2002 November; 20(5): 1069-70. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12449156&dopt=Abstract
•
Is azithromycin the first-choice macrolide for treatment of community-acquired pneumonia? Author(s): Sanchez F, Mensa J, Martinez JA, Garcia E, Marco F, Gonzalez J, Marcos MA, Soriano A, Torres A. Source: Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America. 2003 May 15; 36(10): 1239-45. Epub 2003 May 06. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12746768&dopt=Abstract
•
Is Chlamydia pneumoniae an important pathogen in patients with communityacquired pneumonia? Author(s): Ewig S, Torres A. Source: The European Respiratory Journal : Official Journal of the European Society for Clinical Respiratory Physiology. 2003 May; 21(5): 741-2. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12765413&dopt=Abstract
•
Is pneumonia still the old man's friend? Author(s): Rozzini R, Sabatini T, Trabucchi M. Source: Archives of Internal Medicine. 2003 June 23; 163(12): 1491-2; Author Reply 1492. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12824104&dopt=Abstract
250 Pneumonia
•
Is the gastrointestinal tract the sole source of organisms in ventilator-associated pneumonia? Author(s): Demers RR. Source: Respiratory Care. 2002 June; 47(6): 696; Author Reply 696-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12078653&dopt=Abstract
•
Is ventilator-associated pneumonia an independent risk factor for death? Author(s): Bregeon F, Ciais V, Carret V, Gregoire R, Saux P, Gainnier M, Thirion X, Drancourt M, Auffray JP, Papazian L. Source: Anesthesiology. 2001 April; 94(4): 554-60. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11379672&dopt=Abstract
•
It's time to step up the management of community-acquired pneumonia. Author(s): Idemyor V. Source: Journal of the National Medical Association. 2002 March; 94(3): 178-81. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11918388&dopt=Abstract
•
IV-to-oral switch therapy for community-acquired pneumonia requiring hospitalization: focus on gatifloxacin. Author(s): Pelly L. Source: Adv Ther. 2002 September-October; 19(5): 229-42. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12539883&dopt=Abstract
•
Jail inmates and HIV care: provision of antiretroviral therapy and Pneumocystis carinii pneumonia prophylaxis. Author(s): White MC, Mehrotra A, Menendez E, Estes M, Goldenson J, Tulsky JP. Source: International Journal of Std & Aids. 2001 June; 12(6): 380-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11368819&dopt=Abstract
•
Japanese guidelines for the management of community-acquired pneumonia. Author(s): Yanagihara K, Kohno S, Matsusima T. Source: International Journal of Antimicrobial Agents. 2001; 18 Suppl 1: S45-8. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11574195&dopt=Abstract
•
Joseph Malik Peiris--on the trail of pneumonia in Hong Kong interviewed by Pam Das. Author(s): Peiris JM. Source: The Lancet Infectious Diseases. 2003 May; 3(5): 309-11. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12726983&dopt=Abstract
Studies 251
•
Just the berries. Management of community-acquired pneumonia. Evidence-based update. Author(s): Balter M. Source: Can Fam Physician. 2002 November; 48: 1773-5. Review. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12489243&dopt=Abstract
•
KL-6 as an indicator for lymphocytic interstitial pneumonia (LIP) in a human Tlymphotrophic virus type 1 (HTLV-1) carrier. Author(s): Ishikawa N, Awaya Y, Maeda H, Miyazaki M, Fujitaka K, Yamasaki M, Kondo K, Oguri T, Isobe T, Kohno N. Source: Annals of Hematology. 2002 August; 81(8): 474-7. Epub 2002 July 31. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12224007&dopt=Abstract
•
Knocking out pneumonia. Author(s): Holly J. Source: Nurs Times. 2002 October 8-14; 98(41): 26-7. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12430399&dopt=Abstract
•
Lack of effect of a pneumonia clinical pathway on hospital-based pneumococcal vaccination rates. Author(s): Metersky ML, Fine JM, Tu GS, Mathur D, Weingarten S, Petrillo MK, Meehan TP. Source: The American Journal of Medicine. 2001 February 1; 110(2): 141-3. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11165555&dopt=Abstract
•
Lactobacillus species as a cause of ventilator-associated pneumonia in a critically ill trauma patient. Author(s): Wood GC, Boucher BA, Croce MA, Fabian TC. Source: Pharmacotherapy. 2002 September; 22(9): 1180-2. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12222555&dopt=Abstract
•
Laryngotracheal separation for intractable aspiration pneumonia in neurologically impaired children: experience with 11 cases. Author(s): Takamizawa S, Tsugawa C, Nishijima E, Muraji T, Satoh S. Source: Journal of Pediatric Surgery. 2003 June; 38(6): 975-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12778406&dopt=Abstract
•
Late pulmonary scintigraphic defects after uneventful recovery from focal pneumonia in children: comparison with initial radiograph. Author(s): Dai ZK, Chen YW, Hsu JH, Wu JR, Chen SH, Lai YC. Source: Kaohsiung J Med Sci. 2002 July; 18(7): 334-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12380323&dopt=Abstract
252 Pneumonia
•
Legionella and community-acquired pneumonia: a review of current diagnostic tests from a clinician's viewpoint. Author(s): Waterer GW, Baselski VS, Wunderink RG. Source: The American Journal of Medicine. 2001 January; 110(1): 41-8. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11152864&dopt=Abstract
•
Legionella pneumonia and bacteraemia in association with protein-losing enteropathy after Fontan operation. Author(s): Cheung YF, Leung MP, Yuen KY. Source: The Journal of Infection. 2001 April; 42(3): 206-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11545554&dopt=Abstract
•
Legionella pneumonia. Author(s): Ruggles L. Source: Can Fam Physician. 2001 September; 47: 1737-9. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11570298&dopt=Abstract
•
Legionella pneumonia: an unusual cause of rhabdomyolysis and acute renal failure. Author(s): Kaufman D, Weber K, Gradon JD. Source: Southern Medical Journal. 2002 June; 95(6): 660. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12081226&dopt=Abstract
•
Legionella pneumophila pneumonia in a newborn after water birth: a new mode of transmission. Author(s): Franzin L, Scolfaro C, Cabodi D, Valera M, Tovo PA. Source: Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America. 2001 November 1; 33(9): E103-4. Epub 2001 September 24. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11568855&dopt=Abstract
•
Legionella pneumophila pneumonia successfully treated with intravenous ciprofloxacin. Author(s): Haranaga S, Toyama M, Arakaki N, Miyara T, Shinzato T, Koide M, Higa F, Tateyama M, Saito A. Source: Intern Med. 2002 November; 41(11): 1024-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12487183&dopt=Abstract
•
Legionella pneumophila: not just pneumonia. Author(s): Buising KL, O'Reilly MA, Paull AE, Stanley PA. Source: The Medical Journal of Australia. 2001 May 7; 174(9): 476-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11386595&dopt=Abstract
Studies 253
•
Legionella-like and other amoebal pathogens as agents of community-acquired pneumonia. Author(s): Marrie TJ, Raoult D, La Scola B, Birtles RJ, de Carolis E; Canadian Community-Acquired Pneumonia Study Group. Source: Emerging Infectious Diseases. 2001 November-December; 7(6): 1026-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11747734&dopt=Abstract
•
Legionnaires' disease and pneumonia. Beware the temptation to underestimate this “exotic” cause of infection. Author(s): Akbas E, Yu VL. Source: Postgraduate Medicine. 2001 May; 109(5): 135-8, 141-2, 147. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11381664&dopt=Abstract
•
Lemierre's syndrome with spondylitis and pulmonary and gluteal abscesses associated with Mycoplasma pneumoniae pneumonia. Author(s): Abele-Horn M, Emmerling P, Mann JF. Source: European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology. 2001 April; 20(4): 263-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11399017&dopt=Abstract
•
Leucocyte response and anti-inflammatory cytokines in community acquired pneumonia. Author(s): Kolling UK, Hansen F, Braun J, Rink L, Katus HA, Dalhoff K. Source: Thorax. 2001 February; 56(2): 121-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11209100&dopt=Abstract
•
Levels of IL-8 and myeloperoxidase in the lungs of pneumonia patients. Author(s): Abul H, Abul A, Khan I, Mathew TC, Ayed A, Al-Athary E. Source: Molecular and Cellular Biochemistry. 2001 January; 217(1-2): 107-12. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11269653&dopt=Abstract
•
Levels of interleukin-2, interferon-gamma, and interleukin-4 in bronchoalveolar lavage fluid from patients with Mycoplasma pneumonia: implication of tendency toward increased immunoglobulin E production. Author(s): Koh YY, Park Y, Lee HJ, Kim CK. Source: Pediatrics. 2001 March; 107(3): E39. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11230620&dopt=Abstract
254 Pneumonia
•
Levofloxacin compared with imipenem/cilastatin followed by ciprofloxacin in adult patients with nosocomial pneumonia: a multicenter, prospective, randomized, openlabel study. Author(s): West M, Boulanger BR, Fogarty C, Tennenberg A, Wiesinger B, Oross M, Wu SC, Fowler C, Morgan N, Kahn JB. Source: Clinical Therapeutics. 2003 February; 25(2): 485-506. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12749509&dopt=Abstract
•
Levofloxacin failure in a patient with pneumococcal pneumonia. Author(s): Empey PE, Jennings HR, Thornton AC, Rapp RP, Evans ME. Source: The Annals of Pharmacotherapy. 2001 June; 35(6): 687-90. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11408985&dopt=Abstract
•
Levofloxacin treatment failure in a patient with fluoroquinolone-resistant Streptococcus pneumoniae pneumonia. Author(s): Kays MB, Smith DW, Wack ME, Denys GA. Source: Pharmacotherapy. 2002 March; 22(3): 395-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11898897&dopt=Abstract
•
Limited value of routine microbiological diagnostics in patients hospitalized for community-acquired pneumonia. Author(s): Lidman C, Burman LG, Lagergren A, Ortqvist A. Source: Scandinavian Journal of Infectious Diseases. 2002; 34(12): 873-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12587618&dopt=Abstract
•
Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multicenter study. Author(s): Rubinstein E, Cammarata S, Oliphant T, Wunderink R; Linezolid Nosocomial Pneumonia Study Group. Source: Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America. 2001 February 1; 32(3): 402-12. Epub 2001 January 26. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11170948&dopt=Abstract
•
Linezolid for the treatment of community-acquired pneumonia in hospitalized children. Linezolid Pediatric Pneumonia Study Group. Author(s): Kaplan SL, Patterson L, Edwards KM, Azimi PH, Bradley JS, Blumer JL, Tan TQ, Lobeck FG, Anderson DC; Linezolid Pediatric Pheumonia Study Group. Pharmacia and Upjohn. Source: The Pediatric Infectious Disease Journal. 2001 May; 20(5): 488-94. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11368105&dopt=Abstract
Studies 255
•
Linezolid versus ceftriaxone/cefpodoxime in patients hospitalized for the treatment of Streptococcus pneumoniae pneumonia. Author(s): San Pedro GS, Cammarata SK, Oliphant TH, Todisco T; Linezolid Community-Acquired Pneumonia Study Group. Source: Scandinavian Journal of Infectious Diseases. 2002; 34(10): 720-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12477321&dopt=Abstract
•
Lipoid pneumonia. Author(s): Ikehara K, Suzuki M, Tsuburai T, Ishigatsubo Y. Source: Lancet. 2002 April 13; 359(9314): 1300. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11965275&dopt=Abstract
•
Liver involvement with Mycoplasma pneumoniae community-acquired pneumonia. Author(s): Cunha BA. Source: Journal of Clinical Microbiology. 2003 July; 41(7): 3456; Author Reply 3456-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12843123&dopt=Abstract
•
Low hospital mortality in patients with acute interstitial pneumonia. Author(s): Quefatieh A, Stone CH, DiGiovine B, Toews GB, Hyzy RC. Source: Chest. 2003 August; 124(2): 554-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12907542&dopt=Abstract
•
Low incidence of community-acquired pneumonia among human immunodeficiency virus-infected patients after interruption of Pneumocystis carinii pneumonia prophylaxis. Author(s): Eigenmann C, Flepp M, Bernasconi E, Schiffer V, Telenti A, Bucher H, Wagels T, Egger M, Furrer H; Swiss HIV Cohort Study. Source: Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America. 2003 April 1; 36(7): 917-21. Epub 2003 March 18. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12652393&dopt=Abstract
•
Lung abscess complicating post-varicella pneumonia. Author(s): Prais D, Varsano I, Schwarz M, Ofir-Mintzer H, Lazar E. Source: Archives of Disease in Childhood. 2002 August; 87(2): 110. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12138057&dopt=Abstract
•
Lung biopsy in patients with usual interstitial pneumonia. Author(s): Collard HR, King TE Jr. Source: The European Respiratory Journal : Official Journal of the European Society for Clinical Respiratory Physiology. 2001 November; 18(5): 895-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11757643&dopt=Abstract
256 Pneumonia
•
Lung cancer with focal lymphocytic interstitial pneumonia. Author(s): Bandoh S, Fujita J, Haba R, Tojo Y, Horiike A, Okamoto T, Yokomise H, Satoh K, Kobayashi S, Ishida T. Source: Intern Med. 2002 November; 41(11): 997-1001. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12487177&dopt=Abstract
•
Lung function tests and risk factors for pneumonia in adults with chickenpox. Author(s): Mohsen AH, Peck RJ, Mason Z, Mattock L, McKendrick MW. Source: Thorax. 2001 October; 56(10): 796-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11562520&dopt=Abstract
•
Lymphocyte subsets in lung tissues of interstitial pneumonia associated with untreated polymyositis/dermatomyositis. Author(s): Yamadori I, Fujita J, Kajitani H, Bandoh S, Tokuda M, Ohtsuki Y, Yoshinouchi T, Okahara M, Yamaji Y, Tanimoto Y, Sato Y, Ishida T. Source: Rheumatology International. 2001 November; 21(3): 89-93. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11765227&dopt=Abstract
•
Lymphocytic interstitial pneumonia in children with AIDS: high-resolution CT findings. Author(s): Becciolini V, Gudinchet F, Cheseaux JJ, Schnyder P. Source: European Radiology. 2001; 11(6): 1015-20. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11419146&dopt=Abstract
•
Lymphoid interstitial pneumonia: a narrative review. Author(s): Swigris JJ, Berry GJ, Raffin TA, Kuschner WG. Source: Chest. 2002 December; 122(6): 2150-64. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12475860&dopt=Abstract
•
Management of community-acquired pediatric pneumonia in an era of increasing antibiotic resistance and conjugate vaccines. Author(s): Bradley JS. Source: The Pediatric Infectious Disease Journal. 2002 June; 21(6): 592-8; Discussion 6134. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12182396&dopt=Abstract
•
Management of community-acquired pneumonia at a tertiary care medical center in Lebanon. Author(s): Cherfan AJ, Bizri AR, Steitieh SW, Moukhachen OE. Source: American Journal of Health-System Pharmacy : Ajhp : Official Journal of the American Society of Health-System Pharmacists. 2003 May 1; 60(9): 934-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12756945&dopt=Abstract
Studies 257
•
Management of community-acquired pneumonia in adults. Author(s): Working Group of the South African Thoracic Society. Source: South African Medical Journal. Suid-Afrikaanse Tydskrif Vir Geneeskunde. 2002 August; 92(8 Pt 2): 647-55. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12244941&dopt=Abstract
•
Management of patients with community-acquired pneumonia treated in hospital in Sweden. Author(s): Hedlund J, Ortqvist A, Ahlqvist T, Augustinsson A, Beckman H, Blanck C, Burman LA, Claesson B, Qvarfordt I, Elbel E, Erntell M, Follin P, Goscinski G, Holmberg H, Hofer M, Jorup C, Lidman C, Lindhusen E, Rensfeldt G, Rosenkvist E, Stenlund G, Stalberg A, Verngren K, Vig I, Wendahl S; Swedish Infectious Diseases Society Pneumonia Study Group. Source: Scandinavian Journal of Infectious Diseases. 2002; 34(12): 887-92. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12587620&dopt=Abstract
•
Managing antiinfective therapy of community-acquired pneumonia in the hospital setting: focus on switch therapy. Author(s): Ramirez JA. Source: Pharmacotherapy. 2001 July; 21(7 Pt 2): 79S-82S. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11446522&dopt=Abstract
•
Managing community-acquired pneumonia. Author(s): Bartlett JG. Source: Journal of General Internal Medicine : Official Journal of the Society for Research and Education in Primary Care Internal Medicine. 2001 September; 16(9): 642-3. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11556947&dopt=Abstract
•
Managing pneumonia in general practice. Author(s): Halpin D. Source: Practitioner. 2001 February; 245(1619): 108-13, 115. Review. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11221517&dopt=Abstract
•
Maternal perception of pneumonia in children: a health facility survey in Enugu, eastern Nigeria. Author(s): Uwaezuoke SN, Emodi IJ, Ibe BC. Source: Annals of Tropical Paediatrics. 2002 September; 22(3): 281-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12369495&dopt=Abstract
258 Pneumonia
•
Measles pneumonia: treatment of a near-fatal case with nitric oxide inhalation. Author(s): Kimura A, Kobayashi J, Fawaz M, Masutani S, Nagasaka H, Ohtake A, Sasaki N. Source: Pediatrics International : Official Journal of the Japan Pediatric Society. 2002 August; 44(4): 451-2. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12139577&dopt=Abstract
•
Medical management of pneumonia caused by Rhodococcus equi in a renal transplant recipient. Author(s): Gonzalez-Roncero FM, Gentil MA, Rodriguez-Algarra G, Pereira P, Cisneros JM, Castilla JJ, Rocha JL, Mateos J. Source: American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation. 2002 February; 39(2): E7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11840398&dopt=Abstract
•
Mesalamine-induced unilateral eosinophilic pneumonia. Author(s): Saltzman K, Rossoff LJ, Gouda H, Tongia S. Source: Ajr. American Journal of Roentgenology. 2001 July; 177(1): 257. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11418451&dopt=Abstract
•
Mesenteric lymphadenopathy as a cause of abdominal pain in children with lobar or segmental pneumonia. Author(s): Moustaki M, Zeis PM, Katsikari M, Fretzayas A, Grafakou O, Stabouli S, Tsolia M, Nicolaidou P, Karpathios T. Source: Pediatric Pulmonology. 2003 April; 35(4): 269-73. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12629623&dopt=Abstract
•
Meta-analysis of diagnostic procedures for Pneumocystis carinii pneumonia in HIV1-infected patients. Author(s): Cruciani M, Marcati P, Malena M, Bosco O, Serpelloni G, Mengoli C. Source: The European Respiratory Journal : Official Journal of the European Society for Clinical Respiratory Physiology. 2002 October; 20(4): 982-9. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12412693&dopt=Abstract
•
Methodology for assessing patterns of interstitial pneumonia in children. Author(s): Nicholson AG, Bush A. Source: Archives of Disease in Childhood. 2001 August; 85(2): 172. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11469280&dopt=Abstract
Studies 259
•
Methods for decreasing risk of aspiration pneumonia in critically ill patients. Author(s): Scolapio JS. Source: Jpen. Journal of Parenteral and Enteral Nutrition. 2002 November-December; 26(6 Suppl): S58-61; Discussion S61. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12405624&dopt=Abstract
•
Microbial etiology of community-acquired pneumonia in the adult population of 4 municipalities in eastern Finland. Author(s): Jokinen C, Heiskanen L, Juvonen H, Kallinen S, Kleemola M, Koskela M, Leinonen M, Ronnberg PR, Saikku P, Sten M, Tarkiainen A, Tukiainen H, Pyorala K, Makela PH. Source: Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America. 2001 April 15; 32(8): 1141-54. Epub 2001 March 23. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11283803&dopt=Abstract
•
Microbial investigation in ventilator-associated pneumonia. Author(s): Ioanas M, Ferrer R, Angrill J, Ferrer M, Torres A. Source: The European Respiratory Journal : Official Journal of the European Society for Clinical Respiratory Physiology. 2001 April; 17(4): 791-801. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11401077&dopt=Abstract
•
Microbiological etiology in clinically diagnosed community-acquired pneumonia in primary care in Orebro, Sweden. Author(s): Lagerstrom F, Bader M, Foldevi M, Fredlund H, Nordin-Olsson I, Holmberg H. Source: Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases. 2003 July; 9(7): 645-52. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12925105&dopt=Abstract
•
Microbiological testing and outcome of patients with severe community-acquired pneumonia. Author(s): Rello J, Bodi M, Mariscal D, Navarro M, Diaz E, Gallego M, Valles J. Source: Chest. 2003 January; 123(1): 174-80. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12527619&dopt=Abstract
•
Microbiology of severe aspiration pneumonia in institutionalized elderly. Author(s): El-Solh AA, Pietrantoni C, Bhat A, Aquilina AT, Okada M, Grover V, Gifford N. Source: American Journal of Respiratory and Critical Care Medicine. 2003 June 15; 167(12): 1650-4. Epub 2003 April 10. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12689848&dopt=Abstract
260 Pneumonia
•
Microscopic examination of intracellular organisms in protected bronchoalveolar mini-lavage fluid for the diagnosis of ventilator-associated pneumonia. Author(s): Sirvent JM, Vidaur L, Gonzalez S, Castro P, de Batlle J, Castro A, Bonet A. Source: Chest. 2003 February; 123(2): 518-23. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12576375&dopt=Abstract
•
Mixed bacteremic pneumonia by Streptococcus pneumoniae and Haemophilus influenzae. Author(s): Oteo J, Alos JI, Gomez-Garces JL. Source: Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases. 2001 October; 7(10): 571. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11683801&dopt=Abstract
•
Mixed microbial aetiology of community-acquired pneumonia in children. Author(s): Korppi M. Source: Apmis : Acta Pathologica, Microbiologica, Et Immunologica Scandinavica. 2002 August; 110(7-8): 515-22. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12390408&dopt=Abstract
•
Modulation of pulmonary neuroendocrine cells in idiopathic interstitial pneumonia. Author(s): Ito T, Ogura T, Ogawa N, Udaka N, Hayashi H, Inayama Y, Yazawa T, Kitamura H. Source: Histology and Histopathology. 2002 October; 17(4): 1121-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12371140&dopt=Abstract
•
Molecular analysis of the contribution of the capsular polysaccharide and the lipopolysaccharide O side chain to the virulence of Klebsiella pneumoniae in a murine model of pneumonia. Author(s): Cortes G, Borrell N, de Astorza B, Gomez C, Sauleda J, Alberti S. Source: Infection and Immunity. 2002 May; 70(5): 2583-90. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11953399&dopt=Abstract
•
Molecular detection of Mycoplasma pneumoniae in adults with community-acquired pneumonia requiring hospitalization. Author(s): Dorigo-Zetsma JW, Verkooyen RP, van Helden HP, van der Nat H, van den Bosch JM. Source: Journal of Clinical Microbiology. 2001 March; 39(3): 1184-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11230455&dopt=Abstract
Studies 261
•
Molecular detection of respiratory syncytial virus in postmortem lung tissue samples from Mexican children deceased with pneumonia. Author(s): Bustamante-Calvillo ME, Velazquez FR, Cabrera-Munoz L, Torres J, GomezDelgado A, Moreno JA, Munoz-Hernandez O. Source: The Pediatric Infectious Disease Journal. 2001 May; 20(5): 495-501. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11368106&dopt=Abstract
•
Molecular pathogenesis of pneumococcal pneumonia. Author(s): McCullers JA, Tuomanen EI. Source: Frontiers in Bioscience : a Journal and Virtual Library. 2001 August 1; 6: D87789. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11502489&dopt=Abstract
•
Monotherapy may be suboptimal for severe bacteremic pneumococcal pneumonia. Author(s): Waterer GW, Somes GW, Wunderink RG. Source: Archives of Internal Medicine. 2001 August 13-27; 161(15): 1837-42. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11493124&dopt=Abstract
•
Moraxella catarrhalis bacteraemia associated with Mycoplasma pneumoniae infection and pneumonia. Author(s): Bodasing N, Kennedy D. Source: Scandinavian Journal of Infectious Diseases. 2002; 34(11): 851-2. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12578160&dopt=Abstract
•
Morbidity, mortality and clinical presentation of nursing home-acquired pneumonia in a Swedish population. Author(s): Sund-Levander M, Ortqvist A, Grodzinsky E, Klefsgard O, Wahren LK. Source: Scandinavian Journal of Infectious Diseases. 2003; 35(5): 306-10. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12875515&dopt=Abstract
•
Mortality associated with late-onset pneumonia in the intensive care unit: results of a multi-center cohort study. Author(s): Moine P, Timsit JF, De Lassence A, Troche G, Fosse JP, Alberti C, Cohen Y; OUTCOMEREA study group. Source: Intensive Care Medicine. 2002 February; 28(2): 154-63. Epub 2002 January 16. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11907658&dopt=Abstract
•
Mortality due to ventilator-associated pneumonia: impact of medical versus surgical ICU admittance status. Author(s): Leroy O, Sanders V, Girardie P, Devos P, Yazdanpanah Y, Georges H, Beaucaire G. Source: Journal of Critical Care. 2001 September; 16(3): 90-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11689764&dopt=Abstract
262 Pneumonia
•
Mortality rate attributable to ventilator-associated nosocomial pneumonia in an adult intensive care unit: a prospective case-control study. Author(s): Bercault N, Boulain T. Source: Critical Care Medicine. 2001 December; 29(12): 2303-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11801831&dopt=Abstract
•
Moxifloxacin for community-acquired pneumonia. Author(s): Rijnders BJ. Source: Antimicrobial Agents and Chemotherapy. 2003 January; 47(1): 444; Author Reply 444-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12499236&dopt=Abstract
•
Multicenter, double-blind, placebo-controlled study of the use of filgrastim in patients hospitalized with pneumonia and severe sepsis. Author(s): Root RK, Lodato RF, Patrick W, Cade JF, Fotheringham N, Milwee S, Vincent JL, Torres A, Rello J, Nelson S; Pneumonia Sepsis Study Group. Source: Critical Care Medicine. 2003 February; 31(2): 367-73. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12576938&dopt=Abstract
•
Multidisciplinary approach to improving treatment of community-acquired pneumonia. Author(s): Cregin R, Segal-Maurer S, Weinbaum F, Rahal J, Kabrowitz S, Sixsmith D, Cassata V, Danek M, Battleman D, Callahan M. Source: American Journal of Health-System Pharmacy : Ajhp : Official Journal of the American Society of Health-System Pharmacists. 2002 February 15; 59(4): 364-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11885401&dopt=Abstract
•
Multidrug-resistant Corynebacterium striatum pneumonia in a heart transplant recipient. Author(s): Tarr PE, Stock F, Cooke RH, Fedorko DP, Lucey DR. Source: Transplant Infectious Disease : an Official Journal of the Transplantation Society. 2003 March; 5(1): 53-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12791076&dopt=Abstract
•
Mutations in dihydropteroate synthase gene of Pneumocystis carinii in HIV patients with Pneumocystis carinii pneumonia. Author(s): Visconti E, Ortona E, Mencarini P, Margutti P, Marinaci S, Zolfo M, Siracusano A, Tamburrini E. Source: International Journal of Antimicrobial Agents. 2001 December; 18(6): 547-51. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11738342&dopt=Abstract
Studies 263
•
Mycobacterium xenopi pneumonia in the southeastern United States. Author(s): Faress JA, McKinney LA, Semaan MT, Byrd RP Jr, Mehta JB, Roy TM. Source: Southern Medical Journal. 2003 June; 96(6): 596-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12938788&dopt=Abstract
•
Mycoplasma and Chlamydia pneumonia in pediatrics. Author(s): Nelson CT. Source: Seminars in Respiratory Infections. 2002 March; 17(1): 10-4. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11891514&dopt=Abstract
•
Mycoplasma pneumoniae and Chlamydia pneumoniae infections in children with pneumonia. Mowgli Study Group. Author(s): Esposito S, Blasi F, Bellini F, Allegra L, Principi N; Mowgli Study Group. Source: The European Respiratory Journal : Official Journal of the European Society for Clinical Respiratory Physiology. 2001 February; 17(2): 241-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11334126&dopt=Abstract
•
Mycoplasma pneumoniae associated organising pneumonia in a 10 year old boy. Author(s): Wachowski O, Demirakca S, Muller KM, Scheurlen W. Source: Archives of Disease in Childhood. 2003 March; 88(3): 270-2. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12598403&dopt=Abstract
•
Mycoplasma pneumoniae causes over 50% of community-acquired pneumonia in school-aged children. Author(s): Korppi M, Heiskanen-Kosma T, Kleemola M. Source: Scandinavian Journal of Infectious Diseases. 2003; 35(4): 294. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12839167&dopt=Abstract
•
Mycoplasma pneumoniae community-acquired pneumonia at three hospitals in Bangkok. Author(s): Chaoprasong C, Chanthadisai N, Buasap U, Tirawatnapong S, Wattanathum A. Source: J Med Assoc Thai. 2002 June; 85(6): 643-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12322835&dopt=Abstract
•
Mycoplasma pneumoniae in children with pneumonia at Mbagathi District Hospital, Nairobi. Author(s): Bii CC, Yamaguchi H, Kai M, Nagai K, Sugiura Y, Taguchi H, Chakaya JM, Mbugua GG, Kamiya H. Source: East Afr Med J. 2002 June; 79(6): 317-22. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12643233&dopt=Abstract
264 Pneumonia
•
Mycoplasma Pneumoniae infection in Malaysian children admitted with community acquired pneumonia. Author(s): Chan PW, Lum LC, Ngeow YF, Yasim MY. Source: Southeast Asian J Trop Med Public Health. 2001 June; 32(2): 397-401. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11556595&dopt=Abstract
•
Mycotic aneurysm of the thoracic aorta presenting as pneumonia. Author(s): Mengozzi E, Sartoni Galloni S, Giovannini G, Bronzetti G. Source: Pediatric Radiology. 2001 July; 31(7): 488-90. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11486801&dopt=Abstract
•
Myofibroblasts proliferation of idiopathic and collagen vascular disorders associated nonspecific interstitial pneumonia. Author(s): Niimi T, Yoshinouchi T, Ohtsuki Y, Fujita J, Sato S, Sugiura Y, Ohta K, Kajiura M, Ueda R. Source: Acta Medica Okayama. 2003 February; 57(1): 33-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12765222&dopt=Abstract
•
Myths & facts.about nosocomial pneumonia. Author(s): Munson BL. Source: Nursing. 2003 May; 33(5): 69. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12797342&dopt=Abstract
•
Necrotizing clostridial pneumonia: a case report and review of the literature. Author(s): Cannon JW. Source: Military Medicine. 2002 January; 167(1): 85-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11799823&dopt=Abstract
•
Necrotizing pneumonia caused by Streptococcus pneumoniae in a child with systemic lupus erythematosus. Author(s): Chiu WJ, Kao HT, Huang JL. Source: Acta Paediatr Taiwan. 2002 September-October; 43(5): 291-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12607488&dopt=Abstract
•
Neonatal pneumonia caused by Trichomonas vaginalis. Author(s): Szarka K, Temesvari P, Kerekes A, Tege A, Repkeny A. Source: Acta Microbiol Immunol Hung. 2002; 49(1): 15-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12073821&dopt=Abstract
Studies 265
•
Nerve irritation following pneumonia? Author(s): Landow K. Source: Postgraduate Medicine. 2002 November; 112(5): 146. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12462191&dopt=Abstract
•
New directions in antiinfective therapy for community-acquired pneumonia in the emergency department. Author(s): Moran GJ. Source: Pharmacotherapy. 2001 July; 21(7 Pt 2): 95S-99S. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11446525&dopt=Abstract
•
New insights into transmission, diagnosis, and drug treatment of Pneumocystis carinii pneumonia. Author(s): Kovacs JA, Gill VJ, Meshnick S, Masur H. Source: Jama : the Journal of the American Medical Association. 2001 November 21; 286(19): 2450-60. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11712941&dopt=Abstract
•
Nitric oxide and prostacyclin in acute interstitial pneumonia. Author(s): Ho TB, Rhodes A. Source: Journal of the Royal Society of Medicine. 2002 January; 95(1): 35-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11773351&dopt=Abstract
•
No evidence that vaccination with a polysaccharide pneumococcal vaccine protects drug users against all-cause pneumonia. Author(s): Lindenburg CE, Langendam MW, Benthem BH, Miedema F, Coutinho RA. Source: Aids (London, England). 2001 July 6; 15(10): 1315-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11426080&dopt=Abstract
•
Nocardia asteroides pneumonia with bacteraemia. Author(s): Figgis PA, Glanville AR, Harkness JL. Source: The Medical Journal of Australia. 2003 August 4; 179(3): 171-2. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12885290&dopt=Abstract
•
Non resolving pneumonia in a young boy. Author(s): Guleria R, Thakur M, Sinha S, Sharma SK, Pande JN. Source: Indian J Chest Dis Allied Sci. 2002 July-September; 44(3): 183-5. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12206478&dopt=Abstract
266 Pneumonia
•
Non responding pneumonia with skin lesions. Author(s): Ladhani S, Kamble RT, Sundaram P, Joshi JM. Source: Indian J Chest Dis Allied Sci. 2001 April-June; 43(2): 115-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11529410&dopt=Abstract
•
Non-bronchoscopic bronchoalveolar lavage in the microbiological diagnosis of pneumonia in mechanically ventilated patients. Author(s): Arora SC, Mudaliar YM, Lee C, Mitchell D, Iredel J, Lazarus R. Source: Anaesthesia and Intensive Care. 2002 February; 30(1): 11-20. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11939432&dopt=Abstract
•
Nonbronchoscopic evaluation of ventilator-associated pneumonia. Author(s): Baughman RP. Source: Seminars in Respiratory Infections. 2003 June; 18(2): 95-102. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12840790&dopt=Abstract
•
Noninvasive pressure support ventilation in non-COPD patients with acute cardiogenic pulmonary edema and severe community-acquired pneumonia: acute effects and outcome. Author(s): Domenighetti G, Gayer R, Gentilini R. Source: Intensive Care Medicine. 2002 September; 28(9): 1226-32. Epub 2002 August 02. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12209269&dopt=Abstract
•
Non-invasive pressure support ventilation in severe community-acquired pneumonia. Author(s): Jolliet P, Abajo B, Pasquina P, Chevrolet JC. Source: Intensive Care Medicine. 2001 May; 27(5): 812-21. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11430536&dopt=Abstract
•
Noninvasive ventilation for treating acute respiratory failure in AIDS patients with Pneumocystis carinii pneumonia. Author(s): Confalonieri M, Calderini E, Terraciano S, Chidini G, Celeste E, Puccio G, Gregoretti C, Meduri GU. Source: Intensive Care Medicine. 2002 September; 28(9): 1233-8. Epub 2002 July 06. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12209270&dopt=Abstract
•
Noninvasive ventilation routine therapy for community-acquired pneumonia? Not so fast! Author(s): Hill NS. Source: Intensive Care Medicine. 2001 May; 27(5): 797-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11430533&dopt=Abstract
Studies 267
•
Nonresolving pneumonia and mimics of pneumonia. Author(s): Rome L, Murali G, Lippmann M. Source: The Medical Clinics of North America. 2001 November; 85(6): 1511-30, Xi. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11680114&dopt=Abstract
•
Nonsevere community-acquired pneumonia: correlation between cause and severity or comorbidity. Author(s): Falguera M, Sacristan O, Nogues A, Ruiz-Gonzalez A, Garcia M, Manonelles A, Rubio-Caballero M. Source: Archives of Internal Medicine. 2001 August 13-27; 161(15): 1866-72. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11493128&dopt=Abstract
•
Nonspecific interstitial pneumonia (NSIP), fibrosis pattern. Case report. Author(s): Dalpiaz G, Cancellieri A, Nassetti C, Stasi G. Source: Radiol Med (Torino). 2003 January-February; 105(1-2): 107-11. English, Italian. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12700554&dopt=Abstract
•
Non-specific interstitial pneumonia and Chlamydia pneumoniae infection. Author(s): Fujita J, Bandoh S, Tokuda M, Ohtsuki Y, Yamadori I, Yoshinouchi T, Ishida T. Source: Japanese Journal of Infectious Diseases. 2001 December; 54(6): 225-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11862004&dopt=Abstract
•
Nonspecific interstitial pneumonia and systemic sclerosis. Author(s): King TE Jr. Source: American Journal of Respiratory and Critical Care Medicine. 2002 June 15; 165(12): 1578-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12070054&dopt=Abstract
•
Nonspecific interstitial pneumonia and usual interstitial pneumonia: comparative appearances at and diagnostic accuracy of thin-section CT. Author(s): MacDonald SL, Rubens MB, Hansell DM, Copley SJ, Desai SR, du Bois RM, Nicholson AG, Colby TV, Wells AU. Source: Radiology. 2001 December; 221(3): 600-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11719652&dopt=Abstract
268 Pneumonia
•
Nonspecific interstitial pneumonia as pulmonary involvement of primary Sjogren's syndrome. Author(s): Yamadori I, Fujita J, Bandoh S, Tokuda M, Tanimoto Y, Kataoka M, Yamasaki Y, Yoshinouchi T, Ohtsuki Y, Ishida T. Source: Rheumatology International. 2002 July; 22(3): 89-92. Epub 2002 May 29. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12111081&dopt=Abstract
•
Non-specific interstitial pneumonia as pulmonary involvement of systemic sclerosis. Author(s): Fujita J, Yoshinouchi T, Ohtsuki Y, Tokuda M, Yang Y, Yamadori I, Bandoh S, Ishida T, Takahara J, Ueda R. Source: Annals of the Rheumatic Diseases. 2001 March; 60(3): 281-3. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11171693&dopt=Abstract
•
Nonspecific interstitial pneumonia associated with polymyositis and dermatomyositis: serial high-resolution CT findings and functional correlation. Author(s): Arakawa H, Yamada H, Kurihara Y, Nakajima Y, Takeda A, Fukushima Y, Fujioka M. Source: Chest. 2003 April; 123(4): 1096-103. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12684299&dopt=Abstract
•
Non-specific interstitial pneumonia showing a “crazy paving” pattern on high resolution CT. Author(s): Coche E, Weynand B, Noirhomme P, Pieters T. Source: The British Journal of Radiology. 2001 February; 74(878): 189-91. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11718394&dopt=Abstract
•
Nonspecific interstitial pneumonia/fibrosis completely recovered by adding cyclophosphamide to corticosteroids. Author(s): Nanki N, Fujita J, Yamaji Y, Maeda H, Kurose T, Kaji M, Satoh K, Miyatani K, Yamadori I, Ohtsuki Y, Ishida T. Source: Intern Med. 2002 October; 41(10): 867-70. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12413012&dopt=Abstract
•
Nonspecific interstitial pneumonia: correlation between thin-section CT findings and pathologic subgroups in 55 patients. Author(s): Johkoh T, Muller NL, Colby TV, Ichikado K, Taniguchi H, Kondoh Y, Fujimoto K, Kinoshita M, Arakawa H, Yamada H, Suga M, Ando M, Koyama M, Nakamura H. Source: Radiology. 2002 October; 225(1): 199-204. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12355005&dopt=Abstract
Studies 269
•
Nonspecific interstitial pneumonia: evolving concepts. Author(s): Lynch DA. Source: Radiology. 2001 December; 221(3): 583-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11719646&dopt=Abstract
•
Nonspecific interstitial pneumonia-nobody said it's perfect. Author(s): Nicholson AG, Wells AU. Source: American Journal of Respiratory and Critical Care Medicine. 2001 November 1; 164(9): 1553-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11719289&dopt=Abstract
•
Nonspecificity of assaying for IgG antibody to pneumolysin in circulating immune complexes as a means to diagnose pneumococcal pneumonia. Author(s): Musher DM, Mediwala R, Phan HM, Chen G, Baughn RE. Source: Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America. 2001 February 15; 32(4): 534-8. Epub 2001 Feb 09. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11181114&dopt=Abstract
•
Nontyphoidal salmonella bacteremia and pneumonia as the initial manifestation of human immunodeficiency virus infection in a four-year-old child. Author(s): Eaton EE, Dobrozycski J, Loas R, Laddis D, Fennelly GJ. Source: Aids Patient Care and Stds. 2002 June; 16(6): 247-50. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12133259&dopt=Abstract
•
Nonvalue of the initial microbiological studies in the management of nonsevere community-acquired pneumonia. Author(s): Theerthakarai R, El-Halees W, Ismail M, Solis RA, Khan MA. Source: Chest. 2001 January; 119(1): 181-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11157602&dopt=Abstract
•
Nosocomial bacterial pneumonia in human immunodeficiency virus infected subjects: incidence, risk factors and outcome. Author(s): Tumbarello M, Tacconelli E, de Gaetano Donati K, Bertagnolio S, Cataldo M, Pirronti T, Ardito F, Cauda R. Source: The European Respiratory Journal : Official Journal of the European Society for Clinical Respiratory Physiology. 2001 April; 17(4): 636-40. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11401057&dopt=Abstract
•
Nosocomial outbreak of Legionella pneumophila serogroup 3 pneumonia in a new bone marrow transplant unit: evaluation, treatment and control. Author(s): Oren I, Zuckerman T, Avivi I, Finkelstein R, Yigla M, Rowe JM. Source: Bone Marrow Transplantation. 2002 August; 30(3): 175-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12189536&dopt=Abstract
270 Pneumonia
•
Nosocomial pneumonia after acute stroke: implications for neurological intensive care medicine. Author(s): Hilker R, Poetter C, Findeisen N, Sobesky J, Jacobs A, Neveling M, Heiss WD. Source: Stroke; a Journal of Cerebral Circulation. 2003 April; 34(4): 975-81. Epub 2003 March 13. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12637700&dopt=Abstract
•
Nosocomial pneumonia in pediatric patients: practical problems and rational solutions. Author(s): Zar HJ, Cotton MF. Source: Paediatric Drugs. 2002; 4(2): 73-83. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11888355&dopt=Abstract
•
Nosocomial pneumonia is not prevented by protective contact isolation in the surgical intensive care unit. Author(s): Koss WG, Khalili TM, Lemus JF, Chelly MM, Margulies DR, Shabot MM. Source: The American Surgeon. 2001 December; 67(12): 1140-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11768817&dopt=Abstract
•
Nosocomial pneumonia. Author(s): Johanson WG, Dever LL. Source: Intensive Care Medicine. 2003 January; 29(1): 23-9. Epub 2002 December 04. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12528018&dopt=Abstract
•
Nosocomial pneumonia. Author(s): Mehta RM, Niederman MS. Source: Current Opinion in Infectious Diseases. 2002 August; 15(4): 387-94. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12130935&dopt=Abstract
•
Nosocomial pneumonia. Diagnostic and therapeutic considerations. Author(s): Cunha BA. Source: The Medical Clinics of North America. 2001 January; 85(1): 79-114. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11190353&dopt=Abstract
•
Nosocomial pneumonia: a cost-of-illness analysis. Author(s): Dietrich ES, Demmler M, Schulgen G, Fekec K, Mast O, Pelz K, Daschner FD. Source: Infection. 2002 April; 30(2): 61-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12018471&dopt=Abstract
Studies 271
•
Nosocomial pneumonia: emerging concepts in diagnosis, management, and prophylaxis. Author(s): Craven DE, De Rosa FG, Thornton D. Source: Current Opinion in Critical Care. 2002 October; 8(5): 421-9. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12357110&dopt=Abstract
•
Nosocomial pneumonia: importance of recognition of aetiological agents to define an appropriate initial empirical therapy. Author(s): Costa SF, Newbaer M, Santos CR, Basso M, Soares I, Levin AS. Source: International Journal of Antimicrobial Agents. 2001 February; 17(2): 147-50. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11165120&dopt=Abstract
•
Nosocomial pneumonia: the importance of a de-escalating strategy for antibiotic treatment of pneumonia in the ICU. Author(s): Hoffken G, Niederman MS. Source: Chest. 2002 December; 122(6): 2183-96. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12475862&dopt=Abstract
•
Novel approaches to the treatment of pneumonia. Author(s): Cazzola M, Matera MG, Page CP. Source: Trends in Pharmacological Sciences. 2003 June; 24(6): 306-14. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12823957&dopt=Abstract
•
Novel nonantibiotic therapies for pneumonia: cytokines and host defense. Author(s): Nelson S. Source: Chest. 2001 February; 119(2 Suppl): 419S-425S. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11171779&dopt=Abstract
•
Nucleic acid amplification tests for the diagnosis of pneumonia. Author(s): Murdoch DR. Source: Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America. 2003 May 1; 36(9): 1162-70. Epub 2003 April 22. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12715312&dopt=Abstract
•
Nursing home-acquired pneumonia. Author(s): Mylotte JM. Source: Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America. 2002 November 15; 35(10): 1205-11. Epub 2002 October 28. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12410480&dopt=Abstract
272 Pneumonia
•
Obstructive pneumonia: an indication for surgery in mega aorta syndrome. Author(s): Kalkat MS, Bonser RS. Source: The Annals of Thoracic Surgery. 2003 April; 75(4): 1313-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12683586&dopt=Abstract
•
Occult pneumonia in an eight-year-old child. Author(s): Glasser JL. Source: The Journal of Emergency Medicine. 2002 October; 23(3): 289-90. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12449967&dopt=Abstract
•
Occurrence of ventilator-associated pneumonia in mechanically ventilated pediatric intensive care patients during stress ulcer prophylaxis with sucralfate, ranitidine, and omeprazole. Author(s): Yildizdas D, Yapicioglu H, Yilmaz HL. Source: Journal of Critical Care. 2002 December; 17(4): 240-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12501151&dopt=Abstract
•
Old and new antibiotics for pediatric pneumonia. Author(s): Bradley JS. Source: Seminars in Respiratory Infections. 2002 March; 17(1): 57-64. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11891519&dopt=Abstract
•
Oligoclonal T cell expansions in pulmonary lymphoproliferative disorders: demonstration of the frequent occurrence of oligoclonal T cells in human immunodeficiency virus-related lymphoid interstitial pneumonia. Author(s): Kurosu K, Yumoto N, Rom WN, Takiguchi Y, Jaishree J, Nakata K, Tatsumi K, Mikata A, Kuriyama T, Weiden MD. Source: American Journal of Respiratory and Critical Care Medicine. 2002 January 15; 165(2): 254-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11790664&dopt=Abstract
•
On the trail of community-acquired pneumonia. Recognize the early signs of this respiratory infection to pinpoint effective treatment plan. Author(s): Schultz TR. Source: Nursing Management. 2003 February; 34(2): 27-31; Quiz 31-2. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12576779&dopt=Abstract
•
Optimal threshold for diagnosis of ventilator-associated pneumonia using bronchoalveolar lavage. Author(s): Miller PR, Meredith JW, Chang MC. Source: The Journal of Trauma. 2003 August; 55(2): 263-7; Discussion 267-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12913635&dopt=Abstract
Studies 273
•
Optimal treatment strategies for community-acquired pneumonia: high-risk patients (geriatric and with comorbidity). Author(s): Carbon C. Source: Chemotherapy. 2001; 47 Suppl 4: 19-25; Discussion 26-7. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11586002&dopt=Abstract
•
Optimal treatment strategies for community-acquired pneumonia: non-responders to conventional regimens. Author(s): File TM Jr. Source: Chemotherapy. 2001; 47 Suppl 4: 11-8; Discussion 26-7. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11586001&dopt=Abstract
•
Optimal use of antibiotics for intubation-associated pneumonia. Author(s): Rello J, Diaz E. Source: Intensive Care Medicine. 2001 February; 27(2): 337-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11396275&dopt=Abstract
•
Optimizing therapeutic approaches in ventilator-associated pneumonia. Author(s): Brun-Buisson C. Source: Minerva Anestesiol. 2002 April; 68(4): 258-60. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12024095&dopt=Abstract
•
Oral amoxicillin for childhood pneumonia. Author(s): Richards S. Source: Lancet. 2003 January 4; 361(9351): 76; Author Reply 76-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12517489&dopt=Abstract
•
Oral care reduces pneumonia in older patients in nursing homes. Author(s): Yoneyama T, Yoshida M, Ohrui T, Mukaiyama H, Okamoto H, Hoshiba K, Ihara S, Yanagisawa S, Ariumi S, Morita T, Mizuno Y, Ohsawa T, Akagawa Y, Hashimoto K, Sasaki H; Oral Care Working Group. Source: Journal of the American Geriatrics Society. 2002 March; 50(3): 430-3. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11943036&dopt=Abstract
•
Oral gatifloxacin in outpatient community-acquired pneumonia: results from TeqCES, a community-based, open-label, multicenter study. Author(s): Gotfried M, Quinn TC, Gothelf S, Wikler MA, Webb CD, Nicholson SC. Source: Diagnostic Microbiology and Infectious Disease. 2002 September; 44(1): 85-91. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12376037&dopt=Abstract
274 Pneumonia
•
Oral gemifloxacin versus sequential therapy with intravenous ceftriaxone/oral cefuroxime with or without a macrolide in the treatment of patients hospitalized with community-acquired pneumonia: a randomized, open-label, multicenter study of clinical efficacy and tolerability. Author(s): Lode H, File TM Jr, Mandell L, Ball P, Pypstra R, Thomas M; 185 Gemifloxacin Study Group. Source: Clinical Therapeutics. 2002 November; 24(11): 1915-36. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12501883&dopt=Abstract
•
Oral moxifloxacin vs high-dosage amoxicillin in the treatment of mild-to-moderate, community-acquired, suspected pneumococcal pneumonia in adults. Author(s): Petitpretz P, Arvis P, Marel M, Moita J, Urueta J; CAP5 Moxifloxacin Study Group. Source: Chest. 2001 January; 119(1): 185-95. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11157603&dopt=Abstract
•
Oral or intravenous-to-oral antibiotic switch therapy for treating patients with community-acquired pneumonia. Author(s): Cunha BA. Source: The American Journal of Medicine. 2001 October 1; 111(5): 412-3. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11583649&dopt=Abstract
•
Organising pneumonia caused by transtuzumab (Herceptin) therapy for breast cancer. Author(s): Radzikowska E, Szczepulska E, Chabowski M, Bestry I. Source: The European Respiratory Journal : Official Journal of the European Society for Clinical Respiratory Physiology. 2003 March; 21(3): 552-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12662016&dopt=Abstract
•
Organizing pneumonia adjacent to lung cancer: frequency and clinico-pathologic features. Author(s): Romero S, Barroso E, Rodriguez-Paniagua M, Aranda FI. Source: Lung Cancer (Amsterdam, Netherlands). 2002 February; 35(2): 195-201. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11804693&dopt=Abstract
•
Organizing pneumonia: prognostic implication of high-resolution computed tomography features. Author(s): Lee JS, Lynch DA, Sharma S, Brown KK, Muller NL. Source: Journal of Computer Assisted Tomography. 2003 March-April; 27(2): 260-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12703023&dopt=Abstract
Studies 275
•
Organizing pneumonia: the many morphological faces. Author(s): Oikonomou A, Hansell DM. Source: European Radiology. 2002 June; 12(6): 1486-96. Epub 2001 November 13. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12042959&dopt=Abstract
•
Outbreak of community-acquired pneumonia in Nunavut, October and November, 2000. Author(s): Macey JF, Roberts A, Lior L, Tam TW, VanCaeseele P. Source: Can Commun Dis Rep. 2002 August 15; 28(16): 131-8. English, French. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12387099&dopt=Abstract
•
Outbreak of nosocomial sepsis and pneumonia in a newborn intensive care unit by multiresistant extended-spectrum beta-lactamase-producing Klebsiella pneumoniae: high impact on mortality. Author(s): Martinez-Aguilar G, Alpuche-Aranda CM, Anaya C, Alcantar-Curiel D, Gayosso C, Daza C, Mijares C, Tinoco JC, Santos JI. Source: Infection Control and Hospital Epidemiology : the Official Journal of the Society of Hospital Epidemiologists of America. 2001 November; 22(11): 725-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11842997&dopt=Abstract
•
Outcome and attributable cost of ventilator-associated pneumonia among intensive care unit patients in a suburban medical center. Author(s): Warren DK, Shukla SJ, Olsen MA, Kollef MH, Hollenbeak CS, Cox MJ, Cohen MM, Fraser VJ. Source: Critical Care Medicine. 2003 May; 31(5): 1312-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12771596&dopt=Abstract
•
Outcome of acid ingestion related aspiration pneumonia. Author(s): Tseng YL, Wu MH, Lin MY, Lai WW. Source: European Journal of Cardio-Thoracic Surgery : Official Journal of the European Association for Cardio-Thoracic Surgery. 2002 April; 21(4): 638-43. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11932160&dopt=Abstract
•
Outcome of older patients with severe pneumonia predicted by recursive partitioning. Author(s): El-Solh AA, Sikka P, Ramadan F. Source: Journal of the American Geriatrics Society. 2001 December; 49(12): 1614-21. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11843993&dopt=Abstract
276 Pneumonia
•
Outcome of postoperative pneumonia in the Eole study. Author(s): Dupont H, Montravers P, Gauzit R, Veber B, Pouriat JL, Martin C; Club d'Infectiologie en Anesthesie-Reanimation. Source: Intensive Care Medicine. 2003 February; 29(2): 179-88. Epub 2003 January 14. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12594582&dopt=Abstract
•
Overdiagnosis of pneumonia in children. Author(s): Anadol D, Aydin YZ, Gocmen A. Source: Turk J Pediatr. 2001 July-September; 43(3): 205-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11592510&dopt=Abstract
•
P. carinii pneumonia in African children and the ineffectiveness of TMP-SMX prophylaxis. Author(s): Cruciani M, Malena M, Mengoli C. Source: Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America. 2003 April 1; 36(7): 937-9; Author Reply 939-40. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12652402&dopt=Abstract
•
Paediatric community-acquired pneumonia: current concept in pharmacological control. Author(s): Principi N, Esposito S. Source: Expert Opinion on Pharmacotherapy. 2003 May; 4(5): 761-77. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12739999&dopt=Abstract
•
Parachlamydiaceae as rare agents of pneumonia. Author(s): Greub G, Berger P, Papazian L, Raoult D. Source: Emerging Infectious Diseases. 2003 June; 9(6): 755-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12781026&dopt=Abstract
•
Pathogen of occurrence and susceptibility patterns associated with pneumonia in hospitalized patients in North America: results of the SENTRY Antimicrobial Surveillance Study (2000). Author(s): Hoban DJ, Biedenbach DJ, Mutnick AH, Jones RN. Source: Diagnostic Microbiology and Infectious Disease. 2003 April; 45(4): 279-85. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12730000&dopt=Abstract
•
Pathogenesis of posttraumatic empyema: the impact of pneumonia on pleural space infections. Author(s): Hoth JJ, Burch PT, Bullock TK, Cheadle WG, Richardson JD. Source: Surgical Infections. 2003 Spring; 4(1): 29-35. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12744764&dopt=Abstract
Studies 277
•
Pathology case of the month. Spontaneous pneumothorax in a young woman. Usual interstitial pneumonia (UIP). Author(s): Latif S, Veillon DM, Constantinescu M, Heldmann M, Cotelingam JD. Source: J La State Med Soc. 2003 May-June; 155(3): 131-3. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12873096&dopt=Abstract
•
Pediatric pneumonia. Author(s): Lichenstein R, Suggs AH, Campbell J. Source: Emergency Medicine Clinics of North America. 2003 May; 21(2): 437-51. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12793623&dopt=Abstract
•
Pediatric ventilator-associated pneumonia. Author(s): Elward AM. Source: The Pediatric Infectious Disease Journal. 2003 May; 22(5): 445-6. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12792388&dopt=Abstract
•
Penicillin resistance in pneumococcal pneumonia. Antibiotics with low resistance potential are effective and pose less risk. Author(s): Cunha BA. Source: Postgraduate Medicine. 2003 January; 113(1): 42-4, 47-8, 52-4. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12545592&dopt=Abstract
•
Penicillin-resistant pneumococci-implications for management of communityacquired pneumonia and meningitis. Author(s): Ziglam HM, Finch RG. Source: International Journal of Infectious Diseases : Ijid : Official Publication of the International Society for Infectious Diseases. 2002 March; 6 Suppl 1: S14-20. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12044285&dopt=Abstract
•
Percentage, bacterial etiology and antibiotic susceptibility of acute respiratory infection and pneumonia among children in rural Senegal. Author(s): Echave P, Bille J, Audet C, Talla I, Vaudaux B, Gehri M. Source: Journal of Tropical Pediatrics. 2003 February; 49(1): 28-32. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12630717&dopt=Abstract
•
Persistent pneumonia in a boy with systemic lupus erythematosus. Author(s): Lee AY, Ogershok PR, Weisse ME. Source: Clinical Pediatrics. 2002 July-August; 41(6): 443-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12166798&dopt=Abstract
278 Pneumonia
•
Person-to-person transmission of Pseudomonas pneumonia in the community: documentation by pulsed-field electrophoresis. Author(s): Patel P, Whittier S, Frank E. Source: Southern Medical Journal. 2002 June; 95(6): 653-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12081224&dopt=Abstract
•
Pharmaceutical industry research and cost savings in community-acquired pneumonia. Author(s): Kessler LA, Waterer GW, Barca R, Wunderink RG. Source: Am J Manag Care. 2002 September; 8(9): 798-800. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12234020&dopt=Abstract
•
Plasminogen activator inhibitor type-1 deficiency does not influence the outcome of murine pneumococcal pneumonia. Author(s): Rijneveld AW, Florquin S, Bresser P, Levi M, De Waard V, Lijnen R, Van Der Zee JS, Speelman P, Carmeliet P, Van Der Poll T. Source: Blood. 2003 August 1; 102(3): 934-9. Epub 2003 April 17. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12702502&dopt=Abstract
•
Pneumococcal serotype 19F conjugate vaccine induces cross-protective immunity to serotype 19A in a murine pneumococcal pneumonia model. Author(s): Jakobsen H, Sigurdsson VD, Sigurdardottir S, Schulz D, Jonsdottir I. Source: Infection and Immunity. 2003 May; 71(5): 2956-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12704178&dopt=Abstract
•
Pneumocystis carinii pneumonia after the discontinuation of long-term antiretroviral therapy in an HIV-1-infected pregnant woman. Author(s): Gervasoni C, Vaccarezza M, Ridolfo AL, Moroni M, Galli M. Source: Aids (London, England). 2003 April 11; 17(6): 940-1. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12660551&dopt=Abstract
•
Pneumocystis carinii pneumonia after the discontinuation of secondary prophylaxis. Author(s): Degen O, ven Lunzen J, Horstkotte MA, Sobottka I, Stellbrink HJ. Source: Aids (London, England). 2002 July 5; 16(10): 1433-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12131226&dopt=Abstract
•
Pneumocystis carinii pneumonia as a complication of bendamustine monotherapy in a patient with advanced progressive breast cancer. Author(s): Klippstein A, Schneider CP, Sayer HG, Hoffken K. Source: Journal of Cancer Research and Clinical Oncology. 2003 May; 129(5): 316-9. Epub 2003 May 17. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12756557&dopt=Abstract
Studies 279
•
Pneumocystis carinii pneumonia following a second infusion of infliximab. Author(s): Tai TL, O'Rourke KP, McWeeney M, Burke CM, Sheehan K, Barry M. Source: Rheumatology (Oxford, England). 2002 August; 41(8): 951-2. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12154220&dopt=Abstract
•
Pneumocystis carinii pneumonia in a patient on immunosuppressive drugs for pyoderma gangrenosum. Author(s): McGarry H, McLelland J. Source: The British Journal of Dermatology. 2002 July; 147(1): 192-3. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12100210&dopt=Abstract
•
Pneumocystis carinii pneumonia in an infant with transient hypogammaglobulinaemia of infancy. Author(s): Smart JM, Kemp AS, Armstrong DS. Source: Archives of Disease in Childhood. 2002 November; 87(5): 449-50. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12390932&dopt=Abstract
•
Pneumocystis carinii pneumonia in an untreated HIV-infected patient. Author(s): Ball SC. Source: Aids Read. 2002 November; 12(11): 472-4, 476. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12494907&dopt=Abstract
•
Pneumocystis carinii pneumonia in critically ill patients with malignancy: a descriptive study. Author(s): Zahar JR, Robin M, Azoulay E, Fieux F, Nitenberg G, Schlemmer B. Source: Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America. 2002 October 15; 35(8): 929-34. Epub 2002 September 23. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12355379&dopt=Abstract
•
Pneumocystis carinii pneumonia in HIV negative patients with primary brain tumors. Author(s): Mahindra AK, Grossman SA. Source: Journal of Neuro-Oncology. 2003 July; 63(3): 263-70. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12892232&dopt=Abstract
•
Pneumocystis carinii pneumonia in HIV/AIDS patients at an urban district hospital in Kenya. Author(s): Chakaya JM, Bii C, Ng'ang'a L, Amukoye E, Ouko T, Muita L, Gathua S, Gitau J, Odongo I, Kabanga JM, Nagai K, Suzumura S, Sugiura Y. Source: East Afr Med J. 2003 January; 80(1): 30-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12755239&dopt=Abstract
280 Pneumonia
•
Pneumocystis carinii pneumonia in HIV-infected patients in the HAART era. Author(s): Pulvirenti J, Herrera P, Venkataraman P, Ahmed N. Source: Aids Patient Care and Stds. 2003 June; 17(6): 261-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12880489&dopt=Abstract
•
Pneumocystis carinii pneumonia in patients in the developing world who have acquired immunodeficiency syndrome. Author(s): Fisk DT, Meshnick S, Kazanjian PH. Source: Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America. 2003 January 1; 36(1): 70-8. Epub 2002 December 16. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12491205&dopt=Abstract
•
Pneumocystis carinii pneumonia in patients with and without HIV infection. Author(s): Santamauro JT, Aurora RN, Stover DE. Source: Compr Ther. 2002 Summer; 28(2): 96-108. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12085467&dopt=Abstract
•
Pneumocystis carinii pneumonia in patients with Diamond-Blackfan anemia receiving high-dose corticosteroids. Author(s): Huh WW, Gill J, Sheth S, Buchanan GR. Source: Journal of Pediatric Hematology/Oncology : Official Journal of the American Society of Pediatric Hematology/Oncology. 2002 June-July; 24(5): 410-2. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12142794&dopt=Abstract
•
Pneumocystis carinii pneumonia in patients with malignant haematological diseases: 10 years' experience of infection in GIMEMA centres. Author(s): Pagano L, Fianchi L, Mele L, Girmenia C, Offidani M, Ricci P, Mitra ME, Picardi M, Caramatti C, Piccaluga P, Nosari A, Buelli M, Allione B, Cortelezzi A, Fabbiano F, Milone G, Invernizzi R, Martino B, Masini L, Todeschini G, Cappucci MA, Russo D, Corvatta L, Martino P, Del Favero A. Source: British Journal of Haematology. 2002 May; 117(2): 379-86. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11972521&dopt=Abstract
•
Pneumocystis carinii pneumonia in patients without HIV infection. Author(s): Saksasithon S, Sungkanuparph S, Thanakitcharu S. Source: J Med Assoc Thai. 2003 July; 86(7): 612-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12948254&dopt=Abstract
•
Pneumocystis carinii pneumonia prophylaxis in HIV negative patients with primary CNS lymphoma. Author(s): Mathew BS, Grossman SA. Source: Cancer Treatment Reviews. 2003 April; 29(2): 105-19. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12670453&dopt=Abstract
Studies 281
•
Pneumocystis carinii pneumonia with pleurisy, platypnoea and orthodeoxia. Author(s): Newton PN, Wakefield AE, Goldin R, Govan J. Source: Thorax. 2003 February; 58(2): 185-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12554907&dopt=Abstract
•
Pneumocystis carinii pneumonia. Author(s): Tasci S, Ewig S, Burghard A, Luderitz B. Source: Lancet. 2003 July 12; 362(9378): 124. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12867113&dopt=Abstract
•
Pneumocystis carinii pneumonia: role of high resolution computed tomography. Author(s): Gupta S, Dash SC, Sharma S, Agarwal SK, Bhowmik D, Wani M, Ramasethu R, Tiwari SC, Guleria S, Mehta SN. Source: J Assoc Physicians India. 2002 May; 50(5): 726-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12186137&dopt=Abstract
•
Pneumocystis pneumonia. Author(s): Robberts FJ, Chalkley LJ, Liebowitz LD. Source: Sadj. 2002 December; 57(11): 451-3. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12674864&dopt=Abstract
•
Pneumonia associated with visceral leishmaniasis in childhood. Author(s): Mehmet T, Hokelek M. Source: Journal of Tropical Pediatrics. 2003 February; 49(1): 61. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12630725&dopt=Abstract
•
Pneumonia caused by herpesviruses in recipients of hematopoietic cell transplants. Author(s): Taplitz RA, Jordan MC. Source: Seminars in Respiratory Infections. 2002 June; 17(2): 121-9. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12070831&dopt=Abstract
•
Pneumonia causes panic in Guangdong province. Author(s): Rosling L, Rosling M. Source: Bmj (Clinical Research Ed.). 2003 February 22; 326(7386): 416. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12595377&dopt=Abstract
•
Pneumonia due to an unusual serotype of Salmonella. Author(s): Ghadage DP, Bal AM. Source: Indian J Chest Dis Allied Sci. 2003 January-March; 45(1): 75-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12683717&dopt=Abstract
282 Pneumonia
•
Pneumonia due to Candida krusei. Author(s): Petrocheilou-Paschou V, Georgilis K, Kontoyannis D, Nanas J, Prifti H, Costopoulos H, Stamatelopoulos S. Source: Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases. 2002 December; 8(12): 806-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12519355&dopt=Abstract
•
Pneumonia due to Mycoplasma hominis in a healthy adult. Author(s): Saez A, Monteagudo I, Minambres E, Ots E, Rodriguez-Borregan JC, Garcia C. Source: Scandinavian Journal of Infectious Diseases. 2003; 35(4): 282-4. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12839163&dopt=Abstract
•
Pneumonia due to Mycoplasma pneumoniae with transient proteinuria. Author(s): Kumar PD. Source: Southern Medical Journal. 2002 November; 95(11): 1329-30. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12540002&dopt=Abstract
•
Pneumonia due to viral and atypical organisms and their sequelae. Author(s): Smyth A. Source: British Medical Bulletin. 2002; 61: 247-62. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11997310&dopt=Abstract
•
Pneumonia epidemic caused by a virulent strain of Streptococcus pneumoniae serotype 1 in Nunavik, Quebec. Author(s): Proulx JF, Dery S, Jette LP, Ismael J, Libman M, De Wals P. Source: Can Commun Dis Rep. 2002 August 15; 28(16): 129-31. English, French. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12387098&dopt=Abstract
•
Pneumonia frequencies with different enteral tube feeding access sites. Author(s): Taylor HM. Source: Am J Ment Retard. 2002 May; 107(3): 175-80. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11966330&dopt=Abstract
•
Pneumonia in acute leukemia patients during induction therapy: experience in a single institution. Author(s): Specchia G, Pastore D, Carluccio P, Mele G, Montagna MT, Liso A, Rizzi R, Ianora AS, Liso V. Source: Leukemia & Lymphoma. 2003 January; 44(1): 97-101. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12691147&dopt=Abstract
Studies 283
•
Pneumonia in children. Author(s): Berti I, Faraguna D. Source: The New England Journal of Medicine. 2002 June 13; 346(24): 1916; Author Reply 1916. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12063383&dopt=Abstract
•
Pneumonia in multiple injured patients: a prospective controlled trial on early prediction using clinical and immunological parameters. Author(s): Andermahr J, Greb A, Hensler T, Helling HJ, Bouillon B, Sauerland S, Rehm KE, Neugebauer E. Source: Inflammation Research : Official Journal of the European Histamine Research Society. [et Al.]. 2002 May; 51(5): 265-72. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12056515&dopt=Abstract
•
Pneumonia in pregnant women. Author(s): Salmon B, Bruick-Sorge C. Source: Awhonn Lifelines / Association of Women's Health, Obstetric and Neonatal Nurses. 2003 February-March; 7(1): 48-52. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12674061&dopt=Abstract
•
Pneumonia in term neonates: laboratory studies and duration of antibiotic therapy. Author(s): Engle WD, Jackson GL, Sendelbach DM, Stehel EK, Ford DM, McHugh KM, Norris MR, Vedro DA, Velaphi S, Michelow IC, Olsen KD. Source: Journal of Perinatology : Official Journal of the California Perinatal Association. 2003 July-August; 23(5): 372-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12847531&dopt=Abstract
•
Pneumonia involving Legionella pneumophila and Listeria monocytogenes in an immunocompromised patient: an unusual coinfection. Author(s): Lerolle N, Zahar JR, Duboc V, Tissier F, Rabbat A. Source: Respiration; International Review of Thoracic Diseases. 2002; 69(4): 359-61. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12169753&dopt=Abstract
•
Pneumonia: high-resolution CT findings in 114 patients. Author(s): Reittner P, Ward S, Heyneman L, Johkoh T, Muller NL. Source: European Radiology. 2003 March; 13(3): 515-21. Epub 2002 August 03. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12594553&dopt=Abstract
•
Pneumonia: still the old man's friend? Author(s): Kaplan V, Clermont G, Griffin MF, Kasal J, Watson RS, Linde-Zwirble WT, Angus DC. Source: Archives of Internal Medicine. 2003 February 10; 163(3): 317-23. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12578512&dopt=Abstract
284 Pneumonia
•
Pneumonia: the demented patient's best friend? Discomfort after starting or withholding antibiotic treatment. Author(s): van der Steen JT, Ooms ME, van der Wal G, Ribbe MW. Source: Journal of the American Geriatrics Society. 2002 October; 50(10): 1681-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12366622&dopt=Abstract
•
Polymerase chain reaction is more sensitive than viral culture and antigen testing for the detection of respiratory viruses in adults with hematological cancer and pneumonia. Author(s): van Elden LJ, van Kraaij MG, Nijhuis M, Hendriksen KA, Dekker AW, Rozenberg-Arska M, van Loon AM. Source: Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America. 2002 January 15; 34(2): 177-83. Epub 2001 December 04. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11740705&dopt=Abstract
•
Population-based burden of pneumonia before school entry in Schleswig-Holstein, Germany. Author(s): Weigl JA, Bader HM, Everding A, Schmitt HJ. Source: European Journal of Pediatrics. 2003 May; 162(5): 309-16. Epub 2003 March 06. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12692711&dopt=Abstract
•
Preanaesthetic H2 antagonists for acid aspiration pneumonia prophylaxis. Is there evidence of tolerance? Author(s): Hirota K, Kushikata T. Source: British Journal of Anaesthesia. 2003 May; 90(5): 576-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12697583&dopt=Abstract
•
Preanaesthetic H2 antagonists for acid aspiration pneumonia prophylaxis. Is there evidence of tolerance? Author(s): Timmins A. Source: British Journal of Anaesthesia. 2003 September; 91(3): 446; Author Reply 446-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12925493&dopt=Abstract
•
Predicting survival of lung transplantation candidates with idiopathic interstitial pneumonia: does PaO(2) predict survival? Author(s): Timmer SJ, Karamzadeh AM, Yung GL, Kriett J, Jamieson SW, Smith CM. Source: Chest. 2002 September; 122(3): 779-84. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12226013&dopt=Abstract
Studies 285
•
Prediction of community-acquired pneumonia using artificial neural networks. Author(s): Heckerling PS, Gerber BS, Tape TG, Wigton RS. Source: Medical Decision Making : an International Journal of the Society for Medical Decision Making. 2003 March-April; 23(2): 112-21. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12693873&dopt=Abstract
•
Predictors of aspiration pneumonia in nursing home residents. Author(s): Langmore SE, Skarupski KA, Park PS, Fries BE. Source: Dysphagia. 2002 Fall; 17(4): 298-307. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12355145&dopt=Abstract
•
Predictors of early hospital readmission in HIV-infected patients with pneumonia. Author(s): Palepu A, Sun H, Kuyper L, Schechter MT, O'Shaughnessy MV, Anis AH. Source: Journal of General Internal Medicine : Official Journal of the Society for Research and Education in Primary Care Internal Medicine. 2003 April; 18(4): 242-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12709090&dopt=Abstract
•
Prevalence of Chlamydia pneumoniae infection in Thai children with communityacquired pneumonia. Author(s): Likitnukul S, Nunthapisud P, Prapphal N. Source: The Pediatric Infectious Disease Journal. 2003 August; 22(8): 749-50. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12938677&dopt=Abstract
•
Prevention and management of ventilator-associated pneumonia. Author(s): Ewig S, Torres A. Source: Current Opinion in Critical Care. 2002 February; 8(1): 58-69. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12205408&dopt=Abstract
•
Prevention of ventilator-associated pneumonia. Author(s): Fagon JY. Source: Intensive Care Medicine. 2002 July; 28(7): 822-3. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12349819&dopt=Abstract
•
Prevention of ventilator-associated pneumonia: an evidence-based systematic review. Author(s): Collard HR, Saint S, Matthay MA. Source: Annals of Internal Medicine. 2003 March 18; 138(6): 494-501. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12639084&dopt=Abstract
286 Pneumonia
•
Prevention of ventilator-associated pneumonia: current practice in Canadian intensive care units. Author(s): Heyland DK, Cook DJ, Dodek PM. Source: Journal of Critical Care. 2002 September; 17(3): 161-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12297991&dopt=Abstract
•
Pro/con clinical debate: the use of a protected specimen brush in the diagnosis of ventilator associated pneumonia. Author(s): Heyland D, Ewig S, Torres A. Source: Critical Care (London, England). 2002 April; 6(2): 117-20. Epub 2002 February 13. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11983035&dopt=Abstract
•
Procalcitonin measurement for differential diagnosis between pulmonary embolism and pneumonia. Author(s): Delevaux I, Andre M, Aumaitre O, Begue RJ, Colombier M, Piette JC. Source: Critical Care Medicine. 2003 February; 31(2): 661. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12576992&dopt=Abstract
•
Procalcitonin, C-reactive protein and APACHE II score for risk evaluation in patients with severe pneumonia. Author(s): Brunkhorst FM, Al-Nawas B, Krummenauer F, Forycki ZF, Shah PM. Source: Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases. 2002 February; 8(2): 93-100. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11952722&dopt=Abstract
•
Prophylactic antibiotics adversely affect nosocomial pneumonia in trauma patients. Author(s): Hoth JJ, Franklin GA, Stassen NA, Girard SM, Rodriguez RJ, Rodriguez JL. Source: The Journal of Trauma. 2003 August; 55(2): 249-54. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12913633&dopt=Abstract
•
Prophylaxis against Pneumocystis carinii pneumonia for HIV-exposed infants in Africa. Author(s): Graham SM. Source: Lancet. 2002 December 14; 360(9349): 1966-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12493279&dopt=Abstract
•
Prophylaxis for human immunodeficiency virus-related Pneumocystis carinii pneumonia: using simulation modeling to inform clinical guidelines. Author(s): Goldie SJ, Kaplan JE, Losina E, Weinstein MC, Paltiel AD, Seage GR 3rd, Craven DE, Kimmel AD, Zhang H, Cohen CJ, Freedberg KA. Source: Archives of Internal Medicine. 2002 April 22; 162(8): 921-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11966344&dopt=Abstract
Studies 287
•
Prospective cohort study showing changes in the monthly incidence of Pneumocystis carinii pneumonia. Author(s): Lubis N, Baylis D, Short A, Stebbing J, Teague A, Portsmouth S, Bower M, Nelson M, Gazzard B. Source: Postgraduate Medical Journal. 2003 March; 79(929): 164-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12697918&dopt=Abstract
•
Pseudomonas aeruginosa pneumonia. Author(s): Garau J, Gomez L. Source: Current Opinion in Infectious Diseases. 2003 April; 16(2): 135-43. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12734446&dopt=Abstract
•
Pulmonary embolism and pneumonia may be confounded after acute stroke and may co-exist. Author(s): Kelly J, Hunt BJ, Rudd A, Lewis RR. Source: Age and Ageing. 2002 July; 31(4): 235-9. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12147559&dopt=Abstract
•
Pulmonary matrix metalloproteinase excess in hospital-acquired pneumonia. Author(s): Hartog CM, Wermelt JA, Sommerfeld CO, Eichler W, Dalhoff K, Braun J. Source: American Journal of Respiratory and Critical Care Medicine. 2003 February 15; 167(4): 593-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12588713&dopt=Abstract
•
Pythium insidiosum pleuropericarditis complicating pneumonia in a child with leukemia. Author(s): Heath JA, Kiehn TE, Brown AE, LaQuaglia MP, Steinherz LJ, Bearman G, Wong M, Steinherz PG. Source: Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America. 2002 September 15; 35(6): E60-4. Epub 2002 August 23. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12203186&dopt=Abstract
•
Q fever pneumonia complicated by acute respiratory distress syndrome. Author(s): Oddo M, Jolidon RM, Peter O, Poli S, Cometta A. Source: Intensive Care Medicine. 2001 March; 27(3): 615. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11355136&dopt=Abstract
•
Quality indicators for the management of pneumonia in vulnerable elders. Author(s): Rhew DC. Source: Annals of Internal Medicine. 2001 October 16; 135(8 Pt 2): 736-43. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11601957&dopt=Abstract
288 Pneumonia
•
Quantifying the characteristics of unambiguous chest radiography reports in the context of pneumonia. Author(s): Chapman WW, Fiszman M, Frederick PR, Chapman BE, Haug PJ. Source: Academic Radiology. 2001 January; 8(1): 57-66. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11201458&dopt=Abstract
•
Quantitative culture of endotracheal aspirates in the diagnosis of ventilatorassociated pneumonia in patients with treatment failure. Author(s): Wu CL, Yang DIe, Wang NY, Kuo HT, Chen PZ. Source: Chest. 2002 August; 122(2): 662-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12171848&dopt=Abstract
•
Quinolones for community-acquired pneumonia. Author(s): Frothingham R. Source: Archives of Internal Medicine. 2001 July 9; 161(13): 1681-2. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11434807&dopt=Abstract
•
Radiographic and high-resolution CT findings of influenza virus pneumonia in patients with hematologic malignancies. Author(s): Oikonomou A, Muller NL, Nantel S. Source: Ajr. American Journal of Roentgenology. 2003 August; 181(2): 507-11. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12876036&dopt=Abstract
•
Radiology of pneumonia. Author(s): Gharib AM, Stern EJ. Source: The Medical Clinics of North America. 2001 November; 85(6): 1461-91, X. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11680112&dopt=Abstract
•
Randomized controlled trial of sequential intravenous (i.v.) and oral moxifloxacin compared with sequential i.v. and oral co-amoxiclav with or without clarithromycin in patients with community-acquired pneumonia requiring initial parenteral treatment. Author(s): Finch R, Schurmann D, Collins O, Kubin R, McGivern J, Bobbaers H, Izquierdo JL, Nikolaides P, Ogundare F, Raz R, Zuck P, Hoeffken G. Source: Antimicrobial Agents and Chemotherapy. 2002 June; 46(6): 1746-54. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12019085&dopt=Abstract
Studies 289
•
Randomized, open-label, parallel-group, multicenter study of the efficacy and tolerability of IV gatifloxacin with the option for oral stepdown gatifloxacin versus IV ceftriaxone (with or without erythromycin or clarithromycin) with the option for oral stepdown clarithromycin for treatment of patients with mild to moderate community-acquired pneumonia requiring hospitalization. Author(s): Correa JC, Badaro R, Bumroongkit C, Mera JR, Dolmann AL, Juarez Martinez LG, Mayrinck LR, Tamez R, Yang JY. Source: Clinical Therapeutics. 2003 May; 25(5): 1453-68. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12867221&dopt=Abstract
•
Rapid antibiotic delivery and appropriate antibiotic selection reduce length of hospital stay of patients with community-acquired pneumonia: link between quality of care and resource utilization. Author(s): Battleman DS, Callahan M, Thaler HT. Source: Archives of Internal Medicine. 2002 March 25; 162(6): 682-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11911722&dopt=Abstract
•
Rapid detection of Haemophilus influenzae type b in Bangladeshi children with pneumonia and meningitis by PCR and analysis of antimicrobial resistance. Author(s): Shoma S, Rahman M, Yasmin M. Source: J Health Popul Nutr. 2001 December; 19(4): 268-74. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11855348&dopt=Abstract
•
Rapid imipenem/cilastatin desensitization for multidrug-resistant Acinetobacter pneumonia. Author(s): Gorman SK, Zed PJ, Dhingra VK, Ronco JJ. Source: The Annals of Pharmacotherapy. 2003 April; 37(4): 513-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12659606&dopt=Abstract
•
Rapid urinary antigen test for diagnosis of pneumococcal community-acquired pneumonia in adults. Author(s): Marcos MA, Jimenez de Anta MT, de la Bellacasa JP, Gonzalez J, Martinez E, Garcia E, Mensa J, de Roux A, Torres A. Source: The European Respiratory Journal : Official Journal of the European Society for Clinical Respiratory Physiology. 2003 February; 21(2): 209-14. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12608431&dopt=Abstract
•
Rare presentation of Streptococcus pneumoniae pneumonia with bacteremia and multiple subcutaneous abscesses. Author(s): Shahin GS, Lerner SA. Source: European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology. 2002 August; 21(8): 611-2. Epub 2002 August 21. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12226693&dopt=Abstract
290 Pneumonia
•
Rational prescribing for childhood pneumonia. Author(s): Dawson KP. Source: Journal of Quality in Clinical Practice. 2001 September; 21(3): 86-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11892831&dopt=Abstract
•
Reappraisal of lung tap: review of an old method for better etiologic diagnosis of childhood pneumonia. Author(s): Vuori-Holopainen E, Peltola H. Source: Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America. 2001 March 1; 32(5): 715-26. Epub 2001 February 23. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11229839&dopt=Abstract
•
Recent advances in the epidemiology, prevention, diagnosis, and treatment of fungal pneumonia. Author(s): Pound MW, Drew RH, Perfect JR. Source: Current Opinion in Infectious Diseases. 2002 April; 15(2): 183-94. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11964921&dopt=Abstract
•
Recognising severe pneumonia with simple clinical and biochemical measurements. Author(s): Kamath A, Pasteur MC, Slade MG, Harrison BD. Source: Clinical Medicine (London, England). 2003 January-February; 3(1): 54-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12617416&dopt=Abstract
•
Recurrent bronchiolitis obliterans organizing pneumonia in a patient with limited cutaneous systemic sclerosis. Author(s): Shimizu Y, Tsukagoshi H, Nemoto T, Honma M, Nojima Y, Mori M. Source: Rheumatology International. 2002 September; 22(5): 216-8. Epub 2002 July 27. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12215870&dopt=Abstract
•
Recurrent pneumonia after cardiac surgery. Author(s): Ho N, Genta PR, Takagaki TY. Source: The European Respiratory Journal : Official Journal of the European Society for Clinical Respiratory Physiology. 2002 January; 19(1): 199-201. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11843320&dopt=Abstract
•
Recurrent pneumonia as warning manifestation for suspecting primary immunodeficiencies in children. Author(s): Quezada A, Norambuena X, Bravo A, Castro-Rodriguez JA. Source: J Investig Allergol Clin Immunol. 2001; 11(4): 295-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11908819&dopt=Abstract
Studies 291
•
Recurrent pneumonia due to persistent Chlamydia pneumoniae infection. Author(s): Miyashita N, Fukano H, Hara H, Yoshida K, Niki Y, Matsushima T. Source: Intern Med. 2002 January; 41(1): 30-3. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11838587&dopt=Abstract
•
Recurrent pneumonia from an ileobronchial fistula complicating Crohn's disease. Author(s): Gumbo T, Rice TW, Mawhorter S. Source: Journal of Clinical Gastroenterology. 2001 April; 32(4): 365-7. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11276288&dopt=Abstract
•
Recurrent pneumonia in children. Author(s): Sheares BJ. Source: Pediatric Annals. 2002 February; 31(2): 109-14. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11862721&dopt=Abstract
•
Recurrent pneumonia in children: clinical profile and underlying causes. Author(s): Lodha R, Puranik M, Natchu UC, Kabra SK. Source: Acta Paediatrica (Oslo, Norway : 1992). 2002; 91(11): 1170-3. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12463313&dopt=Abstract
•
Recurrent pneumonia with mild hypogammaglobulinemia diagnosed as X-linked agammaglobulinemia in adults. Author(s): Usui K, Sasahara Y, Tazawa R, Hagiwara K, Tsukada S, Miyawaki T, Tsuchiya S, Nukiwa T. Source: Respiratory Research. 2001; 2(3): 188-92. Epub 2001 April 12. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11686883&dopt=Abstract
•
Recurrent pneumonia with unconsciousness. Author(s): Yamakawa T, Tanaka SI, Ito Y, Shoji A, Sekihara H. Source: Journal of Internal Medicine. 2002 March; 251(3): 278-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11886489&dopt=Abstract
•
Reducing the incidence of nosocomial pneumonia in cardiovascular surgery patients. Author(s): Houston S, Gentry LO, Pruitt V, Dao T, Zabaneh F, Sabo J. Source: Quality Management in Health Care. 2003 January-March; 12(1): 28-41. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12593372&dopt=Abstract
292 Pneumonia
•
Reduction in gram-positive pneumonia and antibiotic consumption following the use of a SDD protocol including nasal and oral mupirocin. Author(s): Nardi G, Di Silvestre AD, De Monte A, Massarutti D, Proietti A, Grazia Troncon M, Lesa L, Zussino M. Source: European Journal of Emergency Medicine : Official Journal of the European Society for Emergency Medicine. 2001 September; 8(3): 203-14. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11587466&dopt=Abstract
•
Refractory Aspergillus pneumonia in patients with acute leukemia: successful therapy with combination caspofungin and liposomal amphotericin. Author(s): Aliff TB, Maslak PG, Jurcic JG, Heaney ML, Cathcart KN, Sepkowitz KA, Weiss MA. Source: Cancer. 2003 February 15; 97(4): 1025-32. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12569602&dopt=Abstract
•
Relationship between methodological trial quality and the effects of selective digestive decontamination on pneumonia and mortality in critically ill patients. Author(s): van Nieuwenhoven CA, Buskens E, van Tiel FH, Bonten MJ. Source: Jama : the Journal of the American Medical Association. 2001 July 18; 286(3): 335-40. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11466100&dopt=Abstract
•
Relative frequency of Haemophilus influenzae type b pneumonia in Chinese children as evidenced by serology. Author(s): Wang YJ, Vuori-Holopainen E, Yang Y, Wang Y, Hu Y, Leboulleux D, Hedman K, Leinonen M, Peltola H. Source: The Pediatric Infectious Disease Journal. 2002 April; 21(4): 271-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12075755&dopt=Abstract
•
Remission of acute myeloblastic leukemia after severe pneumonia treated with highdose methylprednisolone. Author(s): Shimohakamada Y, Shinohara K, Fukuda N. Source: International Journal of Hematology. 2001 August; 74(2): 173-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11594518&dopt=Abstract
•
Reproducibility of Louis' definition of pneumonia. Author(s): Morabia A, Rochat T. Source: Lancet. 2001 October 6; 358(9288): 1188. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11597716&dopt=Abstract
Studies 293
•
Researchers get to grips with cause of pneumonia epidemic. Author(s): Knight J. Source: Nature. 2003 April 10; 422(6932): 547-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12686960&dopt=Abstract
•
Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia. Author(s): Ross JJ, Worthington MG, Gorbach SL. Source: The New England Journal of Medicine. 2002 July 4; 347(1): 65-7; Author Reply 65-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12097545&dopt=Abstract
•
Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia. Author(s): Hutchinson J. Source: The New England Journal of Medicine. 2002 July 4; 347(1): 65-7; Author Reply 65-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12102064&dopt=Abstract
•
Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia. Author(s): Zhanel GG, Hoban DJ, Chan CK. Source: The New England Journal of Medicine. 2002 July 4; 347(1): 65-7; Author Reply 65-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12102063&dopt=Abstract
•
Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia. Author(s): Tillotson GS, Zhao X, Drlica K. Source: The New England Journal of Medicine. 2002 July 4; 347(1): 65-7; Author Reply 65-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12102062&dopt=Abstract
•
Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia. Author(s): Davidson R, Cavalcanti R, Brunton JL, Bast DJ, de Azavedo JC, Kibsey P, Fleming C, Low DE. Source: The New England Journal of Medicine. 2002 March 7; 346(10): 747-50. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11882730&dopt=Abstract
•
Resolution of infectious parameters after antimicrobial therapy in patients with ventilator-associated pneumonia. Author(s): Dennesen PJ, van der Ven AJ, Kessels AG, Ramsay G, Bonten MJ. Source: American Journal of Respiratory and Critical Care Medicine. 2001 May; 163(6): 1371-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11371403&dopt=Abstract
294 Pneumonia
•
Resolution of lymphocytic interstitial pneumonia in a human immunodeficiency virus-infected adult following the start of highly active antiretroviral therapy. Author(s): Ripamonti D, Rizzi M, Maggiolo F, Arici C, Suter F. Source: Scandinavian Journal of Infectious Diseases. 2003; 35(5): 348-51. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12875528&dopt=Abstract
•
Resolution of ventilator-associated pneumonia: prospective evaluation of the clinical pulmonary infection score as an early clinical predictor of outcome. Author(s): Luna CM, Blanzaco D, Niederman MS, Matarucco W, Baredes NC, Desmery P, Palizas F, Menga G, Rios F, Apezteguia C. Source: Critical Care Medicine. 2003 March; 31(3): 676-82. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12626968&dopt=Abstract
•
Respiratory distress in neonates with special reference to pneumonia. Author(s): Mathur NB, Garg K, Kumar S. Source: Indian Pediatrics. 2002 June; 39(6): 529-37. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12084946&dopt=Abstract
•
Respiratory failure caused by tuberculous pneumonia requiring extracorporeal membrane oxygenation. Author(s): Petrillo TM, Heard ML, Fortenberry JD, Stockwell JA, Leonard MK Jr. Source: Perfusion. 2001 November; 16(6): 525-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11761093&dopt=Abstract
•
Respiratory infection in the chronically critically ill patient. Ventilator-associated pneumonia and tracheobronchitis. Author(s): Ahmed QA, Niederman MS. Source: Clinics in Chest Medicine. 2001 March; 22(1): 71-85. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11315460&dopt=Abstract
•
Respiratory rate as a predictor of positive lung aspirates in young Gambian children with lobar pneumonia. Author(s): Falade AG, Adegbola RA, Mulholland EK, Greenwood BM. Source: Annals of Tropical Paediatrics. 2001 December; 21(4): 293-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11732146&dopt=Abstract
•
Respiratory tract pathogens isolated from patients hospitalized with suspected pneumonia in Latin America: frequency of occurrence and antimicrobial susceptibility profile: results from the SENTRY Antimicrobial Surveillance Program (1997-2000). Author(s): Gales AC, Sader H HS, Jones RN. Source: Diagnostic Microbiology and Infectious Disease. 2002 November; 44(3): 301-11. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12493178&dopt=Abstract
Studies 295
•
Reversed halo sign on high-resolution CT of cryptogenic organizing pneumonia: diagnostic implications. Author(s): Kim SJ, Lee KS, Ryu YH, Yoon YC, Choe KO, Kim TS, Sung KJ. Source: Ajr. American Journal of Roentgenology. 2003 May; 180(5): 1251-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12704033&dopt=Abstract
•
Rhabdomyolysis associated with pneumococcal pneumonia: an early clinical indicator of increased morbidity? Author(s): Garcia MC, Ebeo CT, Byrd RP Jr, Roy TM. Source: Tenn Med. 2002 February; 95(2): 67-9. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11845660&dopt=Abstract
•
Rheumatic pneumonia. Author(s): Saraiva LR. Source: Annals of the Rheumatic Diseases. 2002 May; 61(5): 477; Author Reply 477. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11959782&dopt=Abstract
•
Rheumatic pneumonia. Author(s): de la Fuente J, Nodar A, Sopena B, Martinez CA, Fernandez A. Source: Annals of the Rheumatic Diseases. 2001 October; 60(10): 990-1. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11589184&dopt=Abstract
•
Rhinovirus infections in hematopoietic stem cell transplant recipients with pneumonia. Author(s): Ison MG, Hayden FG, Kaiser L, Corey L, Boeckh M. Source: Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America. 2003 May 1; 36(9): 1139-43. Epub 2003 April 21. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12715308&dopt=Abstract
•
Rhodococcus equi and cytomegalovirus pneumonia in a renal transplant patient: diagnosis by fine-needle aspiration biopsy. Author(s): Simsir A, Oldach D, Forest G, Henry M. Source: Diagnostic Cytopathology. 2001 February; 24(2): 129-31. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11169894&dopt=Abstract
•
Rhodococcus equi pneumonia in a heart transplant recipient in Korea, with emphasis on microbial diagnosis. Author(s): Yoo SJ, Sung H, Chae JD, Kim MN, Pai CH, Park J, Kim JJ. Source: Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases. 2003 March; 9(3): 230-3. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12667256&dopt=Abstract
296 Pneumonia
•
Rhodococcus equi pneumonia in a patient with human immunodeficiency virus: case report and review. Author(s): Kwa AL, Tam VH, Rybak MJ. Source: Pharmacotherapy. 2001 August; 21(8): 998-1002. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11718503&dopt=Abstract
•
Rhodococcus equi pneumonia: highly active antiretroviral therapy helps but does not cure lung infection. Author(s): Sanz-Moreno J, Flores-Segovia J, Olmedilla-Arregui G, Gomez-Herruz P, Granell J. Source: Aids (London, England). 2002 February 15; 16(3): 509-11. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11834975&dopt=Abstract
•
Rib fractures after chest physiotherapy for bronchiolitis or pneumonia in infants. Author(s): Chalumeau M, Foix-L'Helias L, Scheinmann P, Zuani P, Gendrel D, Ducoule-Pointe H. Source: Pediatric Radiology. 2002 September; 32(9): 644-7. Epub 2002 July 12. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12195303&dopt=Abstract
•
Right lobar pneumonia complicated by sub-phrenic abscess in a child. Author(s): Ameh EA, Yakubu AA. Source: Niger Postgrad Med J. 2001 June; 8(2): 93-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11487910&dopt=Abstract
•
Risk factors and outcome of varicella-zoster virus pneumonia in pregnant women. Author(s): Harger JH, Ernest JM, Thurnau GR, Moawad A, Momirova V, Landon MB, Paul R, Miodovnik M, Dombrowski M, Sibai B, Van Dorsten P; National Institute of Child Health and Human Development, Network of Maternal-Fetal Medicine Units. Source: The Journal of Infectious Diseases. 2002 February 15; 185(4): 422-7. Epub 2002 January 17. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11865393&dopt=Abstract
•
Risk factors for late-onset nosocomial pneumonia caused by Stenotrophomonas maltophilia in critically ill trauma patients. Author(s): Hanes SD, Demirkan K, Tolley E, Boucher BA, Croce MA, Wood GC, Fabian TC. Source: Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America. 2002 August 1; 35(3): 228-35. Epub 2002 July 02. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12115086&dopt=Abstract
Studies 297
•
Risk factors for nosocomial pneumonia in a geriatric hospital: a control-case onecenter study. Author(s): Rothan-Tondeur M, Meaume S, Girard L, Weill-Engerer S, Lancien E, Abdelmalak S, Rufat P, Le Blanche AF. Source: Journal of the American Geriatrics Society. 2003 July; 51(7): 997-1001. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12834521&dopt=Abstract
•
Risk factors for nosocomial pneumonia in critically ill trauma patients. Author(s): Tejada Artigas A, Bello Dronda S, Chacon Valles E, Munoz Marco J, Villuendas Uson MC, Figueras P, Suarez FJ, Hernandez A. Source: Critical Care Medicine. 2001 February; 29(2): 304-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11246310&dopt=Abstract
•
Risk factors for nosocomial pneumonia. Focus on prophylaxis. Author(s): Fleming CA, Balaguera HU, Craven DE. Source: The Medical Clinics of North America. 2001 November; 85(6): 1545-63. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11680116&dopt=Abstract
•
Risk factors for nursing home-acquired pneumonia. Author(s): Madariaga MG, Thomas A, Cannady PB Jr. Source: Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America. 2003 July 1; 37(1): 148-9; Author Reply 149-50. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12830422&dopt=Abstract
•
Risk factors for pneumonia in adults with chickenpox. Author(s): Mohsen AH, McKendrick MW. Source: The Journal of Infectious Diseases. 2002 October 1; 186(7): 1053; Iauthor Reply 1053-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12232851&dopt=Abstract
•
Risk factors for pneumonia in infants and young children and the role of solid fuel for cooking: a case-control study. Author(s): Mahalanabis D, Gupta S, Paul D, Gupta A, Lahiri M, Khaled MA. Source: Epidemiology and Infection. 2002 August; 129(1): 65-71. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12211598&dopt=Abstract
•
Risk factors for pneumonia in patients with acute stroke. Author(s): Dziewas R, Stogbauer F, Ludemann P. Source: Stroke; a Journal of Cerebral Circulation. 2003 August; 34(8): E105; Author Reply E105. Epub 2003 July 10. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12855820&dopt=Abstract
298 Pneumonia
•
Risk factors for pneumonia in urban-dwelling HIV-infected women: a case-control study in Nairobi, Kenya. Author(s): Penner J, Meier AS, Mwachari C, Ayuka F, Muchina B, Odhiambo J, Cohen CR. Source: Journal of Acquired Immune Deficiency Syndromes (1999). 2003 February 1; 32(2): 223-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12571534&dopt=Abstract
•
Risk factors for prophylaxis failure in patients receiving aerosol pentamidine for Pneumocystis carinii pneumonia prophylaxis. Author(s): Wei CC, Gardner S, Rachlis A, Pack LL, Chan CK. Source: Chest. 2001 May; 119(5): 1427-33. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11348949&dopt=Abstract
•
Risk factors for severe pneumonia in children in Basrah. Author(s): Hassan MK, Al-Sadoon I. Source: Trop Doct. 2001 July; 31(3): 139-41. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11444332&dopt=Abstract
•
Risk factors of aspiration pneumonia in Alzheimer's disease patients. Author(s): Wada H, Nakajoh K, Satoh-Nakagawa T, Suzuki T, Ohrui T, Arai H, Sasaki H. Source: Gerontology. 2001 September-October; 47(5): 271-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11490146&dopt=Abstract
•
Risk factors predicting pneumonia in patients aged 80 and older after cardiac surgery. Author(s): Barnett SD, Halpin LS, Speir AM, Lefrak E. Source: Journal of the American Geriatrics Society. 2002 July; 50(7): 1313-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12133037&dopt=Abstract
•
Risk for Pneumocystis carinii transmission among patients with pneumonia: a molecular epidemiology study. Author(s): Manoloff ES, Francioli P, Taffe P, Van Melle G, Bille J, Hauser PM. Source: Emerging Infectious Diseases. 2003 January; 9(1): 132-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12533297&dopt=Abstract
•
Risk index for postoperative pneumonia. Author(s): Tung A, Klafta JM. Source: Annals of Internal Medicine. 2002 October 1; 137(7): 620; Author Reply 620. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12353955&dopt=Abstract
Studies 299
•
Risk of bacteremia in young children with pneumonia treated as outpatients. Author(s): Shah SS, Alpern ER, Zwerling L, McGowan KL, Bell LM. Source: Archives of Pediatrics & Adolescent Medicine. 2003 April; 157(4): 389-92. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12695236&dopt=Abstract
•
Role of bronchoalveolar lavage in immunocompromised patients with pneumonia treated with a broad spectrum antibiotic and antifungal regimen. Author(s): Hohenadel IA, Kiworr M, Genitsariotis R, Zeidler D, Lorenz J. Source: Thorax. 2001 February; 56(2): 115-20. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11209099&dopt=Abstract
•
Role of galectin-3 as an adhesion molecule for neutrophil extravasation during streptococcal pneumonia. Author(s): Sato S, Ouellet N, Pelletier I, Simard M, Rancourt A, Bergeron MG. Source: Journal of Immunology (Baltimore, Md. : 1950). 2002 February 15; 168(4): 181322. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11823514&dopt=Abstract
•
Role of interleukin-18 and T-helper type 1 cytokines in the development of Mycoplasma pneumoniae pneumonia in adults. Author(s): Tanaka H, Narita M, Teramoto S, Saikai T, Oashi K, Igarashi T, Abe S. Source: Chest. 2002 May; 121(5): 1493-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12006434&dopt=Abstract
•
Role of L-selectin in the development of ventilator-associated pneumonia in patients after major surgery. Author(s): Sasajima K, Onda M, Miyashita M, Nomura T, Makino H, Maruyama H, Matsutani T, Futami R, Ikezaki H, Takeda SH, Takai K, Ogawa R. Source: The Journal of Surgical Research. 2002 June 15; 105(2): 123-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12121698&dopt=Abstract
•
Role of lung epithelial cells in defense against Klebsiella pneumoniae pneumonia. Author(s): Cortes G, Alvarez D, Saus C, Alberti S. Source: Infection and Immunity. 2002 March; 70(3): 1075-80. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11854185&dopt=Abstract
•
Role of serial routine microbiologic culture results in the initial management of ventilator-associated pneumonia. Author(s): Hayon J, Figliolini C, Combes A, Trouillet JL, Kassis N, Dombret MC, Gibert C, Chastre J. Source: American Journal of Respiratory and Critical Care Medicine. 2002 January 1; 165(1): 41-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11779728&dopt=Abstract
300 Pneumonia
•
Roxithromycin-induced eosinophilic pneumonia. Author(s): Perez-Castrillon JL, Jimenez-Garcia R, Martin-Escudero JC, Velasco C. Source: The Annals of Pharmacotherapy. 2002 November; 36(11): 1808-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12398581&dopt=Abstract
•
S-adenosylmethionine concentrations in diagnosis of Pneumocystis carinii pneumonia. Author(s): Skelly M, Hoffman J, Fabbri M, Holzman RS, Clarkson AB Jr, Merali S. Source: Lancet. 2003 April 12; 361(9365): 1267-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12699956&dopt=Abstract
•
S-adenosylmethionine in plasma to test for Pneumocystis carinii pneumonia. Author(s): Helweg-Larsen J. Source: Lancet. 2003 April 12; 361(9365): 1237. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12699946&dopt=Abstract
•
Safety and efficacy of gatifloxacin in community-acquired pneumonia: rationale for the Tequin Clinical Experience Study (TeqCES). Author(s): Mandell LA. Source: Diagnostic Microbiology and Infectious Disease. 2002 September; 44(1): 65-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12376034&dopt=Abstract
•
Sarcoidosis-associated bronchiolitis obliterans organizing pneumonia. Author(s): Rodriguez E, Lopez D, Buges J, Torres M. Source: Archives of Internal Medicine. 2001 September 24; 161(17): 2148-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11570948&dopt=Abstract
•
Scedosporium apiospermum pneumonia and sternal wound infection in a heart transplant recipient. Author(s): Talbot TR, Hatcher J, Davis SF, Pierson RN 3rd, Barton R, Dummer S. Source: Transplantation. 2002 December 15; 74(11): 1645-7. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12490804&dopt=Abstract
•
Screening for pneumonia risk in the elderly. Author(s): Sandlos PA, DuFour LM, Dawson JD. Source: Perspectives. 2002 Winter; 26(4): 8-9. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12715547&dopt=Abstract
Studies 301
•
Seasonal fluctuations in hospitalisation for pneumonia in Finland. Author(s): Saynajakangas P, Keistinen T, Tuuponen T. Source: Int J Circumpolar Health. 2001 January; 60(1): 34-40. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11428221&dopt=Abstract
•
Septic shock and respiratory failure in community-acquired pneumonia have different TNF polymorphism associations. Author(s): Waterer GW, Quasney MW, Cantor RM, Wunderink RG. Source: American Journal of Respiratory and Critical Care Medicine. 2001 June; 163(7): 1599-604. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11401880&dopt=Abstract
•
Serial evaluation of high-resolution computed tomography findings in patients with idiopathic pulmonary fibrosis in usual interstitial pneumonia. Author(s): Nagao T, Nagai S, Hiramoto Y, Hamada K, Shigematsu M, Hayashi M, Izumi T, Mishima M. Source: Respiration; International Review of Thoracic Diseases. 2002; 69(5): 413-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12232448&dopt=Abstract
•
Serological hint suggesting that Parachlamydiaceae are agents of pneumonia in polytraumatized intensive care patients. Author(s): Greub G, Boyadjiev I, La Scola B, Raoult D, Martin C. Source: Annals of the New York Academy of Sciences. 2003 June; 990: 311-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12860644&dopt=Abstract
•
Serum IgG subclasses levels in paediatric patients with pneumonia. Author(s): Mazengera LR, Nathoo KJ, Rusakaniko S, Zegers BJ. Source: Cent Afr J Med. 2001 June; 47(6): 142-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12201019&dopt=Abstract
•
Serum immunoglobulin E levels in human immunodeficiency virus-infected children with pneumonia. Author(s): Zar HJ, Latief Z, Hughes J, Hussey G. Source: Pediatric Allergy and Immunology : Official Publication of the European Society of Pediatric Allergy and Immunology. 2002 October; 13(5): 328-33. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12431191&dopt=Abstract
•
Serum interleukin-6 and tumor necrosis factor-alpha concentrations in children with mycoplasma pneumonia. Author(s): Hsieh CC, Tang RB, Tsai CH, Chen W. Source: J Microbiol Immunol Infect. 2001 June; 34(2): 109-12. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11456355&dopt=Abstract
302 Pneumonia
•
Serum KL-6 levels in pediatric patients: reference values for children and levels in pneumonia, asthma, and measles patients. Author(s): Imai T, Takase M, Takeda S, Kougo T. Source: Pediatric Pulmonology. 2002 February; 33(2): 135-41. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11802251&dopt=Abstract
•
Serum levels of KL-6 reflect disease activity of interstitial pneumonia associated with ANCA-related vasculitis. Author(s): Iwata Y, Wada T, Furuichi K, Kitagawa K, Kokubo S, Kobayashi M, Sakai N, Yoshimoto K, Shimizu M, Kobayashi K, Yokoyama H. Source: Intern Med. 2001 November; 40(11): 1093-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11757762&dopt=Abstract
•
Serum procalcitonin concentrations in bacterial pneumonia in children: a negative result in primary healthcare settings. Author(s): Korppi M, Remes S, Heiskanen-Kosma T. Source: Pediatric Pulmonology. 2003 January; 35(1): 56-61. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12461740&dopt=Abstract
•
Serum procalcitonin in pneumococcal pneumonia in children. Author(s): Korppi M, Remes S. Source: The European Respiratory Journal : Official Journal of the European Society for Clinical Respiratory Physiology. 2001 April; 17(4): 623-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11401055&dopt=Abstract
•
Several hospital traits linked to two pneumonia care quality indicators. Author(s): Levenson D. Source: Rep Med Guidel Outcomes Res. 2002 May 3; 13(9): 5-7. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12484377&dopt=Abstract
•
Severe acute interstitial pneumonia and gefitinib. Author(s): Inoue A, Saijo Y, Maemondo M, Gomi K, Tokue Y, Kimura Y, Ebina M, Kikuchi T, Moriya T, Nukiwa T. Source: Lancet. 2003 January 11; 361(9352): 137-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12531582&dopt=Abstract
•
Severe community-acquired pneumonia due to Acinetobacter baumannii. Author(s): Chen MZ, Hsueh PR, Lee LN, Yu CJ, Yang PC, Luh KT. Source: Chest. 2001 October; 120(4): 1072-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11591541&dopt=Abstract
Studies 303
•
Severe community-acquired pneumonia with acute hypoxemic respiratory failure due to primary infection with Chlamydia pneumoniae in a previously healthy adult. Author(s): Balis E, Boufas A, Iliopoulos I, Legakis NJ, Zerva L. Source: Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America. 2003 June 15; 36(12): E155-7. Epub 2003 Jun 05. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12802780&dopt=Abstract
•
Severe community-acquired pneumonia. Author(s): Ewig S, Torres A. Source: Current Opinion in Critical Care. 2002 October; 8(5): 453-60. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12357115&dopt=Abstract
•
Severe community-acquired pneumonia: current outcomes, epidemiology, etiology, and therapy. Author(s): Restrepo MI, Jorgensen JH, Mortensen EM, Anzueto A. Source: Current Opinion in Infectious Diseases. 2001 December; 14(6): 703-9. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11964888&dopt=Abstract
•
Severe community-acquired pneumonia: the need to customize empiric therapy. Author(s): Wunderink RG, Waterer GW. Source: Chest. 2001 October; 120(4): 1053-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11591535&dopt=Abstract
•
Severe community-acquired pneumonia: use of intensive care services and evaluation of American and British Thoracic Society Diagnostic criteria. Author(s): Angus DC, Marrie TJ, Obrosky DS, Clermont G, Dremsizov TT, Coley C, Fine MJ, Singer DE, Kapoor WN. Source: American Journal of Respiratory and Critical Care Medicine. 2002 September 1; 166(5): 717-23. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12204871&dopt=Abstract
•
Severe community-acquired pneumonia: what's in a name? Author(s): Oosterheert JJ, Bonten MJ, Hak E, Schneider MM, Hoepelman AI. Source: Current Opinion in Infectious Diseases. 2003 April; 16(2): 153-9. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12734448&dopt=Abstract
•
Severe dementia and adverse outcomes of nursing home-acquired pneumonia: evidence for mediation by functional and pathophysiological decline. Author(s): van der Steen JT, Ooms ME, Mehr DR, van der Wal G, Ribbe MW. Source: Journal of the American Geriatrics Society. 2002 March; 50(3): 439-48. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11943038&dopt=Abstract
304 Pneumonia
•
Severe diffuse interstitial pneumonia due to Mycoplasma pneumoniae in a patient with respiratory insufficiency. Author(s): de Boer J, Aerdts SJ, Groeneveld PH. Source: The Netherlands Journal of Medicine. 2003 March; 61(3): 91-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12765231&dopt=Abstract
•
Severe hemolytic anemia and excessive leukocytosis masking mycoplasma pneumonia. Author(s): Daxbock F, Zedtwitz-Liebenstein K, Burgmann H, Graninger W. Source: Annals of Hematology. 2001 March; 80(3): 180-2. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11320906&dopt=Abstract
•
Severe inclusion body myositis with interstitial pneumonia. Author(s): Mori S, Hamada H, Yokoyama A, Kohno N, Kondo K, Hara Y, Kawata H, Hiwada K. Source: Intern Med. 2001 September; 40(9): 940-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11579961&dopt=Abstract
•
Severe Legionella pneumophila pneumonia in a patient with iron overload. Author(s): Vikram HR, Bia FJ. Source: Scandinavian Journal of Infectious Diseases. 2002; 34(10): 772-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12477334&dopt=Abstract
•
Severe pneumococcal pneumonia following treatment with infliximab for Crohn's disease. Author(s): Ritz MA, Jost R. Source: Inflammatory Bowel Diseases. 2001 November; 7(4): 327. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11720324&dopt=Abstract
•
Severe Pneumocystis carinii pneumonia increases the infectious titre of HIV-1 in blood and can promote the expansion of viral chemokine co-receptor tropism. Author(s): Shaunak S, Veryard C, Javan C. Source: The Journal of Infection. 2001 July; 43(1): 3-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11597147&dopt=Abstract
•
Severe pneumonia and a second antibiotic. Author(s): Macfarlane J. Source: Lancet. 2002 April 6; 359(9313): 1170-2. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11955532&dopt=Abstract
Studies 305
•
Severe pneumonia due to Legionella pneumophila: prognostic factors, impact of delayed appropriate antimicrobial therapy. Author(s): Gacouin A, Le Tulzo Y, Lavoue S, Camus C, Hoff J, Bassen R, Arvieux C, Heurtin C, Thomas R. Source: Intensive Care Medicine. 2002 June; 28(6): 686-91. Epub 2002 April 20. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12107671&dopt=Abstract
•
Severe pneumonia in a fifteen-year-old. Author(s): de Jose Gomez MI, Baquero-Artigao F, Miguel MJ. Source: The Pediatric Infectious Disease Journal. 2001 May; 20(5): 553-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11368123&dopt=Abstract
•
Severe respiratory syncytial virus pneumonia associated with primary Epstein-Barr virus infection. Author(s): Abughali N, Khiyami A, Birnkrant DJ, Kumar ML. Source: Pediatric Pulmonology. 2002 May; 33(5): 395-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11948986&dopt=Abstract
•
Severe respiratory syncytial virus pneumonia complicating fludarabine and cyclophosphamide treatment of chronic lymphocytic leukemia. Author(s): Field K, Slavin MA, Seymour JF. Source: European Journal of Haematology. 2002 July; 69(1): 54-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12270063&dopt=Abstract
•
Severity of illness and outcome in adult patients with primary varicella pneumonia. Author(s): Gregorakos L, Myrianthefs P, Markou N, Chroni D, Sakagianni E. Source: Respiration; International Review of Thoracic Diseases. 2002; 69(4): 330-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12169746&dopt=Abstract
•
Shorter hospital stays may harm elderly pneumonia patients. Author(s): Jackson R. Source: Rep Med Guidel Outcomes Res. 2001 January 25; 12(2): 7-9. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11767778&dopt=Abstract
•
Simple measure predicts how pneumonia patients will fare after discharge. Author(s): Levenson D. Source: Rep Med Guidel Outcomes Res. 2002 June 28; 13(12): 7-9. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12506929&dopt=Abstract
306 Pneumonia
•
Simultaneous splenectomy increases risk for opportunistic pneumonia in patients after liver transplantation. Author(s): Neumann UP, Langrehr JM, Kaisers U, Lang M, Schmitz V, Neuhaus P. Source: Transplant International : Official Journal of the European Society for Organ Transplantation. 2002 May; 15(5): 226-32. Epub 2002 April 06. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12012043&dopt=Abstract
•
Solutions for difficult diagnostic cases of community-acquired pneumonia. Author(s): Fine MJ. Source: Chemotherapy. 2001; 47 Suppl 4: 3-10; Discussion 26-7. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11586000&dopt=Abstract
•
Spectrum of clinical and radiographic findings in pediatric mycoplasma pneumonia. Author(s): John SD, Ramanathan J, Swischuk LE. Source: Radiographics : a Review Publication of the Radiological Society of North America, Inc. 2001 January-February; 21(1): 121-31. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11158648&dopt=Abstract
•
Spectrum of CT findings in nosocomial Pseudomonas aeruginosa pneumonia. Author(s): Shah RM, Wechsler R, Salazar AM, Spirn PW. Source: Journal of Thoracic Imaging. 2002 January; 17(1): 53-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11828213&dopt=Abstract
•
Spontaneous rupture of the amyloid spleen in a case of usual interstitial pneumonia. Author(s): Tanno S, Ohsaki Y, Osanai S, Akiba Y, Takeuchi T, Nishigaki Y, Ide H, Nakano H, Miyokawa N, Kikuchi K. Source: Intern Med. 2001 May; 40(5): 428-31. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11393417&dopt=Abstract
•
Sputum induction as a diagnostic tool for community-acquired pneumonia in infants and young children from a high HIV prevalence area. Author(s): Zar HJ, Tannenbaum E, Hanslo D, Hussey G. Source: Pediatric Pulmonology. 2003 July; 36(1): 58-62. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12772225&dopt=Abstract
•
Standard case management of pneumonia in children in developing countries: the cornerstone of the acute respiratory infection programme. Author(s): Pio A. Source: Bulletin of the World Health Organization. 2003; 81(4): 298-300. Epub 2003 May 16. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12764497&dopt=Abstract
Studies 307
•
Standard case management of pneumonia in hospitalized children in Uruguay, 1997 to 1998. Author(s): Pirez MC, Martinez O, Ferrari AM, Nairac A, Montano A, Rubio I, Sarachaga MJ, Brea S, Picon T, Pinchack MC, Torello P, Algorta G, Mogdasy MC. Source: The Pediatric Infectious Disease Journal. 2001 March; 20(3): 283-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11303831&dopt=Abstract
•
Staphylococcus aureus bacteremic pneumonia: differences between community and nosocomial acquisition. Author(s): Gonzalez C, Rubio M, Romero-Vivas J, Gonzalez M, Picazo JJ. Source: International Journal of Infectious Diseases : Ijid : Official Publication of the International Society for Infectious Diseases. 2003 June; 7(2): 102-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12839710&dopt=Abstract
•
Statement of the 4th International Consensus Conference in Critical Care on ICUAcquired Pneumonia--Chicago, Illinois, May 2002. Author(s): Hubmayr RD, Burchardi H, Elliot M, Fessler H, Georgopoulos D, Jubran A, Limper A, Pesenti A, Rubenfeld G, Stewart T, Villar J; American Thoracic Society Assembly on Critical Care; European Respiratory Society; European Society of Intensive Care Medicine; Societe de Reanimation de Langue Francaise. Source: Intensive Care Medicine. 2002 November; 28(11): 1521-36. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12583368&dopt=Abstract
•
Statin-induced fibrotic nonspecific interstitial pneumonia. Author(s): Lantuejoul S, Brambilla E, Brambilla C, Devouassoux G. Source: The European Respiratory Journal : Official Journal of the European Society for Clinical Respiratory Physiology. 2002 March; 19(3): 577-80. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11936540&dopt=Abstract
•
Steady-state free precession projection MRI as a potential alternative to the conventional chest X-ray in pediatric patients with suspected pneumonia. Author(s): Rupprecht T, Bowing B, Kuth R, Deimling M, Rascher W, Wagner M. Source: European Radiology. 2002 November; 12(11): 2752-6. Epub 2002 April 30. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12386769&dopt=Abstract
•
Steady-state plasma and intrapulmonary concentrations of cefepime administered in continuous infusion in critically ill patients with severe nosocomial pneumonia. Author(s): Boselli E, Breilh D, Duflo F, Saux MC, Debon R, Chassard D, Allaouchiche B. Source: Critical Care Medicine. 2003 August; 31(8): 2102-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12973166&dopt=Abstract
308 Pneumonia
•
Steroid treatment based on the findings of transbronchial biopsy in idiopathic interstitial pneumonia. Author(s): Watanabe K, Higuchi K, Ninomiya K, Ohshima T, Aritomi T, Kawabata Y, Yoshida M. Source: The European Respiratory Journal : Official Journal of the European Society for Clinical Respiratory Physiology. 2002 November; 20(5): 1213-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12449176&dopt=Abstract
•
Strategy of antibiotic rotation: long-term effect on incidence and susceptibilities of Gram-negative bacilli responsible for ventilator-associated pneumonia. Author(s): Gruson D, Hilbert G, Vargas F, Valentino R, Bui N, Pereyre S, Bebear C, Bebear CM, Gbikpi-Benissan G. Source: Critical Care Medicine. 2003 July; 31(7): 1908-14. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=128